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Abstract  
Neurotransmitter  dysregulation  and  reactive  oxygen  species  (ROS)  are  a  hallmark  of 
neurodegenerative disease. Microglia, the immune cells of the CNS, express three NADPH 
oxidase  isoforms  (Nox1,  Nox2  and  Nox4),  which  produce  superoxide  that  is  used  as  an 
intracellular signalling molecule, mediating the production of neurotoxic and neurotrophic 
factors.  Microglia  also  express  a  range  of  neurotransmitter  receptors,  enabling  them  to 
respond  to  physiological and pathological  levels  of neurotransmitters. As  both  microglial 
superoxide  production  and  neurotransmitter  dysregulation  are  common  to  many 
neurodegenerative conditions, the interaction between microglial neurotransmitter receptor 
modulation and NADPH oxidase activation was investigated.  
Superoxide production was assessed in primary and BV2 microglia using flow cytometry, 
HPLC,  fluorescence  microscopy,  and  a  colorometric  assay.  Glutamate  (1  µM),  GABA 
(100 µM)  or  BzATP  (250  µM)  induced  NADPH  oxidase  derived  superoxide  production. 
Furthermore,  antagonism  of  the  group  I  mGluRs  induced  Nox1  and  Nox2  dependent 
superoxide production through PKC / PI3-K pathways and p44/42ERK activation. Activation 
of mGluR3 induced Nox2 and Nox4 activation in a p44/42ERK and p38MAPK dependent 
manner,  whilst  activation  of  the  group  III  mGluRs  induced  Nox2  and  Nox4  activation 
dependent  on  p38MAPK  signalling.  Microglial  NMDA  receptor  activation  promoted 
superoxide  production  that  was  dependent  on  p38MAPK  activation.  Modulation  of  the 
microglial  glutamate  receptors  mediated  protection  of  cerebellar  granule  neurons,  as 
deomstrated using microglial conditioned media assays. Activation of the microglial GABAA 
receptor induced Nox1 activation through PKC and p38MAPK signalling which mediated 
TNFʱ release and neurotoxicity, whilst P2Y2/4 receptor activation mediated Nox1 activation 
through  PI3-K  and  p38MAPK  with  neurotoxic  consequences.  The  findings  in  this  thesis 
show that microglial Nox2 and Nox4 activation has neuroprotective consequences, whereas 5 
 
microglial  Nox1  activation  mediates  neurotoxicity.  Modulation  of  the  microglial 
neurotransmitter  receptors  therefore  has  ramifications  for  the  survival  of  neurons  in 
degenerative diseases, which could have important consequences for the production of future 
therapies for neurodegenerative conditions.  
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1.1  Cells of the Central Nervous System  
The  central  nervous  system  (CNS)  is  comprised  of  the  brain  and  spinal  cord,  and  is 
responsible for information processing and interactions with the external environment. The 
CNS is composed of a network of equal numbers of neuronal and non-neuronal cells, with an 
estimated 86.1 billion neurons and 84.6 billion non-neuronal cells (Azevedo et al. 2009), 
which interact in a bi-directional manner allowing the efficient transfer of action potentials 
throughout the CNS.  
1.1.1  Neurons  
Neurons  receive,  store,  process  and  transfer  information  in  the  CNS.  They  are 
electrochemically  excitable  cells  that  communicate  through  the  release  and  up-take  of 
excitatory or inhibitory neurotransmitters, which elicit either excitatory action potentials or 
inhibitory signals depending on the receptors to which they bind (Seal & Edwards 2006). 
Neurons are composed of a soma (cell body), a number of dendrites (processes extending 
from the soma) where input to the neurons occurs, and a myelinated axon, which propagates 
the action potential (Fig. 1.1).  23 
 
 
 
Figure 1.1 Schematic of a Neuron. Neurons have a soma, multiple and highly branched dendrites, a 
single large axon, which is myelinated to aid propagation of the action potential, and a nerve terminal, 
which is rich in synaptic vesicles containing neurotransmitters, neuropeptides and other factors for release 
into the synaptic cleft.  
 
The action potential is induced by the depolarisation of the neuronal membrane, achieved by 
electrical input from adjacent cells through the dendrites. Axonal depolarisation induces an 
electrical signal that promotes neurotransmitter release from the synapse at the nerve terminal 
into the synaptic cleft, where post-synaptic neurons or effector cells are modulated (Catterall 
1984).   
 
The interactions between neurons comprise a complex network of neuronal pathways, which 
are crucial to the functioning of the CNS. Damage to neurons, or inhibition or breaks in 
neuronal networks underlies diseases such as Alzheimer‟s disease (AD), Parkinson‟s disease 
(PD), Multiple Sclerosis (MS) and stroke, along with several other neurological disorders, 
resulting in the manifestation of clinical symptoms.  
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Neuronal  activity  can  be  modelled  in  vitro  using  cell  and  slice  cultures.  In  this  thesis, 
cerebellar granule neurons have been used as a model of neuronal activity. The neurons of the 
cerebellum develop post-natally, therefore allowing the preparation of neurons from early 
post-natal rats. Cerebellar granule cells (CGCs) are predominantly glutamatergic (Pocock & 
Nicholls 1998), making these cells a useful model to study the neurotoxic effects of glia and 
neurotransmitter  dysregulation,  which  underlies  the  pathogenesis  of  several 
neurodegenerative conditions, on neuronal survival.  
 
The cerebellum co-ordinates voluntary movement and balance, and is crucial for the transfer 
of information to other parts of the brain. The cerebellum is composed of three distinct layers 
(Fig. 1.2). The molecular cell layer is comprised of basket cell interneurons and branching 
Purkinje cell dendrites, which enable synaptic activity. The Purkinje cell layer is composed of 
a single row of cell bodies, and finally, the granule cell layer consists of granule and Golgi 
interneurons. The main electrical input to the cerebellum comes from the mossy fibers, which 
form excitatory glutamatergic synapses with granule cells in the granule layer. Furthermore, 
the cerebellum also  receives excitatory input from the climbing fibers of the brain stem, 
which form excitatory glutamatergic synapses with up to ten Purkinje cells. The Purkinje 
cells can process the excitatory inputs from the climbing and mossy fibers, and the inhibitory 
signals from the basket cells. In this way, Purkinje cells can relay neuronal signals to the 
cerebellar nuclei.  25 
 
 
 
Figure 1.2 Cells and circuitry of the cerebellum. The cerebellum consists of four distinct layers – the 
molecular layer into which dendrites of the purkinjie cells project; the purkinjie cell layer, containing 
the purkinjie cells; the granule layer consisting of cerebellar granule cells; and the while matter, from 
which  excitatory  signals  originate.  Excitatory  imputs  originate  in  the  white  matter  from  the  mossy 
fibers, which synapse with the cerebellar granule cells. Excitatory signals are propagated into the 
dendrites of the Purkinjie cells, which process excitatory inputs from the climbing fibers. 
 
1.1.2  Glia  
The CNS consists of four main types of glial cells: astrocytes, oligodendrocytes, ependymal 
cells and brain macrophages (including microglia), which provide maintenance and trophic 
support  to  neurons.  Signalling  between  neurons  and  glia  is  bi-directional,  and  these 
interactions  are  important  for  the  functioning  of  the  CNS,  with  many  neurodegenerative 
diseases  arising  as  a  result  of  the  breakdown  in  these  interactions.  Glia  promote  the 
maintenance,  survival,  repair,  and  also  death  and  clearance  of  damaged  neurons  both  in 
physiological and pathophysiological conditions.  26 
 
1.1.2.1  Astrocytes  
Astrocytes are the predominant glial cell type in the CNS (He & Sun 2007). There are three 
astrocytic types, namely radial, fibrous and protoplasmic astrocytes. Radial astrocytes are 
found radiating from ventricles and at the ventricular zone (VZ), where they are implicated in 
neuronal pathfinding, and promote sub-ventricular zone (SVZ) stem cell production, that aid 
regeneration of the adult brain (Doetsch 2003). Fibrous astrocytes are located in the white 
matter, and their end feet contact the capillaries surrounding the brain, forming the blood 
brain barrier (BBB), a component of the first line of immune defence which prevents the 
infiltration  of  pathogens  or  other  cell  types  into  the  CNS  (Zlokovic  2008).  Protoplasmic 
astrocytes are located in the grey matter, and their end feet envelop synapses, facilitating 
synaptic transmission and synaptogenesis (Pfrieger and Barres, 1997).  
Astrocytes  have  numerous  roles  in  synaptic  transmission,  metabolism  and  regulation  of 
neuronal interactions. One astrocyte in the adult rodent brain interacts with as many as 10,000 
synapses  (Bushong  et  al.  2003;  Bushong  et  al.  2004),  and  a  role  for  astrocytes  in 
synaptogenesis has been suggested by Pfrieger & Barres (1997), who showed that retinal 
ganglion  neurons  (which  can  survive  without  glial  support)  cultured  in  the  absence  of 
astrocytes  formed  fewer  synapses  when  compared  to  cultures  grown  in  the  presence  of 
astrocytes  or  in  astrocyte  conditioned  media,  therefore  suggesting  that  astrocytes  release 
soluble  factors  that  promote  synaptogenesis  (Ullian  et  al.  2004).  Furthermore,  astrocytes 
express neurotransmitter receptors and ion channels, which enable them to regulate neuronal 
activity through their ability to take up neurotransmitters, neuropeptides and ions. This also 
mediates a change in astrocyte activation state and a reduction in their capacity to buffer 
potassium in the extracellular space, consequently enhancing neuronal activity (Hatton 2002).  
Astrocytes are implicated in neuronal metabolism and energy regulation through the lactate 
shuttle  (Fig.  1.3).  Neurons  have  a  preference  for  lactate  as  an  energy  source,  which  is 27 
 
 
 
Figure 1.3 The lactate shuttle. Neurons preferentially use lactate as an energy source, which 
is produced by astrocytes. Glucose is taken up by astrocytes from the capillaries, which is 
stimulates glycolysis to promote the production of pyruvate and lactate. In addition, glutamate 
is taken up by astrocyes through glutamate transporters and is also converted to glucose for 
use in glycolysis. Lactate is then released from astrocytes and taken up by neurons through 
monocarboxylate transporters for use as an energy source.  
produced from glucose in astrocytes in an activity dependant manner (Pellerin et al. 2007). 
Neuronal glutamate release into the extracellular matrix promotes the activity of astrocytes, 
resulting in increased lactate production and subsequent availability to neurons (Porras et al. 
2008).  Furthemore,  down-regulation  of  astrocytic  glutamate  transporters  reduces  lactate 
production,  thereby  decreasing  the  energy  available  to  neurons  and  contributing  to  the 
pathology of neurodegenerative conditions (Cholet et al. 2001).    
 
 
 
 
 
 
 
Neurons and astrocytes interact through gap junctions, and astrocytes represent the largest 
gap-junction  coupled  intracellular  network  within  the  brain  (Nakase  &  Naus  2004).  The 
communication between neurons and glia through gap junctions allows the co-ordination of 
intrinsic or elicited metabolic and electrical responses (Nagy et al. 2004), and in this way the 
breakdown  in  neuronal  glial  interactions  in  neurodegeneration  has  either  a  protective  or 
detrimental effect. In vitro studies have shown that induction of astrocytic inducible nitric 
oxide synthase (iNOS) or an increase in intracellular calcium concentration, often associated 
with  cell  stress,  decreases  gap  junction  communication  between  neurons  and  astrocytes, 28 
 
which protects neurons from cytotoxic signals that require direct cell contact (Bolaños & 
Medina 1996). However, the reduction in communication between astrocytes and neurons 
can result in the depletion of neuronal energy and neuronal damage (Salmina 2009).  
Changes in the interactions between neurons and astrocytes plays an important role in the 
progression  of  neurodegenerative  diseases.  During  neurodegeneration,  astrocytes  undergo 
morphological  and  functional  changes,  including  the  up-regulation  of  glial  fibrillary 
associated protein (GFAP) expression, proliferation, and accumulation at neuronal plaques, 
which can be protective through their degradation of these plaques, but can also lead to a 
change in the metabolic state of astrocytes, and a reduction in lactate production, which is 
detrimental to neuronal survival (Salmina 2009).   
1.1.2.2  Oligodendrocytes  
The  primary  function  of  oligodendrocytes  is  axonal  myelination,  which  enables  the 
propagation of action potentials (Fig. 1.4). Oligodendrocytes are small, highly branched glial 
cells, and a single oligodendrocyte can extend its processes to up to 50 axons, ensheathing 
each axon with 1 mm of myelin (Nave 2010). Myelination is a multistep process, in which 
oligodendrocyte precursor cells (OPC‟s) migrate to and make physical contact with an axon, 
which is mediated by the axonal expression of N-cadherin in the immature CNS, which also 
facilitates OPC maturation to oligodendrocytes (Schnädelbach et al. 2001). Inhibition of N-
cadherin expression attenuates OPC maturation and myelination, and expression of axonal N-
cadherin is down-regulated in the mature CNS, suggesting that myelination is a result of early 
contacts between neurons and oligodendrocytes in the developing brain (Schnädelbach et al. 
2001). The critical role of oligodendrocytes in the CNS is demonstrated in MS, in which the 
myelinating capacity of oligodendrocytes is compromised, and myelin degradation causes 
neurotoxicity, which, coupled with the inability of mature oligodendrocytes to re-myelinate 29 
 
           
Figure  1.4  Schematic  of  an  oligodendrocye  cell  myelinating  axons.  Oligodendrocytes  are  highly 
branched cells that myelinate many neuronal axons. This aids the propagation of the action potential.    
 
axons,  leads  to  an  inability  of  neurons  to  propagate  action  potentials,  resulting  in  MS 
pathology (Fancy et al. 2010). 
 
Oligodendrocytes also regulate extracellular potassium ion concentration, and secrete growth 
factors, including nerve growth factor (NGF), brain derived neurotrophic factor (BDNF) and 
neurotrophin-3 (NT-3), thereby providing trophic support to neurons. Oligodendrocytes are 
also implicated in the metabolism of cholesterol to pregnalone, a neurosteroid involved in the 
regulation  of  neuronal  glial  interactions  (Nichols  1999).  Steroidogenesis  mediated  by 
oligodendrocytes regulates the production of cytokines, growth factors, nitric oxide (NO), 
ApoE  and  heat-shock  proteins,  which  are  all  important  for  neuronal  survival  and 
degeneration (Garcia-Ovejero et al. 2005). Degradation of oligodendrocytes in diseases such 
as  MS  may  therefore  contribute  to  the  reduction  in  neuronal  glial  interactions,  which 
perpetuates neurodegenerative disease.  30 
 
1.1.2.3  Ependymal cells  
Ependymal cells are ciliated epithelial glia that line the ventricular surface of the brain and 
enable the circulation of cerebro-spinal fluid (CSF) around the CNS which facilitates the 
transport of nutrients, and is implicated in the removal of toxins (Del Bigio 2010). The cilia 
of ependymal cells beat in a co-ordinated manner, which is facilitated by communications 
between gap junctions and innervation (Del Bigio 2010). Ependymal cells are typically found 
at the VZ and SVZ and in this location, they mediate the migration of neural stem cells and 
organise the SVZ through the production of extracellular matrix and adhesion  molecules 
(Hauwel et al. 2005).  Furthermore, ependymal cells facilitate axonal guidance in the CNS 
during development, and the movement of the cilia also creates concentration gradients of 
nutrients  and  growth  factors,  enabling  neuroblast  migration  (Sawamoto  et  al.  2006). 
Ependymal cells also provide trophic support to neurons and other glial cells through the 
production of growth factors, such as fibroblast growth factor (FGF), which is up-regulated in 
ependymal cells after ischaemia in rats (Hayamizu et al. 2001).  
1.1.2.4  Brain macrophages  
Brain macrophages consist of several distinct populations of specialised cells. Macrophages 
located in the ventricular margins are known as supraependymal cells; epiplexus cells are 
found in the choroid plexus; subarachnoid macrophages are located in the meninges; and 
microglia are found in the parenchyma. Brain macrophages therefore cover every area of the 
brain,  where  they  act  as  immune  cells  and  survey  the  CNS  for  infiltrating  pathogens  or 
damaged neurons. They can phagocytose or repair damaged neurons, and also interact with 
the adaptive immune system to elicit an immune response, thereby enabling the  entry of 
systemic immune cells into the parenchyma. Microglia are the focus of this study and will be 
discussed in greater detail.  31 
 
1.2  Microglia in heath and disease 
Microglia, the immune-competent cells of the CNS (Färber & Kettenmann 2005), represent 
12% of the total cell number in the brain and 20% of glial cells (Block et al.  2007) and can 
instigate innate immunity within the brain parenchyma following immune challenge (Walter 
&  Neumann  2009).  Microglia  were  first  charachterised    by  Rio  Hortega  (1932),  who 
recognised focal areas of invasion following brain lesions, termed “fountains of microglia” in 
the corpus callosum and other white matter areas (reviewed in Färber & Kettenmann 2005), 
which has lead to further investigations into the protective and immune roles of microglia.  
Microglia are derived from myeloid precursors, and appear in the neuroepithelium during 
early  embryonic  development  (Walter  &  Neumann  2009)  before  invasion  into  the  CNS 
during  late  embryonic  development  where  they  transform  into  microglia  (Ling  &  Wong 
1993). The monocytic origin of microglia was determined in the 1980‟s in studies showing 
that ramified microglia express complement and Fc receptors as well as macrophage specific 
membrane  glycoprotein  (Perry  et  al.  1985).  Furthermore,  (Streit  &  Kreutzberg  1987) 
demonstrated that ramified and amoeboid microglia could be visualised by lectin binding, a 
histochemical marker typically used to label blood monocytes.  
Microglia exist in a range of activation states, enabling them to respond appropriately to their 
environment (Stence et al. 2001) (Fig. 1.5).  In the normal brain, microglia have a ramified 
morphology, and are termed “resting microglia”, however in this state, microglia are highly 
dynamic, enabling them to constantly survey their microenvironment through extension and 
retraction of their processes (Nimmerjahn et al. 2005; Davalos et al. 2005).  In this way, 
microglia monitor a defined area of the CNS and respond rapidly to any changes in their 
microenvironment without making physical contact with other cells (Färber & Kettenmann 
2005). Resting  microglia do not  express  the full repertoire of immune receptors seen on 
activated  microglia,  however,  they  do  express  enzymes  implicated  in  the  removal  of 32 
 
neurotransmitters from the  CSF, and  are involved in  maintaining neuronal  function and 
structure (Booth & Thomas 1991; Rimaniol et al. 2000).  
There  has  been  much  debate  over  the  role  of  microglia  in  the  normal  brain  under 
physiological conditions; however, their highly dynamic resting state suggests that their main 
role is in monitoring the CNS for damage. This suggestion has been supported by in vivo 
imaging of GFP - expressing microglia, which has shown that in situ, microglia continuously 
re-organise their processes, enabling them to probe their environment for activating signals 
radiating  from  damaged  neurons  (Davalos  et  al.  2005;  Fetler  &  Amigorena  2005).  The 
signals  responsible  for  this  continuous  remodelling  of  microglial  processes  are  not  well 
understood (Garden & Möller 2006), although microglia are retained in this ramified state by 
a range of neuronal interactions.  
The  interaction  between  the  neuronal  membrane  glycoprotein  CD200  (OX2)  and  the 
microglial  CD200  receptor  (CD200R)  regulates  microglial  activity  (Hoek  et  al.  2000). 
Microglia  are  less  ramified,  aggregated,  and  express  higher  levels  of  immune  receptors 
typically  found  on  activated  microglia  in  CD2000  knockout  mice,  demonstrating  the 
importance of this interaction in microglial quiescence (Hoek et al. 2000). Microglia are also 
actively repressed by electrically active neurons, and the removal of this tonic inhibition 
following  neuronal  damage  leads  to  microglial  activation  (Neumann  2001).  Two  photon 
microscopy  has  revealed  that  microglia  are  present  at,  and  make  contacts  with  neuronal 
synapses approximately once an hour, with each contact lasting around 5 min, and microglia 
make fewer contacts with less active synapses, which promotes microglial activation (Wake 
et al. 2009). Furthermore, the chemokine fractalkine expressed on neurons also regulates 
microglial  activation, and cleavage of fractalkine from  neurons  is  a microglial  activating 
stimulus  which  promotes  chemotaxis  (Chapman  et  al.  2000).  Neurons  therefore  play  an 
important role in microglial activation state.  33 
 
Microglia are activated by a variety of stimuli released from damaged or dying neurons, and 
other cells of the CNS. In response to immunological stimulation, activated microglia exhibit 
an amoeboid morphology enabling increased mobility to sites of neuronal damage (Fig. 1.5). 
Microglial activation is a plastic process, with cells changing from a ramified morphology, to 
a hyper-ramified morphology before finally becoming amoeboid, which facilitates migration 
to  sites  of  neuronal  injury  (Raivich  2005).  Microglia  respond  to  signals  released  from 
damaged neurons, such as adenosine tri-phosphate (ATP) (Booth & Thomas 1991). Microglia 
fail to respond to CNS injury following blockade of ATP signalling, whilst application of 
ATP to microglia induces activation to levels seen during CNS injury (Davalos et al. 2005). 
Furthermore, physical damage to CNS tissue through the formation of lesions or damage to 
blood vessels or the BBB which results in an influx of immune cells from the periphery, also 
promotes microglial activation, and the damage of blood vessels specifically may induce this 
activation through exposure of microglia to blood-derived factors such as thrombin (Möller et 
al. 2000), albumin or leukocytes (Nimmerjahn et al. 2005).  
Activated microglia are characterised by a number of phenotypic and morphological changes. 
A hallmark of microglial activation is the retraction of processes and enlargement of the cell 
body and nucleus, characteristic of the amoeboid morphology (Fig. 1.5). Activated microglia 
also express a number of immune receptors and immunomodulatory proteins such as the 
major  histocompatibilty  complex  II  (MHC  II),  complement  factors,  and  growth  factors 
(Rimaniol  et  al.  2000).  In  addition,  activation  also  promotes  the  release  of  mediator 
substances  such  as  cytotoxic  proteases,  reactive  oxygen  species  (ROS),  reactive  nitrogen 
species (RNS) and glutamate (reviewed in  Block et al.  2007). Microglial activation also 
correlates with proliferation and recruitment of immune cells to the site of neuronal injury, 
and activated microglia also exhibit a phagocytic phenotype (Ling & Wong 1993). 
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Figure 1.5 Microglial activation states. Microglia are found in a resting, highly ramified state where they 
extend  and  retract  their  processes  in  response  to  changes  in  the  microenvironment.  Activation  induces  a 
retraction of processes and the expression of immune receptors and enhances the antigen presenting properties 
of microglia, and also induces the release of mediator substances. Activated microglia can become migratory 
and move to the sites of neuronal injury, or phagocytic, enabling them to engulf pathogens and toxic proteins.  
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Microglial activation can be either protective or toxic (Streit 2002). Activated microglia can 
maintain  and  support  neuronal  survival  by  releasing  trophic  and  anti-inflammatory 
molecules, such as transforming growth factor-β (TGF-β) and interleukin-6 (IL-6) (Boche et 
al. 2006);  removing invading pathogens or toxic products (Liu et al. 2002), and facilitating 
the  guidance  of  stem  cells  to  lesion  sites  to  promote  neurogenesis  (Walton  et  al.  2006). 
However,  microglial  activation  can  also  release  cytotoxic  substances  such  as  NO  or 
peroxynitrite (Colton & Gilbert 1987), superoxide (Chéret et al. 2008), and pro-inflammatory 
cytokines such as interleukin-1β (IL-1β) and tumour necrosis factor-ʱ (TNF-ʱ) (Bruce et al. 
1996). Furthermore, microglial activation can be perpetuated by autocrine pathways, in which 
cytokines released from microglia may enhance microglial activation (Walter & Neumann 
2009).  
1.3  Micrioglial activation in neurodegeneration  
Microglial  activation  is  a  hallmark  of  several  neurodegenerative  diseases,  and  microglial 
reactivity can perpetuate neurodegeneration. In neurodegenerative diseases such as AD, PD, 
MS and ischaemia, microglia are activated by neurotoxic peptides or blood borne proteins. 
Microglial activation is a characteristic of AD pathology, in which the beta-amyloid (Aβ) 
peptide  (which  aggregates  to  form  neurotoxic  plaques)  promotes  a  reactive  phenotype 
(Rogers  et  al.  2002).  This  activation  can  be  both  protective  and  toxic,  as  Aβ  mediates 
microglial phagocytosis of Aβ plaques through activation of complement cascades (Rogers et 
al.  2002),  which  is  initially  seen  as  a  protective  mechanism  to  prevent  further  neuronal 
damage  (Mandrekar-Colucci  &  Landreth  2010),  however,  this  rapidly  induces  a  toxic 
phenotype, inducing microglial proliferation and the release of cytokines such as TNF-ʱ and 
IL-1β  as the disease progresses and Aβ load increases (Jekabsone et al. 2006).  There is 
evidence to suggest that microglial activation by Aβ is mediated through its interaction with 36 
 
scavenger  receptors  (SR)  (Husemann  et  al.  2002),  and  that  this  promotes  a  phagocytic 
response (El Khoury et al. 1996). The involvement of microglial SR in AD has been further 
studied by (Hooper et al. 2009), who show that chromogranin A (CgA), which is highly 
expressed and released in neurites containing Aβ plaques (Pocock & Liddle 2001), activates 
microglia  through  SR,  and  increases  iNOS  expression  which  is  a  hallmark  of  microglial 
activation. Microglia may also be activated in AD through an interaction of Aβ with receptor 
for advanced glycosylation end products (RAGE), which induces the release of ROS and 
neuronal death (Yan et al. 1996);  and microglia are also activated by Aβ binding to the 
Serpin-enzyme complex receptor, which may be neuroprotective through clearance of Aβ 
monomers (Boland et al. 1996).  
Activated microglia are found in the substantia nigra (SN) of patients with PD, where they 
release high levels of superoxide, which contributes to the loss of dopaminergic neurons (Gao 
et  al.  2002).  Microglia  activated  in  this  way  also  release  TNF-ʱ,  IL-1β  and  interferon-γ 
(IFN-γ) (Hirsch et al. 1998). A pathological hallmark of PD is ʱ-synuclein, which is found in 
aggregates in PD brains, and these aggregates are surrounded by activated microglia which 
release superoxide resulting in dopaminergic neuron toxicity seen in PD (Zhang et al. 2005). 
Excess neuromelanin, which is found in dopaminergic neurons, is also a hallmark of juvenile 
and idiopathic PD, also activates microglia. In vitro studies have shown that microglia treated 
with  neuromelanin  from  PD  brains  expressed  and  released  TNF-ʱ,  IL-6  and  NO,  which 
mediate PD pathogenesis (Wilms et al. 2003).  
Activated microglia are also associated with MS lesions, in which the BBB breakdown and 
presence of myelin debris enhances microglial activation and induces the phagocytosis of 
oligodendrocytes and myelin, which contributes to axonal degeneration (Muzio et al. 2007). 
However, whether these activated microglia contribute to disease progression or facilitate re-
myelination is unclear, as some studies suggest that myelination is increased in the presence 37 
 
of microglia activated by zymosan, a potent microglial activator (Setzu et al. 2006) which 
increases  BDNF  expression  thereby  inducing  oligodendrocyte  recruitment  to  lesion  sites 
(Stadelmann et al. 2002).  
Microglia are therefore implicated in both the maintenance of the CNS and also the course of 
neurodegenerative  diseases.  This  dual  effect  makes  microglia  an  attractive  target  for 
therapeutic intervention in diseases in which microglia contribute to disease progression, as 
harnessing their neuroprotective capacity could slow neurodegeneration, and may facilitate 
neuronal repair. Their interaction with the immune system also has important ramifications 
for diseases with a systemic element, making them important targets for future therapies.  
1.4  The immune system  
There are two branches of the immune system, the innate and adaptive responses (Roit et al 
1987). The innate immune system is the first line of defence against external pathogens and 
infection, and is composed of phagocytes such as macrophages, neutrophils, natural killer 
cells and soluble factors such as lysozyme and complement proteins. Activation of the innate 
immune system induces cytokine production, which recruit cells of the adaptive immune 
system to the site of injury (Roit et al 1987).  The adaptive immune system forms the second 
line of defence, and is composed of B and T cells, which enable the body to mount a long 
lasting  immune  response  to  provide  long-lived  specific  immunity  (Roit  et  al  1987). 
Macrophages, such as microglia, link the innate and adaptive immune responses through the 
expression of MHC II, which enables the presentation of antigen to T cells of the adaptive 
immune system, which then promotes antibody production by B cells.  
1.4.1  The brain as an immune privileged organ  
The  brain  has  long  been  considered  an  immunologically  privileged  site  due  to  the 
inaccessibility  of  circulating  immune  cells  to  the  CNS.  This  immune  privilege  is 38 
 
demonstrated by studies showing that tissue grafts into the brain are not rejected by the host 
(Head & Griffin 1985). Furthermore, the brain also fails to mount an immune response upon 
injection  with  mycobacterium  (which  induces  an  aggressive  immune  response  in  other 
organs) (Matyszak & Perry 1998). However, this view has been challenged in recent years, 
and there is now an increasing focus on the brain as an immune-competent organ (Xiao & 
Link 1998). Research shows that brain immunity is a collection of CNS driven mechanisms 
that actively regulate T cell responses within the CNS parenchyma. The CNS can shape 
immune responses by: allowing activated T cells to traffic through the CNS for surveillance 
(Cserr & Knopf 1992); the presence of a lymph- like system (Ransohoff et al. 2003); and the 
activation of endogenous glial cells which participate in innate immune responses (Owens et 
al. 1994). In this way, the brain is now considered to be immunologically active, enabling a 
variety of responses to aid protection against several inflammatory and neurodegenerative 
diseases.  
The brain is separated from the immune system by the BBB, a physical barrier formed of 
endothelial  cells  and  astrocytes  which  prevents  the  entry  of  migratory  cells  and  other 
pathogens to the CNS parenchyma (Ransohoff et al. 2003) (Fig. 1.6). The endothelial tight 
junctions of the BBB prevent the movement of leukocytes across the epithelium, aiding the 
immunological  isolation  of  the  brain.  Furthermore,  the  BBB  prevents  the  movement  of 
solutes into the CNS parenchyma (Ransohoff et al. 2003).  39 
 
 
 
Figure 1.6 The blood brain barrier. The blood brain barrier (BBB) is a physical barrier to prevent the influx of 
toxins and pathogens into the brain parenchyma. It is composed of endothelial cells, contacted by astrocytic end 
feet,  which  form  tight  junctions  that  act  as  a  barrier.  The  BBB  allows  water,  oxygen,  glucose  and  small 
diffusible metabolites to pass through to the CSF, however astrocytes can sense pathogens and a breakdown in 
endothelial cell integrity after infection, which enables the recruitment of microglia and release of immune 
mediators.  
 
The BBB has a regulatory role in the development of an immune response in the CNS. Injury 
to the CNS activates endothelial cells and astrocytes (attached to the BBB via the astrocytic 
end foot), which compromises the integrity of the tight junctions allowing leukocytes to enter 
the brain, where they then mount an immune response promoting inflammation (Wilson et al. 
2010). The cells of the BBB also secrete cytokines and express adhesion molecules, which 
aid the adhesion and penetration of circulating immune cells (Xiao & Link 1998). Regulation 
of the BBB and the loss of integrity of this physical barrier to the CNS therefore promotes 40 
 
other immune and inflammatory responses in the CNS, seen in several neuroinflammatory 
and neurodegenerative conditions.  
The migration of immune cells such as T cells, macrophages and leukocytes is up regulated 
during the inflammatory response in the CNS, which can be caused by a variety of factors, 
such as the Aβ plaques found in AD, and myelin deposits found in MS, in addition to other 
neuroinflammatory mediators, such as oxygen-glucose deprivation seen in ischaemia (Carson 
et al. 2006). The infiltration of these circulating immune cells into the CNS is a key event in 
the progression of neuroinflammatory conditions.  
The interaction between the nervous and immune systems underlies the regulation of immune 
responses in the CNS. There is a bi-directional communication between both systems that 
modulates the immunological  activity  of the CNS  (Haddad 2008), which is  mediated by 
soluble factors such as cytokines, immune cells and endogenous glial cells that have immune 
functions. Cytokines are secreted both by peripheral immune cells and also by astrocytes and 
microglia within the CNS, and in this way, the immune system can direct the CNS to mount 
an immune response, by eliciting the activation of the endogenous immune cells (microglia); 
or the CNS can induce a further immune response, by cytokines promoting a disruption of the 
BBB, thus enabling the infiltration of T cells and B cells into the CNS parenchyma (Haddad 
2008).  Neurons  themselves  also  regulate  brain  immunity  by  maintaining  microglia  in  a 
quiescent  state  (Neumann  2001)  as  discussed  previously.  Neuronal  activity  regulates 
microglial MHC expression, and facilitates the presentation of antigen and the subsequent 
recruitment  of  T  cells  to  the  brain  parenchyma.  Signals  from  damaged  neurons  are  key 
mediators  of  the  microglial  immune  response,  and  are  also  implicated  in  the  cross  talk 
between the nervous and immune systems.  41 
 
There  is  an  important  interplay  between  the  nervous  and  immune  systems,  and  there  is 
evidence to suggest that the CNS regulates its own immune response. In light of this research, 
the  roles  of  immune  cells  both  within  the  CNS  and  also  those  infiltrating  the  CNS 
parenchyma are becoming a focus of investigation in neurodegenerative disease, however, 
here the roles of the endogenous CNS immune cells, the microglia, and the production of 
superoxide as an immune and regulatory mediator is the focus of this research.  
1.5  Reactive oxygen species in the central nervous system  
ROS include superoxide (O2
.-), hydrogen peroxide (H2O2) and the hydroxyl radical (
.OH) 
(Kamata & Hirata 1999), which are produced in neurons and glia by a number of enzymes. 
Microglia produce large amounts of ROS when activated with neurotoxic peptides such as 
Aβ (Wilkinson et al. 2006), myelin, and PD toxins (Gao et al. 2003), therefore microglial 
ROS production is an important hallmark of neuroinflammatory diseases. 
Mitochondria are an important source of ROS, which is produced as a by-product of energy 
metabolism.  During  ATP  production,  oxygen  accepts  a  hydrogen  ion  to  produce  H2O; 
however, a small percentage (<5%) of electrons are leaked (Halliwell, 2001), which leads to 
the  production  of  superoxide.  The  endoplasmic  reticulum  (ER)  is  another  site  of  ROS 
production, where superoxide is generated by the leakage of electrons from the cytochrome 
p450  reductase  (Cross  &  Jones  1991).  Furthermore,  superoxide  is  also  produced  by  the 
hypoxanthine / xanthine oxidase, lipoxygenase, cyclooxygenase, and the nicotine adenine 
dinucleotide phosphate (NADPH) oxidase (Kamata & Hirata 1999), which is the focus of this 
thesis. To counteract the effects of ROS and to maintain the redox state of the cell, cells 
produce anti-oxidants such as glutathione (GSH), which converts hydrogen peroxide to water 
in  conjunction  with  glutathione peroxidase;  superoxide dismutase (SOD), which converts 
superoxide to hydrogen peroxide then water; catalase, which converts hydrogen peroxide to 42 
 
water; and thioredoxin (TRX), which has a redox sensitive dithiol / disulphide that reduces 
hydrogen peroxide and refolds oxidised proteins (reviewed in Kamata & Hirata 1999). The 
maintenance of cellular redox balance is important for cell health and survival, as increased 
ROS production can lead to pathology or disease progression in several neurodegenerative 
disorders.  
1.5.1  Pathology and physiology of ROS and the immune response  
ROS  are  essential  for  the  activation  of  signalling  pathways,  cellular  processes  and  gene 
regulation (Allen & Tresini 2000). The cellular responses elicited by ROS typically modulate 
cytokine,  growth  factor  or  hormone  action  and  secretion;  ion  transport;  transcription; 
neuromodulation; or apoptosis (Allen & Tresini 2000). In this way, physiological levels of 
ROS maintain the cell homeostasis, whilst during pathology, ROS levels are often increased, 
elevating  the  expression  of  apoptotic  genes  and  inflammatory  mediators,  resulting  in 
inflammation, cell death, and disease progression.  
Many proteins implicated in cell survival and signalling are modulated by ROS generated 
under  physiological  conditions.  The  main  target  of  redox  regulation  on  proteins  is  a 
sulphydryl group (RSH) on cystine residues, which can be oxidised to a disulphide bond 
(RSSR),  sulphenic  acid  (RSOH),  sulphinic  acid  (RSO2H),  or  sulphonic  acid  (RSO3H) 
(Kamata & Hirata 1999). Stimulation of cells with ROS often activates signalling cascades 
that are typically activated by growth factors. For example, mitogen activated protein kinase 
(MAPK), protein kinase C (PKC), phospholipase C (PLC), phosphatidyl inositol-3 kinase 
(PI3-K), c-Jun N-terminal kinase (JNK) and intracellular calcium levels are all modulated by 
ROS (Kamata & Hirata 1999). ROS regulation of cell signalling is important for cell survival. 
For example, hydrogen peroxide promotes Akt phosphorylation through its stimulation of the 
PI3-K  pathway  (Konishi  et  al.  1997).  In  addition,  ROS  play  an  important  role  in  lipid 
metabolism,  and  promote  tyrosine  phosphorylation  on  PLCγ,  which  can  hydrolyse 43 
 
phosphatidylinositol 4,5-bisphosphate (PIP2) into Inositol (1,3,5) triphosphate (Ins(1,4,5)P3), 
which mobilises intracellular calcium from the ER (Schieven et al. 1993); and also promotes 
the  production  of  diacylglycerol  (DAG),  which  activates  PKC    (Qin  et  al.  1995).  Both 
calcium and PKC are second messengers used in a variety of pathways, in particular those 
involved in synaptic plasticity and long term potentiation (LTP) (Berridge 1993). ROS are 
also essential for the activity of transcription factors, which are typically implicated in cell 
surivial or apoptosis (Kamata & Hirata 1999).  
Growth factor or cytokine binding to receptors initiates ROS generation, and inhibition of 
ROS  production  following  ligand  binding  attenuates  signalling  pathways  and  cellular 
responses expected from receptor activation (Finkel 2000). In vascular smooth muscle cells 
(VSMC‟s),  catalase  overexpression  inhibits  the  ability  of  platelet  derived  growth  factor 
(PDGF) to phosphorylate tyrosine residues on a number of effector proteins (Sundaresan et 
al. 1995). However, ROS production from such receptor signalling can be detrimental as well 
as  protective,  and  elevated  ROS  production  is  a  hallmark  of  many  neurodegenerative 
diseases.  
ROS are implicated in pathology, and the over-production of ROS, or stimulation through 
overactivation / inhibition of receptors can induce the release of toxic factors and death in 
several cell types. Exposure of cells to inflammatory cytokines or pathogens can enhance the 
expression and activity of ROS producing enzymes, resulting in a redox disequilibrium, and 
oxidative damage. An increase in ROS is seen in AD and PD. In PD, the levels of cytokines 
such as TNFʱ, IL-1β and IFNγ are increased in the SN (Sawada et al. 2006). It is thought that 
these cytokines are originally released from activated microglia and that they may contribute 
microglial ROS production through autocrine and paracrine feedback loops, as stimulation of 
microglia  in  vitro  with  these  cytokines  alone  promotes  superoxide  production  through 
activation  of  the  NADPH  oxidase,  along  with  expression  of  iNOS  and  subsequent  NO 44 
 
production, which in combination form peroxynitrite, a potent neurotoxin (Brown & Bal-
Price 2003; Brown & Neher 2010). Furthermore, the presence of aggregated ʱ-synuclein and 
lewy bodies characteristic of PD promote microglial activation, and subsequent phagocytosis 
of these aggregates by microglia can induce ROS production (Thomas et al. 2007).  
Microglial ROS production is also implicated in AD progression. Aβ activates microglia, and 
induces superoxide production through NADPH oxidase activation (Brown & Neher 2010). 
In  addition,  Aβ also  promotes  microglial  TNFʱ which  feeds  back onto microglial  TNFʱ 
receptors to enhance microglial activation and ROS production (Meda et al. 1995). Activation 
of microglial NADPH oxidase following exposure to pathological substances such as Aβ, ʱ-
synuclein, neurotoxins and cytokines, and subsequent superoxide production also promotes 
the activation of intracellular signalling cascades, such as PKC (Konishi et al. 1997) and 
NF-κB  (Schreck  et  al.  1991)  which  mediates  the  expression  of  pro-inflammatory  genes, 
exacerbating disease pathology. In this way microglial derived intracellular ROS activate 
microglia and enhance pro-inflammatory signalling (Block 2008). In addition, the Nef protein 
of the HIV virus promotes microglial superoxide production which leads to the activation of 
intracellular signalling pathways and subsequent morphological changes consistent with an 
activated  microglial  phenotype  (Sawada  et  al.  2006).  Intracellular  superoxide  production 
therefore regulates microglial activation state and their neurotoxic or neuroprotective roles in 
pathology (Block 2008).  
1.5.2  Production of superoxide by the NADPH oxidase 
The  NADPH  oxidase  (EC  number  1.6.3.1)  is  a  multi-subunit  enzyme  that  produces 
superoxide  through  the  oxidation  of  NADPH  to  reduced  nicotine  adenine  dinucleotide 
phosphate (NADP) and hydrogen (H
+) (Fig. 1.8) (Babior 2000). The NADPH oxidase was 
first  identified  in  phagocytes,  which  exhibit  increased  oxygen  consumption  during 
phagocytosis,  and  produce  an  oxidative  burst  essential  for  defence  against  invading 45 
 
pathogens (Someya et al. 1999; Sheppard et al. 2005; Mander & Brown 2005). NADPH 
oxidase expression has since been shown in microglia where it is implicated in the production 
of intracellular (Chéret et al. 2008; Harrigan et al. 2008) and released (Wilkinson et al. 2006) 
superoxide.  The  structure  of  the  NADPH  oxidase  (Fig.  1.7)  was  first  elucidated  in 
polymorphonuclear  neutrophils  (PMNs),  and  it  is  composed  of  both  cytoplasmic  and 
membrane bound subunits (reviewed in Baboir 2000). The membrane associated subunits 
form the catalytic domain of the enzyme, which is composed of the gp91phox and p22phox 
subunits, a flavin adenine dinucleotide (FAD) which is the NADPH binding site (Segal et al. 
1992), and two haeme groups, one of which binds gp91phox and the other p22phox (Quinn et 
al. 1992). Together, these form the cytochrome b558 subunit, which facilitates the transfer of 
electrons from the NADPH oxidase to the membrane. The FAD and haeme groups of the 
catalytic domain enable electron transfer, and thereby act as a redox pathway (Sheppard et al. 
2005). Studies using FAD deficient NADPH oxidase have revealed that this component is the 
electron carrying intermediate, as removal of this domain inhibits oxidase activity, which 
could also be mimicked by flavin antagonists (Light et al. 1981). The p22phox and gp91phox 
interact through their proline-rich and Src homology 3 (SH3) domains, and gp91phox is a H
+ 
channel, which regulates steady-state FAD reduction (Henderson et al. 1988). Furthermore, 
truncation of the C-terminal of the gp91phox abolishes NADPH oxidase activity, suggesting 
the importance of this subunit in enzymatic activity (Burritt et al. 2003).  46 
 
 
 
Figure 1.7 Superoxide production from the NADPH oxidase. The NADPH oxidase is a multi- subunit enzyme 
composed of the membrane bound gp91phox and p22phox subunits and the cytoplasmic p47phox, p67phox and 
p40phox  subunits.  The  p47phox  and  p67phox  subunits  are  phosphorylated  to  promote  association  with  the 
membrane bound subunits, which is also facilitated by a Rac GTPase. Upon enzyme assembly, the substrate 
NADPH is reduced to NADP + H
+ which enables the production of superoxide from molecular oxygen.  
 
 
The  NADPH  oxidase  is  activated  upon  the  association  of  cytoplasmic  subunits  to  the 
catalytic membrane bound domain (Fig. 1.8). The three catalytic subunits of the classical 
NADPH  oxidase  are:  p47phox,  p67phox  and  p40phox,  which  are  translocated  to  the 
membrane bound domains through the activity of a Rac GTPase (Sheppard et al. 2005).  
Phosphorylation of the p47phox and p67phox subunits promotes their translocation to the 
catalytic membrane bound subunit. The p47phox subunit contains an N-terminal phox (PX) 
domain,  which  targets  the  p47phox  to  PIP3  in  the  membrane  and  the  membrane  bound 
subunits (Kanai et al. 2001; Zhan et al. 2002). Furthermore, phosphorylation of the p47phox 
subunit  allows  direct  association  with  p22phox,  facilitating  the  binding  of  p67phox  and 
p40phox to the cytochrome b558 (Dang et al. 2001). The C-terminus of p47phox contains 
serine  phosphorylation  sites,  which  are  targets  for  phosphorylation  by  PKC  and  MAPK 
(Yamamori et al. 2000). The p67phox is also essential for catalytic activity of the NADPH 47 
 
 
 
Figure 1.8 Assembly of the NADPH oxidase. The cytoplasmic subunits of the NADPH oxidase – the p47phox and 
p67phox subunits are phosphorylated which promotes the recruitment of the p40phox subunit to the p47phox subunit. 
The three cytoplasmic subunits are then translocated to the membrane bound subunits by a Rac GTPase. This then 
enables the production of superoxide through the reduction of NADPH to NADP + hydrogen.  
oxidase. It contains a catalytic NADPH binding site for the transfer of electrons to FAD 
(Cross  &  Curnutte  1995).  Moreover,  phosphorylation  of  p67phox  is  essential  for 
translocation  of  the  p40phox  to  the  membrane  bound  subunits  (Dusi  et  al.  1996).  The 
p40phox  contains  a  PX  domain  which  is  targeted  to  PIP3  in  the  membrane  and  is  also 
phosphorylated by PI3-K (Ellson et al. 2006) and PKC at the N-terminal domain. The onset 
and level of p40phox phosphorylation affects the level of superoxide production (Fuchs et al. 
1997), and p40phox can down-regulate oxidase activity by competing with the SH3 domain 
interactions between the catalytic subunits (Sathyamoorthy et al. 1997).  
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1.5.3  NADPH oxidase isoforms  
Different cell types express different isoforms of the NADPH oxidase, which each have a 
distinct role in the production of intracellular or released superoxide. Many non-phagocytic 
cells  express  the  p22phox  subunit,  however  of  those  studied,  many  did  not  express  the 
classical gp91phox subunit (Nox2), but instead expressed gp91phox homologues, allowing 
the expression of functional isoforms of the NADPH oxidase. Furthermore, these isoforms 
are  also  comprised  of  different  components  of  the  p47phox,  p40phox  and  p67phox 
cytoplasmic  subunits,  which  form  the  classical  Nox2  isoform.  These  different  NADPH 
oxidase isofoms therefore mediate different activities in the cell.  
Human cells express seven gp91phox homologues, or Nox proteins, which are found mainly 
in non-phagocytic cells (Bokoch & Knaus 2003). These are designated Nox1-5, with Nox1 
and Nox4 being structurally similar to Nox2, the classical NADPH oxidase described above 
(Cheng et al. 2001). Nox isoforms have divergent roles during development and ageing, and 
are  expressed  in  different  cells  at  different  developmental  stage.  Nox2  is  expressed  in 
phagocytic cells and is responsible for neutralizing invading pathogens (Baboir 2000). Nox1 
is predominantly expressed in colon endothelial cells and VSMC‟s (Suh et al. 1999), Nox3 is 
found in fetal kidney cells (Kikuchi et al. 2000) and in the inner ear in adults (Bánfi et al. 
2004).  Nox4  is  predominantly  found  in  the  kidney  (Shiose  et  al.  2001),  whilst  Nox5  is 
expressed in the spleen (Cheng et al. 2001). The remaining NADPH oxidase isoforms are 
designated DUOX1 and DUOX2, which are found in the thyroid, and are implicated in host 
defense (Katsuyama 2010). Nox isoforms are also found in the CNS, which will be discussed 
in greater detail.  
There are many signalling cascades that lead to the activation of different Nox isoforms, 
which  can  phosphorylate  the  different  cytoplasmic  subunits  associated  with  each  Nox 49 
 
isoform. The focus here will be on Nox1, 2, and 4, which are central to this thesis. The Nox1 
and Nox2 isoforms can be independently regulated by different signalling molecules (Chéret 
et al. 2008), which is due to their different cytoplasmic components (Fig. 1.9). Nox2 can be 
independently  activated  by  phosphorylation  of  the  p40phox  subunit  via  activation  of  the 
PI3-K  signalling  pathway,  as  demonstrated  in  a  lymphoma  cell  line  (Ha  &  Lee  2004), 
whereas the Nox1 isoform lacks the p40phox subunit, and is preferentially activated by the 
phosphorylation of the p47phox subunit through a PKCδ dependent mechanism (Seshiah et 
al. 2002).  Nox4 differs from Nox1 and Nox2 as it lacks the cytoplasmic subunits (Fig. 1.9), 
and is composed only of the membrane bound catalytic domains and its activity is therefore 
regulated at the transcriptional level (Ellmark et al. 2005). Nox4 activity can however be 
increased  in  smooth  muscle  cells  via  janus  kinase  /  signal  transducer  and  activator  of 
transcripton  (JAK/STAT)  signalling  and  subsequent  transcription  of  the  isoform,  which 
contains an interferon stimulated response element (ISRE) or interferon activated site (GAS) 
element in its promoter region (Manea et al. 2010). Furthermore, studies in endothelial cells 
deprived of serum in the growth medium have shown that Nox4 is also regulated at the 
translational level through p38MAP kinase (p38MAPK) signalling, therefore suggesting that 
the intracellular ROS produced from this isoform may aid cell survival (Peshavariya et al. 
2009). Activation of different isoforms of the NADPH oxidase is therefore dependent on 
different activating stimuli.  
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Figure 1.9 The structure of Nox1, Nox2 and Nox2. Nox1 is comprised of the Nox1 gp91phox homologue 
which  associates  with  the  p22phox  membrane  bound  subunit.  Nox1activity  is  also  dependent  on  the 
association of the p47phox and p67phoxsubunits to the membrane. The classical NADPH oxidase is Nox2, 
comprised of the p22phocx, gp91phox, p47phox, p67phox, and p40phox subunits. Nox4 is comprised of 
membrane bound subunits only, namely the p22phox and Nox4 gp91phox homologue.  
 
1.5.4  NADPH oxidase in the CNS 
Three Nox isoforms – Nox1, Nox2 and Nox4 are expressed in the CNS. Nox2 is expressed in 
microglia, where it is implicated in the inflammatory response (Infanger et al. 2006), and also 
in astrocytes, where it is implicated in superoxide production in response to the HIV Tat 
protein (Song et  al.  2010). Nox1 is expressed in human fetal brain  tissue  (Infangeret  al.  
2006), and in microglia (Chéret et al.  2008), whilst Nox4 is localized to cortical neurons and 
capillaries after ischaemia (Vallet et al. 2005), and has recently been identified in microglia, 
where it promotes glutamate release (Harrigan et al. 2008). In addition to their expression in 
different cell types, the Nox1, 2 and 4 isoforms also have distinct sub-cellular localizations, 51 
 
which regulates the redox environment in different organelles or intracellular vesicles. Nox1 
has  an  intracellular  localisation  and  is  found  on  the  nuclear  membrane  in  keratinocytes 
(Chamulitrat et al. 2003) and on endosomal membranes in vascular cells (Miller et al. 2007), 
and Nox1 is localised to lysosomes in microglia (Chéret et al. 2008). Nox2, the classical 
NADPH  oxidase  is  an  inducible  isoform,  and  is  localised  predominantly  to  intracellular 
phagosomes and at the plasma membrane in microglia (Chéret et al. 2008); in addition, Nox2 
is  localised  to  endosomes,  specifically  those  responsible  for  early  receptor  mediated 
signalling, called redoxisomes (Oakley et al. 2009). Harrigan et al., (2008) have shown that 
microglia  express  Nox4,  however  its  function  and  subcellular  localisation  are  not  well 
characterised,  but  it  is  believed  to  be  implicated  in  intracellular  H2O2  production  and  is 
localised at the ER in other cell types, where it provides the correct redox environment for 
protein folding (Ambasta et al. 2004). The role of these NADPH oxidase isoforms is under 
investigation in the CNS, and the effects of microglial expression of Nox isoforms will be 
discussed in greater detail. 
1.5.4.1  Microglial expression of the NADPH oxidase  
The expression of Nox1, Nox2 and Nox4 (Fig. 1.9) in microglia have distinct physiological 
and pathophysiological roles (Wilkinson & Landreth 2006; Chéret et al. 2008; Harrigan et al. 
2008). ROS, including superoxide, are required to maintain the redox state of microglia, and 
in  this  way  the  NADPH  oxidase  is  essential  for  the  maintenance  of  this  environment. 
However, in certain circumstances, microglia can become activated or exposed to stimuli that 
cause excessive ROS production following activation of the NADPH oxidase, which can be 
detrimental to both the microglia themselves and surrounding neurons and glia. In this way, 
activation of the microglial NADPH oxidase can be damaging to the CNS and is implicated 
in pathology associated with several neurodegenerative diseases.  52 
 
1.5.4.1.1   Microglial NADPH oxidase in physiological conditions  
Each  NADPH  oxidase  isoform  has  a  distinct  cellular  role.  Nox1  is  responsible  for  the 
production of intracellular superoxide, and as such is implicated in cell signalling cascades. 
Activation  of  microglial  Nox1  induces  iNOS  and  IL-1β  expression  (Fig.  1.10),  and  is 
neurotoxic (Chéret et al.  2008). In addition to being one of the key enzymes responsible for 
the production of ROS in the oxidative burst, Nox2 also mediates intracellular signalling 
events, such as those involved in cytoskeletal rearrangements implicated in cell migration 
(Yan  et  al.  1995).  Furthermore,  Nox2  also  mediates  TNF  receptor  associated  factor  2 
(TRAF2)  binding  to  the  TNF-receptor  1  /  TNF  receptor  associated  death  domain 
(TNFR1/TRADD)  complex,  promoting  NF-κB  translocation  and  cell  death  (Shen  et  al. 
2004).  Nox2  derived  ROS  in  microglia  promote  microglial  activation  and  proliferation 
(Jekabsone  et  al.  2006),  release  of  neurotransmitters  (Barger  et  al.  2007),  and  also 
neurotoxicity through the oxidative burst in conditions such as stroke (Block et al. 2007) 
(Fig. 1.10). Activation of microglial Nox4 is implicated in the release of glutamate through 
volume  regulated  anion  channels  (VRAC)  in  microglia  (Harrigan  et  al.  2008),  and  also 
promotes IL-6 expression in human microglial cells (Li et al. 2010). The main role of the 
microglial NADPH oxidase however appears to be in pathology, in which the production of 
ROS are implicated in either neuronal survival or neurotoxicity, depending on the activating 
stimuli and Nox isoform activated.  
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Figure 1.10 Known ramifications of microglial Nox1, Nox2 and Nox4 activation. This schematic 
summarises the activities of the microglial Nox1, Nox2 and Nox4. Nox1 is localized to the ER and 
superoxide released from this NADPH oxidase isoform acts as a signalling molecule to induce iNOS 
expression,  and  subsequent  NO  production,  which  can  react  with  superoxide  to  produce 
peroxynitrite, a potent neurotoxin. Nox1 also induces the expression and release of IL-1β, which is 
neurotoxic. Nox4 has been shown to be localized to the ER in microglia, where H2O2 released from 
this isoform activated voltage sensitive anion channels (VRAC) to induce the release of glutamate. 
Nox2 is expressed on phagosome membranes, where superoxide is released into the phagosome to 
increase acidity to aid degradation of debris. In addition, Nox2 is involved in the oxidative burst, 
releasing superoxide in response to pathogens. Nox2 is also implicated in proliferation, and the 
release of neurotransmitters such as glutamate. Nox2 also has an apoptotic role, whereby TNFα has 
been shown to induce superoxide production from Nox2, which then promotes the association of 
TRAF2  to  the  TNFR1/TRADD  complex,  to promote  NF-κB  mobilization  to  the  nucleus  where  it 
induces cell death.  
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1.5.4.1.2  Microglial NADPH oxidase in pathology 
Superoxide production following activation of the microglial NADPH oxidase is implicated 
in regulating the expression of pro-inflammatory factors, whilst the release of superoxide is 
implicated in the oxidative burst and the removal of invading pathogens. NADPH oxidase 
activation can represent a protective mechanism, however, excessive or aberrant superoxide 
signaling can be detrimental to the survival of microglia themselves, and surrounding neurons 
and  glia.  Microglial  intracellular  superoxide  production  acts  as  a  second  messenger  to 
regulate down-stream signaling pathways, such as PKC (Mander & Brown 2005), MAPK 
(Guyton  et al. 1996) and NF-κB (Schreck et al. 1991). The activation of these signaling 
pathways modulates microglial reactivity, which promotes microglial mediated neurotoxicity. 
Furthermore,  microglial  superoxide  release  is  a  critical  event  in  inflammation  related 
neurotoxicity (Jeohn et al. 1998), which is supported by findings that toxins such as rotenone 
(Gao et al. 2002), paraquat (Wu et al. 2005) and Aβ (Qin et al. 2002) promote or enhance 
neurotoxicity through the generation of superoxide and microglial activation. Furthermore, 
SOD  or  catalase  mimetics,  which  remove  superoxide  or  H2O2  respectively,  reduce  LPS 
induced  dopaminergic  neurotoxicity,  lending  further  evidence  to  the  suggestion  that 
superoxide and H2O2 play a central role in microglial mediated neurotoxicity (Wang et al. 
2004).  
The microglial expression and activity of Nox1 promotes a neurotoxic phenotype. Microglial 
Nox1 is activated by the yeast cell wall component zymosan and the bacterial endotoxin 
lipopolysaccharide (LPS) which promotes  IL-1β and NO release in Nox2 knockout cells, 
suggesting that the production of these neurotoxins is a consequence of Nox1 activity (Chéret 
et al. 2008). Microglial Nox1 is also activated by angiotensin II (AngII), implicating Nox1 in 
vascular  dementia  (Dikalov  et  al.    2008).  Furthermore,  AngII  signalling  through  Nox1 55 
 
activity modulates CNS blood flow through mediating changes in blood preassure, which is 
detrimental to neuronal survival (Infanger et al. 2006). 
Most research into microglial NADPH oxidase has focussed on the activity and expression of 
Nox2, which is implicated in many neurodegenerative conditions. Microglial Nox2 is up-
regulated  in  AD  (Block  2008),  PD  (Gao  et  al.  2003),  ischaemia  (Hur  et  al.  2010)  and 
traumatic brain injury (TBI) (Dohi et al. 2010), and is also implicated in the clearance of 
viruses and bacteria (Ano et al. 2010; Clement et al. 2010). Studies have shown that LPS 
significantly elevates Nox2 induced superoxide production in microglia after 3 h exposure, 
which correlated with an increase in IL-6, IL-1β and TNFʱ production (Clement et al. 2010).  
Previous  studies  have  shown  that  inhibition  of  LPS  binding  to  toll-like  receptors  (TLR) 
prevents ROS production and the release of these inflammatory mediators (Liu et al. 2000). 
In  addition  to  promoting  superoxide  production  through  Nox2  signalling,  initiating 
intracellular signalling cascades through the activation of NF-κB and subsequent cytokine 
release (Zhang et al. 2010), LPS also stimulates iNOS expression and NO production, which 
synergises  with  microglial  NADPH  oxidase  derived  released  superoxide  to  produce  the 
potent neurotoxin peroxynitrite (Brown 2007), and is seen in AD transgenic mice in which 
NO production and Nox2 activation promotes neurotoxicity (Park et al. 2008). In addition to 
activation by bacterial  infection, microglial  Nox2 is  activated in viral infections,  such as 
encephalomyocarditis virus (EMCV), in which microglial production of superoxide causes 
bystander damage to neurons, leading to neuronal death (Ano et al. 2010).  
Microglial Nox2 is heavily implicated in the neurotoxicity associated with neurodegenerative 
disease, and promotes the pathogenesis of inflammatory degenerative conditions such as AD 
and PD. Aβ can activate Nox2, promoting assembly of the functional enzyme, leading to an 
inflammatory phenotype associated with the production of superoxide radicals (Akiyama et 
al. 2000). This is supported by findings that superoxide production following exposure of 56 
 
microglia to Aβ can be attenuated by inhibition of PI3-K (Bianca et al. 1999), shown to 
phosphorylate p40phox which is unique to Nox2 (Ellson et al. 2008). Nox2 activation in AD 
contributes to cytokine release resulting in neuronal apoptosis (Combs et al. 2001), which 
promotes AD progression. Nox2 activation by Aβ leads to the production of intracellular 
ROS, which acts  as a signalling molecule to promote the expression and release of pro-
inflammatory cytokines (Forman & Torres 2002), in particular TNFʱ, which can be abolished 
by the treatment of microglia exposed to Aβ with the NADPH oxidase inhibitor apocynin 
(Jekabsone  et  al.  2006).  Furthermore,  the  release  of  cytokines  such  as  TNFʱ  from  Aβ 
activated  microglia  can  act  on  TNFʱ  receptors  on  microglia  in  an  autocrine  manner, 
promoting further activation of Nox2, and increased microglial reactivity in AD (Mander et 
al. 2006). Further support for the suggestion that microglial Nox2 is implicated in AD comes 
from studies in which treatment of primary microglia with ibuprofen inhibits Aβ stimulated 
tyrosine  phosphorylation  which  promotes  Nox2  assembly,  thereby  attenuating  superoxide 
production and microglial mediated neurotoxicity  (Wilkinson et al. 2010). These data are 
supported  by  epidemiological  studies  demonstrating  that  long-term  non-steroidal  anti-
inflammatory (NSAI) therapy reduces the risk of AD (McGeer et al. 1996). Furthermore, 
studies  have linked the inflammatory microglial response and Nox2 mediated superoxide 
production in AD with neuronal damage in mouse models of AD (Wilkinson et al. 2010), 
thereby suggesting that Nox2 is an important mediator of AD progression.   
Activation of the microglial Nox2 is also associated with PD. Epidemiological studies have 
shown that idiopathic PD is associated with exposure to pesticides (Priyadarshi et al. 2000), 
and  the  herbicide  rotenone  induces  dopaminergic  neuronal  degeneration  (Betarbet  et  al. 
2000).  Furthermore,  rotenone  promotes  microglial  NADPH  oxidase  activation,  which 
increases the oxidative death of neurons in the SN (Gao et al. 2002). Furthermore, rotenone 
induced microglial superoxide production and subsequent neuronal death could be inhibited 57 
 
with the NADPH oxidase inhibitor apocynin, suggesting the involvement of microglial Nox2 
in the death of dopaminergic neurons seen in idiopathic PD (Gao et al. 2002). The neurotoxin 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is also implicated in the pathogenesis 
of PD, and is used as a model of the disease. MPTP elevates gp91phox expression in the SN 
of mouse models of PD, which correlates with increased oxidative damage and neuronal 
death (Wu et al. 2003). Furthermore, in gp91phox knockout mice, injection of MPTP did not 
induce as severe Parkinsonism symptoms as wild type mice, (Wu et al. 2003), and blockade 
of the microglial NADPH oxidase with minocycline also conferred neuroprotection in the 
MPTP model of PD through inhibiting the release of IL-1β (Wu et al. 2002), which is a 
characteristic of Nox1 activation (Chéret et al. 2008), suggesting a role for Nox1 and Nox2 in 
PD. 
In  vitro  studies  have  shown  that  treatment  of  microglia  with  MPTP  enhanced  reactive 
microgliosis in an NADPH oxidase dependent manner, as co-treatment with MPTP and the 
NADPH oxidase inhibitor apocynin significantly reduced microglial reactivity (Gao et al. 
2003). Moreover, this  also  protected dopaminergic neurons  in  co-culture from  microglial 
mediated  death,  suggesting  an  important  role  for  the  microglial  NADPH  oxidase  in 
dopaminergic neuronal death in PD (Gao et al. 2003). The herbicide paraquat, which has 
structural  similarity  to  MPTP,  can  also  induce  idiopathic  PD  (Peng  et  al.  2005)  through 
NADPH oxidase activation and superoxide production in microglia (Bonneh-Barkay et al. 
2005). Studies using BV2 microglia (a murine microglial cell line) have shown that paraquat 
induces microglial extracellular signal regulated kinase (ERK1/2) signalling, which, as part 
of  the  MAPK  pathway,  mediates  phosphorylation  of  the  Nox2  cytoplasmic  subunits  and 
promotes  assembly  of  the  functional  enzyme  and  subsequent  microglial  superoxide 
production and neuronal death (Miller et al. 2007). In support of this, the growth factor TGFβ 
attenuates microglial production of superoxide and Nox2 assembly by inhibition of ERK1/2 58 
 
in  microglia  exposed  to  MPTP  (Qian  et  al.  2008).  These  studies  therefore  implicate  the 
microlglial Nox2 in the progression of idiopathic PD.  
Microglial Nox2 is also implicated in ischaemia and TBI. Nox2 inhibition is protective in in 
vivo  models  of  ischaemia  reperfusion,  in  which  treatment  with  apocynin  or  gp91phox 
knockout mice showed a significantly reduced infarction volume than wild type mice (Chen 
et al. 2009). Furthermore treatment with the NADPH oxidase inhibitor apocynin improved 
the  outcome  of  transient  middle  cerebral  artery  occlusion  in  a  mouse  model  of  stroke, 
supporting the importance of NADPH oxidase in ischaemia (Tang et al. 2008). In addition, 
chemical ischaemia promotes microglial NADPH oxidase activation in vitro, promoting the 
release of neurotoxic factors in an NADPH oxidase dependent manner, as siRNA knock-
down of gp91phox in microglia attenuated this microglial mediated neurotoxicity (Hur et al. 
2010). Mechanistically, it has been determined in vitro that the increase in superoxide release 
from activation of the microglial NADPH oxidase during re-oxygenation after ischaemia is 
due to the influx of calcium ions through voltage gated channels  (Spranger et al. 1998), 
suggesting that microglial production of superoxide may contribute to reperfusion injury. In 
addition to the involvement of Nox2 in ischaemia, microglial reactivity and Nox2 expression 
and  activation  is  up-regulated  in  TBI,  in  which  gp91phox  knock-out  mice  are  protected 
against neuronal damage following injury (Dohi et al. 2010). These data therefore suggest an 
involvement of Nox2 in ischaemia and TBI, and suggest that pharmacological inhibition of 
Nox2 may be protective in these circumstances.  
Nox4 has also more recently been identified in microglia (Harrigan et al. 2008), and there is 
increasing data linking its activity and expression to glioma, ischaemia, and the release of 
inflammatory cytokines following microglial activation in vitro. Microglial Nox4 expression 
is up-regulated following activation with zymosan, which induced superoxide production that 
could  only  be  inhibited  by  the  Nox4  inhibitor  thioridazine  (Harrigan  et  al.  2008). 59 
 
Furthermore,  microglial  Nox4  activation  mediates  glutamate  release  through  VRACs 
(Harrigan et al. 2008), which is implicated in chronic glutamate toxicity to cortical neurons, 
and is associated with several neurodegenerative conditions (Ha et al. 2010). In addition, in 
vitro  studies  using  human  microglia  have  shown  that  Nox4  activity  is  associated  with 
constitutive  generation  of  the  pro-inflammatory  cytokine  IL-6,  which  contributes  to 
neurotoxicity (Li et al. 2009). These studies have suggested that under certain pathological 
circumstances,  the  source  of  NADPH  oxidase  derived  superoxide  could  switch  from  the 
inducible Nox2 isoform to the constitutive Nox4 isoform, which correlates with constitutive 
expression of pro-inflammatory cytokines and increased neurotoxicity, thereby suggesting 
that  NADPH  oxidase  expression  may  contribute  to  the  neurotoxic  or  neuroprotective 
phenotype  of  microglia  (Li  et  al.  2009).  This  switch  between  NADPH  oxidase  isoform 
expression in microglia has also been demonstrated in models of stroke in rats.  Nox4 is 
expressed initially at 6 h post-ischaemia, whilst Nox2 expression is up-regulated from 24 h 
(McCann et al. 2008). Furthermore, most damage following stroke occurs immediately after 
injury,  therefore  supporting  the  suggestion  of  a  neurotoxic  role  for  microglial  Nox4 
expression, and initial Nox4 mediated microglial neurotoxicity followed by a Nox2 mediated 
neuroprotective phenotype (McCann et al. 200). Nox4 expression is up-regulated in gliomas, 
and is implicated in cell proliferation, where Nox4 activation induces pro-survival signalling 
cascades such as Akt (Shono et al. 2008). Research into the involvement of microglial Nox4 
in neurodegeneration is relatively recent, however, the findings outlined here suggest a role 
for Nox4 in mediating signalling involved in survival and the release of cytokines suggests 
that Nox4 may be an important regulator of microglial mediated neurotoxicity or survival.  60 
 
1.6  Neurotransmitter  and  neurotransmitter  receptor  dysregulation  in 
neurodegeneration 
The regulation of neurotransmitter release by activation of neuronal presynaptic receptors is 
fundamental  to  neuronal  communication  (Patel  et  al.  2001).  In  addition  to  their  role  in 
mediating fast neuronal signalling, neurotransmitters themselves can also act as neurotoxic or 
neuroprotective  substances  (Kuhn  et  al.  2004),  and  the  dysregulation  of  neurotransmitter 
release  is  implicated  in  several  neurodegenerative  conditions  (Greenfield  &  Vaux  2002), 
affecting both neurons and the reactivity of surrounding microglia. Glutamate can act as a 
neurotoxic substance, causing neuronal death through excitotoxicity in ischaemia (Choi & 
Rothman 1990), whilst gamma-aminobutyric acid (GABA) is neuroprotective, and in a model 
of white matter anoxia , GABA attenuates neuronal dysfunction through GABAB receptors 
(Fern et al. 1995). Neurotransmitters released during neurodegenerative diseases can act on 
microglia,  which  express  a  wide  repertoire  of  neurotransmitter  receptors  (Pocock  & 
Kettenmann  2007).  Neuronal  stress  seen  in  neurodegeneration  often  leads  to  metabolic 
dysfunction and release of ATP, which activates microglia, promoting chemotaxis to the site 
of neuronal injury (Färber & Kettenmann 2005), in addition to inducing NADPH oxidase 
activation    (Parvathenani  et  al.  2003).  Glutamate  release  from  astrocytes  and  neurons  is 
aberrant in AD and also in acquired immune deficiency syndrome (AIDS) dementia (Rossi & 
Volterra 2009), and  glutamate release from  astrocytes  acts  on microglia to  induce TNFʱ 
release, which has neurotoxic consequences (Bezzi et al. 2001) . GABA is also dysregulated 
during injury, and elevated levels of GABA have been observed in patients with ischaemia, 
TBI or subarachnoid haemorrhage (Hutchinson et al. 2002). Furthermore, GABA can act on 
microglia to modulate the release of interleukins (Kuhn et al. 2004). GABAergic signalling is 
also  dysregulated  in  AD,  and  excess  GABA  in  the  extracellular  space  is  taken  up  by 
microglia leading to their activation (Casamenti et al. 1999). 61 
 
1.6.1  Glutamate  
The excitatory action of glutamate was first recognised by Hayashi (1952), and in the 1970‟s, 
glutamate was established as the main excitatory neurotransmitter in the CNS. Glutamate is 
implicated in development and learning and memory, however, dysregulation of glutamate 
signalling  is  seen  in  neurodegeneration,  and  its  excessive  release  is  a  hallmark  of  acute 
excitotoxic injury seen in stroke and ischaemia, as well as in chronic conditions such as AD. 
Glutamate is released from neuronal pre-synaptic terminals in vesicles in a Ca
2+ dependant 
manner, involving N and P/Q type voltage dependant Ca
2+ channels which are closely linked 
to  vesicle  docking  sites  (Birnbaumer  et  al.  1994).  Released  glutamate  is  taken  up  by 
transporters, or binds to receptors which are expressed on both neurons and glia. Glutamate 
transporters are Na
+ dependant, where one molecule of glutamate is co-transported with three 
Na
+ and one H
+ with the counter-transport of one K
+ (Levy et al. 1998). Five glutamate 
transporters have been identified in the mammalian CNS, two of which are expressed in glia 
(the glutamate aspartate transporter – EAAT1,  and glutamate transporter 1- EAAT2) and 
three in neurons (excitatory amino acid transporter - EAAT1, EAAT4 and EAAT5), which 
are  linked  to  a  Cl
-  channel  which  opens  when  glutamate  binds  leading  to  membrane 
hyperpolarisation  (Meldrum  2000).  There  are  two  classes  of  glutamate  receptor,  also 
expressed on both neurons and glia, namely the ionotropic glutamate receptors (iGluRs) and 
the metabotropic glutamate receptors (mGluRs), which will be discussed in greater detail 
later.  Briefly,  iGluRs  are  ion  channels,  which  are  opened  upon  ligand  binding  and 
depolarisation of the plasma membrane, which facilitates the influx of ions such as K
+, Na
+ 
and  Ca
2+  to  promote  an  action  potential,  or  mediate  down-stream  effects  through  Ca
2+ 
signalling. mGluRs are G-protein coupled receptors (GPCRs), which activate intracellular 
second messengers such as PLC, or adenylate cyclase upon ligand binding, which have a 
diverse range of effects on the cell (Meldrum 2000). 62 
 
Glutamate  dysregulation  is  central  to  several  neurodegenerative  disorders  and  excess 
glutamate release from neurons contributes to acute neurodegenerative conditions such as 
ischaemia and TBI, as well as influencing cell death in chronic conditions such as AD and 
PD. In acute conditions such as stroke, glutamate acting on neuronal N-Methyl-D-aspartic 
acid  (NMDA)  and  2-amino-3-(5-methyl-3-oxo-1,2-  oxazol-4-yl)propanoic  acid  (AMPA) 
receptors  as  well  as  mGluR1  induces  cell  death,  due  to  ionic  disequilibrium  related  to 
excessive  entry  of  Na
+  and  Ca
2+  through  ligand  gated  voltage  channels.  Calcium  influx 
promotes  the  activation  of  apoptotic  signalling  pathways,  such  as  those  inducing  iNOS 
expression,  PLC  activation  and  caspase  cleavage,  inflammation  and  necrotic  cell  death 
(Meldrum & Garthwaite 1990). Chronic and late-onset neurodegenerative conditions may 
also  be  partially  due  to  glutamate  dysregulation.  In  amyotrophic  lateral  sclerosis  (ALS) 
patients, a reduction in the expression of GLT1 has been detected in the spinal cord and in 
brain  regions  showing  a  loss  of  motorneurons  (Rothstein  et  al.  1995).  Furthermore,  a 
contributing factor to Huntington‟s disease (HD) pathology may be metabolic injury that 
causes  striatal  neurons  to  become  vulnerable  to  excitotoxicity  through  NMDA  receptor 
activation, and excessive activation of glutamate receptors in HD also  leads to increased 
glutamate release and reduced uptake by glia, resulting in neuronal death (DiFiglia 1990).  
There have been many studies demonstrating impaired glutamate uptake by glia in disease. 
Fibrillar Aβ (fAβ) impairs glutamate transport, which has been linked to lipid peroxidation 
and release of TNFʱ from microglia (Mattson & Chan 2003), which contributes to neuronal 
death. Furthermore, glutamate concentrations in the CSF of MS patients  are increased in 
comparison to controls, which is also associated with the severity and course of the disease 
(Stover et  al.  1997). Elevated  glutamate CSF levels  are  also  a hallmark of AD, and  Aβ 
induces  microglial  activation  which  mediates  glutamate  release  through  the  reversal  of 
glutamate  transporter  function,  which  is  potentiated  under  pathophysiological  conditions 63 
 
(Noda  et  al.  1999).  Furthermore,  microglia  produce  ROS  under  pathological  conditions, 
which has also been linked with an increase in glutamate concentration in the extracellular 
space, as free radicals inhibit glutamate transporter efficacy, leading to a reduction in the 
uptake and clearance of extracellular glutamate in pathological conditions  (Volterra et al. 
1994). In addition, activation of the microglial Nox4 in pathology induces glutamate release 
which could contribute to disease pathology (Harrigan et al. 2008).  
The regulation of glutamate signalling has great importance in the correct functioning of the 
CNS, and as shown here, dysregulation of this system can have damaging effects. The role of 
glia in the uptake and release of glutamate is also critical for the survival of neurons, and 
when  this  is  aberrant,  the  release  of  glutamate  or  excessive  activation  of  microglia  by 
glutamate can have serious neurotoxic consequences.   
1.6.2  GABA 
GABA is an inhibitory neurotransmitter in the CNS which acts at inhibitory synapses and 
mediates  membrane  hyperpolarisation  or  depolarisation  to  regulate  neuronal  excitability 
(Roach et al. 2008). GABA is responsible for the migration of neuronal and glial precursor 
cells from the neural tube in the developing brain (Marczynski 1998), and also mediates the 
proliferation of neural progenitor cells, and the migration, differentiation and elongation of 
neurites (Sang et al. 2002). GABA is also implicated in the growth of embryonic and neural 
stem cells, through mediating BDNF expression (Wang et al. 2008).  
Dysregulation of the GABAergic system is implicated in several neurodegenerative diseases, 
such  as  AD,  HD  and  also  AIDS  dementia,  in  addition  to  promoting  normal  ageing 
(Greenfield and Vaux 2002). GABAergic and glutamatergic signalling are finely balanced in 
the normal brain, however, during ageing and in patients with AD, neuronal degeneration 
causes  a  reduction  in  ATP,  which  in  turn  increases  the  production  of  glutamic  acid 64 
 
decarboxylase  (GAD),  the  enzyme  responsible  for  GABA  synthesis  from  glutamic  acid, 
leading  to  an  increase  in  GABA  production  in  these  conditions  (Bao  et  al.  1995).  Post-
mortem  analyses  of  AD  brains  have  shown  increases  in  GAD  activity  of  up  to  105% 
(Reinikainen  et  al.  1988),  suggesting  significant  dysregulation  of  glutamatergic  and 
GABAergic  signalling.  Furthermore,  excess  GABA  is  exocytosed  from  neurons  in  AD 
pathology,  which  can  act  on  presynaptic  GABAA  receptors  exacerbating  neuronal  death 
(Marczynski 1998). The increase in GABA tone seen in AD lowers brain metabolic function, 
resulting in further neuronal loss and neurodegeneration (Marczynski 1998). Furthermore, in 
vitro studies have shown that chronic treatment of neurons with GABA, mimicking the effect 
of the increased GABA tone in AD, increased neuronal vulnerability to glutamate toxicity 
(Erdö  et  al.  1991).  Increased  GABA  activity  is  therefore  detrimental  in  chronic 
neurodegenerartive conditions.  
There  are  few  reports  regarding  the  effect  of  GABA  on  microglia  and  subsequent 
ramifications  for  neuroinflammation  or  neurodegeneration.  However,  microglia  express 
functional GABAB receptors (Kuhn et al. 2004), and also respond to the GABAA receptor 
agonist muscimol (Cheung et al. 2009). GABA has been reported to be neuroprotective by 
attenuating neuronal dysfunction, and may also be protective through interactions with the 
microglial GABAB receptor (Kuhn et al. 2004).  
1.6.3  ATP 
ATP  is  a  key  metabolite  in  all  cell  types.  It  is  a  multifunctional  nucleotide  used  as  a 
coenzyme, and is required for energy transfer in the mitochondrial electron transfer chain. 
ATP is also a substrate in signal transduction pathways and is converted into the second 
messenger cyclic AMP  (cAMP) by adenylate cyclase.  In the CNS, ATP  is an  excitatory 
neurotransmitter,  which  was  first  described  in  1959,  when  it  was  shown  that  ATP  was 
released from nerves upon stimulation (Holton 1959). Furthermore, Holton(1959) showed 65 
 
that  ATP  could  be  co-released  with  noradrenaline  from  sympathetic  nerve  endings,  and 
Burnstock (1972) confirmed that ATP is synthesised and stored in presynaptic terminals, is 
released  upon  nerve  stimulation,  can  be  rapidly  degraded  by  coenzymes,  and 
pharmacological  agents  used to  inhibit the effects  of endogenous  ATP  can also  suppress 
nerve  stimulation.  The  excitatory  action  of  ATP  was  determined  by  (White  1978),  who 
showed ATP release from synaptosomes could be induced by high extracellular potassium 
concentrations, and also that depolarisation of synaptosomes lead to ATP release. Addition of 
ATP  to  cultured  dorsal  horn  neurons  also  induced  depolarisation,  further  confirming  the 
excitatory action of ATP (White, 1978).  
ATP mediates neuronal-glial interactions, and is released from both neurons and glia (North 
& Verkhratsky 2006).  Glia and neurons  express  both  metabotropic (P2Y) and ionotropic 
(P2X) purinergic receptors, which elicit a variety of effects. The ability of neuronal derived 
ATP  to  act  on  glial  cells  enables  glia  to  respond  to  neuronal  activity.  Astrocytes  and 
oligodendrocytes respond to ATP through the metabotropic P2Y purinergic receptors, which 
facilitates the release of intracellular calcium and glial reactivity (Verkhratsky et al. 1998). 
Microglia express both P2Y and P2X receptors, and predominantly respond to ATP released 
from damaged neurons or glia (Möller et al. 2000).  
ATP has a wide ranging action on neurons and glia, and modulates neurite outgrowth, glial 
cell proliferation, microglial activation and induction of glial scar formation (Neary 1996). 
Under  non-pathological  conditions,  ATP  is  present  in  the  CNS  at  the  synaptic  cleft  at 
concentrations of 100 µM (Silinsky 1975), however levels increase during neuronal damage, 
ischaemia and hypoxia (Rathbone et al. 1999), and microglia respond to ATP levels of 1 mM, 
which acts at the ionotropic P2X7 receptor with neurotoxic consequences (Parvathenani et al. 
2003). Local increases in ATP concentrations at sites of neuronal injury induce microglial 
reactivity through the activation of a cation conductance mediated by P2X receptors, and with 66 
 
a delayed activation of an outward directed potassium current mediated by P2Y receptors 
(Walz et al. 1993).  
In  pathological  conditions,  neuronal  release  of  ATP  into  the  microenvironment  induces 
microglial  activation  and  pathology,  such  as  the  production  and  release  of  superoxide 
(Parvathenani et al. 2003). Application of  1 mM – 5 mM ATP to microglia induces TNFʱ 
release in a calcium dependant manner triggered by ERK and JNK signalling (Hide et al. 
2000), and also induces IL-1β release (Takenouchi et al. 2009), which is neurotoxic (Färber 
&  Kettenmann  2006).  Exposure  of  microglia  to  high  levels  of  ATP  is  implicated  in  the 
progression  of  neurodegeneration  and  neuroinflammation,  and  increased  levels  of  ATP  
induce  the  release  of  microglial  response  factor  1  (MRF-1),  which  is  a  177  amino  acid 
peptide up-regulated in response to neuronal death, which mediates a variety of microglial 
actions (Tanaka & Koike 2002); furthermore, microglial production of the endocannabinoid 
2-arachidonylglycerol  (2-AG)  is  increased  upon  exposure  to  ATP,  which  mediates 
neuroinflammation  (Färber  &  Kettenmann  2006).  In  addition,  prolonged  exposure  of 
microglia to ATP results in microglial necrosis, whilst acute exposure favours microglial 
proliferation (Takenouchi et al. 2009). It should however be stressed that only high levels of 
ATP induce microglial activation and a neurotoxic phenotype. Microglia stimulated with low 
levels  of  ATP,  in  the  range  of  30-50  μM  release  neuroprotective  moieties  such  as 
plasminogen and other neurotrophic factors (Inoue 2002). 
Physiological concentrations of ATP mediates microglial proliferation and chemotaxis and is 
neuroprotective (Honda et al. 2001). Furthermore, ATP regulates the movement of microglial 
fine processes in the resting state, as shown by injection of ATP into the thinned skulls of 
mice and the imaging of GFP tagged microglia, which exhibited a rapid chemotactic response 
(Davalos et al. 2005). Microglia can sense astrocyte activity through purinergic receptors, and 
calcium waves propagated in astrocytes can induce potassium currents in microglia, which 67 
 
mimicked  the  response  to  P2Y  receptor  activation  (Schipke  et  al.  2002).  In  this  way, 
microglia  use  ATP  to  sense  changes  in  their  microenvironment,  and  can  respond  to 
pathological changes in ATP levels seen in areas of neuronal death, and also to physiological 
concentrations to promote neuroprotection and the release of neurotrophic factors.   
1.6.4  Neurotransmitter  receptor  modulation  of  microglial  activation  in 
neurodegeneration and involvement of ROS 
Microglia  express  a  range  of  neurotransmitter  receptors,  and  respond  to  a  variety  of 
neurotransmitters, inducing the release of neuroprotective or neurotoxic factors (Pocock & 
Kettenmann  2007).  As  microglia  lack  synaptic  structures,  neurotransmitters  modulate 
microglial reactivity through a model of „volume transmission‟ (Agnati et al. 1995), in which 
neuro-active substances diffuse throughout the extracellular space to activate extrasynaptic 
receptors  (Pocock  &  Kettenmann  2007).  Neurons  express  neurotransmitter  receptors  at 
extrasynaptic regions, and the action of neurotransmitters on these extrasynaptic receptors has 
important roles in the regulation of the neural network, however, neurotransmitters released 
into  the  extracellular  space  may  also  activate  microglial  neurotransmitter  receptors,  with 
consequences for microglial reactivity (Pocock & Kettenmann 2007).    
Modulation  of  neurotransmitter  receptors  on  microglia  has  a  wide  range  of  effects  on 
microglial  reactivity  (Table  1),  and  cytokine,  chemokine  and  ROS  production.  Microglia 
express glutamate, GABA and purinergic receptors of both the ionotropic and metabotropic 
subclasses,  in  addition  to  adenosine,  cholinergic,  cannabinoid,  adrenergic,  dopamine  and 
opioid  receptors,  as  well  as  neuropeptide  receptors  (reviewed  in  Pocock  &  Kettenmann 
2007). The main focus of this thesis however is on glutamatergic, GABAergic and purinergic 
receptor  modulation  on  microglial  activation  and  superoxide  production,  which  will  be 
described in more detail.  68 
 
The modulation of microglial metabotropic glutamate receptors has a diverse range of effects 
on  microglial  reactivity  and  the  surrounding  environment.  Microglia  express  the  group  I 
mGluR1 and mGluR5a receptors (Table 1), which couple to Gq proteins, and promote PLC-
1β activation, resulting in DAG and Ins-1,4,5-P3 production, followed by PKC activation and 
the  opening  of  IP3  gated  calcium  channels  on  the  ER,  leading  to  a  rise  in  intracellular 
calcium, which has a wide range of downstream effects (Ribeiro et al. 2010).  
There  are  scant  data  regarding  the  role  of  mGluR  group  I  modulation  on  microglial 
activation, however treatment of microglia with the mGluR5 specific agonist trans-(1S,3R)-1-
Amino-1,3-dicarboxycyclopentane  (ACPD)  elevates  intracellular  calcium  concentrations 
(Biber et al. 1999). Microglial group I mGluR expression is modulated in neuropathology. 
Microglial mGluR5 expression is down-regulated in the MS brain (Geurts et al. 2003), which 
may contribute to disease progression. Furthermore, microglial mGluR5 activation attenuates 
NADPH oxidase activity and expression of the p22phox and p47phox subunits, and also 
reduces  LPS-generated ROS production (Loane et al. 2009), in addition to inhibiting the 
release  of  LPS-stimulated  pro-inflammatory  mediators  such  as  TNFʱ  and  NO,  thereby 
suggesting  that  activation  of  mGluR5  may  down-regulate  microglia  with  neuroprotective 
consequences  (Farso  et  al.  2009).  This  mGluR5  mediated  inhibition  of  NADPH  oxidase 
activity also attenuated MAPK, NF-κB and STAT1 signalling, thereby down-regulating the 
expression and release of inflammatory modulators (Loane et al. 2009). Furthermore, in vivo 
models of rat spinal cord injury demonstrate that treatment with the mGluR5 agonist (RS)-2-
Chloro-5-hydroxyphenylglycine  (CHPG)  enhanced  recovery  through  down-regulation  of 
NADPH oxidase activity when compared with untreated controls (Byrnes et al. 2009). These 
data  therefore  suggest  that  activation  of  the  microglial  group  I  mGluRs  could  promote 
neuroprotection through reducing microglial reactivity and superoxide production.  69 
 
Microglia  also  express  the  group  II  and  III  mGluRs,  which  are  negatively  coupled  to 
adenylate  cyclase  (Table  1).  Of  the  group  II  receptors,  microglia  express  mGluR2  and 
mGluR3 (Taylor et al. 2002; Taylor et al. 2005), and mGluR3 activation is protective and 
down-regulates  microglial  activation  (Taylor  et  al.  2005).  However,  microglial  mGluR2 
activation  is  neurotoxic,  mediating  microglial  stress  characterised  by  mitochondrial 
depolarisation and TNFʱ and Fas ligand release, which induce neuronal caspase 3 activation 
and subsequent apoptosis through binding to TNF receptor 1 (TNFR1) (Taylor et al. 2005). In 
addition, activation of microglia with CgA and Aβ induce glutamate release from microglia 
(Kingham et al. 1999), which feeds back onto microglial group II mGluRs to exacerbate the 
release of neurotoxic factors (Taylor et al. 2002). Furthermore, activation of microglial group 
II mGluRs enhances CgA mediated neuronal death, which could be attenuated by group II 
mGluR inhibition, suggesting that modulation of this receptor promotes the production and 
release  of  neurotoxic  substances  in  AD  (Taylor  et  al.  2002).    The  microglial  reactivity 
observed during AD promotes glutamate release at concentrations that can feedback onto 
microglial group II mGluRs, which exacerbates microglial mediated neurotoxicity.  
Modulation of the microglial group II mGluRs is implicated in MS, and myelin induced 
microglial neurotoxicity can be exacerbated by modulation of group II mGluRs. Stimulation 
of microglia with (2S,2'R,3'R)-2-(2',3'-Dicarboxycyclopropyl)glycine (DCG-IV) (a group II 
agonist) is neurotoxic, however neurotoxicity following exposure of microglia to myelin was 
also enhanced by co-exposure of microglia to the group II mGluR agonist (Pinteaux-Jones et 
al. 2008). Furthermore, this neurotoxicity could be reduced upon treatment of microglia with 
myelin and the group II mGluR antagonist (RS)-ʱ-Methyl-4-carboxyphenylglycine (MCPG) 
suggesting a role for the group II mGluRs in MS disease progression (Pinteaux-Jones et al. 
2008). There are however differing reports regarding the role of the group II mGluRs in in 
vivo models of PD. Injection of DCG-IV into the striatum of MPTP treated rats elevates 70 
 
BDNF  expression  in  reactive  microglia  close  to  the  injection  site,  which  protected 
dopaminergic terminals against neurotoxicity (Venero et al. 2002). These findings suggest a 
protective role for group II mGluR activation, however the concentrations used and the in 
vivo  nature  of  this  model  may  account  for  the  differences  between  this  and  the  in  vitro 
findings with this agonist.  
Microglia  express  mGluR4,  mGluR6  and  mGluR8  of  the  group  III  subclass  of  mGluRs 
(Table 1), which respond to a higher level of glutamate than the group II receptors (Pin & 
Duvoisin 1995). Activation of these receptors is also negatively coupled to adenylate cyclase, 
is neuroprotective, and can attenuate the neurotoxicity seen following treatment of microglia 
with the mGluR group II agonists (Taylor et al. 2003). In vivo studies of MS lesions have 
shown that mGluR8 is up-regulated in microglia surrounding active, de-myelinating lesions, 
suggesting that microglial group III mGluRs may be implicated in MS progression (Geurts et 
al. 2005). The nature of these studies does not indicate whether mGluR8 up-regulation is 
protective or toxic, however, taken together with in vitro evidence, it could be suggested that 
mGluR8 expression and activity may be protective, and could represent an attempt to limit 
microglial toxicity and protect oligodendrocytes from glutamate toxicity (Geurts et al. 2005). 
In support of this suggestion, activation of the microglial group III mGluRs promotes the 
release of neurotrophic factors in a PKC dependent manner, which is neuroprotective (Liang 
et al. 2010).  
Microglia  also  express  subunits  of  the  ionotropic  glutamate  receptor  subclass,  including 
subunits of the AMPA and NMDA receptors (Table 1). The predominant functional iGluR 
expressed in microglia is the AMPA receptor, and microglia express the GluR2 – GluR4 
subunits (Noda et al. 2000). Little is known about the role of microglial AMPA receptors in 
neurodegenerative disease, however GluR4 subunits are up-regulated in microglia in the CA1 
region  of  the  hippocampus  after  transient  forebrain  ischaemia  in  the  rat,  although  the 71 
 
ramifications of this are yet to be determined (Gottlieb & Matute 1997). Microglial AMPA 
receptor activation mediates TNFʱ release, which could be attenuated by inhibition of the 
AMPA receptor with the antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (Noda, 
2000). As microglial TNFʱ release can be neurotoxic, it could be suggested that activation of 
the microglial AMPA receptors may promote neuronal death, and it has been shown that 
microglial AMPA induced TNFʱ release is toxic to oligodendrocytes (Merrill & Benveniste 
1996).  
Microglia also express NMDA receptor subunits, and resting and hypoxic rat microglial cells 
in vitro express the NR1, NR2A, NR2B, NR2C, NR2D and NR3A subunits (Murugan et al. 
2011). Furthermore, NMDA receptors expressed on activated microglia are functional, as 
demonstrated  by  an  increase  in  intracellular  calcium  upon  treatment  with  glutamate  and 
glycine, which could be attenuated by addition of the open channel blocker (5R,10S)-(-)-5-
Methyl-10,11-dihydro-5H-dibenzo[a,d]cylcohepten-5,10-imine-maleate (MK-801) (Murugan 
et  al.  2011).  The  microglial  NMDA  receptor  is  also  up-regulated  after  ischaemia,  which 
promotes  the  translocation  of  NF-κB  to  the  nucleus,  resulting  TNFʱ,  IL-1β  and  iNOS 
expression (Murugan et al. 2011). Furthermore, in vivo studies have shown that the NR1 
subunit of the NMDA receptor is up-regulated following ischaemic stroke in rats. Treatment 
of  microglia  with  NMDA  also  increases  the  expression  of  neurotrophic  factors  such  as 
BDNF, glial derived neurotrophic factor (GDNF) and NGF, in a PKC dependant manner 
(Noda et al. 1999; Liang et al. 2010). Production of these neurotrophic factors also promotes 
microglial  glutamate  release,  which  can  feedback  onto  these  cells  and  activate  other 
glutamate receptors, or promote excitotoxicity (Matute et al. 2006), however this has not yet 
been investigated in great detail. The ramifications of microglial NMDA receptor activation 
therefore requires further investigation.  72 
 
Microglia respond to GABA, and express the G-protein coupled GABAB receptors (Charles 
et al. 2003; Kuhn et al. 2004), however, they are also responsive to treatment with the ligand 
gated  GABAA  agonist  muscimol  (Synowitz  et  al.  2001)  (Table  1).  Immunocytochemisty 
revealed that activated microglia (detected by ED1 immunoreactivity) expressed GABAB1a, 
GABAB1b and GABAB2 subunits, which sense extracellular GABA to potentiate inhibitory 
signals (Charles et al. 2003). However, immunocytochemisty showed that a high proportion 
of GABA immunoreactivity in microglia was concomitant with  intracellular compartments 
and the nucleus, suggesting a role for GABA in the control of transcription, as the C-terminal 
tail of GABAB receptors interacts with the nuclear transcription factors ATF-4 (Vernon et al. 
2001)  and  CREB-2  (White  et  al.  2000).  Activation  of  microglial  GABAB  receptors  may 
therefore activate transcription factors responsible for the induction of microglial reactivity 
(Charles et al. 2003). This suggestion is supported by findings that activation of the GABAB 
receptor on microglia modulates interleukin release (Kuhn et al. 2004). In vivo studies of the 
axotomized  facial  nucleus  have  shown  elevated  GABAB  receptor  expression  in  reactive 
microglia,  and  that  these  receptors  are  active,  as  treatment  with  the  agonist  3-
Aminopropyl(methyl)phosphinic acid (SKF-97541) transiently elevates intracellular calcium 
levels, that could be reversed by co-treatment with the antagonist baclofen (Kuhn et al. 2004). 
However, in contrast to the studies of Charles et al. (2003), GABAB receptors have also been 
found  at  microglial  lamellaepodia  (Kuhn  et  al.  2004),  and  the  resulting  activation  of 
microglial GABAB receptors could attenuate LPS induced IL-6 and IL-12p40 release, thereby 
suggesting  that  microglial  GABAB  receptors  modulate  the  inflammatory  properties  of 
microglia (Kuhn et al. 2004). This is in line with reports that GABA is neuroprotective, and 
in  vivo  models  have  demonstrated  that  GABA  attenuates  neuronal  dysfunction  through 
GABAB receptors (Fern et al. 1995). The findings that activated microglia express GABAB 
receptors  and  that  these  receptors  may  be  localised  to  the  nucleus  and  subsequent 73 
 
transcription factors may suggest that activation of the microglial GABAB receptor correlates 
with a neuroprotective phenotype, modulating the inflammatory response by down-regulating 
the release of inflammatory cytokines and protecting against neuronal death.  
Microglia  are  also  sensitive  to  GABAA  receptor  agonists  and  antagonists,  however  the 
existence of functional receptors is yet to be determined, and the GABAA receptor may only 
be expressed during pathology (Synowitz et al. 2001). Cells from glioma lines express high 
levels of the GABAA receptor after injection into the rat brain, suggesting that microglial 
GABAA receptor expression may be modulated by the microenvironment (Synowitz et al. 
2001). Furthermore, only glioma cells grown in direct contact with CGCs showed a GABA 
response, and microgial GABAA receptor activation induced a chloride current and a long 
lasting blockade of potassium current, suggesting that activation of the GABAA receptor may 
down-regulate the microglial response (Synowitz et al. 2001). Activation of the microglial 
GABAA receptor with muscimol enhances the release of macrophage inflammatory protein-
1ʱ (MIP-1ʱ), a chemokine implicated in acute inflammation (Cheung et al. 2009), superoxide 
production and oxidative stress (Louboutin et al. 2010). Furthermore, modulation of GABAA 
receptors also induces ROS production through Nox4, and subsequent expression of matrix 
metalloproteinase  9  (MMP9)  which  mediates  BBB  dysfunction  allowing  the  influx  of 
macromolecules to the CNS, which is seen in ischaemia (Tyagi et al. 2009). 
Microglia express purinergic receptors of both the metabotropic (P2Y) and ionotropic (P2X) 
subtype  (Table  1)  (Pocock  &  Kettenmann  2007).  Activation  of  microglial  purinergic 
receptors promotes migration and cytokine release (Davalos et al. 2005), and activation of 
P2Y  receptors  modulates  membrane  ruffling  and  chemotaxis  (Honda  et  al.  2001),  whilst 
activation of the P2X receptors results in TNFʱ release (Suzuki et al. 2004), and stimulation 
NADPH oxidase derived superoxide production (Parvathenani et al. 2003).  74 
 
RT-PCR analysis has shown that BV2 and primary microglia express P2Y1, P2Y2, P2Y6, 
P2Y12  and  P2Y13  (Brautigam  et  al.  2005;  Crain  et  al.  2009).  P2Y  receptors  respond  to 
different  purines;  the  P2Y1,  P2Y12  and  P2Y13  receptors  are  preferentially  activated  by 
adenosine  diphosphate  (ADP),  whilst  P2Y6  receptor  is  activated  by  uridine  diphosphate 
(UDP) and P2Y2/4 is activated by ATP and uridine triphosphate (UTP) (Seo et al. 2008). The 
P2Y12 receptor is implicated in microglial migration through adenylate cyclase activation 
which mediates morphological changes in microglia enabling them to respond to and migrate 
to sites of neuronal injury (Haynes et al. 2006). It has, however, been shown that microglial 
activation by LPS down-regulates P2Y12 receptor expression, whereas in the facial nerve 
axotomy model of microglial activation P2Y12 receptor expression is up-regulated, therefore 
suggesting that the induction of microglial motility through the P2Y12 receptor is specific to 
activation of microglia  by nucleotides rather than toxic peptides (Haynes et al. 2006). This 
has been further supported by findings that in P2Y12 deficient mice, microglial membrane 
ruffling did not occur upon application of ADP or ATP, and microglia did not respond to 
local tissue damage resulting from laser ablation in these models, suggesting that the P2Y12 
receptor is the primary receptor implicated in microglial chemotaxis (Haynes et al. 2006).  
Microglial  phagocytosis  is  mediated  through  P2Y6  receptor  activation  with  UDP,  which 
promotes activation of the PLC signalling pathway and a mobilisation of intracellular calcium 
(Koizumi et al. 2007). In the injured brain, particularly following excitotoxicity, UDP and 
UTP are released into the extracellular space and are taken up by microglia through P2Y6 
receptors (Kim et al. 2011). It has been shown that kainic acid increases extracellular UTP 
concentration  to  over  20  times  normal  levels  (Lazarowski  &  Harden  1999)  which  also 
elevates extracellular UDP, as UTP is converted to UDP by ectonucleoside diphosphokinase 
(Zimmermann 2000). UDP acting on microglial P2Y6 receptors induces the expression of the 
chemokines  CCL2  and  CCL3,  and  UDP  acting  on  astrocytic  P2Y6  receptors  aids  the 75 
 
recruitment of blood monocytes and microglia to sites of injury (Kim et al. 2011). Little is 
known  about  the  ramifications  of  microglial  P2Y2/4  receptor  activation,  however,  these 
receptors could be involved in the release of intracellular calcium, as they are coupled to 
PLC-1β  signalling,  which  induces  the  opening  of  IP3  gated  calcium  channels  on  the  ER 
(Wang et al. 2000).  
Microglia express the P2X4 and P2X7 receptor subtypes (Pocock & Kettenmann 2007). The 
microglial P2X4 receptor is implicated in chemotaxis and pain pathways, and its expression is 
up-regulated in microglia of the spinal cord after nerve injury (Inoue 2006). Furthermore, 
P2X4  receptor  up-regulation  maintains  allodynia  in  rats  injected  with  ATP  activated 
microglia, suggesting that these activated microglia release ATP which acts at P2X4 receptors 
to promote activation of pain pathways (Inoue 2006). The P2X7 receptor differs from the 
other  P2X  receptors,  in  that  its  transient  activation  induces  the  opening  of  a  large  pore, 
permeable  to  molecules  of  up  to  900  Da  (Skaper  et  al.  2010).  Furthermore,  it  is  also 
implicated  in  TNFʱ  release  (Suzuki  et  al.  2004),  and  in  superoxide  production  through 
activation of the NADPH oxidase (Parvathenani et al. 2003). The P2X7 receptor is activated 
by  higher  concentrations  of  ATP  (1 mM),  which  are  released  from  neurons  following 
neuronal injury (Pocock & Kettenmann 2007). ATP is the only known activator of the P2X7 
receptor, and microglial P2X7 receptor activation after LPS treatment induces the release of 
IL-1β through a MAPK signalling cascade (Skaper et al.  2010). Furthermore, microglial 
P2X7  receptor  activation  is  implicated  in  IL-6  production,  as  demonstrated  with  P2X7 
knockout mice which do not produce IL-6 in response to treatment with ATP (Sperlágh & 
Illes 2007).   
Activation of the microglial P2X7 receptor is  both protective and damaging, and regulation of 
the production of protective molecules such as plasminogen, TNFʱ and the endocannabinoid 
2-AG;  or  toxic molecules  such  as  IL-1β  and  NO  could  follow  a  time and  concentration 76 
 
dependant  pattern,  with  the  production  of  protective  molecules  occurring  at  earlier  time 
points  (Inoue  2002a).  The  P2X7 receptor  is  implicated  in  neurodegenerative  disease,  and 
studies using AD transgenic mice have shown that the P2X7 receptor is up-regulated in these 
conditions, which correlated with an increase in superoxide production in these animals in an 
NADPH oxidase dependent manner (Parvathenani et al.  2003). Furthermore, in microglia 
pre-treated with Aβ followed by application of ATP, a significant increase in IL-1β, IL-1ʱ 
and IL-18 was also observed, suggesting a link between P2X7 receptor activation and AD 
(Sperlágh & Illes 2007).  
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Receptor  Activity  Expression 
Group I mGluRs: 
mGluR1 and 
mGluR5a 
Gq coupled. Promote PLC-1β activation and opening of 
IP3  gated  intracellular  calcium  stores.  Modulation  of 
microglial  group  I  mGluRs  affects  superoxide 
production.  
Expressed  in  vivo 
(Geurts  et  al.  2003; 
Ribeiro  et  al.  2010) 
and in vitro (Loane et 
al. 2009). 
Group II mGluRs: 
mGluR2 and 
mGluR3 
Gi/0 coupled. Negatively coupled to adenylate cyclase. 
Microglial  mGluR3  activation  is  neuroprotective, 
whilst mGluR2 activation is toxic.   
Expressed  in  vivo 
(Venero  et  al.  2002) 
and in vitro (Taylor et 
al. 2002; 2005).  
Group III mGluRs: 
mGluR4, mGluR6, 
mGluR8 
Gi/0 coupled. Negatively coupled to adenylate cyclase. 
Microglial  Group  III  mGluR  activation  is 
neuroprotective.   
Expressed  in  vivo 
(Geurts  et  al.  2005) 
and in vitro (Taylor et 
al. 2003). 
AMPA receptor  Ionotropic glutamate receptor – mediates Ca
2+, 
 Na
+, 
and  K
+  influx.  Modulates  TNFʱ  release  from 
microglia.  
Expressed  in  vivo 
(Gottlieb  &  Matute 
1997),  and  in  vitro 
subunits  (Noda  et  al. 
2000).  
NMDA receptor  Ionotropic glutamate receptor – mediates Ca
2+ influx. 
Modulates  PKC  activation  and  the  release  of 
neuroprotective factors.  
Expressed in vivo and 
in  vitro  (Murugan  et 
al. 2011).  
GABAA receptor  Ionotropic  GABA  receptor.  Mediates  a  Cl
- 
conductance, inhibits neurotransmission. In Microglia, 
mediates  the  release  of  MIP-1ʱ  and  enhances 
inflammation.   
Expressed  in  vitro 
(Synowitz et al. 2001). 
No evidence of in vivo 
expression to date. 
GABAB receptor  Metabotropic GABA receptor. In microglia stimulates 
the activation of a K
+ conductance and attenuates the 
nflammatory response.  
Expressed  in  vivo 
(Vernon  et  al.  2001), 
and in vitro (Charles et 
al. 2003).  
Ionotropic P2X 
receptors:  
P2X7, P2X4 
Ionotropic  P2X  receptors  promote  elevated  K
+ 
conductance  and  Ca
2+  influx.  In  microglia,  P2X4 
activation  regulates  membrane  ruffling  and 
chemotaxis, whilst P2X7 receptor activation promotes 
superoxide production.  
Expressed  in  vivo 
(Inoue  2006)  and  in 
vitro  (Parvathenani  et 
al. 2003).  
Metabotropic P2Y 
receptors: 
P2Y1, P2Y2/4, 
P2Y2, P2Y12 and 
P2Y14 
Metabotropic P2Y receptors elevate intracellular Ca
2+ 
levels  via  a  Gq  and  PLC-1β  pathway.  Activation  of 
microglial  P2Y  receptors  mediates  the  movement  of 
fine processes and chemotaxis.  
Expressed  in  vivo 
(Kim et al. 2011) and 
in  vitro  (Brautigam  et 
al.  2005;  Crain  et  al. 
2009).  
Table 1. Neurotransmitter receptor expression on microglia  
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Modulation of microglial neurotransmitter receptors therefore affects microglial reactivity. 
Microglial P2X7 receptor and mGluR5 activation directly modulates the NADPH oxidase 
(Fig. 1.11), with activation of mGluR5 inhibiting microglial NADPH oxidase activation and 
promoting  protection,  and  activation  of  P2X7  receptors  exacerbating  disease  progression 
through superoxide production. As there is strong evidence to suggest that modulation of 
microglial  neurotransmitter  receptors  mediates  microglial  activation,  it  was  important  to 
investigate  whether  this  affected  NADPH  oxidase  activation,  as  little  is  known  of  the 
consequences of modulation of other neurotransmitter receptor subtypes on NADPH oxidase 
activation and superoxide production (Fig. 1.11). The suggestion that receptor modulation 
alters microglial phenotype and that microglia are sensitive to changes in neurotransmitter 
levels could suggest that modulation of microglial neurotransmitter receptors may mediate 
NADPH oxidase activity which could have important consequences for the progression of 
neurodegenerative  diseases.  An  investigation  into  the  effects  of  modulation  of 
neurotransmitter  receptors  on  the  microglial  NADPH  oxidase  and  the  ramifications  for 
neuronal survival could therefore provide further information on microglia in pathology, and 
may provide targets for pharmacological intervention in neurodegenerative conditions.  79 
 
 
 
Figure  1.11  Summary  of  the  activation  of  the  microglial  NADPH  oxidase  following  modulation  of 
neurotransmitter receptors. To date, it has been shown that activation of the microglial mGluR5 down-regulates 
MAPK  activity  and  prevents  NADPH  oxidase  activity,  thus  reducing  the  release  of  TNFα  and  NO,  which  has 
neuroprotective consequences. Activation of the P2X7 receptor has been shown to up-regulate MAPK signalling and 
promote activation of the NADPH oxidase and release of superoxide, and is neurotoxic. It is not yet known whether 
modulation of other mGluR’s, iGluR’s. GABA or P2Y receptors modulates the NADPH oxidase, or the ramifications 
for neuronal survival.  
   
 
 
 80 
 
1.7  Aims and objectives 
Microglial NADPH oxidase activation and subsequent superoxide production is implicated in 
the  production  and  release  of  neurotoxic  or  neuroprotective  factors  in  neurodegenerative 
conditions through the activation of different microglial signalling pathways. Furthermore, 
neurotransmitter  dysregulation  contributes  to  the  progression  of  many  neurodegenerative 
conditions, and microglia express a number of neurotransmitter receptors which mediate a 
variety of down-stream effects, including the modulation of the NADPH oxidase, which has 
ramifications for neuronal survival.  
The aims of this thesis were therefore to investigate whether neurotransmitters or modulation 
of neurotransmitter receptors of the glutamatergic, GABAergic or purinergic subtypes could 
affect NADPH oxidase activation and subsequent superoxide production in BV2 and primary 
microglia.  Superoxide  production  in  BV2  and  primary  microglia  was  robustly  measured 
using four assays: HPLC, flow cytometry, a plate based colorometric assay, and fluorescence 
microscopy,  using  two  superoxide  sensitive  probes  to  validate  findings  and  to  ensure  a 
comprehensive  analysis  of  superoxide  production.  The  signalling  pathways  involved  in 
neurotransmitter and receptor mediated NADPH oxidase activation were also explored, with 
a  focus  on  the  p38MAPK  and  p44/42ERK  signalling  cascades,  which  are  implicated  in 
microglial  activation  and  have  been  shown  to  induce  NADPH  oxidase  activation. 
Furthermore,  the  NADPH  oxidase  isoforms  expressed  following  modulation  of 
neurotransmitter receptors were also investigated, as modulation of different Nox isoforms 
can mediate the release of protective or toxic factors. To investigate whether activation of the 
microglial  NADPH  oxidase,  following  modulation  of  neurotransmitter  receptors,  may 
promote the production and release of protective or toxic fators, microglial conditioned media 
assays were used to investigate the neuoprotection or toxicity on cerebellar granule neurons 
(CGCs). It was hoped that this research may provide some insight into whether microglial 81 
 
NADPH oxidase derived ROS  production, as  a consequence of neurotransmitter receptor 
modulation, could mediate neuronal survival. 
This research therefore aimed to provide an insight into the role of the microglial NADPH 
oxidase activation in pathology in which neurotransmitter signalling is unbalanced, and it was 
hoped  that  these  findings  could  suggest  potential  targets  for  therapeutic  intervention. 
Harnessing the ability of microglia to respond to modulation of neurotransmitter receptors in 
a protective or toxic manner through the production of ROS could represent an important 
target  for  pharmacological  intervention  in  several  severely  debilitating  neurodegenerative 
diseases.  
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Chapter 2 
Materials and Methods  
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2.1 Materials  
Sprage Dawley rat pups were obtained from University College London in-house colonies 
from  Central  Biological Services.  The BV2 microglial  cell line was  a kind  gift  from  Dr 
Claudie Hooper (Kings College London).  
All  chemicals
  and  reagents  were  purchased  from  Sigma-Aldrich  (Dorset,  UK),  unless 
otherwise stated. Foetal bovine serum (FBS), Dulbecco's Modified Eagle's Medium (DMEM) 
and  Minimum  Essential  Medium  (MEM),  phenol-red  free  medium  and  accutase  were 
obtained from Invitrogen (Paisley, UK). Tissue culture
 plasticware, filration units, syringes 
and  glass  Pasteur  pipettes  for  tissue  culture  were  obtained  from  Triple  Red 
(Buckinghamshire, UK) and coverslips were obtained from Scientific Laboratory
 Supplies 
(Nottingham, UK). Glass microscope slides, Eppendorf tubes, 50 ml and 15 ml Falcon tubes, 
and  serological  pipettes  were  from  VWR  International  (Leicestershire,  UK).  Phosphate 
buffered saline (PBS) powder was purchased from ICN
 Biomedicals (Maidenhead, UK).  
Trizol, Tris-Borate-EDTA (TBE) buffer, Agarose, Superscript  II Reverse transcriptase kit 
(containing superscript reverse transcriptase, oligo dT primer, RNase out, DTT, first strand 
buffer), and ethidium bromide were from Invitrogen (Paisley, UK). The PCR kit (containing 
Taq polymerase, magnesium chloride, and PCR buffer) was from Promega (Southampton, 
UK). PCR tubes and caps in strips were obtained from Applies Biosystems (Warrington, 
UK). Primers were designed using the Roche primer design tool, and were made by Sigma 
Custom Oligos (Dorset, UK).  84 
 
Western  blotting  apparatus  was  from  BioRad  (Hertfordshire,  UK).  Acrylamide  was  from 
Severn  Biotech  (Worcestershire,  UK).  ECL  reagent  and  PVDF  membrane  was  from 
Millipore  (Watford,  UK).    X-Ray  film,  developer  and  fixer  solutions  were  from  Kodak 
(supplier, Scientific Laboratory Supplies, Nottingham, UK).  Flow cytometry reagents (FACS 
clean  and  sheath  buffer)  and  consumables  (FACS  tubes)  were  from  Becton  Dickenson 
(Oxford, UK). HPLC vials were from VWR International (Leicestershire, UK).  
Receptor  agonists  or  antagonists  and  pathway  inhibitors  are  listed  in  Table  1.  Nitroblue 
tetrazolium  chloride  (NBT)  was  obtained  from  Calbiochem  (Darmstadt,  Germany),  and 
dihydroethidium (dHEth), Hoechst 33243 nuclear stain, and Propidium Iodide (PI) were from 
Invitrogen  (Paisley,  UK).  Vectashield  was  from  Vector  Labs  (Burlingame,  California). 
Antibodies are listed in Table 3 and Table 7.   
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2.2 Methods  
2.2.1  Cell Culture   
2.2.1.1 BV2 cell culture  
The  BV2  cell  line  was  a  kind  gift  from  Dr  Claudie  Hooper  (MRC  Centre  for 
Neurodegenerative Research, Institute of Psychiatry, Kings College London, UK) and was 
originally obtained from Dr FS Tzeng (Department of Life Sciences, National Cheng Kung 
University,  Taiwan).  BV2  cells  are  a  mouse  microglial  cell  line,  immortalized  by  the 
inculsion of a v-raf/v-myc oncogene carrying retrovirus J2 (Blasi et al. 1990). The cells retain 
the  morphological  and  phenotypical  characteristics  of  primary  microglial  cells  in  culture 
conditions,  and LPS treatment of BV2 microglia induces the up-regulation of inflammatory 
genes  also  seen  following  LPS  treatment  of  primary  microglia,  suggesting  that  BV2 
microglia respond in the same way as primary microglia to activating stimuli, however BV2 
activation is less pronounced (Lund et al. 2006).   
 
BV2 cells were maintained in culture medium (DMEM supplemented with 2 mM glutamine, 
44 mM NaHCO3, 10% FBS, and 100 U/ml penicillin, 100 μg/ml streptomycin) at 37ºC in a 
humidified atmosphere with 6% CO2. BV2 cells were passaged twice weekly. Medium was 
removed and cells were washed with PBS made up in filtered, UV- treated dH2O to remove 
excess medium. Cells were then detached from the culture flask using 2 ml 400 – 600 U/ml 
accutase and were incubated for 1 min at 37ºC to promote enzymatic activity. Accutase was 
neutralised using an equal volume of serum containing media, and cells were transferred to a 
15 ml Falcon tube, then centrifuged at 3645 g for 5 minutes (Eppendorf Centrifuge 5804R). 
The pellet was resuspended in 5 ml medium, and cells were seeded into a new flask. BV2 
cells were cryopreserved at 1x10
6 cells / ml in medium composed of DMEM supplemented 86 
 
with 2 mM glutamine, 44 mM NaHCO3, 100 U/ml penicillin, 100 μg/ml streptomycin, 20% 
FBS  and  10%  dimethyl  sulphoxide  (DMSO).  Cells  were  snap  frozen  in  dry  ice,  and 
transferred to a -80ºC freezer for long-term storage. Cells were thawed by defrosting one 
aliquot and transferring to a T25 culture flask in 10 ml pre-warmed media. Once cells had 
adhered, medium was changed to remove DMSO contamination, and cells were grown to 
confluency. Cells were passaged into larger T175 flasks before use.  
 
BV2 cells were routinely counted using a haemocytometer and plated in 96 well plates at 
1.0x10
4 cells per well, in 24 well plates at 2.5x10
4 cells per well and in 6 well plates at 
1.0x10
5 cells per well. Before treatments, the medium was changed to serum-free DMEM 
(DMEM supplemented with 2 mM glutamine, 44 mM NaHCO3, 100 U/ml penicillin, and 
100 μg/ml streptomycin) for at least 3 h to down-regulate receptor expression, resulting in a 
ramified  morphology  similar  to  that  seen  in  primary  microglial  cells  in  culture,  which 
allowed cells to respond better to activating stimuli.   
2.2.1.2 Primary microglial culture  
Primary microglia were isolated from five day old Sprague Dawley rat pups using a method 
developed by Kingham et al. (1999). Eight post natal pups were killed by cervical dislocation 
and decapitation in accordance with the Scientific Proceedures Act 1986 (United Kingdom). 
Whole brains, minus the cerebellum which were used to culture CGCs (section 2.2.1.3), were 
removed and placed into 1 x PBS (137 mM NaCl, 5.37 mM KCl, 5.65 mM NaH2PO4.H2O, 
13.3 mM Na2HPO4.7H2O, 11.1 mM D-glucose, 0.02% bovine serum albumin (BSA), 100 
units/ml penicillin, 0.1 mg/ml streptomycin, 3 μg/ml ampicillin, pH 7.4, made up in filtered, 
UV-treated  dH2O)  on  ice.  Brains  were  homogenised  with  10  –  15  strokes  of  a  Potter 
homogeniser. The homogenate was transferred into two 50 ml Falcon tubes (approximating 4 
brains  per tube) and centrifuged at  500 g for  5 min (Eppendorf Centrifuge 5804R). The 87 
 
 
 
Figure 2.1 Microglial preparation using a percoll gradient. The brain homogenate is resuspended in 
70% percoll, which is overlaid with 30% percoll and finally 1/PBS (A). Following centrifugation at 
1250 x g for 50 min, microglia are separated from the homogenate and migrate to the 30% / 70% 
percoll interface, whilst blood pellets at the bottom of the tube, and myelin and cell debris is collected 
from the 30% / PBS interface (B).  
supernatant was removed and discarded and pellets were resuspended in 10 ml 70% Percoll. 
A Percoll gradient was made by overlaying 10 ml 30% Percoll on top of the 70% Percoll, and 
finally  10  ml  1xPBS  (Fig.  2.1A).  The  gradients  were  centrifuged  at  1250  g  (Eppendorf 
Centrifuge 5804R) for 50 min with no brake or acceleration. This separated the microglia 
from the remaining brain matter, and enabled microglia to be collected from the interface 
between the 70% and 30% Percoll gradient (Fig. 2.1B).  
 
 
 
 
 
 
 
 
 
 
Following removal of the microglia, cells were washed in 50 ml PBS  to remove Percoll 
contamination  by  centrifugation  at  500  g  (Eppendorf  Centrifuge  5804R)  for  5  min.  The 
resulting pellet was then resuspended in 1 ml medium (MEM supplemented with 10% FBS, 
20 mM KCl, 30 mM D-glucose, 2 mM L-glutamine, 25 mM NaHCO4, 50 U/ml penicillin, 
50 µM  streptomycin,  and  6  µg/ml  ampicillin)  and  microglia  were  counted  using  a 88 
 
 
Figure 2.2 Microglia stained with Isolectin B4 and Hoechst 33342. To 
confirm  the  purity  of  the  microglial  culture,  cells  were  stained  with 
Isolectin  B4  (2  μg/ml),  which  binds  specifically  to  cells  of  a  monocytic 
lineage, and Hoescht 33342 (0.6 μg/ml) to counter stain the nuclei. Arrows 
point to ramified, resting microglia. Cells were imaged using an Axiotop 
Fluorescence microscope (Zeiss) and a x40 objective. Scale bar 20 µm. 
haemocytometer. Microglia were plated on 13 mm glass coverslips at a density of 5x10
4 cells 
per  well  in  a  24  well  plate.  Microglia  were  initially  plated  in  a  small  volume  of  media 
(100 μl) to  allow  cells  to adhere,  which  was  then increased to  500 μl  following 30 min 
incubation in a humidified incubator with 6% CO2 at 37ºC. Microglia were left for 24 h 
before being washed 3 times in medium to remove any debris. The media was then changed 
to serum-free medium (MEM supplemented with  20 mM KCl, 30 mM D-glucose, 2 mM L-
glutamine,  25  mM  NaHCO4,  50  U/ml  penicillin,  50  µM  streptomycin,  and  6 µg/ml 
ampicillin) and microglia were left to rest for at least 3 h before treatment. Microglia were 
used within 48 h of isolation.  
Microglia have been characterized following isolation using  the Percoll method. Staining 
using the microglial  specific marker  Isolectin  B4 (Fig. 2.2) and OX-42 have shown that 
cultures routinely contain 90% microglia, with the remaining contamination being astrocytes 
(Kingham et al. 1999). Furthermore, at 2 DIV only 20% of microglia stain positive for ED-1, 
suggesting a low level of basal activation (Morgan et al. 2004) 
.   
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2.2.1.3 Cerebellar Granule Cell (CGC) culture  
CGCs are excitatory neurons found in the granule layer of the cerebellum, which receive 
excitatory inputs from the mossy fibers and release glutamate (Gallo et al. 1982). In studies in 
which the neurotoxic or neuroprotective effects of microglia are investigated, CGCs are the 
predominant neuronal type used, as the cerebellum can be isolated easily and the remaining 
brain can be used for isolation of microglia.  
 
Cerebellae were collected and CGCs were isolated as described by Courtney et al. (1990). 
Five  day  old  Sprague  Dawley  rat  pups  were  killed  as  described    (section  2.2.1.2),  and 
cerebellae were collected on ice into a buffer  consisting of 153 mM Na
+, 4 mM K
+, 1.5 mM 
Mg
2+, 139 mM Cl
-, 10 mM PO4
2-, 1.5 mM SO4
2-, 14 mM glucose, and 50 µM BSA (pH, 7.4). 
This solution is named solution B and will be referred to as such for the remainder of this 
section. Cerebellae were mechanically dissociated with a sterile razor blade and collected into 
solution B supplemented with 0.5 mg/ml trypsin for enzymatic digestion of the extracellular 
matrix. CGCs in trypsin were incubated for 5 minutes at 37°C with gentle agitation every 1-2 
minutes. Trypsinisation was neutralized by addition of 20 ml solution B containing 8 µg/mL 
soybean trypsin inhibitor (SBTI) and 8 U/ml DNAase, the suspension was centrifuged at 65 g 
for 5 minutes to pellet the CGCs. The supernatant was discarded, and the pellet resuspended 
and triturated in 3 ml of buffer (solution B containing 3 mM Mg
2+ and SO4
2- supplemented 
with 50 µg/mL SBTI and 50 U/ml DNAase) using three fire-polished glass Pasteur pipettes 
of progressively decreasing diameter. Triturated, homogenous perikarya were layered onto 
5 ml 4% BSA in Ca
2+-free Earle‟s Balanced Salts Solution (EBSS) and centrifuging for 5 min 
at 100 g to remove debris. The pellet was resuspended in warmed CGC medium (MEM 
supplemented with 10% FBS, 20 mM KCl, 30 mM D-glucose, 2 mM L-glutamine, 25 mM 
NaHCO4, 50 U/ml penicillin, 50 µM streptomycin, and 6 µg/ml ampicillin) at a density of 90 
 
8x10
6 cells/ml. CGCs were then plated at 8x10
5 cells per well onto 13 mm diameter poly-
Dextro-lysine (PDL)-coated coverslips in a volume of 100 μl media. To give perikarya time 
to adhere, additional CGC medium (to a total volume of 500 μl) was not added until at least 
1 h after plating. After 24 hours, the cells were washed, and half the media was replaced with 
MEM supplemented with 20 µM cytosine furanoarabinoside (Ara-C) to prevent further glial 
proliferation. The cultures were maintained at 37°C in a humidified atmosphere of 6% CO2, 
and were available for use after 6 DIV. 
2.2.2  Cell treatments 
2.2.2.1 Treatment of primary and BV2 microglia  
Primary and BV2 microglia were routinely cultured for 24 h before use. The medium was 
changed to serum free medium for at least 3 h before treatment to ensure that cells were 
down-regulated and in a resting state. Primary and BV2 microglia were treated with LPS, 
PMA, neurotransmitters, and receptor agonists and antagonists for 24 h after initial time and 
concentration  dependency  analysis.  Table  2  provides  a  list  of  the  compounds  used,  the 
concentrations and suppliers, and also solvent controls. The concentrations listed are the final 
concentrations used, as determined by titration assays, or from the literature.  
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Compound  Description  Concentration   Supplier  
PMA  PKC activator   10 ng/ml  Sigma 79346 
LPS  TLR4 agonist and iNOS inducer  1 μg/ml  Sigma L9404 
Glutamate   Excitatory neurotransmitter  1 μM  Sigma G5921 
GABA  Inhibitory neurotransmitter   100 μM  Sigma A2129 
BzATP  Excitatory neurotransmitter   250 μM  Sigma B6396 
L-AP4  mGluR group III agonist  100 μM  Tocris # 0103 
MAP4  mGluR group III antagonist  500 µM  Tocris #0711 
MTEP  mGluR group I antagonist  100 nM  Tocris # 2921 
AIDA  mGluR group I antagonist  250 µM  Tocris # 0904 
CDPPB  mGluR group I agonist  500 nM  Tocris # 3235 
DHPG  mGluR group I agonist   100 µM  Tocris # 0342 
NAAG  mGluR3 (group II) agonist   50 μM  Sigma A5930 
DCG-IV  mGluR group II agonist   500 nM  Tocris # 0975 
APICA  mGluR group II antagonist   200 µM  Tocris # 1073 
NMDA  NMDA receptor agonist   100 µM  Sigma M3262 
MK-801  NMDA receptor antagonist  10 µM  Sigma M107 
Quisqualic Acid   AMPA receptor agonist   10 µM  Sigma Q2128 
CNQX  AMPA receptor antagonist   10 µM  Sigma C127 
Muscimol  GABAA receptor agonist  50 μM  Tocris # 0298 
SKF-97541  GABAB receptor agonist   100 μM  Tocris # 0379 
Picrotoxin   GABAA receptor antagonist   100 µM  Tocris # 1128 
SR95531  GABAA receptor antagonist   10 µM  Tocris # 1262 
UTPγS  P2Y2/4 receptor agonist  100 nM  Tocris # 3279 
MRS2365  P2Y1 receptor agonist  1 μM  Tocris # 2157 
Thioridazine   Nox4 inhibitor   1 µM  Tocris # 3070 
Rottlerin  PKCδ inhibitor   10 µM  Tocirs # 1610 
Wortmannin  PI3-K inhibitor   1 µM  Tocris # 1232 
Apocynin   Nox1/2 inhibitor   10 μM  Calbiochem 
178385 
PD-98059  p44/42ERK inhibitor   30 µM  Tocris # 1213 
SB-203580  p38MAPK inhibitor   10 µM  Tocris # 1202 
DMSO  Solvent   <1%   Sigma D4540 
Table 2. Compounds used for treatment of BV2 cells and primary microglia.  92 
 
Following treatment, the conditioned medium was routinely taken from primary microglia, 
for use in microglial conditioned media (MGCM) studies to investigate the effects of soluble 
factors on neuronal survival. For this reason, microglia were grown in MEM media to enable 
neuronal survival. Medium was removed and centrifuged immediately at 10,000 g for 5 min 
at room temperature (Eppendorf 5415R benchtop centrifuge) to pellet any cell debris, which 
can affect neuronal activation. The supernatants were then aliquotted and stored at -20ºC until 
required. To preserve the integrity of the soluble factors, aliquots were defrosted and used 
only once. 
Microglia and  BV2 microglia treated as  shown in  Table  2 were used  to  assess NADPH 
oxidase expression, activity and the production of superoxide, in addition to an investigation 
into the signalling cascades involved in these processes.  
2.2.2.2 Treatment of CGCs  
CGCs were either treated directly with the compounds described in Table 1 to determine 
whether they had a direct effect on neuronal survival, or were treated with MGCM from 
microglia treated as described in Table 1 to determine whether soluble factors released from 
microglia  affected  neuronal  survival.  CGCs  subjected  to  treatment  with  MGCM  were 
analysed for death using live / dead staining and signalling cascades leading to cell survival 
or death were analysed by Western blotting. 
2.2.2.3 Conditioned media assays  
CGCs were treated with MGCM to assess survival following the release of toxic or protective 
factors from microglia after modulation of the NADPH oxidase, and also to investigate the 
signalling pathways involved in neuronal survival or death. Microglia were plated in 24 well 
plates as described and treated as shown in Table 1, and media was retained as described.  93 
 
During the MGCM assays, half of the medium already on the CGCs (250 µl) was removed 
from each well, and replaced with 250 µl of MGCM. Only half the media could be removed 
as CGCs release growth factors which are essential to their survival, therefore removing all of 
these trophic factors would  have a detrimental  effect  on neuronal  survival  and may also 
increase cell death in a way not attributed to the MGCM (Taylor et al. 2002). Following 
MGCM treatment (which was performed at a number of time points as shown in the relevant 
results sections), CGCs were either imaged to assess cell death by nuclear morphology and 
propidium iodide staining, or were lysed to asses signalling pathway activation for analysis 
by Western blotting.   
2.2.3  Cell imaging  
Primary and BV2 microglia and CGCs were imaged using a Zeiss Axiotop 2 fluorescence 
microscope (Oberkochen, Germany). The microscope was used to obtain images of iNOS and 
ED-1 immunoreactivity of microglia, in addition to the use of nuclear stains to assess cell 
death, and also for use in the imaging and detection of ROS. All cells were viewed using a 
40x Neofluar objective, and images were captured using a Zeiss AxioCam HRc camera and 
Zeiss Axiovision 3.1 software. Images were analysed using Image J software.  94 
 
2.2.3.1 Immunocytochemistry  
Primary microglia plated on 13 mm glass coverslips in 24 well plates  were grown in serum 
free media before activation for 24 h with the compounds shown in Table 1 (either alone or in 
combination). After activation, cells were fixed in 4% paraformaldehyde (PFA) in PBS for 
30 min at room temperature. PFA was then removed, and cells were washed once with PBS, 
before being permeabilised with methanol for 20 min at -20ºC and washed with PBS three 
times. Non-specific antigens were blocked using 4% normal goat serum (NGS) for 30 min at 
room temperature. Cells were then incubated with the primary antibodies (shown in Table 2) 
diluted in 1xPBS, overnight at 4ºC.  The following day, cells were washed in 1xPBS three 
times and incubated with the secondary antibodies as shown in Table 2 for 2 h at room 
temperature.  Cells  were  then  washed  in  PBS  before  being  incubated  with  DAPI  (4'-6-
Diamidino-2-phenylindole – a nuclear stain that binds to double stranded DNA) 1:1000 at 
room temperature for 1 min. The cells were again washed in PBS three times, followed by 
one  final  wash  in  distilled  water.  Coverslips  were  then  mounted  on  glass  slides  using 
Vectashield  mountant.  Slides  were  stored  away  from  light  at  4ºC  until  required,  and 
coverslips were viewed and imaged using a Zeiss fluorescent microscope (Zeiss Axioskop 2, 
Oberkochen,  Germany)  with  tetramethyl  rhodamine  iso-thiocyanate  (TRITC  -  red 
fluorochrome, 543 nm),   fluorescein isothiocyanate (FITC - green fluorochrome 488 nm) and 
DAPI (blue fluorochrome 364 nm) filters.  
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Primary Antibody  Specificity  Dilution  Corresponding 
secondary antibody 
Dilution 
Mouse anti ED1 
(Serotec 
MCA275R) 
Binds to CR3 receptor in 
ramified microglia 
1:100  Sheep anti mouse IgG 
FITC       (Sigma 
F2883) 
1:1000 
Rabbit anti iNOS 
(BD transduction 
lab 610333) 
Binds to inducible nitric 
oxide synthase (iNOS)– a 
marker of activated microglia 
1:500  Goat anti rabbit IgG 
TRITC            (Sigma 
T6778) 
1:1000 
Table 3. Antibodies used for immunostaining.  
2.2.3.2 Assessment of cell death  
Neuronal  death  was  assessed by nuclear morphology  and the incorporation of propidium 
iodide (PI) into necrotic and late apoptotic nuclei (Fig. 2.3). During apoptosis, nuclei become 
smaller and stain brightly with 2´-(4-Ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5´-bi-1H-
benzimidazole (Hoechst 33342) as the chromatin condenses (Kroemer et al. 2009). Hoechst is 
membrane permeable, and can access the nucleus at all stages of cell survival and death, 
allowing  for  assessment  of  health.  The  pyknotic  nuclei  observed  with  Hoescht  staining 
(Fig. 2.3)  are  a  hallmark  of  apoptosis  and  can  therefore  be  counted  to  determine  the 
percentage  of  apoptosis  in  a  culture.  The  necrotic  and  late  apoptotic  marker  PI  is  not 
membrane permeable, and is only incorporated into the nucleus when the nuclear membrane 
is  compromised,  which  is  not  seen  during  early  apoptosis  and  therefore  allows  for  a 
distinction between different types of cell death (Kroemer et al. 2009).  96 
 
 
Figure 2.3 Hoechst 33342 and Propidium Iodide live staining of CGC’s to assess cell death. CGC’s cultured 
for 7DIV were stained with Hoechst 33342 (0.6 μg / ml) to show nuclear morphology and propidium iodide 
(1 μg/ml)  to  show  necrosis.  Cells  were  imaged  using  a  Zeiss  axiotop  fluorescence  microscope  and  a  x40 
objective. Images were taken under separate DAPI and TRITC excitation wavelengths and images were merged 
to show apoptotic and pyknotic nuclei. Arrows in the Hoechst image point to apoptotic nuclei, whilst those in the 
merged image point to necrotic nuclei. In this way apoptosis could be differentiated from necrosis. Scale bar 
20 µm. 
  
Nuclear staining was performed on live, unfixed CGCs to determine the effects of MGCM on 
neuronal survival. Following treatments with MGCM, cells were incubated with PI (1 μg/ml) 
for 30 minutes and Hoechst 33342 (0.6 μg/ml) for 20 minutes. After incubation, the live cells 
were mounted in basic medium (3 mM NaCl, 3.5 mM KCl, 0.4 mM KH2PO4, 20 mM N-
tris(hydroxymethyl)methyl-2-aminoethanesulphonic  acid,  1.2  mM  Na2SO4  and  1.3  mM 
CaCl2 at pH 7.4) and were viewed using the TRITC and DAPI filters (Fig. 2.3). Three fields 
per coverslip were imaged, and the total number of cells and PI positive cells in each field 
were  counted  to  enable  the  calculation  of  the  percentage  of  dead  cells  (PI  stained  and 
pyknotic nuclei). Cell counts were performed using Image J software.  
2.2.4  Measurement of superoxide production  
Throughout this thesis, four methods have been used for the detection of superoxide and ROS 
in BV2 and primary microglia: The nitro-blue tetrazolium chloride (NBT) reduction assay; 
detection of superoxide production by dihydroethidium (dHEth) using fluorescence imaging 
or flow-cytometry; and high performance liquid chromatography (HPLC) of dHEth oxidation 
products, to detect the relative production of superoxide and hydrogen peroxide. 97 
 
There have been many studies investigating and validating the use of exogenous probes and 
methodologies for ROS detection. It was therefore important to use a variety of probes and 
techniques  in  this  thesis,  so  that  data  could  be  compared  and  to  ensure  that  the  effects 
observed were not artefacts of the experimental technique. There are several compounds that 
can be used to detect superoxide production, however as the focus of this study is on the 
production of intracellular superoxide as a signalling molecule; the two compounds used to 
investigate this were NBT, which is reduced to the blue formazan precipitate NBTH2 by 
superoxide, and dHEth, which is oxidised to 2-hydroxyethidium (2-OH-E
+) by superoxide, 
and to ethidium (Eth) by hydrogen peroxide. 
Whilst shown to be effective in studying the production of superoxide, the use of probes that 
are oxidised or reduced can produce artefacts. Probes that exploit the oxidative activity of 
superoxide,  such  as  dHEth,  can  be  oxidised  by  other  ROS  such  as  hydrogen  peroxide, 
peroxynitrite, the thiyl radical and other haeme compounds (Tarpey et al. 2004;  Dikalov et 
al. 2007). Because of this, dHEth may show a lower specificity to superoxide than probes 
which are reduced by superoxide (Janiszewski et al. 2002), such as NBT. However, probes 
that are reduced by superoxide can undergo redox cycling which is caused by the reaction of 
molecular  oxygen  with  partially  reduced  probe,  which  can  itself  generate  superoxide, 
resulting  in  false  positive  results  (Vásquez-Vivar  et  al.  1998;  Spasojevic  et  al.  2000). 
Therefore the use of probes  specific to  the oxidising potential of superoxide reduces  the 
generation  of  false-positive  readings,  whilst  the  use  of  probes  exploiting  the  reductive 
chemistry of superoxide may be more specific (Laurindo et al. 2008). In this thesis, both 
probe types were used to validate findings.  
In this thesis, the specificity of ROS production by the NADPH oxidase was assessed by 
conducting all experiments both in the presence of the activating stimuli alone and also in the 
presence of the activating stimuli plus apocynin, an inhibitor of the NADPH oxidase which 98 
 
prevents the assembly of the enzyme by binding to the gp91phox binding site on p47phox 
and  inhibiting  translocation  and  assembly  of  the  active  NADPH  oxidase  complex,  thus 
preventing superoxide production (Stefanska & Pawliczak 2008). This therefore reduced the 
incidence of false positive results. Furthermore, the use of HPLC enabled the determination 
of  the  reduction  of  dHEth  by  both  superoxide  and  hydrogen  peroxide,  enabling  the 
investigation  into  which  oxidising  species  was  most  prevalent  following  treatment  with 
different activating stimuli. Using these methods, the production of ROS could be attributed 
to the functionality of the NADPH oxidase.  
2.2.4.1 NBT detection of intracellular superoxide  
NBT has been used to assess the production of superoxide both in vivo and in vitro since its 
discovery as a superoxide scavenger (Baehner et al. 1976; Van Noorden & Butcher 1989). 
NBT is converted from a yellow liquid to a blue formazan precipitate following exposure to 
the superoxide anion (Fig. 2.4), which enables quantification of superoxide production  in 
vitro by analysis of the absorbance of the formazan precipitate at 630 nm (Choi et al. 2006). 
The specificity of NBT for superoxide has been demonstrated in studies using SOD, which 
converts  superoxide  to  hydrogen  peroxide.  NBT  reduction  was  diminished  by  60%  after 
addition of SOD to PMN cells, suggesting that the majority of NBT is reduced by superoxide 
rather than hydrogen peroxide (Baehner et al. 1976).  
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Figure 2.4 Reduction of NBT to NBTH2 formazan precipitate.  Yellow NBT is reduced by superoxide to the blue 
NBTH2 formazan precipitate which can be detected by absornance at 630 nm.  
 
The reduction of NBT by superoxide is not isolated to the NADPH oxidase system, however 
in this thesis it has been used to investigate NADPH oxidase activity by co-treating cells with 
activating stimuli in the presence and absence of the NADPH oxidase inhibitor apocynin. The 
reduced  NBT  here  is  localised  within  the  cell,  enabling  the  assessment  of  intracellular 
superoxide production. 
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2.2.4.1.1  NBT assay optimisation 
The NBT assay was optimised from published methodologies (Choi et al. 2006; Serrander et 
al. 2007). BV2 microglia were plated in 96 well plates at 1x10
4 cells per well, and were 
grown to 70% confluency, after which, medium was changed to serum and phenol red free 
media for 3 h before treatment. During the initial optimisation, cells were treated with PMA 
which is a known activator of the NADPH oxidase, shown to induce phosphorylation of the 
p47phox subunit through PKC activation (Tauber et al. 1989); or LPS, a known microglial 
activator  (Andersson  et  al.  1992).  Initially,  an  optimum  time-point  for  the  detection  of 
intracellular superoxide was determined (Fig. 2.5). Cells were treated with 10 ng/ml PMA 
(Cox et al. 1985; Kapus et al. 1992) or 1 μg/ml LPS (Taylor et al. 2005) in the presence of 
10 μg/ml NBT (Choi et al. 2006) for 30 min, 1 h, 4 h, 8 h, 16 h and 24 h, and NBT reduction 
was measured by absorbance at 630 nm at each time point using a Tecan x fluo4 plate reader. 
It was important that formazan precipitate production in BV2 cells treated with the positive 
control PMA or the microglial activator LPS was significantly increased when compared with 
basal  superoxide  production  in  untreated  BV2  cells  incubated  with  NBT  only.  It  was 
determined that BV2 cells treated for 4 h with PMA or LPS induced a significant increase in 
superoxide production when compared with basal superoxide levels (Fig. 2.5).  
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Figure 2.5 Time course analysis of superoxide production by NBT reduction.  BV2 cells 
plated at 1x10
4 cells per well were incubated in serum and phenol-red free media before 
treatment with PMA (10 ng/ml) or LPS (1μg/ml) for 30 min, 1 h, 4 h, 8 h, 16 h and 24 h. in the 
presence  of  10  μg  /ml  NBT.  Control  cells  were  incubated  with  NBT  only  to detect  basal 
superoxide production. NBT reduction to a blue formazan precipitate was measured at each 
time point at 630 nm, and was compared to the reduction of NBT in un-treated cells (basal 
superoxide production). At 4 h incubation there was a significant increase in NBT reduction 
when compared to cells incubated with NBT only. Significance was determined using a one 
way ANOVA with Tukey post-hoc analysis at each time-point. ***p<0.001, **p<0.01 and 
*p<0.05. Data is n=3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Following the finding that 4 h treatment with PMA or LPS induced a significant increase in 
NBT  reduction  and  therefore  superoxide  production,  it  was  important  to  determine  the 
optimal concentration of PMA and LPS required to induce superoxide production in BV2 
microglia  (Fig. 2.6).  Cells  prepared  as  described  previously  were  treated  with  PMA  at 
1 ng/ml, 10 ng/ml or 100 ng/ml (Fig. 2.6A); or LPS at 100 ng/ml, 1 μg/ml or 10 μg/ml 
(Fig. 2.6B) in the presence of NBT for 4 h, and NBT reduction was measured at 630 nm. The 
levels of NBT reduction were compared to cells incubated with NBT only (basal superoxide 
production).  PMA  significantly  increased  NBT  reduction  at  10  ng/ml,  whilst  LPS 
significantly induced NBT reduction at all concentrations (Fig. 2.6A,B).  102 
 
 
 
Figure 2.6 Concentration titration of PMA and LPS. The optimum concentration of PMA and LPS required to 
significantly reduce NBT when compared to basal superoxide production was determined. BV2 cells were plated at 
1x10
4 cells / well and were then incubated in serum and phenol red free media. Cells were then treated with PMA 
(A) at 1 ng/ml, 10 ng/ml or 100 ng/ml; or LPS (B) at 100 ng/ml, 1 μg/ml or 10 μg/ml in the presence of 10 μg/ml 
NBT. NBT reduction was measured after 4 h at 630 nm. Statistical analysis was performed using a one way ANOVA 
with Tukey post-hoc analysis. PMA or LPS induced increases in NBT reduction were compared with untreated cells 
incubated with NBT alone. ***p<0.001, **p<0.01 and *p<0.05. Data are n=3.  
 
 
 
It was next important to determine whether PMA or LPS induced superoxide production was 
a consequence of NADPH oxidase activation, to ensure that this assay was appropriate for the 
measurement of superoxide production by the NADPH oxidase. Cells were treated with the 
optimal concentrations of PMA (10ng/ml) or LPS (1 μg/ml) for 4 h, in the presence of the 
NADPH  oxidase  inhibitor  apocynin,  and  10  μg/ml  NBT.  A  concentration  titration  was 
performed to determine the optimal concentration of apocynin and its ability to inhibit the 
reduction  of  NBT  in  the  presence  of  PMA  or  LPS.  Cells  were  co-treated  with  PMA 
(Fig. 2.7A) or LPS (Fig. 2.7B) and apocynin at 100 nM, 1 μM, 10 μM or 100 μM. It was 
shown that apocynin  at 10 μM significantly decreased superoxide production induced by 
PMA or LPS.  
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Figure  2.7  Concentration  titration  of  apocynin.  To  determine  the  optimum  concentration  of  apocynin 
required to inhibit NBT reduction following PMA (A) or LPS (B) treatment, BV2 cells plated at 1x10
4 cells / 
well were co-treated with PMA or LPS and apocynin at 100 nM, 1 μM, 10 μM, and 100 μM in the presence 
of NBT 10 μg/ml and were compared to cells treted with NBT alone for 4 h. To assess statistical significance, 
a one way ANOVA was performed with Tukey post-hoc analysis. NBT reduction induced by PMA or LPS 
alone  was  compared  to  basal  NBT  reduction  (NBT  treated  cells  only),  whilst  NBT  reduction  from  co-
treatments ie. PMA / LPS plus apocynin was compared to PMA / LPS induced NBT reduction. ***p<0.001, 
**p<0.01 and *p<0.05. Data are n=3.  
.     
 
Superoxide production induced by PMA or LPS was significantly attenuated by apocynin, 
suggesting activation of the NADPH oxidase. To ensure that these data were not a result of 
an increase in proliferation or toxicity of apocynin, cell counts were performed on BV2 cells 
plated in 24 well plates on glass coveslips at 2.5x10
4 cells per well. Cells were stained with 
the nuclear dye Hoechst 33342 (0.6 μg/ml), as described previously, and cells were counted. 
Fig. 2.8  shows  that  apocynin  alone  or  in  combination  with  PMA  (Fig.  2.8A)  or  LPS 
(Fig. 2.8B)  does  not  induce  cell  death,  and  PMA  or  LPS  treatments  do  not  induce 
proliferation.  
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Figure 2.8 PMA, LPS or Apocynin toxicity. BV2 cells were plated in 24 well plates at 2.5x10
4 cells / 
well  and  were  either  un-treated,  or  treated  with  apocynin  10 μM,  PMA  10 ng/ml,  LPS  1  μg/ml  or 
apocynin + PMA (A) or apocynin + LPS(B). Statistical analysis was performed using a one way ANOVA 
with Tukey post-hoc analysis. There was no difference in cell number across the conditions. Data are 
n=3.  
 
Figure  2.9  Optimal  conditions  for  the  detection  of  superoxide  production  using  the  NBT 
assay. BV2 cells treated with 10 ng/ml PMA or 1 μg/ml LPS in the presence of NBT for 4 h 
induced a significant increase in NBT reduction (superoxide production) when compared to 
basal superoxide production (cells incubated with NBT alone). Co-treatment with PMA and 
apocynin or LPS and apocynin significantly reduced superoxide production when compared to 
single  treatments,  suggesting  that  PMA  and  LPS  induce  activation  of  the  NADPH  oxidase. 
Statistical analysis was performed by one way ANOVA, and Tukey post-hoc analysis was used. 
***p<0.001, **p<0.01 and *p<0.05. Data are n=3.  
   
These  optimisation  studies  showed  that  NBT  is  a  suitable  probe  for  the  detection  of 
superoxide produced by the positive controls PMA and LPS, and that the assay could be used 
to measure superoxide production as a consequence of NADPH oxidase activation, as NBT 
reduction following treatment with PMA or LPS could be inhibited by apocynin (Fig. 2.9).  105 
 
2.2.4.1.2  Optimised NBT assay protocol 
BV2 microglia were plated in 96 well plates at a density of 1x10
4 cells per well. Cells were 
grown for 24 h before media was changed to serum and phenol red free media for 3 h before 
the assay. Cells were then treated with the compounds shown in Table 1 (either alone or in 
combination  with  apocynin)  in  triplicate  in  phenol-red  and  serum  free  media  containing 
10 μg/ml NBT. To assess basal superoxide production, and as a control for all comparisons, 
untreated cells were incubated with NBT alone.  Cells were incubated for 4 h (in agreement 
with Jekabsone et al. 2006; Serrander et al. 2007) at 37ºC in a humidified atmosphere with 
6% CO2. The optical density of the formazan precipitate was measured by absorbance at 
630 nm using a plate reader (Tecan x fluo4 plate reader). Experiments were performed using 
three separate cell preparations and were conducted in triplicate. 
 
2.2.4.2 Dihydroethidium  detection  of  intracellular  superoxide  –  assessment  by 
fluorescence microscopy 
Dihydroethidium  (dHEth)  is  a  superoxide  sensitive  probe  used  for  the  detection  of 
intracellular superoxide. It is a hydrophobic, uncharged molecule that can readily cross the 
plasma membrane and can enter membrane bound organelles (Garbett et al. 2004). Upon 
oxidation, dHEth becomes positively charged and is oxidised to 2-OH-E
+, which accumulates 
in  the nucleus of cells  producing superoxide where it intercalates  into the DNA  through 
electrostatic interactions between the phosphate groups (Garbett et al. 2004) and hydrophobic 
interactions between the ethidium moiety and the minor groove of the DNA double helix 
(Jain  et  al. 1977; Garbett et  al. 2004)  and fluoresces red (excitation 490, emission 590). 
Furthermore,  this  red  fluorescence  is  obtained  more  readily  with  superoxide  generating 
systems, such as the xanthine and glucose oxidase (Benov et al. 1998), over oxidants such as 
hydrogen peroxide, peroxynitrite or the hydroxyl radical (Bindokas et al. 1996).  In support 106 
 
 
 
Figure 2.10 The oxidation of dihydroethidium to 2-OH-E
+ by superoxide. Dihydroethidium (HE) is converted 
to 2-OH-E
+ in a step- wise manner. HE is oxidized by superoxide to produce two radical species HE
.-, and 
HE(
.NH). These intermediates react rapidly with another superoxide anion to give hydroperoxide, which forms 
the imino-quinone derivative of HE upon water elimination, and then re-arranges to form 2-OH-E
+. (Figure 
from Zielonka et al. 2008).   
 
 
of this, there have been many reports suggesting that superoxide is the only biologically 
relevant oxidant that reacts with dHEth to form 2-OH-E
+ (Fig. 2.10), making this a highly 
specific marker for superoxide (Zhao et al. 2003; Robinson et al. 2006;  Zielonka et al. 2008).  
 
 
The oxidation of dHEth by superoxide proceeds in a two step manner (Fig. 2.10). The radical 
formed in the first step reacts rapidly with another superoxide anion to form hydroperoxide, 
which forms an imino-quinone derivative of dHEth upon elimination of water, and rearranges 
to form 2-OH-E
+ (Zielonka et al. 2008). The specificity of dHEth for superoxide therefore 
makes it an attractive probe for the detection of superoxide production in vitro (Robinson et 
al. 2006; Dikalov et al. 2007). Furthermore, the fluorescence profile of 2-OH-E
+ enables the 
use of this probe for imaging using fluorescence microscopy as described in this thesis.  107 
 
2.2.4.2.1  Optimisation of dHEth detection of intracellular superoxide by fluorescence 
microscopy 
Here, the imaging of intracellular dHEth fluorescence was used as an alternative assay to 
assess intracellular superoxide production in primary microglia (Zhao et al. 2003). The assay 
was optimised from published protocols (Bucana et al. 1986;  Zhao et al. 2003; Larsen et al. 
2009).  Microglia were plated on glass coverslips in 24 well plates at a density of 5x10
4 cells 
per well, and were grown for 24 h in MEM. Media was changed to serum free medium 3 h 
prior to activation. To optimise the protocol, the known activators of the NADPH oxidase, 
PMA and LPS were used as positive controls. Microglia were treated with the concentrations 
deemed to be optimal from the NBT assay (10 ng/ml PMA and 1 μg/ml LPS). Initially, a time 
course  analysis  was  performed  to  determine  the  optimal  time  after  which  PMA  or  LPS 
induced  an  increase  in  the  number  of  superoxide  positive  cells  (cells  exhibiting  red 
fluorescence  in  the  nuclei)  that  was  significantly  elevated  when  compared  with  control 
untreated cells (Fig. 2.11). Microglia were incubated with PMA or LPS for 30 min, 1 h, 4 h, 
8 h, 16 h and 24 h and after each time point, microglia were incubated with dHEth at 5 μM 
for 40 min (Peshavariya et al. 2007). Microglia were also counterstained with Hoechst 33342 
(0.6μg / ml) for 20 min, and coverslips were mounted in basic medium then imaged using the 
Zeiss  fluorescent  microscope  (Zeiss  Axioskop  2,  Oberkochen,  Germany)  with  excitation 
wavelength  at  550  nm  and  emission  wavelength  at  580  nm  for  dHEth  and  excitation  at 
343 nm and emission at 483 nm for Hoechst 33342. Three fields were imaged per condition 
and  the  experiment  was  performed  in  triplicate.  Microglia  were  considered  superoxide 
positive when the nucleus fluoresced red, and these microglia were counted along with the 
total number of cells to enable the calculation of the percentage of superoxide positive cells.  
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Figure 2.11 Time course analysis of dHEth fluorescence. To determine the 
optimal time for incubation of microglia with NADPH oxidase activators to 
allow the detection of superoxide by dHEth fluorescence, microglia plated on 
coverslips in 24 well plates were incubated with PMA 10 ng/ml or LPS 1 
μg/ml for 30 min, 1 h, 4 h, 8 h, 16 h, and 24 h. Cells were imaged by dHEth 
fluorescence and were counterstained with Hoechst 3342. Total cell number 
and superoxide positive cells were counted and percent superoxide positive 
cells were calculated. Statistical analysis was by one way ANOVA with Tukey 
post hoc analysis. Comparisons were made between PMA or LPS treated cells 
and controls. ***p<0.001, **p<0.01 and *p<0.05. Data are n=3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
From the time-course analysis (Fig. 2.11) 24 h incubation with the activating stimuli induced 
the most significant increase in the number of superoxide positive microglia. This time point 
was used for all further experiments.  
 
It was important to determine whether dHEth was appropriate for the detection of superoxide 
production as a consequence of NADPH oxidase activation. Microglia were therefore treated 
with  PMA  (10  ng/ml)  or  LPS  (1  μg/ml)  for  24  h  in  the  presence  of  apocynin  (10  μM) 
(Fig. 2.12) before incubation with 5 µM dHEth for 40 min and 0.6 µg/ml Hoescht 33342 for 
20  min  before  coverslips  were  mounted  in  basic  medium  and  imaged  as  described 
(Fig. 2.12B).  Apocynin  significantly  reduced  the  number  of  PMA  and  LPS  induced 
superoxide positive cells (Fig. 2.12A and B), showing that this assay was appropriate for the 
measurement of superoxide production by the NADPH oxidase in microglia.  109 
 
 
 
 
 
Figure 2.12 Superoxide production in microglia treated with PMA or LPS in the presence and absence 
of apocynin can be detected by dHEth floursecence. Microglia plated in 24 well plates were activated 
with  PMA  (10  ng/ml)  or  LPS  (1  μg/ml)  in  the  presence  or  absence  of  apocynin  (10 μM)  for  24  h. 
Microglia were then incubated with the superoxide sensitive probe DHEth (5 μM) for 40 min and were 
counterstained with Hoechst 3342 (0.6 μg/ml) for 20 min. Superoxide positive cells were determined by 
red fluorescence in the nuclei as shown (B), which decreased upon treatment with apocynin. Superoxide 
positive cells were counted and a percentage was calculated (A). Statistical analysis was performed 
using a one way ANOVA with Tukey post-hoc analysis ***p<0.001, **p<0.01 and *p<0.05. This showed 
that superoxide production induced by 24 h incubation with PMA or LPS could be reduced by inhibition 
of the NADPH oxidase. Data are n=3.Scale bar 20 µm.  
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2.2.4.2.2  Optimised  dHEth  detection  of  intracellular  superoxide  by  fluorescence 
microscopy protocol 
From these initial experiments, an optimised protocol was developed. Primary microglia were 
plated on glass coverslips at 5x10
4 cells per well and were grown for 24 h in MEM. Medium 
was changed to serum free medium for 3 h before treatment as described in Table 1 either 
alone or in combination with apocynin for 24 h (as determined by the time and concentration 
titrations).  After  this  time,  live,  unfixed  cells  were  assessed  for  superoxide  production. 
Microglia were treated with 5 μM dHEth for 40 min (Zhao et al. 2003), and were co-stained 
with Hoechst 33342 0.6 μg/ml for 20 min. Cells were then mounted in basic medium and 
were  imaged  using  the  Zeiss  fluorescent  microscope  (Zeiss  Axioskop  2,  Oberkochen, 
Germany) with excitation wavelength at 550 nm and emission wavelength at 580 nm for 
dHEth and excitation at 343 nm and emission at 483 nm for Hoechst 33342. Three coverslips 
were  imaged  per  condition,  with  6  fields  of  view  taken  per  coveslip.  Experiments  were 
performed in triplicate, using three separate microglial preparations. Images were analysed 
for  superoxide  production  by  counting  the  number  of  microglia  in  which  dHEth  had 
intercalated  into  the  nucleus  which  indicated  the  oxidation  of  dHEth  to  2-OH-E
+  by 
superoxide.    Some  cells  expressing  high  levels  of  superoxide  exhibited  high  background 
fluorescence where the 2-OH-E
+ had intercalated into the mitochondrial DNA, which gave 
the appearance of non-specific binding. These cells were counted so long as the nucleus 
exhibited red fluorescence. The total cell number was counted, and data were expressed as a 
percentage of superoxide positive microglia.  
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2.2.4.3 Flow cytometry analysis of superoxide production  
As  the  detection  of  superoxide  using  dHEth  fluorescence  imaging  is  a  semi-quantitative 
analysis of superoxide levels within the cell, flow cytometry was used to quantify superoxide 
production. As mentioned previously, dHEth is converted to the superoxide specific product 
2-OH-E
+  upon exposure to  superoxide, which intercalates  into the nucleus of superoxide 
producing cells and fluoresces red. This property of dHEth was exploited to count the number 
of superoxide positive cells within a sample using FACS (fluorescence activated cell sorting) 
analysis. Flow cytometry relies upon the movement of cells in suspension past a detector, 
which  can  measure  cell  size  and  granularity,  and  also  the  fluorescence  of  the  cell  if 
fluorescent markers have been used. The prepared sample in suspension is taken up from a 
FACS tube under pressure and transported to the flow cell, where the sample combines with a 
faster flowing sheath fluid which transports the sample to a light source for excitation, where 
light  scatter  and  fluorescence  are  captured  and  detected  by  photodetectors.  The  flow 
cytometer is able to count single cell events by passing the cell suspension through a narrow 
tube at high pressure, which forces the cell suspension to pass the laser and detector in an 
orderly stream of particles. To count the events, the flow cytometer relies on the ability of 
cells to scatter light if not tagged with a fluorescent probe, or to emit light if tagged with a 
fluorescent  probe.  Light  is  collected  by  the  forward  and  side  collection  lenses,  which 
provides the forward scatter (FSC) and side scatter (SSC) data. These refer to cell size and 
granularity respectively, which can provide information on morphology and the health of the 
cell. The forward scatter and side scatter of light is passed onto a detector which generates an 
electrical pulse. When the electrical pulse exceeds the threshold limit, an event is counted and 
analysed by the acquisition software.  112 
 
2.2.4.3.1  Optimisation of flow cytometry  
As large numbers of cells were required for flow cytometry, BV2 microglia were used in 
place of primary microglia. As dHEth is used to asses superoxide production in live adherent 
cells, it was first important to determine whether live BV2 microglia could be used for this 
protocol,  and  to  ensure  that  the  cells  remained  viable  and  did  not  alter  significantly  in 
morphology following detachment from the culture plates, which was required to generate a 
cell suspension for analysis. Initial optimisation used live, unlabelled cells, detached from the 
culture flasks using accutase. BV2 microglia were grown in 6 well plates at 10x10
4 cells per 
well and were grown to confluencey. The media was changed 3 h before FACS analysis to 
serum free DMEM, which prevented proliferation and ensured that all cells were in the same 
stage of the cell cycle to limit variations in cell morphology and size, and to generate a 
homogenous  population  for  analysis.  The  medium  was  aspirated  from  cells,  which  were 
washed once with PBS. Accutase (100 µM) was added to the cells, which were returned to 
the incubator for 1 min. After this time, cells had detached, and the activity of accutase was 
stopped  by  the  addition  of  an  equal  volume  of  serum  containing  medium.  Cells  were 
transferred to a 15 ml Falcon tube and pelleted by centrifugation at 3645 g for 5 minutes 
(Eppendorf Centrifuge 5804R). Cells were then resuspended in 2 ml ice-cold PBS and were 
kept  on  ice  until  analysis.  For  the  analysis  of  cell  viability  and  morphology,  the  cell 
suspension was transferred to a FACS tube (BD Falcon 5 ml round bottomed tube), which 
was placed in the sample injection port (SIP) and then taken up into the flow cytometer 
(Becton Dickenson FACSCalibur) for analysis. 30,000 events were counted, based on the 
scattering of light from un-labelled cells which provided information of the cell size (FSC), 
and granularity or morphology (SSC), and data was analysed using CellQuest software. The 
cell population routinely seen following FACS analysis of un-labelleed BV2 microglia is 
shown in Fig. 2.13.  113 
 
 
BV2 microglia were found by FACS analysis to be present in a homogenous population that 
did not change morphology or size over time, therefore cells grown and prepared in this 
manner could be used for the detection of superoxide using the dHEth probe.  
It was next important to determine that dHEth labelling of BV2 microglia remained stable 
after cells were detached from their culture wells, and that the fluorescence could be detected 
by flow cytometry. A method by Hererra et al. (2004) was followed, and to validate the 
method, the use of flow cytometry to detect superoxide production in BV2 cells treated with 
the positive control PMA was first tested. BV2 microglia grown to confluency were treated 
with PMA (10 ng/ml) either alone or in the presence of apocynin (10 µM) in serum free 
medium for 24 h. Cells were incubated with dHEth (5 µM) for 40 min, before being washed 
with PBS and detached using accutase. Cells were pelleted and resuspended in PBS (2 ml) 
and kept on ice before analysis using the FACSCalibur and CellQuest acquisition software, 
 
Fig. 2.13 Representative dot-plot from un-labelled BV2 microglia. The dot-plot shows that BV2 
microglia form a distinct homogenous population that have the same size and morphology. The 
gated population was used in all further analysis as this represented the most homogenous 
population of BV2 microglia. This therefore enabled BV2 microglia to be used for the FACS 
analysis of superoxide production in BV2 microglia.  114 
 
set to measure fluorescence intensity at 595 nm. A representative histogram and the mean 
fluorescence  intensity  from  the  analysis  of  dHEth  fluoresenece  in  PMA  treated  BV2 
microglia from three separate cell preparations is shown in Fig. 2.14A, B.  
 
 
PMA significantly elevated dHEth fluorescence in BV2 microglia, which could be attenuated 
by apocynin, suggesting that PMA induced superoxide production through activation of the 
NADPH oxidase. These findings correlated with dHEth imaging by fluorescence microscopy, 
and  showed  that  flow  cytometry  was  appropriate  for  the  quantitative  measurement  of 
superoxide production using dHEth. Furthermore, dHEth labelling remained consistent over 
three  separate  experiments,  therefore  the  menthod  of  labelling  and  cell  preparation  was 
appropriate for FACS analysis of superoxide production. 
 
 
Figure 2.14 FACS analysis  of PMA induced superoxide production in  BV2 microglia.  BV2 microglia were 
treated with PMA (10 ng/ml) in the presence or absence of apocynin (10 µM) for 24 h before incubation with 
dHEth (5 µM) for 40 min and analysis of superoxide production by dHEth fluorescence using flow cytometry. The 
analysis measured the emission of dHEth fluorescence  at 595 nm from 30,000 cells per sample. The experiment 
was performed three times using three separate cell preparations. Data was analysed by one way ANOVA and 
Tukey post-hoc analysis, making comparisons between treated cells and un treated cells and also as indicated. 
*p<0.05. Data are n=3.  115 
 
2.2.4.3.2  Optimised flow cytometry method 
To detect superoxide production in BV2 microglia, a protocol from Herrera et al. (2004) was 
followed. BV2 microglia were plated in 6 well plates at 10x10
4 cells per well and were grown 
to confluencey. The medium was changed to serum free medium for 3 h before treatment as 
shown in Table 1 in the presence or absence of apocynin for 24 h (to maintain consistency 
with this probe), or cells were left untreated to determine basal superoxide production. Cells 
were then incubated with 5 µM dHEth for 40 min before dissociation from the culture vessel 
using accutase. The culture medium was aspirated and cells were washed once with PBS 
before 100 µl accutase was added to the cells. Cells were returned to the incubator for 1 min 
and then tapped gently to detach the cells from the plates. Accutase activity was inhibited by 
the addition of 100 µl serum containing media to the cells, and this cell suspension was 
collected into a 15 ml Falcon tube and cells were pelleted by centrifugation at 3645 g for 
5 min (Eppendorf Centrifuge 5804R). The supernatant was aspirated and the cell pellet was 
resuspended in 2 ml PBS, transferred to a FACS tube, and kept on ice in the dark until 
analysis.  
Analysis of dHEth fluorescence was  measured  using a  Beckton  Dickenson  FACSCalibur 
flow cytometer. For each sample, cells were taken up into the flow cell and excited by a laser 
at 510 nm, which induced the emission of light at 595 nm from superoxide expressing BV2 
microglia  labeled  with  dHEth.  30,000  events  were  counted  and  analysed  with  CellQuest 
software, which then provided a measure of mean fluorescence intensity for each sample. 
Each experiment was performed three times using three separate cell preparations to enable 
the statistical analysis of mean fluorescence intensity for each condition.  
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2.2.4.4 HPLC detection of superoxide and hydrogen peroxide   
In-depth analysis of dHEth oxidation has revealed that it can be oxidised by superoxide but 
also hydrogen peroxide, to the non-specific product Eth. Furthermore, both 2-OH-E
+ and Eth 
can intercalate into the nucleus of ROS producing cells, making it difficult to distinguish 
between superoxide and hydrogen peroxide production by methods other than HPLC (Fink et 
al.  2004;  Laurindo  et  al.  2008).  The  fluorescence  microscopy  analysis  of  superoxide 
production used in this thesis (section 2.2.4.2) relies on the fact that superoxide reacts with 
dHEth to form a fluorescent ethidium product that intercalates within the nucleus of cells. 
However, as shown here, the production of hydrogen peroxide may produce false positive 
results, inducing the production of ethidium which also intercalates into the DNA of cells and 
fluoresces in the red spectrum. The main drawback of the imaging and FACS methods is that 
they  take  into  account  the  total  fluorescence  of  all  dHEth  products,  which  provides 
information about the total cell redox state rather than that of specific ROS (Laurindo et al. 
2008). With this in mind, and the fact that fluorescently, 2-OH-E
+ and Eth are difficult to 
distinguish with conventional fluorescence approaches, HPLC analysis was used to determine 
the relative amounts of 2-OH-E
+ and Eth produced following treatment of cells with the 
activating stimuli in the presence or absence of apocynin. This technique provides an accurate 
analysis of the separation and quantification of the superoxide specific product 2-OH-E
+ and 
the hydrogen peroxide derived product Eth (Fink et al. 2004).  
The method for HPLC analysis of dHEth oxidation followed was from Zielonka et al. (2008). 
HPLC with fluorescence and UV visible absorption was used for the detection of 2-OH-E
+ 
and ethidium. During HPLC, the mobile phase (50 mM phosphate buffer pH 2.6) is passed 
through a chromatography column (the stationary phase), which in this case was a Kromasil 
C18 column, under high pressure. The column contains C18 chains bonded to microscopic 
silicon beads, and hydrophobic interactions between the mobile phase and the C18 chains 117 
 
retard the progress of molecules as they are passed through the column. The time taken for a 
molecule to be eluted from the column (the retention time), depends on its hydrophobicity 
and is identical under the same conditions. Following elution from the column, molecules are 
passed through a UV and fluorescence spectrometer and fluorescence detection at 356 nm 
and 510 nm (excitation) and 595 nm (emission) in addition to absorbance at 220, 250, 290, 
370  and  500  nm  were  used  to  monitor  the  reaction  products  in  the  sample.  Peaks  seen 
following  fluorescence  excitation  at  510 nm  and  emission  at  595  nm  corresponded  to 
2-OH-E
+ and ethidium, depending on the retention time that the peaks were observed at, and 
the peak areas were measured and compared with the standards to calculate the concentration 
of the test sample. The retention times for Eth and 2-OH-E
+ were reported to be 15 and 12 
min respectively (Zielonka et al. 2008). Ethidium exhibited a significant absorbance peak at 
290 nm, with a retention time of 15 min, which could be used to confirm that the peak 
observed in the fluorescence spectra could be attributed to ethidium (Zielonka et al. 2008).  
2.2.4.4.1  Preparation of standards   
Standards  of  2-OH-E
+,  ethidium  and  dHEth  were  prepared.  Ethidium  and  dHEth  were 
obtained from Invitrogen and were diluted from stock solutions to genetrate a concentration 
gradient  that  could  be  subjected  to  HPLC  analysis  to  construct  the  standard  curves  for 
analysis of  ethidium and dHEth concentrations in  the sample. The synthesis  of 2-OH-E
+ 
depended on the oxidation of dHEth using potassium nitrosodisulfonate (Fremy‟s salt). To 
synthesise 2-OH-E
+, a 1 mM stock of Fremy‟s salt was first prepared. 3.6 g of the Fremy‟s 
salt was reconstituted in 10 ml of 50 mM phosphate buffer (pH 7.4) containing 100 µM 
diethylene triamine pentaacetic acid (DTPA), which promoted the dissociation of the yellow 
dimeric Fremy‟s salt to the blue monomeric form of the nitroxide radical, which promotes the 
oxidation of dHEth to 2-OH-E
+. It was important that the UV-visible absorption spectrum (at 
248 and 545 nm) of the dissolved Fremy‟s salt was recorded
 to enable a subtraction of any 118 
 
contaminating Fremy‟s salt in the final synthesised 2-OH-E
+. The concentration of Fremy‟s 
salt was then calculated by:  
Ccuvette[mol/dm
3] = A / ε [dm
3 mol
-1 cm
-1] x l [cm] 
Where: A is the absorbance values at 248 and 545 nm, ε is the extinction co-efficient value of 
1.69 x 10
3 and 20.8 dm
3 mol
-1 cm
-1 at 248 and 545 respectively, and l is the optical path 
length (1 cm).  
Following  the  calculation  of  Fremy‟s  salt  concentration,  dHEth  was  prepared  by  adding 
200 µM dHEth in DMSO to 24 ml of water containing 4 ml of 0.5 mM phosphate buffer pH 
7.4 containing 4 ml of  1 mM  aqueous  DTPA. After mixing, 2-OH-E
+  was  generated by 
adding 8 ml of 1 mM Fremy‟s salt to the dHEth solution and the reaction was left at room 
temperature for 2 h. To determine the production and retention time of 2-OH-E
+ the product 
was analysed by HPLC after dilution in 0.5 mM phosphate buffer pH 2.6 (Fig. 2.15A). HPLC 
analysis of the ethidium (Fig. 2.15B) and the dHEth (Fig. 2.15C) standards diluted in 0.5 mM 
phosphate buffer pH 2.6 was also performed to determine purity and to obtain the retention 
times of these standards.  119 
 
 
 
 
Figure 2.15 HPLC chromatograms of 2-OH-E
+ (A), Ethidium (B) and dHEth (C). Standards of 2-
OH-E
+, Ethidium and dHEth were subjected to HPLC analysis after dilution to 15 µM in 0.5 mM 
phosphate buffer pH 2.6. The chromatograms show that the retention time for 2-OH-E
+ is 12 min, 
and that the 2-OH-E
+ generated contains some contaminating ethidium (retention time 15 min).The 
retention  time  for  dHEth  was  20  min,  and  it  can  be  seen  that  the  dHEth  contains  some 
contaminating  ethidium  and  2-OH-E
+  which  may  be  present  as  a  consequence  of  oxidation  of 
dHEth during storage and following exposure to light.   
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 As shown in the chromatograms (Fig. 2.15), the retention time of 2-OH-E
+ was found to be 
12 min, and that of ethidium was shown to be 15 min. The 2-OH-E
+ synthesised exhibited a 
small peak at 15 min, suggesting the presence of contaminating ethidium, which was also 
reported by Zielonka et al. (2008). The retention time of dHEth was shown to be 20 min, and 
this standard contained ethidium and 2-OH-E
+ contamination, which occurs through storage 
and exposure to light, that can partially oxidise the probe (Zielonka et al. 2008).  
It was next important to construct a standard curve of the 2-OH-E
+, Eth and dHEth standards, 
to  enable  the  calculation  of  concentrations  of  the  2-OH-E
+  and  the  Eth  products  in  the 
biological samples tested. Standards were prepared in  a range of concentrations: 20 µM, 
15 µM, 10 µM, 5 µM and 0 µM, and each concentration was run in triplicate and the HPLC 
analysis for the standard curves was performed three times (Fig. 2.16).  
 
 
 
 
Figure 2.16. Standard curves of 2-OH-E
+, Ethidium, and dHEth. Standard curves of the 2-OH-E
+, ethidium 
and dHEth standards were generated following dilution of the stocks to 5 µM, 10 µM, 15 µM and 20 µM. Each 
standard was run in triplicate and the HPLC was performed three times (n=3). The standard curve was then 
used to calculate the concentration of 2-OH-E
+ and ethidium present in the biological samples tested.  121 
 
2.2.4.4.2  Preparation of cells 
Cells were prepared according to Zielonka et al. (2008). BV2 microglia were plated in 24 
well plates at a density of 5x10
4 cells per well and were grown to confluencey. The medium 
was changed to serum free medium 3 h prior to treatment as described in Table 1 for 24 h. 
After 24 h, cells were incubated with 5 µM dHEth for 40 min, after which the reaction was 
stopped by removing the culture medium and washing cells with ice-cold PBS. The cells 
were scraped immediately into 1 ml of ice-cold PBS and transferred to Eppendorf tubes on 
ice. The cells were then pelleted by centrifugation for 5 min at 1000 g at 4ᵒC (Eppendorf 
5415R benchtop centrifuge), and the supernatant was aspirated and the pellet was lysed in 
150 µM ice-cold PBS containing 0.1% (v/v) of Triton X-100 using an insulin syringe. The 
un-lysed cells were spun down by centrifugation for 5 min at 1000 g at 4ᵒC, and 100 µl of the 
supernatant  was  retained  and  added  to  fresh  Eppenorf  tubes  containg  100  µM  of  0.2 M 
HClO4 in methanol, which promoted the precipitation of the protein from the lysates. The 
samples were left on ice for 2 h to allow protein precipitation. 2 µl of the remaining cell 
lysate was retained for the analysis of protien levels by Bradford assay (see section 2.2.6.2.2) 
which was used later to normalize the levels of 2-OH-E
+ and Eth to protein concentration. 
After 2 h, the precipitated protein was centrifuged for 30 min at 20,000 g at 4ᵒC. 100 µM of 
the  supernatant  was  transferred  to  Eppendorf  tubes  containing  100  µM  phosphate  buffer 
pH 2.6, and the excess buffer and KClO4 was precipitated by centrifugation at 20,000 g at 
4ᵒC for 15 min. 150 µM of the supernatant was transferred HPLC vials which were placed 
into an autosampler cooled to 4ᵒC (Jasco AS-2055 Plus). When all samples were prepared, 
the HPLC analysis was performed.   
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2.2.4.4.3  HPLC detection of 2-OH-E
+ and Eth 
HPLC with fluorescence and UV-visible absorption detection was performed using a Jasco 
HPLC  system  equipped  with  UV  (Jasco  UV-975)  and  fluorescence  (Jasco  FP-1520) 
detectors. To separate 2-OH-E
+ and ethidium, 50 µM of each sample was injected into the 
HPLC system using a cooled autosampler (Jasco AS-2055 Plus) through a 1 cm x 4.6 mm 
Kromasil C18 guard column into a Kromasil C18 analytical column (3.9 x 150 mm, 5 µM 
particle  size).  A  gradient  elution  method  with  two  mobile  phases  was  used  to  separate 
2-OH-E
+ and ethidium: A – 50 mM phosphate buffer (pH 2.6), 10% acetonitrile, 90% water; 
and B – 50 mM phosphate buffer (pH 2.6) 60% acetonitrile buffer, 40% water. The elution 
conditions are shown in Table 4. The mobile phase was pumped through the column with a 
Jasco PU-1580 pump, with a flow rate of 0.4 ml / min which was used to pass the sample 
through  the  column  to  the  detectors.  With  this  set-up,  the  pressure  in  the  column  was 
maintained at 50-70 kg/cm
2, and each HPLC run took 60 min.  
Time (min)  Mobile Phase A (%)  Mobile phase B (%) 
0  80  20 
10  55  45 
30  45  55 
40  0  100 
46  0  100 
50  80  20 
Table  4.  Elution  conditions  for  the  analysis  of  dHEth  and  2-OH-E
+  and  ethidium 
oxidation products by HPLC with fluorescence detection. 
Fluoresence detection at 356 and 510 nm (excitiation) and 595 nm (emission) were used to 
detect 2-OH-E
+ and ethidium production, whilst absorbance at 220, 250, 290, 370 and 500 
nm were used to monitor the levels of ethidium and dHEth not converted to either product in 
the sample. The sample was passed from the detector to the integrator which displayed the 
chromatogram in real time using Jasco EZChrom software.  To quantify the dHEth derived 123 
 
fluorescent  products,  the  peak  areas  of  2-OH-E
+  and  ethidium  were  measured  and  were 
compared  with  the  standard  curves  generated  from  the  2-OH-E
+  and  ethidium  standards. 
Peaks at retention times of 12 min and 15 min were analysed, as these were shown to be the 
retention times of 2-OH-E
+ and ethidium respectively. No residual dHEth was observed in 
biological  samples  tested.  Example  chromatograms  of  control  untreated  cell  lysates 
(Fig.2.17A)  and  of  PMA  cell  lysates  (Fig.  2.17B)  are  shown.  The  area  /  concentration 
correlation obtained from the 2-OH-E
+ and ethidium standards were used to calculate the 
concentrations of each product in the test sample by comparison. This was normalised for 
protein content and data was expressed as nmol (2-OH-E
+ or ethidium) / mg protein.  
Initially,  HPLC  was  performed  on  cell  samples  treated  with  the  positive  control  PMA 
(10 ng/ml) and the NADPH oxidase inhibitor apocynin (10 µM) to ensure that the protocol 
was effective (Fig. 2.17C). As shown, the preliminary studies using PMA demonstrate that 
treatment  of  cells  with  PMA  induces  a  significant  increase  in  2-OH-E
+  which  could  be 
significantly  attenuated  upon  co-treatment  of  cells  with  apocynin,  suggesting  that  PMA 
induces  superoxide  production  in  an  NADPH  oxidase  dependent  manner.  Furthermore, 
control untreated cell and apocynin treated cells also only exhibit low levels of 2-OH-E
+ and 
Eth production (Fig. 2.17C). These investigations therefore suggested that HPLC analysis of 
dHEth oxidation products was suitable for the quantitative analysis of superoxide production 
in BV2 microglia.  
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Figure 2.17 Example chromatograms and HPLC analysis dHEth oxidation products from cells treated with 
PMA in the presence or absence of apocynin. The example chromatograms show peaks corresponding to  2-
OH-E
+ (12 min retention time) amd ethidium (15 min retention time) in control (A) or PMA (B) treated BV2 
microglia. Cells treated as shown in (C) were analysed in triplicate and the concentration of 2-OH-E
+ and 
ethidium were calculated from the peak areas which were compared with the known standards and data was 
normalized to protein concentration. Statistical analysis was performed using students T-Tests for comparison 
between  treatments,  and  two  way  Anova  for  comparisons  between  2-OH-E
+  and  Eth  for  each  treatment. 
*p<0.05. Data are n=3.   125 
 
2.2.5  NADPH oxidase activity assay 
It is known that the NADPH oxidase converts molecular oxygen to superoxide through the 
oxidation  of  NADPH  to  NADP  plus  H
+,  therefore  an  assay  to  determine  the  enzymatic 
activity of the NADPH oxidase was devised by Brightman et al. (1992). NADPH has an 
absorbance spectrum at 340 nm, and the reduction in absorbance at 340 nm is proportional to 
the decrease in NADPH through its consumption by the NADPH oxidase  (Thannickal & 
Fanburg 1995). It was shown that NADPH has an absorption coefficient of 6.22 mM
-1cm
-1, 
which was used to calculate the amount of NADPH consumed during the assay (Thannickal 
& Fanburg 1995). For investigation into specific oxidase activities, for example the NADPH 
oxidase, Thannickal & Fanburg (1995) used DPI, an NADPH oxidase inhibitor to show that 
activation  with  a  specific  stimuli  induced  NADPH  oxidase  activation.  Here,  the  same 
approach has been used with apocynin to show that the NADPH oxidase could be activated 
with the stimuli shown in Table 1.   
2.2.5.1 Optimised protocol for NADPH oxidase activity assay  
The protocol followed was optimised from Carmona-Cuenca et al. (2008). BV2 microglia 
were plated in 6 well plates at a density of 1x10
5 cells per well and were grown to confluency. 
After this time, medium was changed to serum free media for 3 h before cells were activated 
initially with the known NADPH oxidase activators PMA (10 ng/ml) and LPS (1 μg/ml). 
Cells were treated in the presence or absence of apocynin, administered 30 min before the 
reading  (Thannickal  &  Fanburg  1995)  so  that  NADPH  reduction  could  be  attributed  to 
activity of the NADPH oxidase rather than any other system. To determine the optimum time 
point  at  which  the  NADPH  oxidase  was  significantly  active  when  compared  to  control 
untreated cells or apocynin treated cells, a time course analysis was performed (Fig. 2.18) 
which showed that 4 h incubation with the activators PMA (Fig. 2.18A) or LPS (Fig. 2.18B) 
induced  a  significant  increase  in  NADPH  oxidase  activity,  which  could  be  inhibited  by 126 
 
apocynin. Therefore during the assay, cells were incubated at 37ºC at 6% CO2 for 4 h with 
the activators shown in Table 1. After this, cells were removed from the incubator, and were 
washed once with PBS, before detachment from the culture vessels using 500 µl accutase. 
Once detached, accutase was neutralised with an equal volume of serum containing media. 
The 1 ml cell suspension was transferred to an Eppendorf tube and centrifuged at 2500 g at 
4ºC (Eppendorf 5415R benchtop centrifuge) for 5 min. The resulting pellet was resuspended 
in 300 µl PBS and transferred to a 96 well plate, where 100 µl of each sample was transferred 
to each well (therefore each sample was tested in triplicate). Immediately before the plate was 
read  in  the  plate  reader,  250  µM  NADPH  was  added  to  each  well,  and  the  decrease  in 
absorbance as NADPH was converted to NADP was measured at 340 nm every minute for 
10 min using a Tecan x fluo4 plate reader. The raw data were plotted and a graph showing 
the gradient was used to calculate the initial rate of activity. 
To determine the protein concentration in each sample, an aliquot of cells were lysed in lysis 
buffer and a Bradford protein assay was performed on each sample (see section 2.2.6.2.2). 
This information, along with that of the initial rate of activity and the absorbance extinction 
co-efficient  for  NADPH  (6.22mM
-1cm
-1)  then  allowed  determination  of  how  many 
micromoles one microgram of protein could convert to product in 1 min. Data was expressed 
in μM NADP / μg protein / min, and was calculated using the equation C=A/(ExL) where C 
is the concentration of NADP reduced by the NADPH oxidase, A is the absorbance (the 
gradient  of  the  initial  rate  of  reaction),  E  is  the  extinction  coefficient  of  NADPH 
(6.11 mM
1cm
-1) and L is the path length (1 cm).  127 
 
 
Figure 2.18 Time course analysis of NADPH oxidase activity. BV2 cells were treated with the NADPH 
oxidase activators PMA 10 ng/ml (A) or LPS 1 μg/ml (B) in the presence or absence of apocynin 10 μM 
administered  for  30  min  before  the  reading.  The  time-course  analysis  shows  that  there  is  a  significant 
increase  in  NADPH  oxidase  activity,  which  can  be  inhibited  by  apocynin  at  2,  4,  and  8  h  incubation. 
Statistical analysis was performed using a one way ANOVA with Tukey post-hoc analysis, and comparisons 
were made between treatment and treatment plus apocynin and treatment and control groups. ***p<0.001, 
**p<0.01 and *p<0.0. All data are n=3. 
 
2.2.6  Expression analysis  
2.2.6.1 mRNA analysis using reverse transcription and polymerase chain reaction 
Reverse  transcription  and  polymerase  chain  reaction  (RT-PCR)  enables  the  analysis  of 
expressed (transcribed) genes of interest. The method is semi-quantitative, however provides 
an insight into modulation of gene expression. The protocol has four stages: RNA extraction, 
in  which  total  RNA  is  isolated  from  the  cell  culture;  reverse  transcription,  in  which  a 
complementary  (cDNA)  copy  of  the  RNA  is  produced  from  the  cells  using  an  RNA 
dependent DNA polymerase; PCR in which the gene of interest is amplified using specific 
primers for sections of the gene to be analysed; and finally the PCR products are resolved by 
agarose gel electrophoresis and imaged using a UV-transilluminator.  
The principle behind RT-PCR therefore depends on the extraction of RNA which can be 
converted  into  cDNA,  and  also  on  the  specificity  of  the  PCR  primers.  PCR  primers  are 
designed complementary to a section of the cDNA of interest, therefore ensuring that the 
PCR reaction is specific to a particular gene.    128 
 
2.2.6.1.1  RNA extraction 
Primary microglia were used for RT-PCR analysis. Cells were plated at 1x10
6 cells per well 
in 6 well plates, and following serum deprivation for 3 h, cells were treated according to 
Table 1 for 24 h before RNA was extracted. RNA extraction was performed using a modified 
acid guanidinium thiocyanate-phenol-chloroform extraction method (Chomczynski & Sacchi 
1987). Cells were lysed with 1 ml Trizol and incubated at room temperature for 5 min, before 
200 µl chloroform was added and samples were shaken vigorously then incubated at room 
temperature for 2 min to begin the separation of protein, DNA and RNA. Samples were 
centrifuged  at  11600  g  for  15  min  at  4  ºC  (Eppendorf  5415R  benchtop  centrifuge). 
Chloroform and centrifugation promotes phase separation, in which RNA can be found in the 
top aqueous layer, DNA is found in the white middle layer, and protein is isolated in the pink 
lower layer. The top aqueous layer was therefore removed and retained, and from this, RNA 
was precipitated with 500 μl isopropyl alcohol, followed by incubation at room temperature 
for 10 min. The samples were then centrifuged again at 11600 g for 10 min at 4 ºC, and the 
supernatant was discarded leaving the RNA pellet, which was washed with 1 ml 75% ethanol 
and centrifuged at 6200 g for 5 min at 4 ºC. The supernatants were discarded and the pellet 
was  air  dried  then  dissolved  in  an  appropriate  volume  of  DEPC  dH2O  (typically  10 µl). 
Samples were heated to 60 ºC for 10 min to aid dissolving. RNA concentration was measured 
by absorbance at A260/280 (Ultrospec 2000 UV/Visible spectrophotometer, Pharmacia Biotec). 
The A260/280 ratio indicates the purity of the RNA, where pure RNA has a ratio of 2. RNA 
concentration was calculated using the Beer-Lambert law, which states that: 
 
A260 = RNA extinction coefficient (25 µl.µg
-1.cm
-1 x RNA concentration (μg.μl
-1)) x 
path length (1 cm).  
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Therefore, RNA concentration (μg.μl
-1) = A260 x 40 x dilution factor  
 
In this case, [RNA] (μg.μl
-1) = A260 x ((400/3) x 40 / 1000) = A260 x (16/3) 
 
The RNA concentration was required to determine the volume of isolated RNA required to 
reverse transcribe 3 µg RNA in the next step of the reaction.  
2.2.6.1.2  Reverse transcription  
Total RNA was reverse transcribed to cDNA using the Superscript Reverse Transcriptase kit 
(Invitrogen) according to manufacturer‟s instructions. The superscript reverse transcriptase is 
isolated from  the Moloney murine leukaemia virus (M-MLV) and is  an RNA dependant 
DNA polymerase used to synthesise first strand cDNA for use in PCR.  For each reaction 
3 μg RNA was used, which was first incubated with 1 μL Oligo dT primer12-18, 1 μl 10 mM 
dNTP mix and distilled water to 12 μl. The solution was incubated at 65 ºC for 5 min, to 
promote annealing of the primer to the single stranded RNA. The reaction was then quenched 
on  ice.  Following  this,  4 μl  5  x  first  strand  buffer,  2  μl  0.1  M  DTT  and  1  μl  40  U/ml 
ribonuclease inhibitor RNase out was added to each sample, resulting in a final volume of 
19 µl. The reaction was then incubated at 42 ºC for 2 min to prime the reaction before the 
addition of 1 μl (equivalent 200 U / reaction) of Superscript II Reverse Transcriptase, giving 
a final volume of 20 µl. Samples were then incubated at 42 ºC for 50 min, and the reaction 
was inactivated by heating to 70 ºC for 15 min. The resulting cDNA samples were subjected 
to PCR analysis. A sample was run alongside each RT reaction that contained no reverse 
transcriptase, as a negative control to check for contamination with DNA, which could occur 
during the RNA extraction stage. This was subjected to PCR with primers for a housekeeping 
gene such as β-actin.  130 
 
 
 
Figure 2.19 The polymerase chain reaction. PCR begins with the melting of the DNA duplex using high 
temperatures to break the bonds between the base-pairs. Primers then anneal to their complementary DNA, 
and Taq polymerase synthesizes the complementary strand by aiding the addition of dNTP’s to the primer. 
This is repeated, and gives rise to an exponential increase in copy number of the DNA.  
2.2.6.1.3  Polymerase Chain Reaction (PCR) 
PCR amplification of reverse transcribed RNA results in the production of a single amplicon, 
as only the gene of interest is transcribed due to the use of unique primers to amplify a small 
region of the cDNA of interest. PCR amplification of a gene of interest relies on temperature 
changes that direct the annealing of primers, the elongation of the sequence from the primer 
sites and finally the melting of the double stranded product to enable further annealing of 
primers, and subsequent elongation (Fig. 2.19).  131 
 
The process is exponential, producing a high copy number of DNA. Temperature changes 
therefore  control  PCR, with  an initial  high temperature (typically in the region of 95ºC) 
driving  the  melting  of  double  stranded  DNA  to  expose  the  complementary  sites  for  the 
annealing of the primers. The next temperature therefore determines the annealing of the 
primers, and is termed the optimal annealing temperature (OAT), which is calculated for each 
individual primer and is averaged for the primer pair. This is calculated by: 
OAT = Tm - 4ºC 
Where Tm is the melting temperature of the DNA, which is calculated from the G/C content, 
and is calculated by: 
Tm = 4(G+C) + 2(T+A) ºC 
The interaction between G-C base pairs involves 3 hydrogen bonds, which requires a higher 
energy to break than the A-T base pairs, which only contains 2 hydrogen bonds. The melting 
temperature  is  therefore  driven  by  G-C  content,  and  primers  are  designed  to  contain 
approximately 50% G/C bases, as this provides a strong bond between the template DNA and 
primer, without requiring too high an annealing temperature. The annealing temperature is 
typically around 60ºC which must be significantly different from the elongation temperature. 
In the elongation phase, the DNA polymerase,  Thermophilius Aquqticus (Taq) is used to 
polymerise the formation of a complementary strand of DNA from the primers using the 
dNTPs in the PCR mix. The Taq polymerase was isolated from the Thermophilius Aquaticus 
bacterium found in hot springs, which enables it to withstand the high temperatures of PCR. 
Typically  the  elongation  stage  is  carried  out  at  72ºC,  the  optimum  temperature  for  Taq 
polymerase activity. Each dissociation- annealing – elongation cycle doubles the amount of 
DNA so that the reaction increases DNA product exponentially. With each gene of interest 132 
 
analysed in this thesis, the number of cycles was optimised to ensure that no artefacts of the 
PCR reaction were generated.  
Here,  cDNA  was  subjected  to  PCR  amplification  to  investigate  the  expression  of  Nox1, 
Nox2, Nox4, TNFʱ, and the GABA receptor subunits, using β-actin as a housekeeping gene 
in microglia and CGCs (primer sequences shown in Table 4). The Promega GoTaq Flexi 
DNA polymerase kit was used to amplify DNA according to manufacturer‟s instructions. 
Each reaction contained 2 μl cDNA (reverse transcribed from total RNA as above), and 10 μl 
5X Go-Taq flexi buffer, 2.5 mM MgCl (2 μl), 1 μl of 10 mM dNTPs, 2.5 μM each primer 
(primers were custom made by Sigma and were supplied at 100 μM, sequences shown in 
Table 5), 5 U/ml GoTaq polymerase (0.25 μl) and nuclease free water to 50 μl.  
PCR was performed in a thermal cycler (GeneAmp PCR system 9700, Applied Biosystems) 
using the following conditions: 95ºC for 2 min for initial annealing of primers, followed by 
30 cycles of 95ºC for 45 s for separation of double stranded DNA, 59ºC for 45 s for primer 
annealing, 72ºC for 45 s for extension and elongation of the DNA construct, followed by a 
final elongation stage at 72ºC for 10 min, and finally 4ºC for storage.  
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Primer  Forward sequence (5’-3’)  Reverse sequence (5’-3’)  Fragment Size  
Nox1 Rat  CATAAGATGGTAGCTT
GGAT 
GAGTGCTACTGAATA
TGGGT 
115 bp 
Nox2 Rat  AAGCCATTGGATCACA
ACCT 
GGCTTCTACTGTAGC
GTTCA 
123 bp 
Nox4 Rat   TGACTGAGGTACAGTG
GATGTT 
CCTGAGGTTACAGCT
TCTACCT 
100 bp 
TNFʱ  CCCAGACCTCACACTA
GTATC 
TCGTAGCAAACCACC
AAGCAG 
150 bp 
GABAA  Receptor 
ʱ1 subunit  
TGACAGTCATTCTCTC
CCAAGTC 
TCAGAACGGTCGTCA
TCC 
100 bp 
GABAA  Receptor 
ʱ2 subunit  
GGTTTCCGCTGCTTGTT
CT 
TTCTTGGATGTTAGCC
AGCAC 
150 bp 
GABAA  Receptor 
ʱ3 subunit  
GGTCATGTTGTTGGGA
CAGA 
TCAGATGAAAGTGGG
TTGTCA 
173 bp 
GABAA  Receptor 
ʱ4 subunit  
CTTCTGGATCAATAAG
GAGTCTG 
TCATCGTGAGGACTG
TGGTT 
125 bp 
GABAA  Receptor 
ʱ5 subunit  
GGTCTTGGATGGCTAT
GAC 
ACCTGCGTGATTCGC
TCT 
110 bp 
GABAA  Receptor 
ʱ6 subunit  
AATGTCAGTCGGATTC
TTGACA 
TTTTGACCTCTGTTAC
AGCACCT 
150 bp 
GABAA  Receptor 
β1 subunit  
CAAACTGGAGATGAAC
AAAGTC 
CCAGGGTGCTGAGGA
GAATA 
125 bp 
GABAA  Receptor 
β2 subunit 
GGGTCTCCTTTTGGAT
CAACTA 
GGTCATCGTCAGGAC
AGTTGTA 
683 bp 
GABAA  Receptor 
β3 subunit 
TCATGGGTGTCCTTCT
GGAT 
ATGGTGAGCACGGTA
AT 
500 bp 
GABAA Receptor γ1 
subunit 
TCATGGACTATGGAAC
CTTGC 
GCATGGAGGACCTGG
GGTA 
175 bp 
GABAA Receptor γ2 
subunit 
TGCTCACTGGATCADG
ACTC 
ATTGCAACTGGCACT
CAGC 
150 bp 
GABAA Receptor γ3 
subunit 
AGCCTTCAAGCACCCT
CTAA 
CGTGCCAGTACATGG
AATTG 
150 bp  
β-actin Mouse, Rat  ATCGTCGGCCGCCCTA
GGCAC 
TGGCCTTAGGGTTCA
GAGGGGC 
243 bp 
 
Table  5.  PCR  primers  Primers  were  designed  using  the  Roche  primer  design  tool  and 
generated by Sigma. β-actin primers were from sigma, and are standard non-custom primers.  
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2.2.6.1.4  Resolution of PCR products  
The  PCR  products  were  resolved  on  a  1%  agarose  gel  (agarose  dissolved  in  1x 
Tris/borate/EDTA  (TBE)  buffer),  containing  0.5  μg/ml  ethidium  bromide,  and  were 
visualised by UV illumination of intercalated ethidium bromide using a UV transilluminator 
(GelPro Imager). Images were captured using a CoolSNAP-Pro camera, and band densities 
were determined using ImageJ. The densities of the bands correspond directly to the amount 
of mRNA in the original sample. 
2.2.6.2 Western blotting  
Western blotting is a gel electrophoresis and blotting method used to separate and identify 
proteins of interest in a biological sample. The technique was used in this thesis to determine 
the expression levels of different proteins of interest. Here, denaturing gels were used, and 
the Western blotting protocol relied upon the denaturation of all expressed proteins in the 
cell, of which single proteins could be identified by immunoblotting with antibodies directed 
against epitopes of the proteins of interest. The technique begins with cell lysates, which are 
denatured by the addition of sodium dodecyl sulphate (SDS) which cleaves disulphide bonds, 
reverting the proteins to their primary structure. SDS also coats the proteins in a negative 
charge, so that they may not re-fold. Following lysis, lysates are subjected to a protein assay 
to determine the amount of total protein present, so that an equal amount may be loaded onto 
the gel to ensure that any differences in band intensity are a result of modulation of protein 
expression rather than a difference in loading. Following the loading of protein into a sodium 
dodecyl sulphate polyacrylamide gel, electrophoresis is performed (SDS - PAGE) by passing 
an electrical current through the gel so that the negatively charged proteins migrate to the 
positive electrode (the cathode). Polyacrylamide gels are made with different percentages of 
acrylamide according to the molecular weight of the protein of interest, as lower molecular 
weight proteins migrate faster through the gel  than higher molecular weight proteins.  To 135 
 
investigate a low molecular weight protein, a higher percentage gel is required. Following 
SDS-PAGE,  proteins  are  transferred  onto  a  polyvinylidine  fluoride  (PVDF)  membrane, 
which is a positively charged material that the negatively charged proteins bind to. Following 
transfer, the membrane  is  incubated with  primary  antibodies of interest which are raised 
against a specific epitope of a protein of interest. To visualise the bands on the membranes, 
secondary antibodies conjugated to horseradish peroxidise (HRP) are used, and visualisation 
is by enhanced chemiluminescense (ECL).  
2.2.6.2.1  Cell lysis and sample preparation 
CGCs, and primary microglia were used for Western blot analysis. Cells were prepared as 
described previously and were lysed in 15 µl lysis buffer containing 20
 mM Tris-acetate 
buffer (pH 7), 1 mM ethylene diamine tetraacetic acid (EDTA) to chelate calcium, 1 mM 
ethylene glycol tetraacetic acid (EGTA) to chelate magnesium, 10 mM of the phosphatase 
inhibitor  sodium-β-glycerophosphate,
  1  mM  of  the  tyrosine  phosphatase  sodium 
orthovanadate, 5% glycerol to depress the solution‟s freezing temperature, 1% Triton X-100 
membrane solubiliser, 0.27 M
  sucrose, 1 mM of the protease inhibitor benzamidine, 4 µg/ml 
of the protease inhibitor leupeptin, 1 μM of the phosphatase inhibitor microcystin LR and 
0.1% of the reducing agent  -mercaptoethanol (Evans & Pocock, 1999; Kingham & Pocock, 
2000). Samples were left on ice for 30 min and then centrifuged for 5 min at 10 000 g to 
pellet  the  nuclear  fraction.  Supernatants  (the  cyosolic  fraction)  were  transferred  to  new 
eppendorf tubes and all samples were stored at -20
oC until used. The formulation of the lysis 
buffer is such that the buffer lyses the cells and also solubilises the membranes, in addition to 
preserving the proteins at the time of lysis by preventing phosphorylation, dephosphorylation 
and proteolysis.  136 
 
2.2.6.2.2  Bradford assay 
The  Bradford  assay  was  used  to  determine  the  total  protein  concentration  of  the  sample 
(Bradford, 1979). As all proteins of interest studied in this thesis were cytosolic, the cytosolic 
fractions were measured for protein content. In a 96 well plate, 1 µl of each sample was 
placed into one well – each sample was measured in triplicate, and 200 µl Bradford reagent 
was added onto this. Samples were shaken and left at room temperature for 5 min before the 
absorbance shift of the Coomassie dye towards the blue spectrum following the binding of 
protein was measured at 595 nm on a Tecan X Fluor 4 plate reader. The absorbance of each 
sample was compared to a standard curve of BSA of known concentrations, constructed on 
the same plate as each experimental sample. From this, the volume of lysate required for each 
sample  to  contain  45  µg  of  protein  was  derived,  and  samples  were  removed  to  another 
Eppendorf  tube.  To  these  samples,  an  equal  volume  of  sample  buffer  (2%  SDS,  10% 
glycerol, 2.5% mercaptoethanol, 125 mM Tris/HCl  (pH 6.8) and a few bromophenol blue 
crystals  (Laemmli,  1970))  was  added  to  denature  the  protein,  and  to  aid  loading  and 
visualisation of the gel front. Samples were then boiled for 5 min before loading.  
2.2.6.2.3  SDS-PAGE 
Bio-Rad mini gel apparatus were used to cast polyacrylamide gels fresh on the day of the 
experiment. As mentioned previously, the percent of the gel was changed depending on the 
molecular  weight  of  the  protein  of  interest.  Typically,  gels  were  used  at  10%  and  12% 
polyacrylamide (Table 5), with the higher percentage gel used for the separation of lower 
molecular weight proteins. Gels were cast between two glass plates separated by spacers 
mounted on a pouring stand. Resolver gel was made first and poured between the glass plates 
(Table 6). The resolver buffer was composed of 1.4 M Tris Base and 0.1% SDS at pH 8.8. 
The  ammonium  persulphate  (APS)  and  the  N,  N,  N',  N'-tetramethylethylenediamine 137 
 
(TEMED) are setting agents added to the gel just before pouring. Gels were topped wth 100% 
ethanol to level off the interface and were left to set for around 1 h.  
Resolver Gel 10%  Resolver Gel 12 %  Stacker gel 4% 
3.33 ml 30% Polyacrylamide   4 ml 30% Polyacrylamide   1.33 ml 30% polyacrylamide  
2.5 ml Resolver buffer (pH 7.8)  2.5 ml Resolver buffer (pH 7.8)  2.5 ml Stacker buffer (pH 6.8) 
4.17 ml H2O   3.5 ml H2O  6.17 ml H2O 
50 µl 10% APS (fresh)  50 µl 10% APS (fresh)  50 µl 10 % APS (fresh) 
5 µl TMED  5 µl TMED  5 µl TMED 
Table 6. Composition of resolver gels for 10% and 12% gels and stacker gel 
Stacker gels were layered on top of the set resolver gels. The stacker gels were made as 
shown in Table 5 with stacker buffer made of 0.5 M Tris base and 0.1% SDS at pH 6.8. A 
comb was placed into the gel, which was left to set for a further hour.  
Once set, the gels were placed into a holder and into a gel tank, which was filled with running 
buffer (125 mM Tris/HCl, 1 M glycine, 0.01% SDS) and the prepared samples were loaded 
into  each  well.  Gels  were  electrophoressed  at  150  V  until  the  proteins  were  separated 
completely. After the proteins  had separated, the  gels  were removed from  the tanks  and 
equilibrated in ice cold transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, 0.01% 
SDS) for 20 min. At the same time, fiber pads and 3 mm filter paper was also soaked in 
transfer buffer. Whilst the gel was equilibrating, the PVDF membrane was activated in ice 
cold methanol for 1 min, after which the membrane was washed in dH2O for 5 min. The 
membrane was then soaked in transfer buffer until the gels were ready for transfer.  
2.2.6.2.4  Transfer  
Proteins were transferred onto PVDF membrane using a wet transfer system. One pre-soaked 
fibre pad was placed onto the black side of the transfer cassette. A piece of 3 mm filter paper 
was put on top of this, and then the gel was laid onto the paper. The membrane was then 
carefully laid over the gel, and a further piece of 3 mm filer paper was put over that. Air 138 
 
bubbles were removed from the stack, and the final fibre pad was added, and cassettes were 
then closed. The cassettes were then placed into a holder which was put into a tank filled with 
transfer buffer and an ice pack. A current of 80 V was applied for 1 h which allowed proteins 
to transfer onto the membrane. The proteins migrated from the negative anode to the positive 
cathode, and attached to the positively charged membrane. Following transfer, membranes 
were washed in Tween-20 Tris buffer saline (TTBS: 10 mM Tris HCl, 150 mM NaCl, 0.5% 
Tween-20,  pH  7.4)  for  10  min,  and  membranes  were  then  blocked  in  5%  non-fat  milk 
solution in TTBS for 1 h to prevent non-specific binding of the antibody. The membranes 
were then ready for immunoblotting.  
2.2.6.2.5  Immunoblotting  
After blocking with 5% non-fat milk solution, membranes were incubated with the primary 
antibody  diluted  in  5%  non-fat  milk  as  shown  in  Table  7.  Typically  membranes  were 
incubated with the primary antibodies overnight at 4ºC on an orbital shaker. 
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Primary Antibody  Dilution and 
incubation 
Corresponding 
secondary antibody 
Dilution and 
incubation 
Rabbit anti mouse 
iNOS (BD transduction 
lab 610333) 
1:5000 2 h room temp  Goat anti-rabbit IgG 
peroxidise 
(Sigma A-0545) 
1:2000 1 h room temp 
Rabbit monoclonal anti 
phospho-p38MAPK 
(Thr 180/ Tyr 182) 
(Cell Signalling 
Technology 9211S) 
1:1000 overnight 4ᵒC  Goat anti-rabbit IgG 
peroxidise 
(Sigma A-0545) 
1:2000 1 h room temp 
Rabbit polyclonal anti 
total p38MAPK (Santa 
Cruz SC-7149) 
1:1000 overnight 4 ᵒC  Goat anti-rabbit IgG 
peroxidise 
(Sigma A-0545) 
1:2000 1 h room temp 
Rabbit monoclonal anti 
phospho-p44/42MAPK 
(Thr 202 / Tyr 204) 
(Cell Signalling 
Technology 9100S) 
1:1000 overnight 4ᵒC  Goat anti-rabbit IgG 
peroxidise 
(Sigma A-0545) 
1:2000 1 h room temp 
Rabbit monoclonal anti 
phospho-Akt (Ser 473) 
(Cell Signalling 
Technology 4060B) 
1:1000 overnight 4ᵒC  Goat anti-rabbit IgG 
peroxidise 
(Sigma A-0545) 
1:2000 1 h room temp 
Rabbit polyclonal anti  
Caspase 12 (full length 
and cleaved) (Abcam 
ab18766) 
1:1000 overnight 4ᵒC  Goat anti-rabbit IgG 
peroxidise 
(Sigma A-0545) 
1:2000 1 h room temp 
Rabbit polyclonal anti-
TNFR1 (Santa Cruz 
SC-7895) 
1:1000 overnight 4ᵒC  Goat anti-rabbit IgG 
peroxidise 
(Sigma A-0545) 
1:2000 1 h room temp 
Goat polyclonal anti-
TNFʱ (Santa Cruz 
SC-32155) 
1:1000 overnight 4ᵒC  Bovine anti-goat IgG 
HRP (Santa Cruz SC-
2384) 
1:2000 1 h room temp  
Mouse anti rabbit beta 
actin  (Sigma A2066) 
1:2000 2 h room temp  Rabbit anti-mouse IgG 
HRP (Santa Cruz SC – 
358914) 
1:1000 1 h room temp 
  Table 7. List of primary and secondary antibodies used for Western blotting. 
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Following incubation with the primary antibodies (Table 7), the membranes were washed 
three times with TTBS and then incubated with the secondary antibodies as shown in Table 6 
for 1 h at room temperature on an orbital shaker. The membranes were then washed a further 
three  times  with  TTBS  and  were  exposed  using  enhanced  chemiluminescence  (ECL). 
Membranes  were drained and placed in  a tray  containing an equal  volume of each ECL 
solution  and  were  incubated  for  1  min.  Membranes  were  then  blotted  on  filter  paper  to 
remove excess ECL solution, and were wrapped in saran wrap and fixed in an X-ray cassette. 
In the dark, a piece of photographic film was placed onto the membranes to expose the 
protein bands. Photographic paper was then developed in developing solution and immersed 
in fixing solution before finally being rinsed in water. The films were dried and analysed and 
the expression of each protein was quantified using densitometry (ImageJ). Western blots 
were performed three times and those presented here are representative blots. Blots were 
routinely re-probed for β-actin as a loading control to ensure equal loading of protein, which 
was also used for densitometry.  
2.2.7  Enzyme linked immunosorbent assays (ELISA) of TNFα release  
Enzyme-linked immunosorbent assays (ELISAs) quantify the amount of protein in a sample 
(Engvall  &  Perlmann,  1971;  Van  Weemen  &  Schuurs,  1971).  A  quantitative  sandwich 
ELISA kit was used here to measure the quantity of TNFʱ released in control and treated cell 
culture medium samples from microglia treated as shown in Table 1. In the sandwich ELISA 
a primary monoclonal antibody is bound to the surface of a well in 96 well plate format, 
which  enables  the  antigen  under  investigation  to  bind  directly  onto  the  bound  antibody 
(Belanger et al. 1973). The antigen is then visualised by a second polyclonal antibody that 
binds to it, and the signal is amplified and visualized using a plate reader.  141 
 
Microglia were treated as outlined in Table 1, and media was removed and centrifuged at 
10 000 g for 5 min to pellet debris. The resulting supernatant was placed into fresh Eppendorf 
tubes and samples were frozen until required. When the assay was perfomed, samples were 
defrosted on ice. The assay was performed according to the manufacturer‟s instructions, in 96 
well plates precoated with a monoclonal rat TNFʱ specific antibody. First, 50 μl of assay 
diluent were added to each well, followed by 50 μl of standard rat TNFʱ samples of known 
concentrations, TNFʱ kit control or media samples. The samples were incubated for 2 h at 
room temperature followed by four washes with wash buffer. Samples were then incubated 
with 100 μl of rat TNFʱ conjugate for 2 h at room temperature, which was followed by four 
washes with wash buffer. 100 μl of substrate solution was added to the wells for 30 minutes 
in the dark, after which, 100 μl of stop solution was added to terminate the reaction. The 
wells were mixed and optical density was measured with a microplate reader at 450 nm with 
a reference filter at 540 nm to correct for optical imperfections. The concentration of TNFʱ in 
the cell medium samples was determined against a standard curve from the standard TNFʱ 
samples used on the same 96 well plate.  
2.2.8  Statistical analysis  
To assess statistical significance in all experiments, experiments were performed in triplicate 
using three separate cell preparations. In imaging experiments, three coverslips were imaged 
per condition, and a minimum of six fields of view per coverslip were imaged and analysed. 
Where percentages were calculated, statistical analysis was performed on transformed data. 
Statistical analysis was performed using the GraphPad Prism software. Data were analysed 
using  one-way  ANOVA  with  Tukey  post-hoc  analysis,  a  two-way  ANOVA  (for  HPLC 
analysis), or the Student‟s T test. Significance was stated as *p<0.05, **p<0.01, ***p<0.001.  
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Chapter 3 
Neurotransmitter modulation of superoxide production 
in microglia 
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3.1  Introduction and summary of results  
Neurotransmitter  dysregulation  is  a  hallmark  of  several  neurodegenerative  conditions 
(Greenfield & Vaux 2002), and is a consequence of neuronal damage induced by insults such 
as  Aβ  plaques,  ʱ-synuclein  deposits,  traumatic  injury,  and  ischemia,  resulting  in 
neurotransmitter release into the extracellular matrix (Vesce et al. 2007; Rossi & Volterra 
2009). Microglia have the capacity for neurotransmitter uptake (Rimaniol et al. 2000), and 
express a wide repertoire of neurotransmitter receptors (Pocock & Kettenmann 2007), which 
enables  them  to  respond  to  both  physiological  and  pathophysiological  levels  of 
neurotransmitters in the extracellular space.  Furthermore, ROS production is a hallmark of 
almost all neurodegenerative conditions (Patel & Chu 2011), and can be either protective 
(Groeger  et  al.  2009),  or  can  enhance  disease  progression  (Abramov  et  al.  2007). 
Neurotransmitter  dysregulation  and  ROS  production  are  therefore  key  events  in  the 
progression of neurodegenerative disease.  
Glutamate is implicated in almost all neurodegenerative conditions, with excessive release 
seen during stroke, AD, (Rossi & Volterra 2009) and HD (DiFiglia 1990); whilst GABA tone 
is increased in AD pathology (Marczynski 1998), and ATP is released from degenerating 
neurons  to  recruit  microglia  to  sites  of  neuronal  injury  (North  &  Verkhratsky  2006). 
Modulation of microglial neurotransmitter receptors affects microglial reactivity (Pocock & 
Kettenmann 2007), and as ROS are a hallmark of microglial activation (Block 2008) it could 
be  suggested  that  modulation  of  microglial  neurotransmitter  receptors  may  mediate 
microglial  activity  through  activation  of  the  NADPH  oxidase,  which  was  therefore 
investigated here.  
As neurotransmitter release in the CNS is  a key pathological event, and microglial ROS 
production  has  pathological  or  protective  consequences,  the  aim  of  this  chapter  was  to 144 
 
determine  whether  neurotransmitters  and  modulation  of  neurotransmitter  receptors  could 
influence microglial superoxide production through activation of the NADPH oxidase.  
Treatment  of  microglia  with  the  neurotransmitters  glutamate,  GABA  or  BzATP  induced 
superoxide production in BV2 and primary microglia. Furthermore, superoxide production 
was a consequence of NADPH oxidase activation, as neurotransmitter induced superoxide 
production  was  inhibited  by  co-treatment  of  cells  with  the  NADPH  oxidase  inhibitor 
apocynin.  
Modulation of the microglial mGluRs induced superoxide production in an NADPH oxidase 
dependent  manner.  Inhibition  of  the  group  I  mGluRs  with  3-((2-Methyl-1,3-thiazol-4-
yl)ethynyl)pyridine  hydrochloride  (MTEP),  activation  of  the  group  II  mGluR3  with  N-
Acetyl-L-aspartyl-L-glutamic acid (NAAG), and activation of the group III mGluRs with L-
(+)-2-Amino-4-phosphonobutyric  acid  (L-AP4)  significantly  elevated  NADPH  oxidase 
derived superoxide production. In addition, activation of the NMDA receptor, but not the 
AMPA receptor promoted superoxide production in an NADPH oxidase dependent manner. 
Furthermore, NMDA derived superoxide was attenuated by co-treatment with the receptor 
agonist and antagonist, lending support to findings that microglia express functional NMDA 
receptors (Murugan et al. 2011).  
Microglia  also  responded  to  GABAA  receptor  activation,  and  treatment  with  muscimol 
significantly elevated superoxide production as a consequence of NADPH oxidase activation. 
Furthermore, this was a consequence of receptor activation, as co-treatment of microglia with 
the GABAA receptor agonist and the highly specific GABAA receptor antagonists 6-Imino-3-
(4-methoxyphenyl)-1(6H)-pyridazinebutanoic  acid  hydrobromide  (SR95531)  or  picrotoxin 
attenuated  superoxide  production.  Microglia  were  also  shown  to  express  subunits  of  the 
GABAA receptor required for the formation of functional receptors, in support of findings 145 
 
from Lee et al (2011). Finally, activation of the microglial P2Y2/4 receptor also induced 
superoxide production in an NADPH oxidase dependent manner.  
In  this  chapter,  four  methods  were  employed  to  perform  a  thorough  investigation  into 
microglial superoxide production. The NBT assay was used to detect superoxide production 
in BV2 microglia, as this method is highly sensitive to superoxide specifically. To validate 
the NBT findings, the dHEth probe was used. Superoxide production in primary microglia 
was assessed by dHEth fluorescence microscopy, and was quantified by flow cytometry and 
HPLC, in which the specific oxidation products of dHEth were detected to determine whether 
superoxide or H2O2 were produced following neurotransmitter and receptor induced NADPH 
oxidase activation. To attribute superoxide production to the NADPH oxidase, all treatments 
were  performed  in  the  presence  or  absence  of  the  NADPH  oxidase  inhibitor  apocynin, 
whereby attenuation of superoxide production upon co-treatment with apocynin suggested 
that the treatments induced superoxide production in an NADPH oxidase dependent manner. 
To further implicate the NADPH oxidase in superoxide production following modulation of 
neurotransmitter  receptors,  enzymatic  activity  was  analysed  using  the  NADPH  oxidase 
activity assay.  
It was anticipated that this robust analysis into superoxide production and NADPH oxidase 
activity would provide strong evidence to show that modulation of the mGluRs, iGluRs, 
GABA and purinergic receptors mediate microglial superoxide production in an NADPH 
oxidase dependent manner.   
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3.2  Results 
3.2.1  Glutamate, GABA and ATP induce superoxide production in microglia which is 
due to NADPH oxidase activation  
Initially, it was important to determine whether neurotransmitters could induce superoxide 
production  in  microglia  through  activation  of  the  NADPH  oxidase,  before  further 
investigations  into  neurotransmitter  receptor  mediated  superoxide  production  were 
performed.  
The NBT assay was used first to determine whether neurotransmitters induced superoxide 
production  in  BV2  microglia,  and  to  determine  the  optimal  concentration  of  glutamate, 
GABA  or  BzATP  required  to  promote  superoxide  production.  Initially  a  concentration 
titration  of  the  neurotransmitters  glutamate  (Fig.  3.1A),  GABA  (Fig.  3.1B),  and  BzATP 
(Fig. 3.1C) was performed. The NBT analysis revealed that treatment of BV2 microglia with 
glutamate at 1 µM significantly increased NBT reduction following incubation of cells for 
4 h. Treatment of BV2 microglia with 1 µM or 100 µM GABA induced a significant increase 
in NBT reduction (Fig. 3.1B), however, as treatment with 100 µM GABA promoted higher 
levels  of  superoxide  production  (**p<0.01),  this  concentration  was  used  for  all  further 
experiments.  Treatment  of  BV2  microglia  with  250  µM  or  1  mM  BzATP  significantly 
increased NBT reduction (Fig. 3.1C). BzATP was used in place of ATP, as ATP was rapidly 
hydrolysed in the culture media, and could not exert an effect in vitro (Parvathenani et al. 
2003). The findings that the highest concentration of 1 mM BzATP induced a significant 
increase  in  superoxide  production  is  in  line  with  published  data  showing  that  this 
concentration  induces  microglial  reactivity  through  the  opening  of  a  large  pore  in  the 
membrane, which enables the passage of large (900 Da) molecules across the membrane, and 
also promotes microglial phagocytosis and chemotaxis (Skaper et al. 2010) . This was not 147 
 
under investigation in this thesis, therefore the lower concentration of 250 µM was used, in 
agreement with Parvathenani et al. (2003). 
A time course NBT assay was then performed following the findings that 1 µM glutamate, 
100 µM  GABA  and  250  µM  BzATP  were  optimal  concentrations  for  the  production  of 
superoxide in BV2 microglia. The time course analysis was carried out to confirm that 4 h 
incubation with neurotransmitters elicited an increase in NBT reduction in BV2 microglia, in 
line with the optimised protocol. The data (Fig. 3.1D) show that 4 h incubation of BV2 
microglia  with  glutamate  (1  µM),  GABA  (100  µM)  or  BzATP  (250  µM),  induced  a 
significant  increase  in  NBT  reduction  (*p<0.05).  However,  at  16  h  incubation  with 
glutamate, superoxide production was also significantly elevated (***p<0.001). To maintain 
consistency with the assay however, all readings were taken at the 4 h time point (Fig,3.1D). 
It was next important to determine whether glutamate, GABA or BzATP induced superoxide 
production (shown by  NBT reduction) in  BV2 microglia was  a consequence of NADPH 
oxidase activity. BV2 microglia were treated with each neurotransmitter in the presence of 
the specific NADPH oxidase inhibitor apocynin (10 µM), and superoxide production was 
assessed  by  NBT  reduction  (Fig.  3.1E).  Treatment  of  BV2  microglia  with  the 
neurotransmitters  glutamate,  GABA  or  BzATP  in  the  presence  of  apocynin  significantly 
decreased NBT reduction and therefore superoxide production.  This suggests that glutamate, 
GABA and BzATP induce superoxide production through activation of the NADPH oxidase.  148 
 
 
 
Figure 3.1 NBT analysis showing induction of superoxide production by neurotransmitters. BV2 cells were 
treated with the neurotransmitters glutamate 100 nM, 1µM, 10 µM or 100 µM (A), GABA 100 nM, 1µM, 10 µM 
or 100 µM (B), or BzATP 1µM, 10 µM, 100 µM, 250 µM or 1 mM (C), to determine the optimal concentration 
of each neurotransmitter required to induce a significant increase in NBT reduction when compared to basal 
NBT  reduction  in  un-treated  BV2  microglia.  BV2  microglia  were  also  treated  with  the  neurotransmitters 
glutamate (1 µM), GABA (100 µM) or BzATP (250 µM) in the presence of NBT for 30 min, 1 h , 4 h, 8 h , 16 h 
and 24 h to validate the use of the 4 h time point in the NBT assay (D). To determine whether NBT reduction 
following treatment with glutamate, GABA or BzATP was a consequence of the NADPH oxidase, BV2 microglia 
were co-treated with the neurotransmitters glutamate (1 µM), GABA (100 µM) or BzATP (250 µM) in the 
presence of the NADPH oxidase inhibitor apocynin (10 µM) (E). Data were analysed using one way ANOVA 
with Tukey post-hoc analysis, and comparisons were made between treatments and basal superoxide production 
(ie. NBT) and also between treatment with the neurotransmitters and cells treated with the neurotransmitters 
and apocynin as appropriate. *p<0.05, **p<0.01, ***p<0.001. All data are n=3.  
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It  was  important  to  determine  whether  these  findings  could  be  replicated  in  primary 
microglia.  The  NBT  assay  was  not  suitable  for  use  with  primary  microglia,  as  primary 
microglia could not to grow in 96 well plates directly on plastic and at the low cell density 
required.  However  the  fluorescent  probe  dHEth  was  used  to  investigate  the  superoxide 
production in primary microglia using fluorescence microscopy. Microglia plated on glass 
coverslips were treated with glutamate (1 µM), GABA (100 µM) or BzATP (250 µM) either 
alone or in the presence of apocynin (10 µM), for 24 h (Fig. 3.2A and B) as determined by 
optimisation of the assay. The data (Fig. 3.2A) shows that treatment with glutamate, GABA 
or BzATP significantly increased the number of superoxide positive microglia, which could 
be  significantly  attenuated  by  co-treatment  with  the  NADPH  oxidase  inhibitor  apocynin 
(representative images are shown in Fig. 3.2B), therefore treatment of primary microglia with 
the  neurotransmitters  glutamate,  GABA  or  BzATP  induces  superoxide  production  in  an 
NADPH oxidase dependent manner.  
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Figure  3.2  Neurotransmitters  induce  microglial  superoxide  production  –  analysis  by  dHEth  fluorescence 
imaging. Microglia plated on glass coverslips were treated with the neurotransmitters glutamate (1 µM), GABA 
(100 µM) or BzATP (250 µM) either alone or in combination with apocynin (10 µM) for 24 h in line with the assay 
optimisation. Data in (A) shows the percent superoxide positive cells across three experiments, assessed by red 
fluorescence in the nuclei, and (B) shows representative images. Data were analysed using one way ANOVA with 
Tukey post-hoc analysis. Each condition was compared with basal superoxide production in control untreated 
cells, and cells treated with apocynin were compared with their corresponding condition. *p<0.05, **p<0.01, 
***p<0.001. Data are n=3.Scale bar 20 µm.  
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As the dHEth fluorescence microscopy data are semi-quantitative, flow cytometry and HPLC 
analysis were used to quantify the imaging data showing that glutamate, GABA and BzATP 
induced superoxide production in an NADPH oxidase dependent manner. Due to the large 
numbers of cells required, and the fact that primary microglia can be activated by detachment 
from  culture  vessels,  which  can  induce  a  change  in  morphology  and  the  production  of 
activation markers such as superoxide; BV2 microglia were used for these analyses. Cells 
were treated with the neurotransmitters in the presence or absence of apocynin for 24 h in line 
with the use of the probe in primary microglial cells.  
For flow cytometry (Fig. 3.3A, B, C, D), BV2 microglia were treated with glutamate (1 µM), 
GABA (100 µM), or BzATP (250 µM) in the presence or absence of apocynin (10 µM) for 
24  h.  Dihydroethidium  fluorescence  was  detected  following  incubation  of  cells  with  the 
probe for 40 min, and the data were analysed by calculating the mean fluorescence intensity 
of the population, enabling a quantitative analysis of the total cell population. A significant 
increase in  mean  fluorescence intensity  was seen  upon treatment  of  BV2 microglia  with 
glutamate (1 µM), GABA (100 µM) or BzATP (250 µM), when compared with untreated 
controls labelled with dHEth (basal superoxide production), which could be attenuated by co-
treatment with apocynin, however, the increase in dHEth fluorescence induced by GABA 
treatment was not significantly attenuated by apocynin (Fig. 3.3A). GABA may therefore 
induce  the  activation  of  other  NADPH  oxidase  isoforms  which  may  be  insensitive  to 
apocynin, or GABA may induce superoxide production through other oxidase systems.  
HPLC analysis was also used to quantify superoxide production following treatment with the 
neurotransmitters glutamate, GABA or BzATP (Fig. 3.3E). Cells were treated for 24 h with 
the  neurotransmitters  glutamate  (1  µM),  GABA  (100  µM)  or  BzATP  (250  µM)  in  the 
presence or absence of apocynin (10 µM), and were incubated with dHEth for 40 min before 
analysis. The production of 2-OH-E
+, the superoxide specific oxidation product of dHEth, 152 
 
and the production of the H2O2 oxidation product ethidium (Eth), was measured (Fig. 3.3E). 
Incubation  of  untreated  cells  with  dHEth  showed  that  basal  levels  of  2-OH-E
+  and  Eth 
production  were  low,  and  treatment  of  cells  with  apocynin  had  little  effect  on  ROS 
production. Treatment with glutamate (1 µM) or BzATP (250 µM) significantly increased 
2-OH-E
+ levels when compared with untreated controls, which could be significantly reduced 
upon co-treatment with apocynin, suggesting that glutamate and BzATP induce superoxide 
production  in  an  NADPH  oxidase  dependent  manner.  Treatment  of  BV2  microglia  with 
GABA  (100  µM)  significantly  elevated  Eth  production  when  compared  with  untreated 
controls, which was also significantly higher than the 2-OH-E
+ produced. Furthermore, Eth 
production  was  significantly  reduced  following  co-treatment  of  cells  with  apocynin, 
suggesting that GABA induces the production of ROS rather than superoxide through the 
NADPH oxidase.  
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Figure 3.3 Quantification of neurotransmitter induced  superoxide production by flow cytometry measuring 
dHEth fluorescence and analysis of dHEth oxidation by HPLC. BV2 microglia were treated for 24 h with the 
neurotransmitters glutamate (1 µM), GABA (100 µM) or BzATP (250 µM) in the presence or absence of apocynin 
(10 µM).  Cells  were  analysed  for  dHEth  fluorescence  by  flow  cytometry,  counting  30,000  events.  The  mean 
fluorescence intensity for each condition was analysed and is shown in (A). Representative histograms are shown 
for glutamate (B), GABA (C) and BzATP (D), and show the fluorescence of treatment with neurotransmitters alone 
and in combination with apocynin (denoted by the red histogram). Data were analysed by one way ANOVA and 
Tukey post-hoc analysis. *p<0.05. BV2 microglia were also analysed for superoxide production by HPLC (E). 
Cells were treated as described in the presence or absence of apocynin for 24 h. The production of the superoxide 
specific oxidation product 2-OH-E was measured as was the production of the H2O2 specific product Eth.  Data 
were analysed by Student’s T-Test and also by two way ANOVA for comparisons between 2-OH-E and Eth data. 
*p<0.05, **p<0.01, ***p<0.001. All data are n=3.   
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These quantitative analyses using the dHEth probe as a sensor for superoxide production 
show  that  glutamate  (1  µM)  and  BzATP  (250  µM)  induce  superoxide  production  in  an 
NADPH  oxidase  dependent  manner.  Treatment  with  GABA  (100  µM)  induces  ROS 
production rather than superoxide specifically (as shown by HPLC), which was attenuated by 
co-treatment  of  cells  with  apocynin,  suggesting  that  GABA  induces  NADPH  oxidase 
activation, although may activate other NADPH oxidase isoforms.  
Following  the  findings  that  microglia  produce  superoxide  after  treatment  with 
neurotransmitters in an NADPH oxidase dependent manner, it was important to confirm that 
superoxide production was a result of NADPH oxidase enzymatic activity. BV2 microglia 
were  used  to  investigate  NADPH  oxidase  activity,  and  cells  were  treated  with  the 
neurotransmitters glutamate (1 µM), GABA (100 µM) or BzATP (250 µM) in the presence or 
absence of apocynin (10 µM) for 4 h. The data (Fig. 3.4) show that treatment with glutamate 
or GABA significantly increased NADPH oxidase activity, which could be reduced to basal 
levels by co-treatment of cells with apocynin. However, BzATP did not significantly increase 
NADPH oxidase activity, although co-treatment with apocynin attenuated enzymatic activity, 
thereby suggesting that BzATP may mediate the activation of the NADPH oxidase and other 
oxidase systems.  
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Figure 3.4 NADPH oxidase activity following treatment with neurotransmitters. BV2 microglia were 
treated with glutamate (1 µM), GABA (100 µM) or BzATP (250 µM) in the presence or absence of 
apocynin (10 µM) for 4 h. The reduction of NADPH to NADP was followed over 10 min at 340 nm, and 
the reduction of NADPH was normalized to protein content. Data were analysed by one way ANOVA and 
Tukey post-hoc analysis was performed, in which all conditions were compared with contro untreated 
cells, and the treatments plus apocynin were compared with their respective treatment groups.*p<0.05,  
**p<0.01. Data are  n=3.  
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Together these data show that superoxide production through NADPH oxidase activity can be 
induced  by  the  neurotransmitters  glutamate,  GABA  and  BzATP  in  microglia.  Following 
these findings, it was important to determine which neurotransmitter receptors glutamate, 
GABA or ATP were acting through to induce NADPH oxidase activation, to investigate the 
mechanisms  involved  in  superoxide  production,  and  to  learn  more  about  the  signalling 
pathways leading to activation of the NADPH oxidase following exposure of microglia to 
neurotransmitters.   
3.2.2  Neurotransmitter  receptor  agonists  and  antagonists  induce  superoxide 
production in microglia as a consequence of NADPH oxidase activation  
As glutamate, GABA and BzATP induced superoxide production through NADPH oxidase 
activation,  superoxide  production  through  modulation  of  mGluRs,  iGluRs,  GABA  or 
purinergic receptors were investigated. In each case, the NBT assay was used to test whether 
a wide variety of receptor agonists or antagonists could modulate superoxide production, 
before the more sensitive assays (dHEth imaging, HPLC and flow cytometry) were used to 
investigate positive results in more detail.  
3.2.2.1 Modulation of mGluRs induces superoxide production in microglia  
Group I mGluR agonists reduce NADPH oxidase expression in microglia in vivo after spinal 
cord  damage  (Byrnes  et  al.  2009),  which  is  protective  through  the  inhibition  of  ROS 
production and microglial reactivity (Loane et al. 2009). Here, group I, II and III mGluRs 
were modulated to investigate the production of NADPH oxidase dependent superoxide in 
microglia. Initially, an NBT assay was performed to investigate whether modulation of the 
group I, II or III mGluRs could induce NBT reduction suggesting superoxide production 
(Fig. 3.5). BV2 microglia were treated with the group I agonists DHPG (100 µM) (Palmer et 
al. 1997), an activator of mGluR1 and mGluR5, or CDPPB (500 nM) (Kinney et al. 2005) a 
selective activator of mGluR5; and the antagonists AIDA (250 µM) (Melendez et al. 2005) an 157 
 
mGluR1a  antagonist,  or  MTEP  (100  nM)  (Cosford  et  al.  2003),  a  selective  mGluR5 
antagonist (Fig. 3.5A). Treatment with CDPPB (500 nM) or MTEP (100 nM) significantly 
increased NBT reduction (Fig. 3.5A). NBT reduction was also measured following treatment 
of BV2 microglia with the group II agonists DCG-IV (500 nM) (Cartmell et al. 1998) or 
NAAG (50 µM) (Wroblewska et al. 1997)  a highly selective mGluR3 agonist (Neale et al. 
2000); and the antagonist APICA (250 µM) (Zhou et al. 2006) (Fig. 3.5B). Treatment with 
the  selective  mGluR3  agonist  NAAG  significantly  increased  NBT  reduction  in  BV2 
microglia  (Fig.  3.5B).  The  NBT  assay  was  also  performed  following  treatment  of  BV2 
microglia with the group III agonist L-AP4 (100 µM) (Zhou et al. 2006) and antagonist 
MAP4 (500 µM) (Faden et al. 1997) (Fig. 3.5C), with a significant increase in NBT reduction 
observed following treatment with L-AP4 (Fig. 3.5C).  
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Figure 3.5 NBT assay to investigate superoxide production following treatment of BV2 microglia with (A) 
group I, (B) group II and (C) group III mGluR agonists and antagonists. BV2 microglia were treated with the 
group I mGluR agonists DHPG (100 µM) or CDPPB (500 nM), or antagonists AIDA (250 µM) or MTEP (100 
nM) (A); the group II agonists DCG-IV (500 nM) or NAAG (50 µM) or antagonist APICA (200 µM) (B); or the 
group III agonist L-AP4 (100 µM) or the antagonist MAP4 (500 µ) (C). BV2 microglia were analysed for NBT 
reduction, which was measured after 4 h treatment. Data were analysed using one way ANOVA, in which all 
conditions were compared with the NBT only control (basal NBT reduction). *p<0.05, ***p<0.001. All data are 
n=3.  
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These data show that inhibition of the group I mGluR with MTEP, activation of the group II 
mGluR3 with NAAG and activation of the group III mGluR with L-AP4 induces superoxide 
production  in  BV2  microglia  (Fig.  3.5).  To  investigate  this  further,  a  dose  dependency 
analysis of MTEP, NAAG and L-AP4 was performed (Fig. 3.6) to determine the optimal 
concentration of each mGluR modulator required to significantly increase NBT reduction, 
and therefore induce superoxide production in BV2 microglia. Treatment of BV2 microglia 
with MTEP at a concentration of 100 nM significantly increased NBT reduction (Fig. 3.6A), 
whilst NAAG used at 5 µM or 50 µM increased NBT reduction (Fig. 3.6B), and treatment 
with L-AP4 at 10 µM or 100 µM also significantly increased NBT reduction (Fig. 3.6C). 
Following these dose-dependency NBT analyses, the group I antagonist MTEP was used in 
all  later  experiments  at  100  nM,  whilst  NAAG  was  used  at  50 µM,  as  this  higher 
concentration  acts specifically at the mGluR3 receptor (Wroblewska et al. 1997); and L-AP4 
was used at 100 µM, which has been shown in the literature to induce receptor activation 
(Zhou et al. 2006). Furthermore, both NAAG at 50 µM (***p<0.001) and L-AP4 at 100 µM 
(***p<0.001) induced a more significant increase in NBT reduction when compared with 
their  use  at  a  lower  concentration,  suggesting  that  these  are  the  optimal  concentrations 
required for superoxide production.  
Following the findings that MTEP at 100 nM, NAAG at 50 µM and L-AP4 at 100 µM 
induced a significant increase in NBT reduction, it was important to determine whether this 
was a consequence of NADPH oxidase activation. BV2 microglia were treated with MTEP 
(100 nM), NAAG (50 µM) or L-AP4 (100 µM) in the presence or absence of apocynin 
(10 µM),  and  superoxide  production  was  assessed  by  NBT  reduction  (Fig.  3.6D).  NBT 
reduction  following  modulation  of  the  mGluRs  was  attenuated  by  co-treatment  with 
apocynin, showing that inhibition of the group I mGluR, and activation of mGluR3 and the 
group III mGluRs induced NADPH oxidase activation. 160 
 
 
 
Figure 3.6 Dose-dependency NBT analysis of MTEP (A), NAAG (B) and L-AP4 (C) to determine the optimal 
concentration  required  to  induce  superoxide  production  in  an  NADPH  oxidase  dependent  manner.  BV2 
microglia were treated with MTEP 10 nM, 100 nM or 1 µM (A); NAAG 5 µM. 50 µM or 500 µM (B); L-AP4 10 
µM, 100 µM or 1 mM (C) for 4 h before measurement of NBT reduction. Statistical analysis was performed 
using a one way ANOVA with Tukey post hoc analysis, in which each condition was compared with the NBT only 
control (basal superoxide production). The involvement of the NADPH oxidase was then confirmed with the use 
of apocynin (D). BV2 microglia were treated with MTEP (100nM), NAAG (50 µM) or L-AP4 (100 µM) in the 
presence or absence of the NADPH oxidase inhibitor apocynin (10 µM) for 4 h before NBT reduction was 
analysed at 630 nm. Statistical analysis was performed as described, with comparisons being made between all 
conditions and the NBT only control, and also between each treatment in the presence or absence of apocynin. 
*p<0.05, **p<0.01, ***p<0.001. All data are n=3.  
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The  findings  that  treatment  of  BV2  microglia  with  MTEP,  L-AP4  or  NAAG  induced 
superoxide production in a NADPH oxidase dependent manner was replicated in primary 
microglia using fluorescence imaging of dHEth (Fig. 3.7). Primary microglia were treated 
with MTEP (100 nM), NAAG (50 µM) or L-AP4 (100 µM) in the presence or absence of 
apocynin for 24 h before cells were incubated with dHEth and imaged for red fluorescence in 
the nuclei (Fig. 3.7B). Inhibition of the group I mGluR, and activation of mGluR3 and the 
group  III  mGluRs  induced  NADPH  oxidase  dependent  superoxide  production,  as  dHEth 
fluorescence  could  be  attenuated  by  co-treatment  with  the  NADPH  oxidase  inhibitor 
apocynin (Fig. 3.7). This imaging data is therefore in agreement with the NBT analysis.  
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Figure  3.7  dHEth  fluorescence  showing  NADPH  oxidase  dependent  superoxide  production  in  primary 
microglia  following  treatment  with  MTEP,  NAAG  or  L-AP4.  Primary  microglia  were  plated  on  glass 
coverslips at 50,000 cells per well and were used within 24 h of isolation. Microglia were treated with the 
mGluR modulators MTEP (100 nM), NAAG (50 µM) or L-AP4 (100 µM) in the presence or absence of the 
NADPH oxidase inhibitor apocynin (10 µM). Dihydroethidium fluorescence was then assessed by counting the 
number  of  cells  exhibiting  red  fluorescence  in  the  nuclei  (A).  Representative  images  are  shown  in  (B). 
Statistical analysis was performed using a one way ANOVA with Tukey post-hoc analysis. All conditions were 
compared with untreated controls (basal superoxide production), and each treatment was compared to the 
respective treatment plus apocynin. *p<0.05, **p<0.01, ***p<0.001. All data are n=3. Scale bar 20 µm. 
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Quantitative  analysis  of  mGluR  induced  dHEth  fluorescence  was  performed  using  flow 
cytometry and HPLC (Fig, 3.8). BV2 microglia were treated with the mGluR modulators 
MTEP  (100  nM),  NAAG  (50  µM)  or  L-AP4  (100  µM)  in  the  presence  or  absence  of 
apocynin (10 µM) for 24 h, and cells were incubated with dHEth for 40 min before flow 
cytometry (Fig. 3.8A, B, C, D) or HPLC (Fig. 3.8E) were performed. The flow cytometry 
data was in agreement with both the fluorescence imaging and NBT analysis, revealing that 
L-AP4  (Fig.  3.8A,  B),  NAAG  (Fig.  3.8A,  C)  and  MTEP  (Fig.  3.8A,  D)  significantly 
increased  mean  dHEth  fluorescence  intensity  which  was  attenuated  by  co-treatment  with 
apocynin (Fig. 3.8A). This therefore provides further support to the previous findings that 
modulation of the microglial mGluRs induces superoxide production in an NADPH oxidase 
dependent manner.  
Quantitative analysis of dHEth oxidation products by HPLC (Fig. 3.8E) also correlated with 
the flow cytometry and imaging data. Treatment of BV2 microglia with MTEP (100 nM) or 
L-AP4 (100 µM) significantly elevated the production of the superoxide specific product 2-
OH-E
+  when  compared  with  control  levels,  which  could  be  significantly  reduced  by  co-
treatment with apocynin, suggesting that MTEP and L-AP4 induced superoxide production 
was  through  activation  of  the  NADPH  oxidase.  MTEP  or  L-AP4  did  not  significantly 
modulate Eth production, suggesting that inhibition of the group I mGluRs and activation of 
the  group  III  mGluRs  induce  superoxide  production  specifically  in  an  NADPH  oxidase 
dependent manner. Treatment of BV2 microglia with NAAG (50 µM) did not significantly 
elevate 2-OH-E
+ or Eth production. As neither 2-OH-E
+ nor Eth production was significantly 
increased  when  compared  with  controls,  it  could  be  suggested  that  NAAG  induces  the 
production of low levels of ROS possibly through different Nox isoforms.  
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Figure  3.8  Quantitative  analysis  of  superoxide  production  following  modulation  of  mGluR’s  by  flow 
cytometry analysis of dHEth fluorescence and HPLC analysis of dHEth oxidation products.  For flow 
cytometry analysis of dHEth fluorescence, BV2 microglia were treated with the group III activator L-AP4 
(100 µM) (B), the mGluR3 agonist NAAG (50 µM) (C) or the group I antagonist MTEP (100 nM) (D) in the 
presence or absence of the NADPH oxidase inhibitor apocynin (10 µM) (denoted with a gray line on the 
representative  histograms).  The  histograms  show  that  each  treatment  induces  a  shift  in  the  dHEth 
fluorescence which can be attenuated by co-treatment with apocynin. The mean fluorescence intensity (A) 
was calculated and analysed using a one way ANOVA with Tukey post-hoc analysis, in which all treatments 
were compared with basal dHEth fluorescence and comparisons were also made between treatments with 
and without apocynin. *p<0.05, **p<0.01, ***p<0.001. HPLC analysis (E) was performed on cells treated 
with the receptor agonists or antagonists in the presence or absence of apocynin for 24 h. Cells were then 
analysed for 2-OH-E and Eth production to detect superoxide and H2O2 production respectively. Data were 
analysed by Student’s T-Test and two way ANOVA to compare 2-OH-E and Eth production. *p<0.05.  All 
data are n=3.   
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Investigation into the enzymatic activity of the NADPH oxidase following treatment with the 
mGluR modulators also agreed with the analysis of superoxide production (Fig. 3.9). The 
NADPH  oxidase  activity  assay  revealed  that  treatment  with  MTEP  (100  nM),  NAAG 
(50 µM)  or  L-AP4  (100  µM)  significantly  increased  NADPH  oxidase  activity  when 
compared  with  control  untreated  cells  (basal  NADPH oxidase activity). Furthermore, co-
treatment of cells with each mGluR modulator and the NADPH oxidase inhibitor apocynin 
attenuated NADPH oxidase activity, lending support to the previous findings that superoxide 
production following inhibition of the group I mGluR with MTEP, and activation of mGluR3 
or the group III mGluRs is through activation of the NADPH oxidase.  
Together these data show that inhibition of the group I mGluRs and activation of mGluR3 
and the group III mGluRs induce superoxide production in an NADPH oxidase dependent 
manner.  
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Figure 3.9 Modulation of mGluR’s induces NADPH oxidase activity. BV2 microglia were treated 
with the mGluR modulators MTEP (100 nM), NAAG (50 µM) or L-AP4 100 µM) in the presence or 
absence of apocynin (10 µM) for 4 h before analysis of NADPH oxidase activity. Enzymatic activity 
was normalized to protein content. Statistical analysis was performed on normalized data using a 
one way ANOVA, and comparisons were made between treated cells and control untreated cells 
(basal NADPH oxidase activity), and also between cells treated with modulators alone and those 
co-treated with apocynin. *p<0.05, **p<0.01, ***p<0.001. Data are n=3. 
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3.2.2.2 Modulation iGluRs induces superoxide production in microglia  
It  was  next  important  to  determine  whether  iGluR  modulation  could  mediate  microglial 
superoxide production. Microglia express subunits of the AMPA and Kainate receptors, with 
activation of each receptor subtype inducing an inward current seen by electrophysiology, 
(Noda et al. 2000), which could be attenuated by co-treatment with receptor antagonists, 
suggesting  the  presence  of  functional  receptors  on  microglia  (Hagino  et  al.  2004). 
Furthermore,  microglia  express  all  AMPA  receptor  subunits  (GluR1-4),  lending  further 
support to the presence of functional receptors on microglia (Hagino et al. 2004).  Recent in 
vivo studies have shown that microglia express functional NMDA receptors, demonstrated by 
the presence of an enhanced calcium influx following administration of NMDA which could 
be inhibited by co-treatment of microglia with the antagonist MK-801 (Murugan et al. 2011). 
Furthermore, microglia  express  the NMDA receptor subunits  NR1,  NR2A-D and  NR3A, 
which are up-regulated after ischaemia (Murugan et al. 2011). In addition, modulation of the 
microglial  NMDA  receptor  induces  NO  production,  suggesting  that  modulation  of  the 
NMDA receptor induces microglial activation (Murugan et al. 2011).  
The  involvement  of  AMPA  and  NMDA  receptor  modulation  in  microglial  superoxide 
production  and  NADPH  oxidase  activation  was  investigated  here.  BV2  microglia  were 
assessed for superoxide production using the NBT assay. Cells were treated with NMDA 
(100 µM) (Liang et al. 2010) or MK-801 (10 µM) (Murugan et al. 2011) either alone or in 
combination with apocynin (10µM) (Fig. 3.10Ai); or were treated  with the AMPA receptor 
agonist Quisqualic Acid (QA) (10 µM) (Noda et al. 2000) or  the AMPA receptor antagonist 
CNQX (10 µM) (Noda et al. 2000) either alone or in combination with apocynin (10 µM) 
(Fig.  3.10Aii).  Treatment  with  NMDA  significantly  increased  NBT  reduction  when 
compared with basal NBT reduction, which could be attenuated by co-treatment with the 
NADPH  oxidase  inhibitor  apocynin,  suggesting  that  activation  of  the  microglial  NMDA 168 
 
receptor promotes NADPH oxidase activity (Fig. 3.10Ai). A significant increase in NBT 
reduction compared with basal levels was also seen following treatment of BV2 microglia 
with the NMDA receptor antagonist MK-801, however this could not be attenuated by co-
treatment of cells with apocynin (Fig. 3.10.Ai), suggesting that inhibition of NMDA receptors 
on microglia may induce the production of ROS through other oxidase systems. Treatment of 
BV2  microglia  with  the  AMPA  receptor  agonist  QA  did  not  significantly  increase  NBT 
reduction  when  compared  with  basal  levels  (Fig.  3.10Aii);  however  treatment  with  the 
AMPA receptor antagonist CNQX significantly elevated NBT reduction when compared with 
basal levels (Fig. 3.10Aii). This increase could not be reduced by co-treatment with apocynin, 
suggesting that CNQX could not activate the NADPH oxidase (Fig. 3.10Aii).  
Further investigations were performed using primary microglial cells and dHEth fluorescence 
(Fig. 3.10Bi,ii and Fig. 3.10Ci, ii) to support the NBT analysis. The imaging showed that 
treatment of microglia with NMDA (100 µM) significantly increased the percent of dHEth 
positive microglia (Fig. 3.10Bi and Ci), which was attenuated by co-treatment with apocynin, 
and  also  by  co-treatment  with  NMDA  and  the  NMDA  receptor  antagonist  MK-801 
(Fig. 3.10Bi  and  Ci).  This  therefore  suggests  that  it  is  activation  of  the  NMDA  receptor 
specifically  that  induces  NADPH  oxidase  activation,  and  lends  some  support  to  the 
suggestion that microglia express functional NMDA receptors. Treatment of microglia with 
the AMPA receptor agonist QA (10 µM) significantly increased the percentage of dHEth 
positive  microglia,  however  this  was  not  dependent  on  NADPH  oxidase  activation 
(Fig. 3.10Bii and Cii). Furthermore, treatment with the AMPA receptor antagonist CNQX did 
not  induce  a  significant  increase  in  the  number  of  dHEth  positive  cells,  suggesting  that 
modulation  of  the  AMPA  receptor  does  not  affect  superoxide  production  in  primary 
microglia.  
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Figure 3.10 Analysis of superoxide production in BV2 cells (Ai, ii) and primary microglia (Bi, ii and Ci, ii) 
following  modulation  of  the  NMDA  and  AMPA  receptors.  BV2  microglia  were  analysed  for  superoxide 
production using the NBT assay (Ai, ii). Cells were treated with NMDA (100 µM), MK-801 (10 µM) in the 
presence or absence of apocynin (10 µM)(Ai), or QA (10 µM), CNQX (10 µM) in the presence or absence of 
apocynin  (10  µM).  Cells  were  analysed  for  NBT  reduction  after  4  h  incubation.  Primary  microglia  were 
analysed for superoxide production by dHEth fluorescence (Bi, ii and Ci, ii). Primary microglia were treated 
with NMDA (100 µM) or MK-801 (10 µM) either alone or in combination, or in combination with apocynin for 
24 h (Bi, Ci). Primary microglia were also treated with the AMPA agonist QA (10 µM) or the antagonist CNQX 
(10 µM) either alone or in combination, or in combination with apocynin (10 µM) for 24 h (Bii, Cii). Microglia 
were considered superoxide positive when exhibiting red fluorescence in the nuclei. All data were analysed using 
one way ANOVA and Tukey post hoc analysis, making comparisons between basal superoxide production and 
treatments and also between treatments with and without apocynin. *p<0.05, *p<0.01, ***p<0.001. All data are 
n=3.  Scale bar 20 µm.  
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These data (Fig. 3.10) demonstrate that activation of the NMDA receptor promotes microglial 
superoxide production; whilst modulation of the AMPA receptor has no effect on NADPH 
oxidase induced superoxide production. This was confirmed using flow cytometry and HPLC 
analysis (Fig. 3.11). BV2 microglia were treated with NMDA (100 µM) or QA (10 µM) in 
the presence or absence of apocynin (10 µM) for 24 h. Cells were incubated with dHEth 
before  analysis  by  flow  cytometry  or  HPLC.  The  flow  cytometry  analysis  (Fig. 3.11A) 
showed  that  treatment  with  NMDA  significantly  increased  dHEth  mean  fluorescence 
intensity, which was  attenuated by  co-treatment with  apocynin  (Fig. 3.11A,B). Treatment 
with QA did not significantly increase mean dHEth fluorescence intensity (Fig, 3.13A, C), in 
line with the NBT assay and the dHEth fluorescence. HPLC analysis (Fig, 3.11E) showed 
that  treatment  with  NMDA  (100  µM)  significantly  increased  2-OH-E
+  production  when 
compared with control untreated cells, which was attenuated by co-treatment of cells with the 
NADPH  oxidase  inhibitor  apocynin.  Eth  was  also  increased  following  treatment  with 
NMDA,  and  could  be  decreased  upon  apocynin  co-treatment,  however  this  was  not 
significant, but could point to the involvement of other NADPH oxidase isoforms. Treatment 
of  BV2  microglia  with  QA  had  no  effect  on  2-OH-E
+  or  Eth  levels,  suggesting  that 
modulation of the AMPA receptor does not modulate superoxide production.  
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Figure 3.11 Quantative analysis of iGluR induced superoxide production by flow cytometry analysis of 
dHEth fluorescence and HPLC analysis of dHEth oxidation products.  BV2 microglia were treated with 
NMDA (100 µM) or QA (10 µM) in the presence or absence of apocynin (10 µM) for 24 h. Cells were then 
incubated with dHEth before analysis by flow cytometry (A,B,C) or HPLC (D). For flow cytometry, cells were 
analysed for mean fluorescence intensity of dHEth fluorescence (A) Representative histograms are shown in 
(B) and (C) for NMDA or QA treatment respectively. Data was analysed by one way ANOVA and Tukey post-
hoc analysis, making comparisons between basal superoxide production and treatments, and treatments with 
and without apocynin. *p<0.05. HPLC analysis (D) was performed to analyse 2-OH-E and Eth production 
following oxidation of dHEth by NMDA or QA. Data were analysed by Student’s T-Test and by two way 
ANOVA for comparisons between 2-OH-E and Eth.*p<0.05, **p<0.01.  All data are n=3.  
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The data (Fig. 3.11) confirms that NMDA receptor activation induces superoxide production 
in an NADPH oxidase dependent manner; whilst modulation of the AMPA receptor does not 
induce  NADPH  oxidase  mediated  superoxide  production.  To  validate  these  findings  the 
NADPH oxidase activity assay was used. BV2 microglia were treated with NMDA (100 µM) 
or MK-801 (10 µM) either alone, in combination or in the presence of apocynin (Fig. 3.12A); 
or with QA (10 µM) or CNQX (10 µM) either alone, in combination, or in the presence of 
apocynin  (Fig. 3.12B).  Treatment  with  NMDA  alone  induced  a  significant  increase  in 
NADPH oxidase activity when compared with basal activity, in line with the superoxide 
production analysis, which could be decreased upon co-treatment with apocynin, or upon co-
treatment with NMDA and MK-801 (Fig. 3.12A), suggesting that induction of superoxide 
production  and  NADPH  oxidase  activity  is  a  consequence  NMDA  receptor  activation. 
Treatment with QA or CNQX did not significantly increase NADPH oxidase activity when 
compared with control untreated cells (Fig. 3.12B), suggesting that modulation of the AMPA 
receptor cannot induce superoxide production through activation of the NADPH oxidase, in 
line with the analysis of superoxide production.  
Modulation  of  the  microglial  NMDA  receptor  therefore  induces  superoxide  production 
through activation of the NADPH oxidase, whereas modulation of the AMPA receptor has no 
effect on NADPH oxidase induced superoxide production or activity.  
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Figure  3.12  NADPH  oxidase  activity  assay  following  modulation  of  the  NMDA  (A)  and 
AMPA receptors (B). BV2 microglia were treated with  NMDA (100 µM) or MK-801 (10 µM) 
in the presence or absence of apocynin (10 µM) or in combination for 4 h. BV2 microglia were 
also treated with the AMPA receptor agonist QA (10 µM) or the antagonist CNQX (10 µM) in 
the  presence  or absence of apocynin  (10  µM)  or  in  combination  for  4 h.  NADPH oxidase 
activity was measured following 4 h incubation, and data was normalized to protein content. 
Data  were  analysed using a  one  way  ANOVA  with  Tukey  post  hoc  analysis  comparing  all 
treatments to basal NADPH oxidase activity, and also comparing treatments in the presence 
and absence of apocynin. *p<0.05, **p<0.01, ***p<0.001. All data are n=3.  
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3.2.2.3 Modulation of GABA receptors induces superoxide production in microglia  
Following the finding that treatment of microglia with GABA induced superoxide production 
in  an  NADPH  oxidase  dependent  manner,  it  was  important  to  determine  which  GABA 
receptor was implicated in this superoxide production. Microglia express functional GABAB 
receptors (Charles et al. 2003), and treatment of microglia with the GABAB receptor agonist 
promotes  an  inward  rectifying  K+  current  (Kuhn  et  al.  2004).  Microglia  respond  to  the 
GABAA  receptor  agonist  muscimol,  and  receptor  subunit  expression  is  up-regulated  on 
glioma cells co-cultured with neurons (Synowitz et al. 2001). These data therefore suggest 
that microglia may express the GABAA receptor under certain pathological conditions.  
Superoxide production in response to the GABAA receptor agonist muscimol, or the GABAB 
receptor agonist SKF-97541 was investigated first using the NBT assay in BV2 microglia 
(Fig.  3.13A).  A  dose  dependency  analysis  of  each  agonist  was  initally  performed,  using 
muscimol at 5 µM, 50 µM or 500 µM (Kuhn et al. 2004), and SKF-97541 at 1 µM, 10 µM or 
100  µM  (Synowitz  et  al.  2001).  Treatment  with  the  GABAA  receptor  agonist  muscimol 
induced a significant increase in NBT reduction when used at 50 µM when compared with 
untreated controls, whereas treatment with the GABAB receptor agonist SKF-97541 did not 
significantly increase NBT reduction when each concentration was compared with untreated 
controls.  To  determine  whether  superoxide  production  induced  as  a  consequence  of 
microglial GABAA receptor activation was due to NADPH oxidase activation, BV2 microglia 
were  co-treated  with  muscimol  and  apocynin  (Fig.  3.13B).  The  significant  increase  in 
muscimol induced NBT reduction was attenuated by co-treatment of cells with the NADPH 
oxidase  inhibitor,  suggesting  that  activation  of  the  GABAA  receptor  induces  superoxide 
production in an NADPH oxidase dependent manner. It was important to determine whether 
these findings could be replicated in primary microglia (Fig. 3.13C, D). Primary microglia 
were treated with muscimol (50 µM) in the presence or absence of apocynin, or SKF-97541 175 
 
(10 µM) in the presence or absence of apocynin for 24 h before superoxide production was 
assessed by dHEth fluorescence (Fig. 3.13D). Treatment with muscimol (50 µM) induced an 
increase  in  superoxide  production  that  could  be  inhibited  by  co-treatment  of  cells  with 
apocynin (Fig. 3.13C), in line with the NBT analysis. There was no change in superoxide 
production  upon  treatment  of  primary  microglia  with  the  GABAB  receptor  agonist 
SKF-97541, also in line with NBT data.  
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Figure 3.13 Analysis of superoxide production in BV2 and primary microglia following modulation of the 
GABAA and GABAB receptors. A dose dependency analysis of GABAA and GABAB modulators was performed 
(A).  BV2 microglia were treated with muscimol (5 µM, 50 µM or 500 µM) or SKF-97541 (1 µM, 10 µM or 100 
µM) and NBT reduction was measured (A). BV2 microglia were then treated with muscimol (50 µM ) in the 
presence  and  absence  of  apocynin  (10  µM)  (B)  and  NBT  reduction  was  measured,  to  attribute  superoxide 
production to the NADPH oxidase. The study was replicated in primary microglia using fluorescence imaging of 
dHEth (C, D) in which microglia were treated with muscimol (50 µM) or SKF-97541 (10   ) in the presence or 
absence of apocynin (10 µM ) and cells were counted to give the percent superoxide positive microglia. All data 
were analyzed using a One Way ANOVA and Tukey post-hoc analysis. *p<0.05, **p<0.01, ***p<0.001. All data 
are n=3. Scale bar 20 µm.  
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It was important to quantify the muscimol induced superoxide production in microglia using 
flow cytometry (Fig. 3.14A, B) and HPLC (Fig. 3.14C). BV2 microglia were treated with 
muscimol  (50  µM)  in  the  presence  or  absence  of  apocynin  (10  µM)  for  24  h  for  both 
analyses. The flow cytometry data (Fig. 3.14 A, B) show a significant increase in the mean 
dHEth fluorescence intensity in cells treated with muscimol when compared with control 
untreated cells, which could be attenuated by co-treatment with apocynin, suggesting that 
activation of the GABAA  receptor induced superoxide production in  an NADPH oxidase 
dependent manner. The increase in dHEth fluorescence intensity was also replicated in the 
HPLC  analysis,  in  which  a  significant  increase  2-OH-E
+  production  following  muscimol 
treatment in comparison with untreated cells was observed, which was significantly reduced 
upon co-treatment with apocynin (Fig. 3.14C). Muscimol also enhanced Eth production in 
comparison  with  control  cells,  however,  this  was  not  attenuated  by  co-treatment  with 
apocynin,  suggesting  that  Eth  production  may  be  a  result  of  muscimol  induced  ROS 
production  through  activation  of  other  systems  or  other  NADPH  oxidase  isoforms.  As 
muscimol significantly elevated 2-OH-E
+ levels when compared with Eth levels, it could be 
suggested  that  modulation  of  the  GABAA  receptor  predominantly  acts  on  the  NADPH 
oxidase to induce superoxide production.   
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Figure 3.14. Quantitative analysis of GABAA induced superoxide production by flow cytometry of 
dHEth fluorescence and HPLC analysis of dHEth oxidation products. BV2 microglia were treated 
with muscimol (50 µM) in the presence or absence of apocynin (10 µM) for 24  . For both flow 
cytometry and HPLC, cells were incubated with dHEth for 30 min. (A) shows the mean fluorescence 
intensity  of  dHEth  by  flow  cytometry  with  a  representative  histogram  shown  in  (B).  Data  were 
analysed by one way ANOVA and Tukey post-hoc analysis. (C) shows HPLC analysis of 2-OH-E and 
Eth production, and data were analysed by Student’s T-Test and by two way ANOVA to compare 2-
OH-E levels with Eth production. **p<0.01, ***p<0.001.  All data are n=3.  179 
 
To  confirm  that  muscimol  induced  superoxide  production  in  microglia  was  a  result  of 
NADPH oxidase activation, an activity assay was performed (Fig. 3.15). BV2 microglia were 
treated with mucsimol (50 µM) in the presence or absence of apocynin (10 µM) for 4 h 
before NADPH oxidase activity was measured. The data confirmed that activation of the 
GABAA  receptor  with  muscimol  significantly  increased  NADPH  oxidase  activity  when 
compared with control levels, and that this activity could be attenuated by co-treatment with 
apocynin (Fig. 3.15). 
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Figure 3.15 NADPH oxidase activity after treatment of BV2 microglia with muscimol. BV2 microglia 
were treated with muscimol (50 µM) in the presence or absence of apocynin (10 µM) for 4 h. NADPH 
oxidase activity was measured and data was normalized to protein concentration. Data were analysed 
using a one way ANOVA with Tukey post-hoc analysis. **p<0.01, ***p<0.001. Data are n=3.  181 
 
Modulation  of  the  microglial  GABAA  receptor  therefore  promotes  superoxide  production 
through  activation  of  the  NADPH  oxidase.  However,  as  the  expression  of  the  GABAA 
receptor  in  primary  microglia  is  controversial,  it  was  important  to  investigate  whether 
primary microglia isolated from the rat brain expressed the appropriate subunits required for 
the formation of a functional GABAA receptor, and also to investigate whether modulation of 
the  GABAA  receptor  by  co-treatment  with  an  agonist  and  an  antagonist  could  attenuate 
superoxide production in primary microglia. Functional GABAA receptors are composed of 
tetramers of alpha, beta and gamma subunits (ʱ2β2γ1). There are six alpha subunit isoforms, 
three beta and three gamma subunit isoforms which the GABAA receptor may be composed 
of. RT-PCR was used to determine whether primary microglia express the necessary subunits 
to form functional GABAA receptors (Fig. 3.16A). To determine whether the expression of 
these subunits changed depending on the activation state of microglia, cells were either left 
untreated, or were treated with the known microglial  activator LPS (1 µg/ml). Untreated 
microglia express ʱ2, ʱ3 and ʱ6 subunits, as well as β2 and γ3 subunits, suggesting that 
resting microglia express subunits that could form functional GABAA receptors (Fig. 3.16A). 
Expression of the ʱ6 and β2 subunits were increased following LPS treatment of microglia 
(Fig.  3.16A),  suggesting  that  functional  GABAA  receptors  are  more  highly  expressed  on 
activated  microglia,  however,  as  expression  of  the  γ  subunits  were  not  elevated,  further 
functional analyses would be required to determine whether GABAA receptor activation was 
enhanced on reactive microglia.  
It  was  also  important  to  determine  whether  modulation  of  the  GABAA  receptor  by  co-
treatment with muscimol and the GABAA receptor antagonists picrotoxin (Ptx 100 µM) or the 
highly selective GABAA receptor antagonist SR-95531 (10 µM) could inhibit superoxide 
production, to determine whether superoxide production was a direct result of activation of 
the GABAA receptor and not a consequence of an off target effect, such as activation of the 182 
 
benzodiazepine receptor. Treatment of microglia with muscimol and Ptx or muscimol and 
SR95531  significantly  decreased  superoxide  production  induced  by  muscimol  treatment 
alone  (Fig.  3.16B),  therefore  GABAA  receptor  activation  induces  superoxide  production. 
Furthermore, treatment with GABA (100 µM) as shown previously, also acts through the 
GABAA receptor, as co-treatment with GABA and Ptx or SR95531 significantly reduced 
GABA induced superoxide production in primary microglia (Fig. 3.16B).  
Together, these data show that microglia express all subunits necessary for the formation of a 
functional  GABAA  receptor  and  that  activation  of  the  GABAA  receptor  with  muscimol 
induces superoxide production through NADPH oxidase activation.  
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Figure 3.16 Legend overleaf 184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Analysis of GABAA receptor subunit expression (A) and modulation of superoxide production 
following  co-treatment  of  microglia  with  GABAA  receptor  agonists  and  antagonists  (B,  C).  Primary 
microglia were either left untreated or were treated with LPS (1 µg/ml) for 24 h. Microglia were then subjected 
to RT-PCR for analysis of GABAA receptor subunit expression (A). PCR was performed using primers for six 
alpha subunits, and the three beta and three gamma subunits, and products were resolved on a 1% agarose gel. 
The experiment was performed in triplicate, and the gel presented here is representative. Primary microglia 
were  then  treated  with  the  specific  GABAA  receptor  antagonists  Ptx  (100  µM)  or  SR95531  (10  µM)  plus 
muscimol  (50  µM)  or  GABA  (100  µM).  Microglia  were  analysed  for  superoxide  production  by  dHEth 
fluorescence imaging and microglia were counted to show the number of superoxide positive cells (B, C). Data 
were analysed using a one way ANOVA and Tukey post-hoc analysis. **p<0.01, ***p<0.001. All data are 
n=3. Scale bar 20 µm.  
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3.2.2.4 Modulation  of  the  metabotropic  purinergic  receptors  induces  superoxide 
production in microglia  
BzATP induced superoxide production in primary microglia, and is strong activator of the 
NADPH oxidase through its activation of the P2X7 receptor (Parvathenani et al 2003). As it 
is  known  that  modulation  of  the  ionotropic  purinergic  receptors  can  induce  superoxide 
production,  the  effects  of  modulation  of  the  metabotropic  purinergic  (P2Y)  receptors  on 
microglial  superoxide  production  through  NADPH  oxidase  activation  were  investigated. 
Microglia express the P2Y1, 2/4, 6, 7, 12 and 14 receptors, and expression of these receptors 
is modulated by the activation state of microglia (Bianco et al. 2005). Furthermore, P2Y 
receptor  activation  affects  microglial  motility,  chemotaxis  and  phagocytosis  (Pocock  & 
Kettenmann 2007), suggesting that activation of these receptors has important consequences 
for microglial reactivity.  
Here, superoxide production following P2Y receptor activation was first investigated using 
the NBT assay (Fig. 3.17A). The P2Y2/4 receptor was activated using UTPγS and a dose 
dependency analysis was performed in which BV2 microglia were treated with 1 µM, 10 µM 
or  100  µM  UTPγS  for  4  h.  The  optimal  concentration  required  to  induce  a  significant 
increase in NBT reduction was shown to be 100 µM (Fig. 3.17A), which induces an inward 
K
+ current in microglia (Bianco et al. 2005). The P2Y1 receptor was activated by MRS-2365, 
and a dose dependency NBT analysis was also performed in which BV2 microglia were 
treated with 10 nM, 100 nM or 1 µM (Fig. 3.17A), however, activation of the P2Y1 receptor 
did not significantly increase NBT reduction at any of the concentrations tested. Following 
the finding that UTPγS (100 µM) induced NBT reduction, it was important to determine 
whether this was dependent on NADPH oxidase activation. BV2 microglia were treated with 
UTPγS in the presence or absence of apocynin (10 µM) for 4 h and NBT reduction was 
assessed (Fig. 3.17B). Superoxide production induced by UTPγS was attenuated by inhibition 186 
 
of the NADPH oxidase; therefore microglial P2Y2/4 receptor activation induces NADPH 
oxidase  activity.  It  was  important  to  determine  whether  superoxide  production  through 
activation of the P2Y2/4 receptor could be induced in primary microglia, therefore dHEth 
fluorescence imaging was performed using primary microglia treated with UTPγS (100 µM) 
in  the  presence  or  absence  of  apocynin  (10  µM),  and  activation  of  the  microglial  P2Y1 
receptor  with  MRS-2365  (100  nM)  was  also  performed  in  the  presence  or  absence  of 
apocynin (10 µM) (Fig. 3.17C, D). Primary microglia were treated for 24 h before imaging of 
dHEth  fluorescence.  UTPγS  significantly increased the percentage of superoxide positive 
microglia when compared with control untreated microglia, which was significantly reduced 
upon  co-treatment  with  apocynin,  whilst  treatment  with  MRS-2365  had  no  effect  on 
superoxide production in primary microglia (Fig. 3.17 C,D). These data therefore show that 
modulation of the P2Y2/4 receptor induces superoxide production in an NADPH oxidase 
dependent manner.  
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Figure 3.17 Analysis of superoxide production in BV2 and primary microglia after modulation of the P2Y2/4 
and P2Y1 receptors. BV2 microglia were treated with UTPγS (1 µM, 10 µM or 100 µM) or MRS-2365 (1 nM, 
10 nM or 100 nM), for 4 h and were assessed for superoxide production by NBT reduction (A). BV2 microglia 
were then assessed for superoxide production following treatment with UTPγS (100 µM) in the presence or 
absence of apocynin (10 µM) for 4 h, using the NBT assay (B). The study was replicated in primary microglia 
(C, D), in which superoxide production was assessed by dHEth fluorescence. Microglia were treated with 
UTPγS (100 µM) or MRS-2365 (100 nM) in the presence or absence of apocynin (10 µM), and superoxide 
production was assessed after 24 h incubation by counting the dHEth fluorescent cells (C). All analysis was 
performed using a one way ANOVA with Tukey post-hoc analysis. *p<0.05, ***p<0.001. All data are n=3. 
Scale bar 20 µm.  188 
 
Quantitative  analysis  of  dHEth  fluorescence  following  treatment  of  BV2  microglia  with 
UTPγS was performed by flow cytometry (Fig. 3.18A, B) and HPLC (Fig. 3.18C). The flow 
cytometry data showed that treatment of BV2 microglia with UTPγS (100 µM) for 24 h 
significantly  increased  mean  dHEth  fluorescence  intensity  when  compared  with  control 
untreated cells, which could be significantly reduced by co-treatment with apocynin (10 µM) 
(Fig. 3.18A). HPLC analysis (Fig. 3.18C) agreed with these findings, showing that treatment 
with UTPγS significantly elevated the production of the dHEth superoxide specific oxidation 
product,  2-OH-E
+, when compared with  untreated controls,  which  was  attenuated by  co-
treatment  with  apocynin.  Furthermore,  2-OH-E
+  production  by  UTPγS  was  significantly 
elevated in comparison to Eth production, suggesting that UTPγS preferentially activates the 
NADPH oxidase to induce superoxide production. 
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Figure 3.18 Quantitative analysis of P2Y2/4 receptor induced dHEth fluorescence by flow cytometry and 
of dHEth oxidation products by HPLC. Flow cytometry (A) was used to quantify dHEth fluorescence after 
treatment of BV2 microglia with UTPγS (100 µM) for 24 h in the presence or absence of apocynin (10 µM). 
The mean fluorescence intensity is shown (A) along with a representative histogram (B). Data were analysed 
by one way ANOVA and Tukey post-hoc analysis. HPLC analysis was performed to determine the production 
of the dHEth oxidation products 2-OH-E and Eth after treatment of BV2 microglia with UTPγS (100 µM) in 
the presence or absence of apocynin (10 µM ) for 24 h (C). Data were analyzed by Student’s T-Test and two 
way ANOVA for comparisons between 2-OH-E and Eth production. *p<0.05, **p<0.01.  All data are n=3 190 
 
It was important to confirm that superoxide production as a result of UTPγS treatment of 
microglia was a consequence of increased NADPH oxidase activity, therefore an NADPH 
oxidase activity  assay  was  performed in  which BV2 microglia were  treated with  UTPγS 
(100 µM) in the presence or absence of apocynin (10 µM) for 4 h. Enzymatic activity was 
measured and shown in Fig. 3.19. Treatment with UTPγS significantly increased NADPH 
oxidase activity when compared with control untreated cells, and this activity was attenuated 
by co-treatment of cells with apocynin, therefore indicating that superoxide production from 
P2Y2/4 receptor activation is a consequence of increased NADPH oxidase activity.  
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Figure 3.19 NADPH oxidase activity after treatment of BV2 microglia with UTPγS. BV2 microglia 
were treated with UTPγS (100 µM) for 4 h in the presence or absence of apocynin (10 µM) and NADPH 
oxidase activity was measured. The data were analysed using a one way ANOVA with Tukey post-hoc 
analysis. *p<0.05. Data are n=3.  192 
 
3.3  Discussion  
The data presented in this chapter show that NADPH oxidase derived superoxide production 
in  microglia  can  be  induced  by  the  neurotransmitters  glutamate,  GABA  or  BzATP,  and 
agonists  or  antagonists  of  the  corresponding  neurotransmitter  receptors.  Four  different 
methods were used to assess superoxide production, and NADPH oxidase activity was also 
analysed.  The  data  presented  here  are  therefore  a  comprehensive  analysis  of  superoxide 
production in microglia as a consequence of neurotransmitter and receptor modulation.   
3.3.1  Neurotransmitters modulate superoxide production in microglia  
Treatment with the neurotransmitters glutamate, GABA or BzATP significantly increased 
superoxide production when compared with control un-treated cells. Glutamate significantly 
elevated  superoxide  production  when  used  at  1  µM,  which  is  within  the  physiological 
concentration range of 1-4 µM found at non-synaptic sites (Baker et al. 2002; Nyitrai et al. 
2006). However, microdialysis has shown that glutamate is present at lower concentrations in 
the CNS, with levels of 25 nM reported in resting hippocampal slices (Herman & Jahr 2007). 
It  has  however  been  shown  that  physiological  stimulation  of  glutamate  receptors  occurs 
within the micromolar range, thereby indicating that the glutamate concentration used here 
may  be  physiological.  Furthermore,  the  EC50  for  the  NMDA  receptor  is  reported  to  be 
2.3 µM (Patneau & Mayer 1990),  and the EC50 for the group I mGluRs is between 3-13 µM, 
for mGluR3 is 4-5 µM and for the group III mGluRs is between 0.02 and 1000 µM (Conn & 
Pin,  1997),  thereby  suggesting  that  micromolar  and  therefore  physiological  levels  of 
glutamate  may  promote  the  stimulation  of  microglial  glutamate  receptors.  According  to 
Herman & Jahr (2007) the concentration of glutamate used here may not lie within the basal 
range, and may be more representative of either physiological stimulation, or  excitotoxic 
injury  seen  during  ischaeimia  and  in  AD,  in  which  degenerating  neurons  and  activated 
astrocytes release glutamate into the extracellular space (Vesce et al. 2007). Here, treatment 193 
 
of BV2 microglia with lower levels of glutamate (100 nM) did not significantly elevate NBT 
reduction, suggesting activation of the microglial NADPH oxidase following exposure to 
glutamate may only occur under physiological stimulatory conditions or during pathology, 
rather than in response to basal glutamate levels.  
GABA is present at extrasynaptic sites at a concentration of 2.9 µM (Lerma et al. 1986), 
whilst here, exposure of microglia to 100 µM GABA induced a more significant increase in 
NBT  reduction,  and  subsequent  superoxide  production  when  compared  with  exposure  to 
lower concentrations. Treatment of BV2 microglia with 1 µM GABA significantly elevated 
NBT reduction; however, as treatment with the higher concentration of 100 µM induced a 
more significant increase in NBT reduction, this was used in later experiments. These data do 
however suggest that microglia respond to physiological concentrations of GABA as well as 
higher  concentrations,  which  may  mimic  the  increase  in  GABA  tone  seen  during  AD 
pathology (DiFiglia 1990). GABA is released from neurons during AD (Marczynski 1998), 
and these elevated GABA levels exacerbate neuronal vulnerability (Erdö et al. 1991). It could 
be suggested that the GABA released in neurodegenerative processes could act on microglia 
to enhance reactivity and induce ROS production. 
Whilst treatment of BV2 and primary microglia with GABA (100 µM) siginifcantly elevated 
superoxide production that could be inhibited by apocynin as determined by the NBT assay 
and by dHEth fluorescence microscopy, flow cytometry analysis showed that GABA induced 
dHEth fluoresenence  could not be significantly attenuated upon co-treatment with apocynin, 
suggesting the involvement of another oxidase system or activation of other NADPH oxidase 
isoforms,  such  as  Nox4,  which  are  insensitive  to  apocynin  (Harrigan  et  al.  2008). 
Furthermore,  HPLC  analysis  showed  that  GABA  treatment  significantly  increased  Eth 
production, indicative of H2O2 generation (Zielonka et al. 2008), which was significantly 
reduced  by  apocynin,  demonstrating  that  GABA  induces  ROS,  rather  than  superoxide 194 
 
production through activation of the NADPH oxidase. The NADPH oxidase activity assay 
showed that enzymatic activity was increased upon treatment with GABA, which could be 
attenuated by co-treatment with apocynin, supporting the findings that GABA induced ROS 
production was a consequence of NADPH oxidase activity, however this finding does not 
rule out the possibility that GABA may induce the activation of additional NADPH oxidase 
isoforms.  
Superoxide production from the NADPH oxidase isoforms Nox1 and Nox4, shown to be 
expressed in microglia (Harrigan et al. 2008; Chéret et al. 2008),  is more rapidly dismutased 
to H2O2 than superoxide produced from Nox2 (Dikalov et al. 2008; Lassègue & Griendling 
2010), which suggests that GABA induces microglial Nox1 or Nox4 activation. The findings 
could  however  also  suggest  that exposure of  BV2 microglia to  GABA may enhance the 
enzymatic activity or expression of SOD, which converts superoxide to H2O2 (Vaziri et al. 
2004).  This  has  been  demonstrated  in  an  in  vivo  model  of  rat  renal  failure,  in  which 
administration of GABA to the kidney increased SOD expression, which protected against 
oxidative damage through the enhanced production of H2O2 rather than superoxide (Sasaki et 
al. 2006). There are no reports of this in the CNS; however it could be an interesting point for 
further investigation.  
Treatment  of  BV2  and  primary  microglia  with  250 µM  BzATP  significantly  increased 
superoxide production in line with published findings (Parvathenani et al. 2003; Skaper et al. 
2006). BzATP was used in place of ATP, which was readily hydrolysed in the culture media, 
and had no effect on microglial reactivity or the production of superoxide in vitro (Skaper et 
al. 2006), however, ATP is released from dying neurons as an activating signal for microglia, 
and therefore exerts an effect in vivo (North & Verkhratsky 2006). Whilst BzATP induced 
superoxide production in primary and BV2 microglia, it did not significantly elevate NADPH 
oxidase  activity.  These  findings  therefore  suggest  that  treatment  of  BV2  microglia  with 195 
 
BzATP may induce superoxide production through NADPH oxidase activation, and also by 
another superoxide generating system.  
Superoxide production following treatment of BV2 microglia with BzATP was observed by 
HPLC  analysis,  showing  a  significant  increase  in  2-OH-E
+,  which  was  attenuated  by 
apocynin. However, Eth production was also elevated, which could not be attenuated by co-
treatment  with  apocynin,  suggesting  a  low  level  of  activity  of  another  H2O2  generating 
system, or enhanced activation of the mitochondrial respiratory chain, leading to increased 
release of H2O2 (Rigoulet et al. 2011). There are reports that activation of microglia with Aβ 
promotes ATP release which activates the NADPH oxidase in an autocrine manner, elevating 
ROS production rather than superoxide specifically (Moon et al. 2008), which supports the 
elevated Eth seen here by HPLC. Furthermore, activation of the microglial P2X7 receptor 
with BzATP promotes TNFʱ production (Suzuki et al. 2004) which elevates ROS generation 
from the mitochondria (Goossens et al. 1999). It could therefore be suggested that whilst 
BzATP induces superoxide production through the NADPH oxidase, the production of TNFʱ 
as a consequence of increased microglial reactivity following activation of the P2X7 receptor 
could increase H2O2 production through mitochondrial pathways (Morgan & Liu 2010). In 
addition, TNFʱ release from microglia following activation of the P2X7 receptor (Suzuki et 
al. 2004) can feed-back onto microglial TNF receptors (TNFR‟s) in an autocrine manner 
(Kuno et al. 2005), resulting in elevated ROS production through enhanced expression and 
activity of the NADPH oxidase (Mir et al. 2009) and also mitochondrial pathways (Suzuki et 
al.  2004). The contribution  of TNFʱ induced ROS,  produced as  a consequence of P2X7 
receptor activation of microglia could explain why here, increased superoxide production is 
observed in the assays detecting ROS production, but that the NADPH oxidase activity assay 
shows a non-significant increase in enzymatic activity. The NADPH oxidase does indeed 196 
 
play a role in BzATP induced production of superoxide in microglia, however the levels may 
be enhanced by TNFʱ induced activation of the mitochondrial respiratory pathway.   
3.3.2  Modulation  of  neurotransmitter  receptors  induces  superoxide  production  in 
microglia  
Modulation  of  microglial  glutamate,  GABA  and  purinergic  receptors  induced  NADPH 
oxidase derived superoxide production. In line with published findings, the group I mGluR 
agonist  DHPG  did  not  induce  NADPH  oxidase  derived  superoxide  production  in  BV2 
microglia  (Loane  et  al.  2009).  However,  treatment  of  BV2  microglia  with  CDPPB  (an 
mGluR5  specific  agonist)  increased  NBT  reduction.  The  agonist  CDPPB  may  induce 
superoxide  production  through  the  activation  of  other  oxidase  systems.  Activation  of 
neuronal  mGluR5  promotes  mitochondrial  ROS  production,  which  elevates  neuronal 
excitability  (Li  et  al.  2011),  suggesting  that  in  BV2  microglia,  mGluR5  activation  may 
promote mitochondrial ROS production, whilst antagonism of the mGluR5 mediates NADPH 
oxidase derived superoxide production.    
Antagonism of the group I mGluRs (mGluR5) with MTEP significantly increased superoxide 
production in an NADPH oxidase dependent manner. Activation of mGluR5 promotes PLC 
signalling (Mao &Wang 2002) which can attenuate NADPH oxidase activation in leukocytes 
(Traynor et al. 1993). Furthermore, inhibition of the astrocytic group I mGluRs can down-
regulate PLC signalling, which correlates with reactive gliosis (Floyd et al. 2004), of which 
ROS production is a hallmark (Jekabsone et al.  2006), and agrees with the data presented 
here. In addition, neuronal group I mGluR activation inhibits glutamate release (Wiśniewski 
& Car 2002; Zhang et al. 2002), and  treatment of astrocytes with the mGluR group I agonist 
ACPD decreased astrocytic glutamate release (Ye & Sontheimer 1999). Glutamate released 
from  neurons  can  facilitate  microglial  activation  (Rogove  &  Tsirka  1998)  and  NADPH 
oxidase activity (Harrigan et al. 2008). It could be suggested that in microglia, activation of 197 
 
the group I mGluRs inhibits glutamate release, thereby inhibiting an autocrine feedback of 
glutamate onto other microglial glutamate receptors, preventing NADPH oxidase activation. 
In contrast, antagonists of the group I mGluRs may induce glutamate release from microglia, 
which  could  feedback  onto  mGluRs  or  iGluRs,  inducing  superoxide  production  through 
activation of these receptors in addition to NADPH oxidase activation through the direct 
effect of inhibition of the group I mGluR (Fig. 3.20).  
Activation of mGluR3 with NAAG induced microglial superoxide production in an NADPH 
oxidase  dependent  manner.  Activation  of  the  neuronal  mGluR3  elevates  PKC  activity 
(Tyszkiewicz  et  al.  2004),  which  promotes  NADPH  oxidase  activation  through 
phosphorylation of the cytoplasmic subunits (Yamamori et al. 2000). Furthermore, mGluR3 
mediated PKC activation promotes NMDA receptor activation  (Tyszkiewicz et al. 2004), 
which  enhances  NADPH  oxidase  activity  (Zhang  et  al.  2010),  suggesting  that  mGluR3 
activation  may  enhance  NADPH  oxidase  activity  directly  through  PKC  signalling  and 
indirectly through NMDA receptor activation.  
Treatment of BV2 and primary microglia with NAAG induced superoxide production that 
could be detected by the NBT assay, dHEth fluorescence microscopy, and flow cytometry, 
however,  HPLC  analysis  did  not  show  a  significant  increase  in  2-OH-E
+  or  Eth  when 
compared with  control  untreated cells.  This  could  suggest  that multiple NADPH oxidase 
isoforms are induced by mGluR3 activation. The inability of NAAG to significantly elevate 
2-OH-E
+  or  Eth  levels  could  however  be  a  result  of  increased  antioxidant  production. 
Activation of mGluR3 in dorsal root neurons co-cultured with Schwann cells induced an 
increase in glutathione, which reduced ROS production (Berent-Spillson & Russell 2007). It 
could  therefore  be  suggested  that  in  microglia,  NAAG  elevates  ROS  production  through 
modulation of the NADPH oxidase, however NAAG may also increase the production of free 198 
 
radical  scavengers, which would reduce the concentration of detectable ROS  (Fig. 3.20), 
leading to the non-significant effect observed by HPLC analysis.  
Treatment of BV2 and primary microglia with the group III activator L-AP4 significantly 
increased NADPH oxidase derived superoxide production. Lymphocytes express functional 
group  III  mGluRs,  and  treatment  with  L-AP4  elevates  ROS  production  (Boldyrev  et  al. 
2004),  in  support  of  the  findings  here.  Furthermore,  group  III  mGluR  induced  ROS 
production in lymphocytes facilitates the communication between the immune and nervous 
systems  (Boldyrev  et  al.  2005),  which  is  supported  by  findings  that  ROS  production  in 
dendritic cells can regulate the T-cell response (Olofsson et al. 2003).The predominant dHEth 
oxididation  product  observed  by  HPLC  was  2-OH-E
+,  suggesting  that  superoxide  is 
specifically induced by activation of the group III mGluRs, and NADPH oxidase activity was 
increased by treatment with this agonist. Activation of group III mGluRs in the rat entorhinal 
cortex promotes glutamate release and PKC signalling (Evans et al. 2001), which promotes 
NADPH oxidase activation through p47phox phosphorylation (Raad et al. 2009), suggesting 
a mechanism for L-AP4 mediated NADPH oxidase activation.  In addition, activation of the 
neuronal group III mGluRs mediates PI3-K signalling (Iacovelli et al. 2002), which mediates 
NADPH oxidase activation through phosphorylation of the cytoplasmic p40phox (Ellson et 
al. 2006). It could therefore be suggested that a combination of effects such as enhanced PKC 
or  PI3-K  activity  and  excess  glutamate  release  could  contribute  to  the  NADPH  oxidase 
derived superoxide production in microglia following activation of the group III mGluRs 
seen here (Fig. 3.20).   
Modulation of the microglial iGluRs induced superoxide production in an NADPH oxidase 
dependent manner. Treatment of microglia with NMDA significantly elevated superoxide 
production which could be inhibited by apocynin. Furthermore, co-treatment of microglia 
with NMDA and the NMDA receptor antagonist MK-801 inhibited superoxide production, 199 
 
suggesting that direct modulation of the NMDA receptor induced NADPH oxidase mediated 
superoxide production. These findings are supported by in vivo studies demonstrating that 
direct  activation  of  the  NMDA  receptor  mediates  NADPH  oxidase  derived  superoxide 
production (Zhang et al. 2010). HPLC analysis of dHEth oxidation following treatment of 
BV2 microglia with NMDA showed a significant increase in the superoxide specific product 
2-OH-E
+; however, Eth was also elevated, suggesting NMDA also induced H2O2 production. 
In support of this finding, NMDA treatment of cortical neurons promotes Nox4 mediated 
H2O2 production (Ha et al.  2010). Induction of ROS and superoxide production in microglia 
could therefore originate from the activation of more than one Nox isoform, which could 
explain the almost equal production of 2-OH-E
+ and Eth.  
The  findings  that  NMDA  mediated  superoxide  production  could  be  attenuated  by  co-
treatment with the antagonist MK-801 lends support to findings that microglia in vivo express 
functional  NMDA  receptors,  and  that  activation  of  these  NMDA  receptors  mediates  NO 
production,  suggesting  that  modulation  of  the  microglial  NMDA  receptor  induces  the 
production of free radicals  (Murugan et  al.  2011). Whilst  the findings reported here that 
modulation of the microglial NMDA receptor induces superoxide in an NADPH oxidase 
dependent manner are novel, it has been reported that in neurons, modulation of the NMDA 
receptor mediates NADPH oxidase derived superoxide production, as inhibition of NADPH 
synthesis prevented NMDA receptor mediated superoxide production (Brennan et al. 2009), 
in line with the findings reported here.  In vivo models have shown that application of NMDA 
to the mouse neocortex significantly elevated ROS production, which was not seen in Nox2 
knock-out  mice,  suggesting  that  NMDA  induced  ROS  production  was  a  consequence  of 
NADPH  oxidase  activation  (Girouard  et  al.  2009).  Activation  of  the  neuronal  NMDA 
receptor  induces  PKCδ  activity  (Koponen  et  al.  2003),  which  mediates  NADPH  oxidase 200 
 
activation by p47phox phosphorylation (Leverence et al. 2011), and could be implicated in 
microglial NMDA induced NADPH oxidase activation (Fig. 3.20).  
Treatment of BV2 and primary microglia with the NMDA receptor antagonist MK-801 also 
induced superoxide production, however this could not be attenuated by co-treatment with 
apocynin. Blockade of the mouse NMDA receptor with ketamine in vivo initially elevates 
NADPH oxidase dependent ROS production, however prolonged exposure down-regulates 
Nox2 activity, and induces glutamate release (Sorce et al. 2010). The increase in superoxide 
production  observed  following  NMDA  receptor  antagonism  shown  here  could  be  a 
combinatorial  effect  of  NADPH  oxidase  dependent  superoxide  production  as  well  as  the 
production  of  superoxide  from  other  apocynin  insensitive  Nox  isoforms  (such  as  Nox4). 
Furthermore, blockade of neuronal NMDA receptors with ketamine elevates IL-6 production 
which enhances inflammation, and is associated with increased ROS production (Behrens et 
al. 2008) through Nox4 activation (Li et al. 2009). The production of IL-6 from blockade of 
NMDA  receptors  could  therefore  contribute  to  the  increase  in  ROS  observed  following 
treatment of BV2 microglia with MK-801 (Fig. 3.20).  
Modulation  of  the  microglial  AMPA  receptor  did  not  affect  superoxide  production. 
Activation of the AMPA receptor with QA failed to induce superoxide production that could 
be detected by any method in either BV2 or primary microglia, in aggrement with findings in 
cortical neurons, in which activation of the AMPA receptor did not mediate H2O2 production 
(Ha  et  al.  2010).  In  hippocampal  neurons,  application  of  AMPA  mediates  superoxide 
production, however this increase was counterbalanced by elevated SOD activity, and AMPA 
induced superoxide production was only observed after SOD knock-down (Rego et al. 2003). 
Furthermore, activation of the AMPA receptor in vivo was shown to increase superoxide 
production, but also elevated SOD expression, and the effect could be reversed after co-
treatment of rats with AMPA and the receptor antagonist CNQX (Radenović et al. 2005).  201 
 
Any  increase  in  superoxide  production  seen  here  may  therefore  be  masked  by  an  up-
regulation of SOD. Increased superoxide production was observed following antagonism of 
the  AMPA  receptor  with  CNQX.  This  could  not  be  inhibited  with  apocynin  however, 
suggesting that the NADPH oxidase was not activated. Modulation of the neuronal AMPA 
receptor  induces  superoxide  production  from  the  mitochondria  (Radenović  et  al.  2005). 
Furthermore,  CNQX  was  shown  to  inhibit  SOD  production  in  hippocampal  neurons 
(Radenović et al. 2005), suggesting that the increase in superoxide observed in microglia 
shown here could be a result of decreased SOD activity and increased mitochondrial ROS 
production.  
 
Figure  3.20  Possible  mechanisms  of  NADPH  oxidase  activation  following  modulation  of  microglial 
glutamate receptors. Microglia treated with the mGluR group I antagonist increased superoxide production. 
This could be direct, but also through the release of glutamate, which may feed back onto other glutamate 
receptors or transporters. Activation of the group III mGluR’s induced superoxide production, possibly through 
PKC activation, however glutamate has also been shown to be released from glial cells following modulation of 
this  receptor,  which  could  feedback onto  microglia.  Activation  of  mGluR3  induced  superoxide  production, 
however  levels  were  low.  It  has  been  suggested  that  modulation  of  this  receptor  induces  an  increase  in 
glutathione, which may reduce superoxide levels. Activation of the AMPA receptor did not induce superoxide 
production, whilst activation of the NMDA receptor could induce superoxide production which may be through 
modulation of PKC. Inhibition of NMDA receptors also induced superoxide production, which could be direct, 
or may be a result of production of IL-6 and subsequent microglial activation.  202 
 
Activation of the microglial GABAA receptor significantly increased superoxide production. 
There  is  some  debate  over  the  expression  of  functional  GABAA  receptors  on  microglia 
(Synowitz et al. 2001); however functional GABAA receptors have been identified on human 
glioma cells (Labrakakis et al. 1998), and more recently on human microglia (Lee et al. 
2011).  Here,  a  significant  decrease  in  superoxide  production  was  observed  in  primary 
microglia following co-treatment with the GABAA receptor agonist in the presence of the 
antagonists Ptx or SR95531 suggesting that direct activation of the GABAA receptor mediates 
superoxide production. Furthermore, primary microglia were shown to express the subunits 
required for the assembly of a functional GABAA receptor, and expression of these subunits 
was elevated upon microglial activation, in agreement with findings that microglia in gliomas 
express  GABAA  receptors,  suggesting  that  increased  microglial  reactivity  up-regulates 
GABAA receptor expression (Synowitz et al. 2001). The suggestion that activated microglia 
express functional GABAA receptors may indicate that the microglial cultures prepared here 
could be basally activated as a consequence of dissociation from other cell types (Tham et al. 
2003),  as  untreated  microglia  expressed  GABAA  receptor  subunits  and  responded  to 
muscimol. It would be important to investigate this further using immunocytochemistry to 
determine whether microglia in co-culture with neurons or microglia in organotypic slice 
cultures  expressed  GABAA  receptors.  However,  microglial  cultures  prepared  using  the 
method in this thesis express low levels of the activation marker ED1 (Morgan et al. 2004), 
and in support of the findings that resting microglia express subunits of the GABAA receptor, 
ramified human microglial cells have recently been shown to express protein and mRNA for 
the GABAA receptor, and modulation of these receptors with muscimol induces TNFʱ and 
IL-6 release (Lee et al. 2011). It could therefore be suggested that TNFʱ reseased following 
GABAA  receptor  activation  could  feedback  onto  microglial  TNFR‟s  to  induce  NADPH 
oxidase activation and subsequent superoxide production (Shen et al. 2004) (Fig. 3.21) 203 
 
HPLC analysis of dHEth oxidation following treatment of BV2 microglia with muscimol 
significantly  elevated  both  2-OH-E
+  and  Eth,  suggesting  that  activation  of  the  GABAA 
receptor  induces  ROS  and  superoxide  production.  However,  2-OH-E
+  production  was 
significantly  higher  than  Eth  production,  and  could  be  attenuated  by  co-treatment  with 
apocynin. The production of Eth corresponds with the GABA data, in which treatment with 
GABA alone significantly elevated Eth levels, suggesting that GABA may act through the 
GABAA receptor to induce superoxide production in an NADPH oxidase dependent manner. 
The production of Eth  corresponds with Nox4 induction,  and modulation of the GABAA 
receptor up-regulates Nox4 activation in endothelial cells (Tyagi et al. 2009). Furthermore, 
activation of the neuronal GABAA receptor mediates MAPK signalling (Obrietan et al. 2002), 
which mediates Nox4 activation and ROS production (Wagner et al. 2007).  
There are no published reports regarding the effects of modulation of the GABAA receptor on 
superoxide production either in neuronal or glial cells. However, ROS production facilitates 
the binding of ligands to the GABAA receptor (Yoneda et al. 1985; Sah et al. 2002). These 
data  show  that  pre-treatment  of  cells  with  xanthine  to  induce  activation  of  the  xanthine 
oxidase system, and subsequent superoxide production, increases the binding of muscimol to 
GABAA receptors, and elevates superoxide production (Yoneda et al. 1985). Furthermore, 
exposure  of  the  rat  hippocampus  to  H2O2  also  increased  muscimol  binding  to  GABAA 
receptors (Sah et al. 2002). It could therefore be suggested that treatment of microglia with 
muscimol induces ROS production through Nox4, and that this ROS facilitates the binding of 
muscimol to the GABAA receptor, which may perpetuate ROS production through increased 
activation of the GABAA receptor (Fig. 3.21).  
Modulation  of  the  metabotropic  purinergic  (P2Y)  receptors  on  microglia  promoted 
superoxide production through NADPH oxidase activation. Treatment of microglia with the 
P2Y2/4 receptor agonist UTPγS significantly elevated superoxide production, which could be 204 
 
inhibited by apocynin, suggesting that activation of this receptor induced NADPH oxidase 
activity.  This  was  confirmed  by  the  NADPH  oxidase  activity  assay.  The  main  oxidative 
species  produced  from  treatment  of  BV2  microglia  with  UTPγS  was  superoxide,  as 
demonstrated  by  HPLC  analysis,  in  which  there  was  a  significant  increase  in  2-OH-E
+ 
production when compared with control untreated cells, and also when compared with the 
production of Eth. Modulation of the P2Y1 receptor did not significantly elevate superoxide 
production in BV2 or primary microglia. In rat alveolar macrophages, activation of the P2Y1 
receptor with ADP promotes superoxide release through the respiratory burst (Gozal et al. 
2001), as opposed to the production of intracellular superoxide measured here, suggesting 
that modulation of the microglial P2Y1 receptor may enhance the production of released 
superoxide, which could be investigated further.   
The microglial P2Y receptors are implicated in microglial chemotaxis (Ohsawa et al. 2007), 
phagocytosis (Koizumi et al. 2007) and the movement of microglial fine processes (Haynes et 
al. 2006).  Little however, is known about the function of the microglial P2Y2/4 receptor, 
other  than  it  is  expressed  on  microglia  (Boucsein  et  al.  2003;  Bianco  et  al.  2005),  it‟s 
expression remains constant regardless of miroglial activation state, and receptor activation 
promotes  an  inward  rectifying  K
+  current,  suggesting  that  activation  of  these  receptors 
mediates microglial reactivity (Bianco et al. 2005).  P2Y2/4 receptors have been linked to the 
stimulation of pathways involving p38-MAPK, and PKC isoforms, which are both implicated 
in NADPH oxidase activation (Guerra et  al. 2007), although there are no published data 
regarding  the  direct  effect  of  modulation  of  P2Y2/4  on  the  microglial  NADPH  oxidase 
activation to date. It has however been shown that treatment of human neutrophils with UTP 
can  induce  superoxide  production  (Kuhns  et  al.  1988),  and  can  enhance  the  superoxide 
produced following priming of neutrophils with toxic moieties such as fMLP in an NADPH 
oxidase  dependent  manner  (Seifert  et  al.  1989).  Furthermore,  modulation  of  the  P2Y2/4 205 
 
receptor with UTP promotes ROS production and mediates intracellular Ca
2+ mobilisation in 
human eosinophils, and chelation of intracellular calcium inhibits ROS production (Ferrari et 
al.  2000). The findings  that in  immune cells  modulation  of the P2Y2/4 receptor induces 
superoxide  production  therefore  lends  support  to  the  finding  here  that  activation  of  the 
microglial  P2Y2/4  receptor  induces  NADPH  oxidase  activity  and  superoxide  production, 
which could have an important immune regulatory role. These data also suggest a role for 
intracellular calcium as a second messenger for NADPH oxidase activation, which could be 
an interesting route of further investigation, along with the activation of signalling pathways 
such as PKC and p38-MAPK (Fig. 3.21).  
 
 
Figure 3.21. Possible mechanisms by which modulation of the GABAA and P2Y2/4 receptors may 
induce  superoxide  production  in  microglia.  Microglia  treated  with  the  GABAA  agonist  muscimol 
induced superoxide production, which may occur through direct mechanisms, but could also induce the 
release  of  TNFα,  which  may  feedback  onto  TNFR’s  to  induce  activation  of  the  NADPH  oxidase. 
Activation of the P2Y2/4 receptor induces superoxide production, which may be through activation of 
PKC  or  through  the  mobilization  of  intracellular  calcium  stores,  which  may  modulate  superoxide 
production.  206 
 
3.3.3  Conclusions  
Exposure  of  microglia  to  the  neurotransmitters  glutamate,  GABA  or  BzATP  induces 
superoxide production through NADPH oxidase activation. Further investigations showed 
that inhibition of the group I mGluR, and activation of the group II and group III mGluRs 
induce superoxide production, whilst of the iGluRs, activation of the NMDA receptor, rather 
than the AMPA receptor mediates microglial superoxide production. Furthermore, activation 
of  the  GABAA  receptor  rather  than  the  GABAB  receptor,  and  activation  of  the  P2Y2/4 
receptor  rather  than  the  P2Y1  receptor  promotes  superoxide  production  in  an  NADPH 
oxidase  dependent  manner.  There  have  been  some  indications  from  the  literature  as  to 
possible mechanisms involved in NADPH oxidase activity and superoxide production as a 
result of modulation of neurotransmitter receptors, such as the involvement of TNFʱ, the 
activation of signalling pathways such as PKC and p38-MAPK, and also the involvement of 
multiple NADPH oxidase isoforms in superoxide and H2O2 production. These avenues of 
investigation have been explored in the next chapter, to determine which NADPH oxidase 
isoforms  were  modulated  as  a  result  of  neurotransmitter  receptor  activation,  and  which 
signalling pathways were activated and contributed to NADPH oxidase activation, which 
may  provide  further  insight  into  the  role  of  microglial  NADPH  oxidase  activation  after 
modulation of neurotransmitter receptors.  
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4.1 Introduction and summary of results 
The previous chapter showed that exposure of  microglia to  neurotransmitters or receptor 
modulators mediated NADPH oxidase activation. Microglial superoxide production induced 
as a consequence of NADPH oxidase activation can be protective or toxic (Hultqvist et al. 
2009) depending on the NADPH oxidase isoform activated and the subsequent signalling 
pathways that are modulated (Chéret et al. 2008; Harrigan et al. 2008; Hultqvist et al. 2009). 
Microglial Nox1 activation is neurotoxic through the release of IL-1β (Chéret et al. 2008), 
and microglial Nox2 activation is associated with the progression of diseases such as AD 
(Block 2008) and PD (Gao et al. 2002), but also has important physiological functions in 
regulating intracellular processes such as the activity of transcription factors (Dröge 2002), 
and microglial proliferation (Mander et al. 2006). Furthermore, macrophage Nox2 activation 
and superoxide release down-regulates  the T-cell response, which  attenuates  autoimmune 
disease progression (Hildeman et al. 2003; Hultqvist et al. 2009). Activation of the microglial 
Nox4 is associated with IL-6 production, however it is not known if this is protective or toxic, 
but is implicated in the regulation of the immune response (Li et al. 2009). Nox2 and Nox4 
activation in the retina has been shown to be protective in models of cellular stress using 
serum starvation (Groeger et al. 2009), suggesting a dual role for these Nox isoforms. It was 
therefore considered important to investigate which NADPH oxidase isoforms were induced 
by neurotransmitter receptor modulation, to provide some insight as to whether activation of 
these isoforms may induce a protective or toxic microglial phenotype.  
It was also important to investigate the signalling pathways implicated in NADPH oxidase 
isoform activation following modulation of microglial neurotransmitter receptors. Activation 
of microglial NADPH oxidase isoforms involves and induces the p44/42ERK (Miller et al. 
2007) and p38MAPK (Sun et al. 2008) signalling cascades, which can promote a neurotoxic 
phenotype (Pocock &  Liddle 2001). Activation  of the MAPK signalling pathway is  also 209 
 
implicated in the progression of neurodegenerative diseases such as AD (Giovannini et al. 
2002), ALS (Tortarolo et al. 2003), and PD (Miller et al. 2007). Furthermore, treatment of 
microglia with LPS mediates p38MAPK dependent NADPH oxidase activation and promotes 
phagocytosis (Sun et al. 2008), and activation of microglia with the HIV tat protein mediates 
p38MAPK dependent activation of the NADPH oxidase and neurotoxicity (Gupta et al. 2010; 
Song et al. 2011). Exposure of microglia to the herbicide paraquat, implicated in PD, also 
mediates  p44/42ERK  activation  and  NADPH  oxidase  activity  (Miller  et  al.  2007).  The 
MAPK  signalling  pathway  is  therefore  a  key  regulator  of  microglial  NADPH  oxidase 
activation in neurodegenerative conditions.  
This chapter therefore presents experiments detailing which NADPH oxidase isoforms are 
induced following modulation of neurotransmitter receptors, and also that p44/42ERK and 
p38MAPK  signalling  is  involved  in  this  superoxide  production,  which  could  provide 
information  on  the  neurotoxic  or  neuroprotective  roles  of  neurotransmitter  induced  ROS 
production in microglia.   
The  published  findings  that  microglia  express  Nox1,  Nox2  and  Nox4  NADPH  oxidase 
isoforms, and suggestions that the expression and activity of these isoforms can be modulated 
by the activity of different signalling pathways led to an investigation to determine which 
NADPH  oxidase  isoforms  were  induced  following  treatment  of  microglia  with 
neurotransmitters  and  receptor  agonists  and  antagonists.  Glutamate  was  shown  to  induce 
Nox4 expression, and also enhanced Nox1 and Nox2 activity, whilst treatment with GABA 
or BzATP increased Nox1 and Nox4 expression and activity. The group I mGluR antagonist 
MTEP,  the  GABAA  receptor  agonist  muscimol  and  the  P2Y2/4  receptor  agonist  UTPγS 
enhanced Nox1 and Nox2 activity; whilst the mGluR3 agonist and the group III mGluR 
agonist increased Nox2 and Nox4 activity. NADPH oxidase isoform expression was only 
modulated by GABAA or P2Y2/4 receptor activation, suggesting that superoxide production 210 
 
is  controlled  predominantly  through  kinase  activation  and  subsequent  phosphorylation  of 
NADPH oxidase cytoplasmic domains following modulation of neurotransmitter receptors. 
Inhibition of the AMPA receptor induced Nox1 expression, whilst modulation of the NMDA 
receptor had little effect on NADPH oxidase isoform expression.  
An investigation into the activity of the p38MAPK or p44/42ERK signalling pathway was 
performed  to  determine  whether  neurotransmitter  receptor  mediated  ROS  could  affect 
microglial  reactivity  through  cell  signalling.  Inhibition  of  p38MAPK  attenuated  NADPH 
oxidase induced superoxide production following GABAA receptor activation with muscimol, 
P2Y2/4 receptor activation with UTPγS, group III mGluR activation with L-AP4 or NMDA 
receptor activation; whilst inhibition of p44/42ERK inhibited NADPH oxidase activation and 
superoxide production following inhibition of the group I mGluR with MTEP or activation of 
mGluR3 with NAAG. Western blot analysis of phospho-p38MAPK or phospho-p44/42ERK 
showed that inhibition of superoxide production following modulation of the neurotransmitter 
receptors  regulated  the  phosphorylation  state  of  these  signalling  molecules,  which  would 
suggest a mechanism whereby MAPK signalling is dependent on NADPH oxidase activation, 
and that this signalling could also regulate NADPH oxidase induced superoxide production in 
microglia.  
The data presented here therefore demonstrate that different NADPH oxidase isoforms are 
activated  following  modulation  of  different  neurotransmitter  receptors,  and  that  MAPK 
signalling is modulated by neurotransmitter induced NADPH oxidase activation, which may 
have important consequences for microglial reactivity and neuronal survival. 
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4.2 Results  
4.2.1  Neurotransmitters induce expression and activity of Nox1, Nox2 and Nox4 
The  previous  chapter  showed  that  neurotransmitters  induced  microglial  superoxide 
production  through  NADPH  oxidase  activation;  however  these  analyses  did  not  provide 
information on which NADPH oxidase isoforms were expressed or activated. Different Nox 
isoforms  preferentially  produce  either  superoxide  (Nox1  and  Nox2)  or  H2O2  (Nox1  and 
Nox4).  HPLC analysis of dHEth oxidation showed that treatment with glutamate or BzATP 
induced  the  production  of  the  superoxide  specific  product  2-OH-E
+  suggestive  of  Nox2 
activation, whilst GABA induced a significant increase in NADPH oxidase derived H2O2 
production,  suggestive  of  Nox4  activation.  These  findings  lead  to  the  investigation  into 
neurotransmitter and receptor induced NADPH oxidase isoform expression and activity in 
microglia. 
Nox1, Nox2 and Nox4 expression were investigated in primary microglia treated with the 
neurotransmitters glutamate (1 µM), GABA (100 µM) or BzATP (250 µM) using RT-PCR 
analysis  (Fig.  4.1).  Microglia  were  also  treated  with  the  positive  control  for  microglial 
activation, LPS (1 µg/ml), the known NADPH oxidase activator PMA (10 ng/ml), or the 
NADPH oxidase inhibitor apocynin (10 µM). Microglia were treated for 24 h and RNA was 
extracted and reverse transcribed before PCR was performed using primers for Nox1, Nox2, 
Nox4, or β-actin which was used as a loading control (Fig. 4.1A).  The RT-PCR was carried 
out  three  times,  using  three  different  microglial  preparations,  and  densitometry  was 
performed in which expression levels of each NADPH oxidase isoform were normalised to 
β-actin (Fig. 4.1B).  212 
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Figure  4.1  NADPH  oxidase  isoform  expression  in  primary  microglia  treated  with  the  neurotransmitters 
glutamate, GABA or BzATP. Primary microglia were treated with Glutamate (1 µM), GABA (100 µM) or BzATP 
(250 µM), or the positive controls LPS (1 µg/ml) or PMA (10 ng/ml), or the NADPH oxidase inhibitor apocynin 
(10 µM) for 24 h. RNA was then extracted, and was reverse transcribed to cDNA. PCR was used to amplify Nox1, 
Nox2 or Nox4 transcribed genes, and β-actin was used as a loading control. PCR products were resolved on a 1% 
agarose gel by electrophoresis (A). The experiment was carried out three times, and densitometry was performed 
(B), in which expression of Nox1, Nox2 or Nox4 was normalised to β-Actin. Statistical analysis was performed on 
densitometry data, using a one way ANOVA, with post hoc analysis. All treatments were compared with control 
untreated  cells,  which  is  representative  of  basal  NADPH  oxidase  isoform  expression.  *p<0.05,  *p*<0.01, 
***p<0.001. All data are n=3.  213 
 
Glutamate significantly increased microglial Nox4 expression, whilst treatment with GABA 
or BzATP significantly increased microglial Nox1 and Nox4 expression (Fig. 4.1B). These 
data therefore support the findings that Nox4 is predominantly regulated at the transcriptional 
level (Sorce & Krause 2009). As neurotransmitters have varying effects on Nox isoform 
expression, it was important to investigate the effects of glutamate, GABA or BzATP on the 
regulation of Nox isoform induced superoxide production and activity. 
NADPH  oxidase  induced  superoxide  production  is  also  regulated  through  the 
phosphorylation and translocation of cytoplasmic subunits, which is dependent on activation 
of signalling cascades. It was therefore important to investigate whether glutamate, GABA or 
BzATP  could  induce  Nox1,  Nox2  or  Nox4  activity.  Modulation  of  signalling  pathways 
regulates NADPH oxidase activation and superoxide production, therefore NADPH oxidase 
isoform  activation  following  neurotransmitter  treatment  was  investigated  by  treating 
microglia  with  each  of  the  neurotransmitters  in  the  presence  of  different  protein  kinase 
inhibitors.  To  investigate  the  activation  of  Nox1/2,  cells  were  treated  with  apocynin,  as 
before, which prevents phosphorylation of the cytoplasmic p47phox subunit, which is part of 
the  Nox1  and  Nox2  NADPH  oxidase,  thereby  inhibiting  the  assembly  of  the  functional 
enzyme (Stefanska & Pawliczak 2008). To investigate Nox4 activation, cells were treated 
with  neurotransmitters  in  the  presence  of  thioridazine,  which  inhibits  Nox4  enzymatic 
activity (Harrigan et al. 2008) through binding to the catalytic domain to inhibit electron 
transport across the Nox4 subunit (Serrander et al. 2007). To distinguish between Nox1 or 
Nox2 activation, microglia were treated with neurotransmitters in the presence of rottlerin, 
which is a PKCδ inhibitor shown to inhibit Nox1 expression and activation (Fan et al. 2005; 
Wei et al. 2010), or the PI3-K inhibitor wortmannin, which inhibits phosphorylation of the 
Nox2 specific p40phox (Kanai et al. 2001; Ellson et al. 2006). It was hoped that inhibition of 214 
 
these kinases could show whether glutamate, GABA or BzATP induced signalling cascades 
that could modulate Nox1 or Nox2 activity.  
BV2 and primary microglia were treated with glutamate (1 µM) (Fig. 4.2Ai, ii, iii), GABA 
(100 µM) (Fig. 4.2Bi, ii, iii) or  BzATP  (250 µM) (Fig. 4.2Ci, ii, iii)  in  the presence or 
absence of the inhibitors apocynin (10 µM), thioridazine (1 µM – Harrigan et al. 2008), 
rottlerin (10 µM – Fan et al. 2005) or wortmannin (1 µM – Kanai et al. 2001). The inhibitors 
did  not  induce microglial  apoptosis  or proliferation (Fig, 4.2Div)  or modulate superoxide 
production or NADPH oxidase activity (Fig, 4.2Di, ii, iii) when applied to microglia alone. 
Superoxide production was measured by NBT analysis in BV2 microglia (Fig. 4.2Ai, Bi, Ci), 
or  by  dHEth  fluorescence  in  primary  microglia  (Fig.  4.2Aii,  Bii,  Cii).  NADPH  oxidase 
activity was also assessed after treatment of BV2 microglia with  neurotransmitters in the 
presence of the inhibitors (Fig. 4.2Aiii, Biii, Ciii).  
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Figure 4.2 Analysis of NADPH oxidase isoform activity after treatment of BV2 or primary microglia with 
glutamate (Ai, ii, iii), GABA (Bi, ii, iii) or BzATP (Ci, ii, iii). Superoxide production in BV2 microglia was 
analysed using the NBT assay (Ai, Bi, Ci), and superoxide production in primary microglia was measured by 
dHEth fluorescence (Aii, Bii, Cii). NADPH oxidase activity was investigated in BV2 microglia using the 
activity assay (Aiii, Ciii, Biii). BV2 microglia were treated with glutamate (1 µM – panel A), GABA (100 µM 
– panel B) or BzATP (250 µM – panel C) in the presence or absence of apocynin (Apo, 10 µM), thioridazine 
(Thi, 1 µM), rottlerin (Rott, 10 µM) or wortmannin (Wort, 1 µM) for 4 h for the NBT assay (Ai, Bi, Ci) and 
the NADPH oxidase activity assay (Aiii, Biii, Ciii).Primary microglia were treated as above for 24 h for the 
dHEth fluorescence assay (Aii, Bii, Ciii) in which microglia exhibiting red fluorescence in the nuclei were 
counted and expressed as a percent of superoxide positive microglia. NBT assays (Di), dHEth assays (Dii) 
and activity assays (Diii) were performed on BV2 and primary microglia treated with apocynin (10 µM), 
Thioridazine (1 µM), Rottlerin (10 µM) or Wortmannin (1 µM) alone to confirm that these inhibitors did not 
modulate superoxide production. To ensure that the inhibitors did not affect neuronal survival, cell counts 
were made of microglia treated with the inhibitors alone (Div).  All data analysis was performed using a one 
way  ANOVA  with  Tukey  post-hoc  analysis.  Comparisons  were  made  between  cells  treated  with 
neurotransmitters alone and those co-treated with glutamate and inhibitors as indicated *p <0.05, *p*<0.01, 
***p0.001. All data are n=3. 
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Glutamate  significantly  increased  NBT  reduction  in  BV2  microglia  in  comparison  to 
untreated controls (basal NBT reduction), which could be attenuated by co-treatment with 
apocynin, thioridazine, rottlerin or wortmannin (Fig. 4.2Ai). The most significant decrease in 
NBT reduction was seen upon co-treatment of BV2 microglia with glutamate and apocynin 
(***p<0.001), followed by co-treatment with rottlerin (**p<0.01), therefore suggesting that 
Nox1 and Nox2 are predominantly activated after glutamate treatment of BV2 microglia, and 
that exposure of BV2 microglia to glutamate induces PKCδ activity. Treatment of primary 
microglia with glutamate significantly elevated dHEth fluorescence, which was attenuated by 
co-treatment with apocynin, thioridazine, rottlerin or wortmamnnin (Fig. 4.2Aii). However, 
the most significant  decrease in  superoxide production was  observed following treatment 
with glutamate and apocynin or wortmannin (***p<0.001), suggesting the involvement of 
Nox2 in glutamate induced superoxide production in primary microglia, and indicating that 
glutamate induces PI3-K activation in primary microglia. In agreement with the NBT assay, 
treatment  of  BV2  microglia  with  glutamate  and  apocynin  or  rottlerin  induced  the  most 
significant decrease in NADPH oxidase activity (**p<0.01), however co-treatment of BV2 
microglia  with  glutamate  and  wortmannin  also  significantly  reduced  enzymatic  activity 
(*p<0.05)  (Fig.  4.2Aiii).  Together,  these  data  show  that  glutamate  induces  superoxide 
production through Nox1 and Nox2 activation.  
GABA induced NBT reduction was attenuated by co-treatement with GABA and apocynin, 
thiorodazine, rottlerin  or wortmannin  (Fig. 4.2Bi), implicating  Nox1, 2, and 4 in  GABA 
induced ROS production. Treatment of primary microglia with GABA significantly increased 
the  percentage  of  dHEth  fluorescent  microglia,  which  was  attenuated  by  co-treatment  of 
primary microglia with apocynin (Fig. 4.2Bii), suggesting that GABA preferentially activates 
Nox2. This was supported by the activity assay (Fig. 4.2Biii), which showed a significant 
decrease in NADPH oxidase activity following co-treatment of BV2 microglia with GABA 217 
 
and apocynin, rottlerin or wortmannin, implicating Nox1 and Nox2 in GABA induced ROS 
production.  These  data  suggest  that  in  BV2  microglia,  GABA  induces  PI3-K  and  PKCδ 
activation to induce Nox1 and Nox2 mediated superoxide production, as well as inducing 
Nox4 activity, whereas in primary microglia, GABA mediates Nox1 and Nox2 activation in a 
PKCδ and PI3-K independent manner.   
Treatment of BV2 microglia with BzATP significantly increased NBT reduction which was 
attenuated  by  co-treatment  of  BV2  microglia  with  apocynin,  thioridazine,  rottlerin  or 
wortmannin, suggesting that all three NADPH oxidase isoforms are implicated in BzATP 
induced  superoxide  production  in  BV2  microglia  (Fig.  4.2Ci).  BzATP  induced  dHEth 
fluorescence could only be attenuated by co-treatment with apocynin (Fig. 4.2Cii), suggesting 
that BzATP only induces Nox2 activation in primary microglia, and that this is independent 
of PI3-K or PKC signalling. Co-treatment of primary microglia with BzATP and rottlerin or 
wortmannin  significantly  increased  superoxide  production  when  compared  with  control 
untreated microglia (Fig. 4.2Cii). Inhibition of NADPH oxidase isoforms following BzATP 
treatment may therefore promote further superoxide production through increased activation 
of other NADPH oxidase isoforms or other ROS producing enzymes. The NADPH oxidase 
activity assay (Fig. 4.2Ciii) agreed with the imaging data, showing a significant decrease in 
NADPH oxidase activity upon co-treatment of BV2 microglia with BzATP and apocynin, 
suggesting that Nox2 is predominantly activated by BzATP.  
In summary, glutamate induced microglial Nox4 expression and Nox1 and Nox2 activation in 
a PKCδ and PI3-K dependent manner; GABA increased Nox1 and Nox4 expression and 
activity; and BzATP up-regulated Nox1 and Nox4 expression, and Nox1/2 activity. GABA or 
BzATP induced Nox1 and Nox2 activation in primary microglia was independent of PI3-K or 
PKCδ activation. These data lead on to investigations to determine which NADPH oxidase 
isoforms could be activated by modulation of neurotransmitter receptors.  218 
 
4.2.2  Neurotransmitter  receptor  modulation  affects  the  expression  and  activity  of 
Nox1, Nox2, and Nox4  
Initially,  RT-PCR  was  used  to  examine  Nox1,  Nox2  and  Nox4  expression  in  primary 
microglia treated with the mGluR group I antagonist MTEP (100 nM), the mGluR3 agonist 
NAAG (50 µM), the mGluR group III agonist L-AP4 (100 µM), the GABAA receptor agonist 
muscimol  (50 µM)  or  the  P2Y2/4  receptor  agonist  UTPγS  (100  µM)  in  the  presence  or 
absence of apocynin (10 µM) for 24 h (Fig. 4.3). PCR was used to amplify Nox1, Nox2, 
Nox4 and β-actin as a loading control (Fig. 4.3A). The RT-PCR was performed three times, 
using  three  separate  microglial  preparations,  and  densitometry  was  performed,  in  which 
expression  levels  of  Nox1  (Fig.  4.3Bi),  Nox2  (Fig.  4.3Bii)  or  Nox4  (Fig.  4.3Biii)  were 
normalised to the β-actin loading control.  
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Figure 4.3 Nox1, Nox2 and Nox4 expression in primary microglia after treatment with neurotransmitter receptor 
agonists and antagonists. Primary microglia were treated with the controls LPS (1 µg/ml), PMA (10 ng/ml) or 
apocnin (10 µM), or the mGluR group I receptor antagonist MTEP (100 nM), the group III agonist L-AP4 (100 µM), 
the mGluR3 agonist NAAG (50 µM), the GABAA receptor agonist muscimol (50 µM) or the P2Y2/4 receptor agonist 
UTPγS (100 µM) in the presence or absence of apocynin (10 µM) for 24 h. RNA was then extracted and reverse 
transcribed to cDNA. PCR was performed using primers for Nox1, Nox2 or Nox4, as well as primers for the loading 
control β-actin. Products were subjected to electrophopresis on a 1% agarose gel, with EthBr for visualisation (A). 
The experiment was conducted in triplicate using three separate microglial preparations, to enable densitometry to 
be performed. Expression of Nox1 (Bi), Nox2 (Bii) and Nox4 (Biii) was normalised to β-actin, to quantify expression 
of each NADPH oxidase isoform. Densitometry was analysed by one way ANOVA with Tukey post-hoc analysis, 
comparing all treatments with control un-treated cells, and comparisons were also made between cells treated with 
neurotransmitter  receptor  agonists  /  antagonists  alone  or  in  the  presence  of  apocynin  as  indicated.  *p<0.05, 
**p<0.01, ***p<0.001.  All data are n=3.  
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Muscimol  or  UTPγS  treatment  significantly  elevated  microglial  Nox1  expression 
(Fig. 4.3Bi),  and  in  the  case  of  muscimol,  Nox1  expression  could  be  attenuated  by  co-
treatment of microglia with muscimol and apocynin, suggesting the presence of a feedback 
mechanism  in  which  attenuation  of  superoxide  production  inhibits  Nox  gene  expression. 
Treatment of microglia with the mGluR3 agonist NAAG did not significantly elevate Nox1 
expression,  however,  co-treatment  of  microglia  with  NAAG  and  apocynin  significantly 
decreased  Nox1  expression  when  compared  with  Nox1  expression  elicited  by  NAAG 
treatment alone (Fig. 4.3Bi).  
Nox2 expression was significantly up-regulated by treatment of microglia with muscimol or 
UTPγS (Fig. 4.3Bii). NAAG plus apocynin treatment of microglia also significantly elevated 
Nox2 expression when compared with control untreated cells or NAAG treatment alone. This 
could  suggest  that  a  decrease  in  superoxide  production  through  inhibition  of  enzymatic 
activity may promote Nox2 expression to regulate superoxide levels in microglia.   
Treatment  of  primary  microglia  with  muscimol  or  UTPγS  significantly  elevated  Nox4 
expression, however, this was not modulated by co-treatment with apocynin (Fig. 4.3Biii). 
Treatment  of microglia with  MTEP and apocynin  significantly elevated Nox4 expression 
when compared with control untreated cells, and also when compared with MTEP treatment 
alone  (Fig.  4.3Biii),  again  suggesting  the  presence  of  a  regulatory  mechanism  in  which 
inhibition of receptor induced Nox1 or Nox2 expression with apocynin may enhance Nox4 
expression.  
As modulation of microglial neurotransmitter receptors had little effect on NADPH oxidase 
isoform  expression,  it  was  important  to  determine  whether  neurotransmitter  receptor 
modulation could affect NADPH oxidase isoform activity. BV2 and primary microglia were 
treated with the receptor agonists or antagonists in the presence or absence of the Nox1/2 222 
 
inhibitor  apocynin  (10  µM),  the  Nox4 inhibitor  thioridazine  (1  µM),  the  PKCδ  inhibitor 
rottlerin (10 µM), or the PI3-K inhibitor wortmannin (1 µM) before superoxide production 
and NADPH oxidase activity was measured.  
To asses whether modulation of mGluRs mediated the activity of different NADPH oxidase 
isoforms,  BV2  microglia  were  treated  with  MTEP  (100  nM)  (Fig.  4.4Ai,  ii,  iii),  NAAG 
(50 µM) (Fig. 4.4Bi, ii, iii) or L-AP4 (100 µM) (Fig. 4.4Ci, ii, iii) in the presence or absence 
of apocynin (10 µM), thioridazine (1 µM), rottlerin (10 µM), or wortmannin (1 µM). The 
NBT assay was used to investigate superoxide production after inhibition of NADPH oxidase 
isoforms  (Fig. 4.4Ai,  Bi,  Ci).  Superoxide  production  in  primary  microglia  was  also 
investigated using dHEth fluorescence microscopy, following treatment of microglia with 
MTEP (Fig. 4.4Aii), NAAG (Fig. 4.4Bii) or L-AP4 (Fig. 4.4Cii) in the presence or absence 
of the inhibitors apocynin, thioridazine, rottlerin or wortmannin. NADPH oxidase activity 
was  also  investigated  in  BV2  microglia  after  4  h  incubation  with  the  aforementioned 
conditions (Fig. 4.4Aiii, Biii, Ciii).  
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Figure 4.4 Modulation of NADPH oxidase isoform activity after treatment of microglia with the group I 
mGluR antagonist MTEP (Ai, ii, iii), the mGluR3 agonist NAAG (Bi, ii, iii) or the group III mGluR agonist 
L-AP4 (Ci, ii, iii). BV2 microglia were treated with the group I mGluR agonist MTEP (100 nM) (Ai, ii, iii), the 
mGluR3 agonist NAAG (Bi, ii, iii,), or the group III mGluR agonist L-AP4 (Ci, ii, iii) in the presence or 
absence of the NADPH oxidase inhibitors apocynin (apo, 10 µM), thioridazine (Thi, 1 µM), rottlerin (Rott, 
10 µM) or wortmannin (Wort, 1 µM) for 4 h before NBT reduction was measured (Ai, Bi, Ci). Dihydroethidium 
fluorescence was used to investigate superoxide production in primary microglia treated as above for 24 h, and 
the percentage superoxide positive cells were determined (Aii, Bii, Cii) from images taken. NADPH oxidase 
activity was also analysed after treatment of BV2 microglia as described for 4 h  (Aiii, Biii, Ciii). For all 
analyses, data were analysed using a one way ANOVA with Tukey post-hoc analysis, in which comparisons 
were  made  between  treated  and  control  un-treated  cells,  and  also  between  treatments  in  the  presence  or 
absence of inhibitors as indicated. *p<0.05, *p*<0.01, ***p<0.001.  All data are n=3.  224 
 
Antagonism  of  the  group  I  mGluR  with  MTEP  significantly  increased  NBT  reduction 
(Fig. 4.4Ai)  and dHEth  fluorescence (Fig. 4.4Aii) when  compared with control  untreated 
microglia. The increased NBT reduction after treatment of BV2 microglia with MTEP was 
inhibited by co-treatment with apocynin, thioridazine, rottlerin or wortmannin (Fig. 4.4Ai); 
suggesting that MTEP induces the activity of all NADPH oxidase isoforms in BV2 microglia 
through  PKCδ  and  PI3-K  activation.  However,  the  MTEP  induced  increase  in  dHEth 
fluorescence  in  primary  microglia  was  only  attenuated  by  co-treatment  with  apocynin 
(Fig. 4.4Aii), suggesting that only Nox1/2 is activated by inhibition of the group I mGluR, 
which is independent of PKCδ or PI3-K activation.  In contrast, MTEP induced NADPH 
oxidase activity was significantly attenuated by all inhibitors tested, lending support to the 
NBT analysis (Fig. 4.4Aiii). In BV2 microglia, inhibition of the group I mGluRs induces 
superoxide production through activation of PKCδ and PI3-K to  induce Nox1 and Nox2 
activation, as well as inducing Nox4 activity, whereas in primary microglia, MTEP induced 
superoxide production is a result of Nox1/2 activation only, and is independent of PKC and 
PI3-K signalling. 
The mGluR3 mediated NBT reduction was significantly attenuated by co-treatment of cells 
with apocynin, thioridazine, rottlerin or wortmannin (Fig. 4.4Bi), therefore suggesting that in 
BV2 microglia NAAG induces superoxide production through Nox1 and Nox2 activation in a 
PKCδ and PI3-K dependent manner, and also promotes Nox4 activation. NAAG induced 
dHEth fluorescence in primary microglia could only be significantly reduced by co-treatment 
with apocynin, suggesting that superoxide production is a consequence of Nox1 and Nox2 
activation only, and is independent of PI3-K and PKCδ activation (Fig. 4.4Bii). Treatment of 
primary microglia with NAAG and the PKCδ inhibitor rottlerin significantly increased dHEth 
fluorescence when compared with control untreated cells (Fig.4.4Bii) which suggests that 
Nox1  inhibition  enhances  the  activity  of  other  NADPH  oxidase  isoforms.  The  activity 225 
 
analysis correlated with the primary microglial dHEth fluorescence analysis, showing that 
treatment of BV2 microglia with NAAG significantly increased NADPH oxidase activity, 
which could be attenuated by co-treatment with apocynin or thioridazine (Fig. 4.4Biii). These 
data therefore suggest that NAAG induced superoxide production is mediated by Nox1 and 
Nox4 activation. 
L-AP4 treatment significantly elevated NBT reduction, which was attenuated by co-treatment 
of BV2 microglia with each inhibitor tested (Fig. 4.4Ci). Co-treatment of BV2 microglia with 
L-AP4 and wortmannin, thioridazine or apocynin induced the most significant decrease in 
NBT reduction (***p<0.001), suggesting that activation of the group III mGluRs in BV2 
microglia  induces  Nox2  and  Nox4  activation  through  PI3-K  activation.  These  findings 
correlated with NADPH oxidase activity in BV2 microglia (Fig. 4.4Ciii). L-AP4 induced 
superoxide production in primary microglia could only be attenuated by co-treatment of cells 
with apocynin (Fig. 4.4Cii), and co-treatment of microglia with L-AP4 and thioridazine or 
wortmannin significantly elevated the number of superoxide positive microglia (Fig. 4.4Cii). 
This could suggest that in primary microglia, inhibition of one isoform following activation 
of the group III mGluR may induce superoxide production through the enhanced activation of 
other NADPH oxidase isoforms.  
It was next important to investigate whether modulation of the GABAA or P2Y2/4 receptors 
induced Nox1, Nox2 or Nox4 mediated superoxide production. BV2 and primary microglia 
were treated with muscimol (50 µM) (Fig. 4.5Ai, ii, iii) or UTPγS (100 µM) (Fig. 4.5Bi, ii, 
iii) in the presence or absence of apocynin (10 µM), thioridazine (1 µM), rottlerin (10 µM) or 
wortmannin (1 µM). Cells were assessed for superoxide production using the NBT assay 
(Fig. 4.5Ai, Bi), and superoxide production was analysed in primary microglia using dHEth 
fluorescence microscopy (Fig. 4.5Aii, Bii). NADPH oxidase activity in BV2 microglia was 
assessed using the activity assay after treatment as described for 4 h (Fig. 4.5Aiii, Biii).  226 
 
   
 
 
 
 
 
 
 
Figure 4.5 Modulation of NADPH oxidase isoform activity after treatment of microglia with the GABAA 
receptor   agonist muscimol (Ai, ii, iii) or the P2Y2/4 receptor agonist UTPγS (Bi, ii,iii). BV2 microglia were 
treated with the GABAA receptor agonist muscimol (50 µM) (Ai, ii, iii) or the P2Y2/4 receptor agonist UTPγS 
(Bi, ii, iii) in the presence or absence of the NADPH oxidase inhibitors apocynin (apo, 10 µM), Thioridazine 
(Thi, 1 µM), rottlerin (Rott, 10 µM) or wortmannin (Wort, 1 µM) for 4 h before NBT reduction was measured 
(Ai, Bi). Dihydroethidium fluorescence was used to investigate superoxide production in primary microglia 
treated as above for 24 h, and the percent superoxide positive cells were determined  (Aii Bii) from images 
taken. NADPH oxidase activity was also analysed after treatment of BV2 microglia as described for 4 h (Aiii, 
Biii). For all analyses, data were analysed using a one way ANOVA with Tukey post-hoc analysis, in which 
comparisons  were  made  between  treated  and  control,  untreated  cells,  and  also  between  treatments  in  the 
presence or absence of inhibitors as indicated. *p<0.05, **p<0.01, ***p<0.001.All data are n=3.    
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Muscimol significantly increased NBT reduction when compared with untreated controls, 
which  was  attenuated  by  co-treatment  with  apocynin,  thioridazine  or  rottlerin  in  BV2 
microglia (Fig. 4.5Ai). Muscimol induced superoxide production in primary microglia was 
attenuated by co-treatment with apocynin or rottlerin (Fig. 4.5Aii), in agreement with the 
NADPH  oxidase  activity  assay,  demonstrating  that  muscimol  induced  NADPH  oxidase 
activity  could  be  reduced  most  significantly  by  co-treatment  with  rottlerin  (**p<0.01) 
(Fig. 4.5Aiii).  Furthermore,  apocynin  or  wortmannin  also  attenuated  muscimol  induced 
NADPH oxidase activity (Fig. 4.5Aiii). These data therefore suggest that GABAA receptor 
activation induces NADPH oxidase derived superoxide production through the activation and 
expression of Nox1 and Nox2, in a PKCδ dependent manner.   
UTPγS  induced  NBT  reduction  was  significantly  attenuated  by  apocynin,  thioridazine, 
rottlerin  or  wortmannin  (Fig.  4.5Bi).  In  contrast,  UTPγS  induced  dHEth  fluorescence  in 
primary  microglia  could  only  be  attenuated  by  co-treatment  of  cells  with  apocynin 
(Fig. 4.5Bii)  and  this  treatment  also  induced  the  most  significant  attenuation  of  NADPH 
oxidase activity (**p<0.01) (Fig. 4.5Biii). Co-treatment of primary microglia with UTPγS 
and  rottlerin  significantly  increased  dHEth  fluorescence  when  compared  with  control 
untreated cells and those treated with UTPγS alone (Fig. 4.5Bii), and co-treatment of BV2 
microglia with UTPγS and rottlerin had no effect on NADPH oxidase activity (Fig. 4.5Biii). 
Treatment of BV2 microglia with UTPγS and wortmannin significantly reduced  NADPH 
oxidase activity (Fig. 4.5Biii). These data together suggest that modulation of the P2Y2/4 
receptor induces superoxide production Nox1 and Nox2 activation, and in BV2 microglia this 
is dependent on PI3-K activation.  
The  expression  and  functional  analysis  therefore  showed  that  antagonism  of  the  group  I 
mGluR with MTEP, activation of the GABAA receptor with muscimol, and activation of the 
P2Y2/4  receptor  with  UTPγS  induced  superoxide  production  through  Nox1  and  Nox2 228 
 
activation, whereas activation of the group II mGluR3 with NAAG and activation of the 
group III mGluR with L-AP4 induced Nox2 and Nox4 derived superoxide production.  
Nox1, Nox2 and Nox4 expression were next investigated after modulation of the microglial 
iGluRs, as it was shown in the previous chapter that activation of the microglial NMDA 
receptor elevated superoxide production, whilst modulation of the AMPA receptor had no 
effect on ROS production. Primary microglia were treated with NMDA (100 µM) or MK-801 
(10 µM) either alone, in combination, or in the presence of apocynin (10 µM); or were treated 
with the AMPA receptor agonist QA (10 µM) or the antagonist CNQX (10 µM) either alone, 
in combination, or in the presence of apocynin (10 µM).  PCR was performed using primers 
for Nox1, Nox2 and Nox4, as well as β-actin as a loading control (Fig. 4.6A). The PCR was 
conducted in triplicate, using three separate microglial preparations, and densitometry was 
performed,  in  which  Nox1  (Fig.  4.6Bi),  Nox2  (Fig. 4.6Bii)  and  Nox4  (Fig.  4.6Biii) 
expression was normalised to β-actin.  
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Figure 4.6 legend overleaf  
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Figure 4.6 Nox1, Nox2 and Nox4 expression in primary microglia after treatment with iGluR receptor 
agonists and antagonists. Primary microglia were treated with the NMDA receptor agonist NMDA (100 
µM), or the antagonist MK-801 (10 µM) either alone, in combination or in the presence of apocynin (10 µM) 
for 24 h. Microglia were also treated with the AMPA receptor agonist QA (10 µM), or the antagonist CNQX 
(10 µM) either alone, in combination or in the presence of apocynin for 24 h. RNA was then extracted and 
reverse transcribed to cDNA. PCR was performed using primers for Nox1, Nox2 or Nox4, as well as the 
loading control β-actin. Products were subjected to electrophopresis on a 1% agarose gel, with EthBr for 
visualisation (A). The experiment was conducted in triplicate using three separate microglial preparations, 
to enable densitometry to be performed. Expression of Nox1 (Bi), Nox2 (Bii) and Nox4 (Biii) was normalised 
to β-actin, to quantify expression of each NADPH oxidase isoform. Densitometry was analysed by one way 
ANOVA with Tukey post-hoc analysis, comparing all treatments with control un-treated cells, and making 
comparisons between cells treated with neurotransmitter receptor agonists / antagonists alone or in the 
presence of apocynin as indicated. *p<0.05, **p<0.01, ***p<0.001. All data are n=3.    
 231 
 
Modulation  of  the  NMDA  receptor  did  not  significantly  alter  Nox1  (Fig. 4.6Bi),  Nox2 
(Fig. 4.6Bii) or Nox4 (Fig. 4.6Biii) expression when compared with control untreated cells. 
Co-treatment of microglia with the AMPA receptor agonist QA and the antagonist CNQX 
significantly increased Nox1 expression (Fig. 4.6Biii) when compared with control untreated 
microglia, and also when compared with CNQX or QA treatments alone. Activation of the 
NMDA receptor was previously shown to elevate superoxide production, however as NMDA 
did not increase NADPH oxidase isoform expression, it could be suggested that activation of 
the  NMDA  receptor  may  induce  phosphorylation  of  cytoplasmic  subunits  through  the 
activation  of  signalling  pathways  to  modulate  NADPH  oxidase    activity  rather  than 
expression.                                                                                                                                                                                      
4.2.3  MAPK  signalling  in  neurotransmitter  receptor  modulated  NADPH  oxidase 
activation  
Activation  of  the  microglial  MAPK  signalling  cascade  is  implicated  in  several 
neurodegenerative conditions, and MAPK signalling can be regulated by the redox state of 
microglia,  which  is  perturbed  following  microglial  activation  (Pawate  et  al.  2004).  In 
microglia,  MAPK  signalling  is  modulated  by  exposure  to  growth  factors,  modulation  of 
GPCR‟s, cellular stresses or inflammatory mediators which promote the phosphorylation and 
activation of p38MAPK or p44/42ERK. Activation of microglial p38MAPK with Aβ induces 
an inflammatory phenotype, characterised by the release of cytokines, which can feedback 
onto  microglia  perpetuating  inflammation  and  enhancing  disease  progression  (Pocock  & 
Liddle 2001). Activation of the microglial p44/42ERK is detrimental to neuronal survival, 
and treatment with LPS, Aβ or inflammatory cytokines can induce a neurotoxic phenotype 
through up-regulation of ERK1/2 (Koistinaho & Koistinaho 2002). Furthermore, modulation 
of the microglial cannabinoid receptor type 2 (CBR2) can down-regulate ERK activation 
following exposure to LPS, and is protective against neurotoxicity (Romero-Sandoval et al. 232 
 
2009).  In  addition,  anti-inflammatory  drugs  attenuate  microglial  Aβ  induced  p44/42ERK 
phosphorylation, which prevents the cognitive deficits associated with AD in mouse models 
(Zhu et al. 2008). 
As the p44/42ERK and p38MAPK signalling molecules are implicated in the activation of 
the microglial NADPH oxidase (Miller et al. 2007; Sun et al. 2008) and microglial induced 
neurotoxicity,  it  was  considered  important  to  investigate  whether  modulation  of 
neurotransmitter  receptors  could  mediate  NADPH  oxidase  activation  through  the  MAPK 
signalling pathway, which may provide important information on the role of receptor induced 
ROS on microglial reactivity.  
To investigate the involvement of p44/42ERK and p38MAPK activity in neurotransmitter 
receptor induced NADPH oxidase activation and ROS production, the NBT assay, dHEth 
fluorescence imaging and the NADPH oxidase activity assay were used following treatment 
of microglia with the receptor modulators and MAPK inhibitors. BV2 and primary microglia 
were treated with the mGluR group I receptor antagonist MTEP (100 nM) (Fig. 4.7Ai, ii, iii), 
the mGluR3 agonist NAAG (50 µM) (Fig. 4.7Bi, ii, iii) or the mGluR group III agonist 
L-AP4 (100 µM) (Fig. 4.7Ci, ii, iii), either alone, or in combination with apocynin (10 µM), 
the  p44/42ERK  inhibitor  PD-98059  (PD,  30 µM  (Kim  et  al.  2002))  or  the  p38MAPK 
inhibitor SB-203580 (SB, 10 µM (Han et al. 2002)), which were shown not to modulate 
superoxide production (Fig. 4.7Di, ii, iii) or microglial survival (Fig. 4.7Div). Superoxide 
production  was  assessed  by  NBT  reduction  in  BV2  (Fig.  4.7Ai,  Bi,  Ci),  and  dHEth 
fluorescence microscopy in primary (Fig.4.7Aii, Bii, Cii) microglia. NADPH oxidase activity 
was assessed in BV2 microglia using the NADPH oxidase activity assay (Fig. 4.7Aiii, Biii, 
Ciii).  233 
 
 
 
Figure 4.7 Inhibition of p44/42ERK or p38MAPK attenuates superoxide production and NADPH oxidase 
activity  following  modulation  of  microglial  mGluRs.  Primary  and  BV2  microglia  were  treated  with  the 
mGluR group I antagonist MTEP (100 nM – panel A), the mGluR3 agonist NAAG (50 µM – panel B) or the 
mGluR group III agonist L-AP4 (100 µM – panel C) in the presence or absence of apocynin (10 µM), the 
p44/42ERK  inhibitor  PD-90859  (PD  –  30  µM),  or  the  p38MAPK  inhibitor  SB-203580  (SB  –  10  µM). 
Superoxide  production  was  analysed  in  BV2  microglia  by  NBT  reduction  (Ai,  Bi,  Ci),  and  in  primary 
microglia using dHEth fluorescence and imaging of superoxide positive cells (Aii, Bii, Cii,), whilst NADPH 
oxidase activity was analysed in BV2 microglia using the NADPH oxidase activity assay  (Aiii, Biii, Ciii). 
Superoxide production and NADPH oxidase activity was assessed following treatment of microglia with PD-
98059 or SB-203580 alone (Di, Dii, Diii,) and microglial proliferation and survival was measured by cell 
counts (Div). All data were analysed by one way ANOVA with Tukey post-hoc analysis, and comparisons were 
made between treatments and un-treated control cells, and also between treatments alone and co-treatment 
with the inhibitors as indicated. *p<0.05, **p<0.01, ***p<0.001. All data are n=3.  234 
 
Attenuation of p38MAPK and p44/42ERK significantly reduced mGluR group I mediated 
NBT reduction in BV2 microglia (***p<0.001) (Fig. 4.7Ai). In primary microglia however, 
only  inhibition  of  p44/42ERK  could  attenuate  MTEP  induced  superoxide  production 
(Fig. 4.7Aii), which correlated with the NADPH oxidase activity assay (Fig. 4.7Aiii). Co-
treatment of BV2 microglia with MTEP and the p38MAPK inhibitor significantly increased 
NADPH oxidase activity thereby suggesting that MTEP induced NADPH oxidase activity 
and subsequent superoxide production is mediated through p44/42ERK activation.  
Activation of the BV2 and primary microglial mGluR3 with NAAG elevated NBT reduction 
and  dHEth  fluorescence  respectively,  which  was  attenuated  by  co-treatment  with  the 
p44/42ERK  inhibitor  or  the  p38MAPK  inhibitor  (Fig.  4.7Bi,  Bii).  In  primary  microglia 
however,  p38MAPK  inhibition  decreased  NAAG  induced  superoxide  production  more 
significantly (***p<0.001) than inhibition of p44/42ERK (*p<0.05). This correlated with the 
NADPH  oxidase  activity  analysis,  which  showed  that  NAAG  induced  NADPH  oxidase 
activity was attenuated by p38MAPK inhibition, whilst p44/42ERK inhibition had no effect 
on NAAG induced NADPH oxidase activity (Fig. 4.7Biii). These data show that mGluR3 
induced superoxide production is mediated by p38MAPK activation. 
NBT reduction induced by activation of the BV2 microglial group III mGluR was attenuated 
by p44/42ERK and p38MAPK inhibition (Fig. 4.7Ci). However, in primary microglia L-AP4 
induced dHEth fluorescence could only be attenuated by co-treatment with apocynin and the 
p38MAPK inhibitor (Fig. 4.7Cii), which corresponded with  the NADPH oxidase activity 
assay data (Fig. 4.7Ciii). NADPH oxidase activation and superoxide production induced by 
activation of the group III mGluRs is therefore mediated by p38MAPK activation.  
The involvement of p38MAPK and p44/42ERK in GABAA and P2Y2/4 receptor induced 
superoxide  production  was  next  investigated  (Fig.  4.8).  As  before,  primary  and  BV2 235 
 
microglia  were  treated  with  the  GABAA  receptor  agonist  muscimol  (50  µM) 
(Fig. 4.8Ai, ii, iii), or the P2Y2/4 receptor agonist UTPγS (100 µM) (Fig. 4.8Bi, ii, iii) in the 
presence or absence of apocynin (10 µM), the p44/42ERK inhibitor PD-98059 (PD, 30 µM), 
or the p38MAPK inhibitor SB-203580 (SB, 10 µM). Superoxide production was assessed by 
NBT reduction in BV2 microglia (Fig. 4.8Ai, Bi), dHEth fluorescence microscopy in primary 
microglia (Fig. 4.8Aii, Bii), whilst NADPH oxidase activity was assessed by the NADPH 
oxidase activity assay in BV2 microglia (Fig. 4.8Aiii, Biii).  
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Figure 4.8 Inhibition of p44/42ERK or p38MAPK attenuates superoxide production and NADPH oxidase 
activity following modulation of the GABAA receptor or the P2Y2/4 receptor. Primary and BV2 microglia 
were treated with the GABAA receptor agonist muscimol (50 µM) (Ai, ii, iii), or the P2Y2/4 receptor agonist 
UTPγS (100 µM) (Bi, ii, iii) in the presence or absence of apocynin (10 µM), the p44/42ERK inhibitor PD-
90859  (PD,  30 µM),  or  the  p38MAPK  inhibitor  SB-203580  (SB,  10  µM).  Superoxide  production  was 
measured by NBT reduction following treatment of BV2 microglia for 4 h as described (Ai, Bi), and dHEth 
fluorescence was used to analyse superoxide production in primary microglia after treatment for 24 h  (Aii, 
Bii), whilst NADPH oxidase activity was analysed in BV2 microglia after 4 h incubation, using the NADPH 
oxidase activity assay (Aiii, Biii). All data were analysed by one way ANOVA with Tukey post-hoc analysis, 
and  comparisons  were  made  between  untreated  controls  and  treatments  in  the  presence  of  inhibitors  as 
indicated. *p<0.05, **p<0.01, ***p<0.001. All data are n=3.  
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Muscimol induced NBT reduction in BV2 microglia was attenuated by co-treatment with the 
p44/42ERK  or  the  p38MAPK  inhibitor  (Fig.  4.8Ai),  which  correlated  with  the  NADPH 
oxidase activity data (Fig. 4.8Aiii). However, the increase in dHEth fluorescence following 
activation of the microglial GABAA receptor with muscimol could only be attenuated by 
p38MAPK inhibition (Fig. 4.8Aii).  In  BV2 microglia, activation of the GABAA receptor 
therefore induces superoxide production in a p38MAPK and p44/42ERK dependent manner, 
whereas in primary microglia, only p38MAPK is implicated in GABAA receptor induced 
NADPH oxidase activation.  
UTPγS significantly elevated NBT reduction in BV2 microglia, which was attenuated by 
p38MAPK  and  p44/42ERK  inhibition  (Fig.  4.8Bi).  Activation  of  the  P2Y2/4  receptor  in 
primary microglia significantly increased dHEth fluorescence, which was attenuated by co-
treatment  with  the  p38MAPK  inhibitor  (Fig.  4.8Bii).  P2Y2/4  induced  NADPH  oxidase 
activity  was  also  attenuated  by  p38MAPK  inhibition  (Fig. 4.8Biii),  whereas  inhibition  of 
p44/42ERK increased P2Y2/4 receptor induced NADPH oxidase activity when compared 
with  untreated  cells,  which  may  suggest  a  mechanism  by  which  p44/42ERK  negatively 
modulates  P2Y2/4  receptor  mediated  superoxide  production.  These  data  show  that 
p38MAPK  activation  regulates  P2Y2/4  receptor  induced  NADPH  oxidase  activation  and 
superoxide production. 
The involvement of p38MAPK and p44/42ERK in iGluR induced superoxide production was 
also investigated. BV2 or primary microglia were treated with NAAG (100 µM) or MK-801 
(10 µM) (Fig. 4.9Ai, ii), or QA (10 µM) or CNQX (10 µM) (Fig. 4.9Bi, ii), in the presence or 
absence  of  apocynin  (10  µM),  PD-98059  (30  µM)  or  SB-203580  (10µM).  Superoxide 
production was assessed in BV2 microglia using the NBT assay (Fig. 4.9 Ai, Bi), and in 
primary microglia using dHEth fluorescence miscroscopy (Fig. 4.9 Aii, Bii).  238 
 
 
 
Figure 4.9 Inhibition of p44/42ERK or p38MAPK attenuates superoxide production and NADPH 
oxidase activity following modulation of iGluR’s. Primary and BV2 microglia were treated with the 
NMDA receptor agonist NMDA (100 µM) (Ai, ii), or the NMDA receptor antagonist MK-801(10 µM) 
(Ai, ii),  or the AMPA receptor agonist QA (10 µM) (Bi, ii) or the antagonist CNQX (10 µM) (Bi, ii) in 
the presence or absence of apocynin (10 µM), the p44/42ERK inhibitor PD-90859 (30 µM), or the 
p38MAPK inhibitor SB-203580 (10 µM). Superoxide production was assessed in BV2 microglia using 
the NBT assay (Ai, Bi)  following treatment for 4 h. Superoxide production was analysed in primary 
microglia after treatment for 24 h, using dHEth fluorescence and imaging of superoxide positive cells 
(Aii, Bii). All data were analysed by one way ANOVA with Tukey post-hoc analysis and comparisons 
were made between control untreated cells and treatments, and also as indicated. *p<0.05, **p<0.01, 
***p<0.001.Data are n=3.  
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Activation of the BV2 microglial NMDA receptor significantly elevated NBT reduction that 
could  be  attenuated  by  p38MAPK  inhibition,  but  not  by  inhibition  of  p44/42ERK 
(Fig. 4.9Ai). Induction of superoxide production through inhibition of the NMDA receptor 
with  MK-801  in  BV2  microglia  could  not  be  attenuated  by  apocynin,  PD-98059  or 
SB-203580 (Fig. 4.9Ai), suggesting that superoxide production induced by inhibition of the 
NMDA receptor is through the activation of another oxidase system. In primary microglia 
(Fig.  4.9Aii),  NMDA  induced  superoxide  production  was  attenuated  by  p38MAPK  or 
p44/42ERK  inhibition,  whereas  MK-801  induced  dHEth  fluorescence  could  only  be 
attenuated by co-treatment with apocynin (Fig. 4.9Aii). In BV2 microglia therefore, NMDA 
receptor induced superoxide production is mediated by p38MAPK signalling, whereas  in 
primary microglia, both p38MAPK and p44/42ERK activation are implicated in NADPH 
oxidase activation.  
Activation of the BV2 microglial AMPA receptor with QA did not significantly elevate NBT 
reduction (Fig. 4.9Bi), as shown previously. Inhibition of the AMPA receptor with CNQX 
increased  NBT  reduction;  however  this  could  not  be  attenuated  by  any  of  the  inhibitors 
(Fig. 4.9Bi). Treatment of primary microglia with the AMPA receptor agonist QA or the 
antagonist CNQX could not increase dHEth fluorescence, and attenuation of the p38MAPK 
or p44/42ERK pathways had no effect on superoxide production.   
It has been suggested that in addition to activation of p38MAPK or p44/42ERK inducing 
NADPH oxidase activation and subsequent  superoxide production, superoxide production 
itself can modulate the phosphorylation of these signalling molecules (Sun et al. 2008), which 
may in turn perpetuate NADPH oxidase activity and superoxide production. To determine 
whether neurotransmitter receptor induced superoxide production could modulate p38MAPK 
or p44/42ERK phosphorylation, primary microglia were treated with the mGluR group III 
agonist  L-AP4  (100  µM),  the  mGluR  group  I  antagonist  MTEP  (100  nM),  the  mGluR3 240 
 
agonist NAAG (50 µM), the GABAA receptor agonist muscimol (50 µM) or the P2Y2/4 
receptor agonist UTPγS (100 µM) in the presence or absence of apocynin (10 µM) for 24 h. 
Microglia were then lysed, and lysates were subjected to Western blot analysis for phospho-
p38MAPK (Fig. 4.10Ai, ii) or phospho-p44/42ERK (Fig. 4.10Bi,  ii) expression. Western 
blots  were  run  three  times,  using  lysates  from  three  separate  microglial  preparations. 
Expression  of  phospho-p38MAPK  was  normalised  to  total  p83MAPK  expression 
(Fig. 4.10Aii),  and  expression  of  phospho-p44/42ERK  was  normalised  to  β-actin 
(Fig. 4.10Bii).  
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Figure 4.10 legend overleaf  242 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.10  Neurotransmitter  receptor  induced  superoxide  production  modulates  p38MAPK  and 
p44/42ERK  phosphorylation.  Primary  microglia  were  treated  with  the  mGluR  group  III  agonist  L-AP4 
(100 µM), the mGluR group I antagonist MTEP (100 nM), the mGluR3 agonist NAAG (50 µM), the GABAA 
receptor  agonist  muscimol  (50  µM)  or  the  P2Y2/4  receptor  agonist  UTPγS  (100  µM)  in  the presence  or 
absence of apocynin (10 µM) for 24 h. Microglia were lysed and Western blotting was performed using 45 µg 
cell lysate. After transfer to a PVDF membrane, membranes were probed for phospho-p38MAPK using a 
rabbit-anti-phospho-p38MAPK(T180)antibody  (1:1000,  4ᵒC,  overnight),  followed  by  an  anti-rabbit-HRP 
secondary antibody (1:2000, 1 h room temperature) and visualisation was by ECL (Ai). The membrane was 
stripped  and  re-probed  with  an  anti-rabbit-total  p38MAPK  antibody  (1:1000,  4  ᵒC,  overnight),  before 
incubation with the aforementioned secondary antibody and visualisation by ECL (Ai). The Western blots were 
performed three times to enable semi-quantitative expression analysis by densitometry (Aii). Optical density of 
phospho-p38MAPK was normalised to total p38MAPK for each condition to show expression levels  (Ai). 
Lysates were also analysed for p44/42ERK expression, in which membranes were incubated with an anti-
rabbit-p44/42ERK  antibody  (1:1000,  4ᵒC,  overnight),  followed  by  incubation  with  the  anti-rabbit-HRP 
secondary antibody (1:2000, 1 h , room temperature) and visualisation by ECL (Bi). Membranes were then 
stripped  and  incubated  with  mouse-anti-β-actin  antibody (1:2000, 2  h  room  temperature),  and  were  then 
incubated with the anti-mouse-HRP secondary antibody (1:1000, 1 h room temperature) before visualisation 
by ECL (Bi). The Western blots were again performed three times using lysates from three separate microglial 
preparations to enable semi-quantitative analysis of phospho-p44/42ERK expression, which was determined 
by  densitometry  (Bii).  Data  were  analysed  by  one  way  ANOVA  and  Tukey  post  hoc  analysis  where 
comparisons were  made between treatments and control un-treated cells, and also between conditions as 
indicated. *p<0.05, **p<0.01, ***p<0.001. All data are n=3.   
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Treatment  of  primary  microglia  with  NAAG  significantly  elevated  phospho-p38MAPK 
expression when compared with control untreated cells, which was significantly decreased 
upon  inhibition  of  NADPH  oxidase  derived  superoxide  production  with  apocynin 
(Fig. 4.10Ai, ii), suggesting that mGluR3 induced superoxide production mediates p38MAPK 
activation. Treatment of microglia with the mGluR group I antagonist MTEP and apocynin 
significantly increased p38MAPK phosphorylation when compared with control untreated 
microglia (Fig. 4.10Ai, ii), therefore suggesting that attenuation of MTEP induced NADPH 
oxidase activation mediates p38MAPK phosphorylation.  
Treatment  of  primary  microglia  with  MTEP,  NAAG  or  UPTγS  significantly  elevated 
p44ERK phosphorylation in an NADPH oxidase dependent manner, as phosphorylation was 
significantly reduced upon co-treatment with apocynin (Fig. 4.10Bi, ii). Activation of the 
group  III  mGluRs  with  L-AP4  significantly  enhanced  p44/42ERK  phosphorylation  when 
compared with control untreated cells; however, this phosphorylation was not dependent on 
activation of the NADPH oxidase.  
The  phosphorylation  of  p38MAPK  was  next  investigated  after  modulation  of  iGluRs. 
Primary microglia were treated with NMDA (100 µM) or MK-801 (10 µM) alone, in the 
presence of apocynin (10 µM), or in combination for 24 h. Western blotting for phospho-
p38MAPK was then performed (Fig. 4.11Ai,ii) using three separate microglial preparations 
to enable densitometry to be performed (Fig. 4.11Aii). Microglia were also treated with the 
AMPA  receptor  agonist  QA  (10  µM),  the  antagonist  CNQX  (10  µM)  either  alone,  in 
combination, or in the presence of apocynin (10 µM) for 24 h before Western blot analysis 
for  phospho-p38MAPK  expression  (Fig.  4.11Bi,  ii),  and  densitomety  (Fig.  4.11Bii)  were 
performed.  244 
 
 
 
 
 
 
 
Figure 4.11 legend overleaf  245 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.11  iGluR  induced  superoxide  production  modulates  p38MAPK  phosphorylation.  Primary  microglia 
were treated with the NMDA receptor agonist NMDA (100 µM) or the NMDA receptor antagonist MK-801 (10 µM) 
either alone, in combination or with apocynin (10 µM) for 24 h (Ai, ii). Microglia were also treated with the AMPA 
receptor agonist QA (10 µM), or the AMPA receptor antagonist CNQX (10 µM) either alone, in combination or in 
the presence of apocynin (10 µM) for 24 h (Bi, ii). Microglia were lysed and Western blotting was performed using 
45 µg cell lysate. After transfer to a PVDF membrane, membranes were probed for phospho-p38MAPK using a 
rabbit-anti-phospho-p38MAPK(T180)  antibody  (1:1000,  4ᵒC,  overnight),  followed  by  incubation  with  an  anti-
rabbit-HRP secondary antibody (1:2000, 1 h room temperature) and visualisation by ECL (Ai, Bi). The membrane 
was  stripped  and  re-probed  with  an  anti-rabbit-total  p38MAPK  antibody  (1:1000,  4  ᵒC,  overnight),  before 
incubation with the aforementioned secondary antibody and visualisation by ECL (Ai, Bi). The Western blots were 
performed three times to enable semi-quantitative expression analysis by densitometry. Optical density of phospho-
p38MAPK was normalised to total p38MAP for each condition to show expression levels  (Aii, Bii). Data were 
analysed by one way ANOVA and Tukey post-hoc analysis. *p<0.05, **p<0.001. All data are n=3.  
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NMDA  significantly  increased  p38MAPK  phosphorylation  in  comparison  with  control 
untreated cells, which was attenuated by co-treatment of microglia with NMDA and apocynin 
(Fig. 4.11Ai, ii), suggesting that NMDA receptor induced activation of the NADPH oxidase 
and subsequent superoxide production regulates p38MAPK phosphorylation. Treatment of 
primary microglia with the AMPA receptor agonist QA or the antagonist CNQX did not 
significantly modulate p38MAPK phosphorylation, however co-treatment of microglia with 
CNQX and apocynin significantly elevated p38MAPK phosphorylation when compared with 
control or CNQX treatments alone (Fig. 4.11Bi, ii) therefore suggesting that inhibition of the 
NADPH oxidase after inhibition of the AMPA receptor mediates p38MAPK activation.  
Microglial  p44/42ERK  phosphorylation  was  next  investigated  after  iGluR  modulation. 
Primary  microglia  were  treated  with  the  NMDA  receptor  agonist  NMDA  (100  µM),  the 
antagonist MK-801 (10 µM) either alone, in combination or in the presence of apocynin 
(10 µM); or the AMPA receptor agonist QA (10 µM), the antagonist CNQX (10 µM) either 
alone,  in  combination,  or  with  apocynin  (10 µM)  for  24  h  before  lysis.  Lysates  were 
subjected to Western blotting for p44/42ERK phosphorylation (Fig. 4.12A), and densitometry 
was performed following normalisation of protein levels to β-actin (Fig. 4.12B).  
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Figure  4.12  iGluR  induced  superoxide  production  modulates  p44/42ERK  phosphorylation.  Primary 
microglia were treated with the NMDA receptor agonist NMDA (100 µM) or the NMDA receptor antagonist 
MK-801 (10 µM) either alone, in combination or with apocynin (10 µM) for 24 h, or with the AMPA 
receptor  agonist  QA  (10  µM),  or  the  AMPA  receptor  antagonist  CNQX  (10  µM)  either  alone,  in 
combination or in the presence of apocynin (10 µM) for 24 h.. Microglia were lysed and Western blotting 
was performed using 45 µg cell lysate. After transfer to a PVDF membrane, membranes were probed for 
phospho-p44/42ERK using a rabbit-anti-phospho-p44/42ERK antibody (1:1000, 4ᵒC, overnight), followed 
by an anti-rabbit-HRP secondary antibody (1:2000, 1 h room temperature) and visualisation was by ECL 
(A). The membrane was stripped and re-probed with a mouse-anti-β-actin antibody (1:2000, 2 h room 
temperature),  before  incubation  with  an  anti  mouse  HRP  secondary  antibody  (1:1000,  1h,  room 
temperature) and visualisation was by ECL (A). The Western blots were performed three times to enable 
semi-quantitative  expression  analysis  by  densitometry.  Optical  density  of  phospho-p44/42ERK  was 
normalised to β-actin for each condition to quantify expression levels (B). Data were analysed by one way 
ANOVA with Tukey post-hoc analysis. ***p<0.001. All data are n=3.  
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Modulation  of  the  microglial  iGluRs  had  no  effect  on  p44/42ERK  phosphorylation 
(Fig. 4.12);  however,  co-treatment  of  microglia  with  the  NMDA  receptor  agonist  and 
antagonist significantly elevated p44/42ERK phosphorylation which was not a consequence 
of  NADPH  oxidase  activation.  Modulation  of  the  NMDA  receptor  and  induction  of 
superoxide production therefore elevates p38MAPK phosphorylation rather than p44/42ERK 
phosphorylation.  
Together,  these  data  show  that  there  may  be  a  feedback  activation  mechanism  whereby 
superoxide production following receptor modulation may induce p38MAPK or p44/42ERK 
activation, and that this p38MAPK or p44/42ERK activation may regulate NADPH oxidase 
activity and superoxide production. 
4.2.4  Microglial activation is not modulated by neurotransmitter induced superoxide 
production  
Modulation of the microglial p44/42ERK and p38MAPK pathways can induce a reactive 
microglial  phenotype.  To  investigate  whether  neurotransmitter  and  receptor  modulation, 
shown to induce NADPH oxidase activity through activation of p44/42ERK and p38MAPK, 
could  modulate  the  activation  state  of  microglia,  immunocytochemisty  for  the  activation 
markers iNOS or ED1, was performed. Western blotting for iNOS was also conducted.  
Primary  microglia  were  treated  with  the  positive  control  for  microglial  activation,  LPS 
(1 µg/ml), or the positive control for NADPH oxidase activation, PMA (10 ng/ml), and the 
neurotransmitters glutamate (1 µM), GABA (100 µM) or BzATP (250 µM) for 24 h before 
immunocytochemistry  was  performed  using  antibodies  for  iNOS  (red)  or  ED1  (green) 
(Fig. 4.13A).  To  investigate  microglial  reactivity  further,  Western  blotting  for  iNOS 
expression was also performed on primary microglia treated as above for 24 h, and β-actin 
expression was used as a loading control (Fig. 4.13B).  249 
 
 
 
 
 
 
Figure  4.13  Modulation  of  microglial  reactivity  after  treatment  with  neurotransmitters.  Microglia  were 
treated with the positive control LPS (1 µg/ml), PMA (10 ng/ml), or the neurotransmitters glutamate (1 µM), 
GABA (100 µM), or BzATP (250 µM) for 24 h. Cells were then either fixed for immunocytochemistry (A), or 
lysed for Western blotting (B). Immunocytochemistry was performed using a mouse-anti-ED1 antibody (1:100) 
(Green)  and  a  rabbit-anti-iNOS  antibody  (1:500)  (Red).  Cells  were  incubated  with  the  primary  antibodies 
overnight before incubation with the secondary antibodies anti-mouse FITC antibody (1:1000) for ED1, and 
anti-rabbit TRITC antibody (1:1000) for iNOS. Cells were counterstained with DAPI (1:2000) and were imaged 
using by fluorescence microscopy with a 40x objective (A). Microglia were lysed in lysis buffer for Western blot 
analysis, and 45 µg of protein was run on a 10% SDS-PAGE gel before transfer to a PVDF membrane. After 
blocking,  the  membrane  was  incubated  with  the  rabbit-  anti-iNOS  antibody(1:5000)  for  2  h  at  room 
temperature,  then  with  the  anti-rabbit-HRP  secondary  antibody  (1:2000)    for  1  h  at  room  temperature. 
Visualisation  was  by  ECL.  The  membrane  was  then  stripped  and  re-probed  with  the  mouse-anti-β-actin 
antibody (1:2000) for 2 h at room temperature, and then the anti-mouse HRP secondary antibody (1:1000) for 
1 h at room temperature, Visualisation was by ECL (B). Both experiments are n=3. Scale bar 20 µm.  
 250 
 
The immunocytochemistry (Fig. 4.13A) and Western blotting (Fig. 4.13B) data show that 
treatment of primary microglia with LPS (1 µg/ml) elevates iNOS expression in comparison 
to control untreated cells and also when compared with PMA, glutamate, GABA or BzATP 
treatments, which could not induce iNOS expression in primary microglia. The marker for 
phagocytosis (ED1) was up-regulated in microglia treated with LPS, glutamate or BzATP 
(Fig. 4.13A), suggesting that these neurotransmitters induce a phagocytic phenotype. This 
may not however, be a fully active phenotype, as iNOS expression was not increased.  
The  effects  of  neurotransmitter  receptor  modulation  on  microglial  reactivity  was  next 
investigated using Western blot analysis to detect iNOS expression in microglia treated with 
LPS (1 µg/ml), the mGluR group III agonist L-AP4 (100 µM), the mGluR3 agonist NAAG 
(50 µM),  the  mGluR  group  I  antagonist  MTEP  (100  nM),  the  GABAA  receptor  agonist 
muscimol (50 µM), or the P2Y2/4 receptor agonist UTPγ (100 µM) for 24 h (Fig. 4.14A). 
Western blotting was also performed for β-actin, to semi-quantify iNOS expression levels 
following normalisation to β-actin (Fig. 4.14B). 
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Figure 4.14 Microglial recactivity following modulation of neurotransmitter receptors. Microglia were 
treated with the microglial activator LPS (1 µg/ml), the mGluR group III agonist L-AP4 (100 µl), the 
mGluR3 agonist NAAG (50 µM), the mGluR group I antagonist MTEP (100 nM), the GABAA receptor 
agonist muscimol (50 µM), or the P2Y2/4 receptor agonist UTPγ (100 µM) for 24 h. Microglia were lysed 
in lysis buffer for Western blot analysis, and 45 µg of protein was run on a 10% SDS-PAGE gel before 
transfer to a PVDF membrane. After blocking, the membrane was incubated with the rabbit- anti-iNOS 
antibody  (1:5000)  for  2  h  at  room  temperature,  then  with  the  anti-rabbit-HRP  secondary  antibody 
(1:2000) for 1 h at room temperature. Visualisation was by ECL. The membrane was then stripped and re-
probed with the mouse-anti-β-actin antibody for 2 h at room temperature, and then the anti-mouse HRP 
secondary for 1 h at room temperature. Visualisation was by ECL (A). Densitometry was performed to 
determine iNOS expression levels normalised to β-actin (B).  The experiment was performed three times, 
and statistical analysis on the densitomety was performed using a one way ANOVA with Tukey post-hoc 
analysis, in which comparisons were made between all conditions and the control cells, and as inducated. 
*p<0.05, **p<0.01, ***p<0.001. Data are n=3.  
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Treatment of microglia with the mGluR group I receptor antagonist MTEP, the mGluR3 
agonist NAAG and the group III mGluR agonist L-AP4 all induced a significant increase in 
iNOS  expression  when  compared  with  control  untreated  cells  (Fig.  4.14),  however,  LPS 
induced iNOS expression was significantly elevated in comparison with these treatments. 
Activation of the GABAA receptor with muscimol did not induce a significant increase in 
iNOS  expression,  whilst  activation  of  the  P2Y2/4  receptor  induced  an  increase  in  iNOS 
expression comparable to that of LPS. This therefore suggests that modulation of mGluRs 
and the P2Y2/4 receptor induces a reactive phenotype, but that activation of the GABAA 
receptor may not.  
These data could also suggest that neurotransmitter receptor mediated superoxide production, 
shown  to  be  modulated  by  the  MAPK  signalling  pathway,  may  be  a  consequence  of 
microglial activation, and could represent a neuroprotective or neurotoxic phenotype, which 
will be investigated in the next chapter.  
4.3  Discussion  
Here,  modulation  of  microglial  neurotransmitter  receptors  altered  Nox1,  Nox2  or  Nox4 
expression and activity, which are regulated by PKCδ or PI3-K signalling. Furthermore, the 
MAPK  signalling  pathway  was  also  shown  to  regulate  neurotransmitter  receptor  induced 
superoxide  production,  and  superoxide  production  itself  could  also  modulate  the 
phosphorylation of MAPK signalling molecules. The microglial NADPH oxidase and MAPK 
signalling cascade are implicated in the progression of neurodegenerative conditions, and the 
findings presented here showing cross-talk between NADPH oxidase activation and MAPK 
signalling  could  suggest  that  the  activation  or  inhibition  of  microglial  neurotransmitter 
receptors may exacerbate or protect against inflammatory neurodegenerative conditions.  253 
 
4.3.1  Neurotransmitter and receptor induced NADPH oxidase isoform expression and 
activity in microglia 
As described previously, microglia express Nox1 (Chéret et al. 2008), Nox2 (Wilkinson et 
al. 2006) and Nox4 (Harrigan et al. 2008) NADPH oxidase isoforms. Following the findings 
in the previous chapter that neurotransmitters or receptor agonists or antagonists induced 
microglial  superoxide  production,  it  was  important  to  determine  which  NADPH  oxidase 
isoforms  were induced  as  a consequence of this  receptor modulation, as  this  could  have 
important consequences for microglial reactivity.   
Nox4  expression  was  significantly  enhanced  by  glutamate,  GABA  or  BzATP.    Nox4  is 
predominantly  regulated  at  the  transcriptional  level  (Manea  et  al.  2010),  as  it  lacks  the 
cytoplasmic subunits that are required for Nox1 and Nox2 activation (Brown & Griendling 
2009). Nox4 transcription can be induced by  NF-κB, and also  by JAK/STAT signalling, 
which  promotes  the  binding  of  the  STAT1/2  transcription  factor  to  specific  regulation 
sequences in the Nox4 promotor, known as GAS elements or ISRE‟s (Manea et al. 2010) 
which induce the expression of redox regulated genes  (Wesoly et  al.  2007).  In a human 
microglial cell line, Nox4 expression is induced by IFNγ (Li et al. 2009), which activates 
STAT1/2 and facilitates Nox4 transcription through activation of the GAS element (Manea et 
al.  2010).  Glutamate,  GABA  or  BzATP  may  therefore  induce  the  translocation  of 
transcription factors such as NF-κB or STAT1/2 to the nucleus, resulting in microglial Nox4 
expression. 
Nox1 is regulated by phosphorylation induced translocation of cytoplasmic subunits and also 
at the transcriptional level (Fan et al. 2005; Wei et al. 2010), and GABA and BzATP both 
induced Nox1 transcription.  The transcriptional regulation of Nox1 has been demonstrated in 
VSMC‟s, in which Nox1 expression was induced by TNFʱ mediated activation of NF-κB 
(Manea et al. 2010). In addition, TNFʱ binding to TNFR1 mediates the binding of Nox1 to 254 
 
TNFR1 associated death domain (TRADD), which promotes ROS induced JNK activation 
and perpetuates superoxide production in endothelial cells (Kim et al. 2007). Furthermore, 
TNFʱ  can  induce  sustained  activation  of  p38MAPK  and  JNK,  which  enhances  the 
phosphorylation  of  the  transcription  factors  c-Jun  and  c-Fos,  resulting  in  further  Nox1 
transcription  and  enhanced  superoxide  production  (Kuwano  et  al.  2008).  Treatment  of 
microglia with BzATP promotes TNFʱ release (Suzuki et al. 2004), which may therefore 
feedback onto microglia to enhance Nox1 expression and activation (Mir et al. 2009).  
In cardiovascular tissue Nox1 expression is induced by the transcription factor c-Jun, which 
is activated by p44/42ERK phosphorylation (Cevik et al. 2008), and Nox1 expression is also 
down-regulated in adenocarcinoma cells following inhibition of p44/42ERK (Adachi et al. 
2008).  In  microglia,  activation  of  p44/42ERK  induces  NADPH  oxidase  activity  after 
exposure to paraquat (Miller et al. 2007) or LPS (Zhao et al. 2011), suggesting a role for 
p44/42ERK in microglial Nox1 activation.  This could therefore imply that GABA or BzATP 
treatment promote Nox1 expression through p44/42ERK signalling in microglia. 
In  addition  to  regulating  phosphorylation  of  the  NADPH  oxidase  p47phox  and  p67phox 
subunits, PKCδ can induce Nox1 expression through p44/42ERK phosphorylation dependent 
activation of activating transcription factor 1 (ATF-1) and subsequent binding to the Nox1 
promoter  (Fan  et  al.  2005).    GABA  mediates  PKCδ  activation  (Fukura  et  al.  1996)  and 
modulates p44/42ERK activation (Bell-Horner et al. 2006), whilst P2X7 receptor activation 
mediates  p44/42ERK  phosphorylation  (Takenouchi  et  al.  2007),  which  promotes  Nox1 
transcription, lending further support to the suggestion that GABA and BzATP enhance Nox1 
expression. 
 Nox2 expression was not modulated by glutamate, GABA or BzATP, and is not thought to 
be controlled at the transcriptional level. Rather, modulation of Nox2 activity occurs through 255 
 
the regulated phosphorylation of cytoplasmic subunits (El-Benna et al. 2009). The regulation 
of NADPH oxidase isoform activity through phosphorylation of cytoplasmic subunits was 
investigated using inhibitors of kinases known to induce subunit phosphorylation, along with 
the specific inhibitors apocynin, shown to inhibit p47phox phosphorylation, and therefore act 
on  Nox1  and  Nox2  (Stefanska  &  Pawliczak  2008);  and  thioridazine,  a  Nox4  inhibitor 
(Serrander et al. 2007; Harrigan et al. 2008). Nox1 activity was inhibited with the PKCδ 
inhibitor rottlerin (Miller et al. 2007), and the PI3-K inhibitor wortmannin was used to inhibit 
p40phox phosphorylation and Nox2 activity (Ellson et al. 2006).  
Glutamate - induced superoxide production and NADPH oxidase activity was attenuated by 
wortmannin  and  rottlerin,  suggesting  that  glutamate  mediates  Nox1  and  Nox2  activation 
through PKCδ and PI3-K signalling. Glutamate mediates the PKC induced expression of 
neurotrophic factors in microglia (Liang et al. 2010), and in astrocytes, glutamate promotes 
PKCδ activation and translocation to the plasma membrane through Ca
2+ signalling (Codazzi 
et al. 2001), which could suggest a mechanism whereby glutamate promotes PKC mediated 
Nox1/2 activation. Glutamate promotes PI3-K activity in glial cells during development, in 
which  PI3-K  activity  promotes  the  mobilisation  of  NF-κB  to  the  nucleus  to  induce 
transcription  of  trophic  factors  (Balazs  2006).  NF-κB  activation  also  promotes  Nox1 
expression (Manea et al. 2010), therefore glutamate induced PI3-K signalling may mediate 
Nox1 and Nox2 activation.  Glutamate induces  p38MAPK phosphorylation in  Bergmann 
glial  cells  (Zepeda  et  al.  2008),  which  promotes  Nox2  activity  (Anilkumar  et  al.  2008). 
Furthermore, there may be cross-talk between p38MAPK and PI3-K, as it has been shown 
that NO can activate both pathways and induce superoxide production in a Nox2 dependent 
manner in VSMC‟s (Doronzo et al. 2011). Glutamate could therefore facilitate microglial 
Nox1  and  Nox2  activation  in  this  manner.  Microglial  glutamate  induced  superoxide 
production was  also attenuated by thioridazine, suggesting that glutamate regulates Nox4 256 
 
activity. In cortical neurons, glutamate induces H2O2 production in a Nox4 dependent manner 
(Ha et al. 2010), which may also occur in microglia, and supports the findings presented here.  
GABA  induced  superoxide  production  and  NADPH  oxidase  activity  was  attenuated  by 
inhibitors  of  all  three  NADPH  oxidase  isoforms  in  BV2  microglia,  however,  in  primary 
microglia,  superoxide  production  could  only  be  attenuated  by  co-treatment  of  cells  with 
GABA and apocynin. Inhibition of GABA induced superoxide production by rottlerin in BV2 
microglia suggests that GABA promotes PKCδ activity, which enhances Nox1 expression 
and activity (Fan et al. 2005). This also correlates with the expression analysis showing that 
GABA  up-regulates  Nox1  transcription.  There  is  a  close  relationship  between  GABAA 
receptor activation and PKC phosphorylation, and PKC interacts with the GABAA receptor to 
regulate  GABA  binding  (Moss  et  al.  1992).  Furthermore,  in  neurons  GABAA  receptor 
activation induces PKC phosphorylation through PKC binding to the γ subunit of the receptor 
(Brandon  et  al.  1999).  Exposure  of  microglia  to  GABA  could  therefore  induce  PKC 
activation which facilitates Nox1 activity and expression, and could perpetuate Nox1 and 
PKC activity through a feedback mechanism.  
In primary microglia only treatment with the Nox1/2 inhibitor apocynin attenuated GABA 
induced superoxide production, therefore GABA-induced Nox1/2 activation was independent 
of PKCδ or PI3-K activation. The differences observed may be due to the cell types used. 
BV2 microglia may respond slightly differently to primary microglia, however studies have 
shown  that  BV2  microglia  are  a  suitable  substitute  for  primary  microglia  in  a  range  of 
experimental protocols (Henn et al. 2009). Here therefore, GABA may elicit the activation of 
different signalling pathways in BV2 or primary microglia; however in both cell types GABA 
induces Nox1/2 activation.  257 
 
BzATP  induced  superoxide  production  in  BV2  microglia  was  attenuated  by  apocynin, 
thioridazine,  rottlerin  and  wortmannin,  however,  in  primary  microglia  only  apocynin 
attenuated  superoxide  production.  Co-treatment  of  primary  microglia  with  BzATP  and 
rottlerin or wortmannin significantly increased superoxide production when compared with 
control un-treated cells. Expression analysis showed that BzATP induced Nox1 and Nox4 
transcription, which differs from the functional data. Together, the data show that BzATP 
induces superoxide production through Nox1 or Nox2 activation.  
There are few reports regarding NADPH oxidase isoform activation by ATP, however, in 
macrophages,  ATP  stimulation  induces  Nox2  activity  (Moore  &  MacKenzie  2009). 
Furthermore,  ATP  activation  of  macrophages  elevates  Nox2  dependent  superoxide 
production through p38MAPK phosphorylation (Noguchi et al. 2008; Anilkumar et al. 2008).  
The increase in BzATP derived superoxide production following PKC and PI3-K inhibition 
in  primary  microglia  could  represent  a  feedback  mechanism  in  which  attenuation  of 
superoxide  production  from  specific  Nox  isoforms  may  enhance  superoxide  production 
through the activation of other Nox isoforms. In support of this suggestion, the redox state of 
embryonic  stem  cells  regulates  the  transcription  of  NADPH  oxidase  isoforms,  with 
mechanisms  in  place  to  enhance  Nox1  and  Nox4  transcription  upon  enhanced  H2O2 
production (Buggisch et al. 2007). Whilst it has not been shown that a deficit in superoxide 
production  may  enhance  Nox  isoform  activity  or  expression,  the  presence  of  this  feed-
forward mechanism suggests that a regulatory mechanism may act to enhance Nox isoform 
activation upon inhibition of superoxide production.   
Modulation  of  neurotransmitter  receptors  had  little  effect  on  NADPH  oxidase  isoform 
expression; however, modulation of microglial neurotransmitter receptors may have a greater 
effect  on  Nox  isoform  activity  through  the  activation  of  signalling  molecules  known  to 
induce phosphorylation of the cytoplasmic subunits of the NADPH oxidase.  258 
 
Treatment of primary microglia with the mGluR group I antagonist MTEP did not increase 
NADPH  oxidase  expression,  however,  co-treatment  of  microglia  with  MTEP  and  the 
NADPH oxidase antagonist apocynin significantly elevated Nox1 and Nox4 expression when 
compared  with  control  untreated  cells.  This  could  suggest  that  inhibition  of  Nox2  with 
apocynin may induce a feedback mechanism to enhance Nox1 and Nox4 expression, thereby 
regulating the intracellular redox potential.  
MTEP induced superoxide production and NADPH oxidase activity in BV2 microglia was 
attenuated by all NADPH oxidase isoform inhibitors, therefore MTEP induces superoxide 
production  through  Nox1,  Nox2  and  Nox4  in  a  PKCδ  dependent  manner.  In  primary 
microglia  however,  MTEP  induced  superoxide  production  could  only  be  attenuated  by 
apocynin, and was independent of PI3-K or PKC signalling. Nox2 activation can be mediated 
by phospholipase-D (PLD) in neutrophils  (Patel et al. 2010), and in the rat hippocampus, 
antagonism of the group I mGluRs mediates PLD signalling  (Pellegrini-Giampietro et al. 
1996), suggesting that in primary microglia, Nox2 activation following treatment with MTEP 
may  be  through  PLD  induction.  Furthermore,  PLD  mediates  Nox2  activation  through 
p44/42ERK  induction  (Patel  et  al.  2010),  and  p44/42ERK  inhibition  was  shown  here  to 
attenuate MTEP induced superoxide production in  primary microglia, suggesting a novel 
mechanism of MTEP induced Nox2 activation which should be investigated further. 
The finding that in primary microglia, MTEP induced superoxide production is not mediated 
by  PKC  signalling  may  be  a  consequence  of  the  inhibitory  action  of  mGluR  group  I 
antagonism on PKC activation, as it has been shown in spinal cord homogenates that group I 
mGluR inhibition attenuates PKC activity (Ferguson et al. 2008). Furthermore, activation of 
the group  I mGluRs with DHPG increases PKC activation in  glial  cells  (Peavy & Conn 
1998), therefore here, inhibition of the group I mGluR may attenuate PKC signalling. The 259 
 
data here therefore suggests that inhibition of the group I mGluRs with MTEP induces Nox1 
and Nox2 mediated superoxide production, however a mechanism is still to be elucidated.  
Activation of the microglial mGluR3 did not enhance NADPH oxidase isoform expression; 
however, Nox2 expression was up-regulated following treatment of microglia with NAAG 
and  apocynin,  suggesting  the  presence  of  a  feedback  mechanism  in  which  inhibition  of 
superoxide production increases  Nox isoform  expression. This is  supported by studies  in 
VSCM‟s in which attenuation of Nox1 induced superoxide production was shown to elevate 
Nox4 expression (Wosniak et al. 2009), which further supports suggestions that NADPH 
oxidase derived ROS are essential to normal cellular functions in the CNS (Infanger et al. 
2006).  
MGluR3 induced superoxide production was attenuated in BV2 microglia by all inhibitors, 
thereby suggesting that NAAG induces PKC and PI3-K activation. Activation of neuronal 
group II mGluRs  elevates PKC activity, which also enhances  NMDA receptor activation 
(Tyszkiewicz  et  al.  2004).  Enhanced  NMDA  receptor  activity  also  significantly  elevated 
NADPH  oxidase  mediated  superoxide  production,  which  could  suggest  a  mechanism 
whereby mGluR3 activation directly induces NADPH oxidase derived superoxide production 
and enhances NMDA receptor mediated NADPH oxidase activation in a PKC dependent 
manner. In addition, activation of mGluR3 in astrocytes induces PI3-K activity (Ciccarelli et 
al.  2007), which mediates Nox2 activation (Ellson et al. 2006). These studies therefore lend 
support to the findings that activation of mGluR3 in BV2 microglia induces Nox2 activity. 
In  primary  microglia,  mGluR3  mediated  superoxide  production  was  only  attenuated  by 
apocynin, thereby suggesting that mGluR3 induced Nox2 activation is independent of PI3-K 
or PKC signalling. Inhibition of PKC with rottlerin significantly enhanced NAAG induced 
superoxide production, lending support to the suggestion of a feedback mechanism in which 260 
 
decreased superoxide production through inhibition of one Nox isoform may enhance the 
production  of  superoxide  through  promoting  the  activity  of  other  Nox  isoforms.  This  is 
supported by findings that in gp91phox (Nox2) knockout mice, Nox4 activity is enhanced 
after ischaemia, indicating a compensatory effect for superoxide production  (Byrne et al. 
2003). 
Another mechanism could be suggested for mGluR3 mediated NADPH oxidase activation in 
primary microglia. Microglial mGluR3 activation is negatively coupled to adenlylate cyclase 
(Prézeau et al. 1994), and activation of adenylate cyclase with pituitary adenylate cyclase 
activating  polypeptide  (PACAP)  inhibits  microglial  NADPH  oxidase  activity  resulting  in 
neuroprotection  after  LPS  induced  superoxide  production,  which  can  protect  against 
dopaminergic  neurotoxicity  in  mixed  neuronal  glial  mesencephalic  cultures  (Yang  et  al. 
2006). The inhibition of adenylate cyclase after activation of mGluR3 in primary microglia 
may induce NADPH oxidase activation, which is supported by findings that inhibition of 
adenylate cyclase stimulation following treatment of microglia with the inhibitor PACAP6-38 
could not induce neuroprotection, and enhanced NADPH oxidase activity (Yang et al. 2006). 
Superoxide production through microglial mGluR3 activation could therefore be mediated 
through enhanced NMDA receptor activation (Tyszkiewicz et al. 2004) or through negative 
coupling  to  adenylate  cylcase  (Yang  et  al.  2006)  in  primary  microglia,  whereas  in  BV2 
microglia,  mGluR3  induced  Nox2  activation  may  be  a  consequence  of  PI3-K  and  PKC 
signalling.   
Activation of the group III mGluRs with L-AP4 did not modulate NADPH oxidase isoform 
expression, however L-AP4 induced superoxide production and NADPH oxidase activity in 
BV2  microglia  was  attenuated  by  treatment  with  apocynin,  thioridazine  or  wortmannin, 
suggesting  Nox2  and  Nox4  activation.  In  primary  microglia,  L-AP4  induced  superoxide 
production was only attenuated by apocynin, suggesting that Nox2 activation is independent 261 
 
of PKC and PI3-K signalling. Activation of neuronal group III mGluRs does not induce PKC 
signalling,  rather  elicits  down-stream  effects  through  attenuating  cyclic  adenosine 
monophosphate (cAMP) signalling (Martín et al. 2007). Studies in VSMC‟s have shown that 
attenuation  of  cAMP  elevates  oxidative  stress  in  an  NADPH  oxidase  dependent  manner 
(Saha  et  al.  2008).  Furthernore,  attenuation  of  cAMP  elevated  PMA  induced  -NADPH 
oxidase dependent superoxide production in neutrophils (Mitsuyama et al. 1993), suggesting 
a  mechanism  whereby  attenuation  of  cAMP  by  L-AP4  may  enhance  NADPH  oxidase 
activation in microglia.  
Co-treatment of primary microglia with L-AP4 and thiorodazine or wortmannin increased 
superoxide production, suggesting that in primary microglia inhibition of Nox2 or Nox4 may 
increase  superoxide  production  through  activation  of  other  Nox  isoforms.  Treatment  of 
mesenchymal cells with L-AP4 mediates PI3-K signalling and NADPH oxidase activation 
(Wagner et al. 2007), and activation of the group III mGluRs is coupled to the p44/42ERK 
and PI3-K pathways in CGCs (Iacovelli et al. 2002), which induces Nox4 (Schröder et al. 
2009) and Nox2 activation respectively (Ellson et al. 2006). These findings lend support to 
the data here, showing that activation of the microglial group III mGluRs induces Nox2 and 
Nox4 activation.  
The GABAA receptor agonist muscimol significantly elevated Nox1 and Nox2 expression in 
primary microglia, which correlated with the functional data. Muscimol induced superoxide 
production  was  attenuated  by  co-treatment  of  BV2  microglia  with  apocynin,  rottlerin  or 
thioridazine, whist NADPH oxidase activity and superoxide production in primary microglia 
was significantly reduced by co-treatment with apocynin and rottlerin,  therefore suggesting 
that  GABAA receptor activation induces Nox1 and Nox2 activity and expression in a PKC 
dependent  manner.  As  discussed  previously,  PKC  activation  modulates  GABAA  receptor 
activity (Moss et al. 1992), and activation of the GABAA receptor can induce PKC activation 262 
 
(Brandon  et  al.  1999).  Furthermore,  in  intact  growth  cones,  GABAA  receptor  agonists 
induced PKC activation and phosphorylation of down-stream signalling molecules activated 
by a GABAA receptor mediated Ca
2+ influx (Fukura et al. 1996). ROS also modulate GABAA 
receptor activity and its release of Cl
- ions from CA1 pyramidal neurons (Sah et al. 2002), 
suggesting a close interaction between ROS production through GABAA receptor activation, 
subsequent  Cl
-  release  and  Ca
2+  influx,  and  PKC  activation,  which  may  promote  and 
perpetuate superoxide production through the activation (Byun et al. 2008) and enhanced 
expression  (Wei  et  al.  2010)  of  Nox1.  The  data  presented  here  therefore  suggest  that 
activation of the microglial GABAA receptor favours Nox1 and Nox2 activation through PKC 
signalling.  
Activation  of  the  microglial  P2Y2/4  receptor  enhanced  Nox2  and  Nox4  expression.  
Furthermore, P2Y2/4 receptor induced superoxide production was attenuated by co-treatment 
of  primary  microglia  with  apocynin,  suggesting  Nox2  activation,  whilst  P2Y2/4  receptor 
induced superoxide production in BV2 microglia was attenuated by co-treatment with all 
inhibitors. Treatment of primary microglia with UTPγS and rottlerin significantly increased 
superoxide production, which could suggest that Nox1 inhibition may induce the activity of 
other Nox isoforms, and also lends support to the findings that in microglia, co-treatment 
with UTPγS and apocynin induced a significant increase in Nox4 expression, suggesting that 
inhibition of superoxide generated by Nox1/2 may promote enhanced Nox4 expression and 
activity (Byrne et al 2003).  
In  other  cell  types,  P2Y2/4  receptor  activation  induces  PI3-K  activity  (Kaczmarek  et  al. 
2005), which activates Nox2 (Ellson et al. 2006), and was shown here to be implicated in 
P2Y2/4  receptor  mediated  superoxide  production  in  BV2  microglia.  Furthermore,  in 
astrocytes P2Y2 receptor activation induces chemotaxis in a PI3-K and MAPK dependent 
manner (Wang et al. 2005).  PI3-K did not however mediate UTPγS induced superoxide 263 
 
production in primary microglia. In contrast, activation of microglial P2Y receptors induces 
PLC  activation,  through  promoting  calcium  release  from  intracellular  stores  (Illes  et  al. 
1996),  and  PLC  mediates  Nox2  activation  in  macrophages  (Bae  et  al.  2009),  thereby 
suggesting that in primary microglia Nox2 activation may be induced by PLC rather than 
PI3-K signalling after P2Y2/4 receptor activation as seen in BV2 microglia.  
Preliminary  investigations  were  conducted  into  NADPH  oxidase  isoform  expression 
following  iGluR  modulation.  AMPA  receptor  inhibition  significantly  increased  Nox1 
expression. No functional analyses were performed, however, it has been suggested in the 
literature that the modulation of the AMPA and NMDA receptors promotes ROS production 
through Nox4 activation in primary cortical neurons (Ha et al. 2010). The data presented here 
therefore suggest that NMDA and AMPA receptor activation may induce activation rather 
than expression of the NADPH oxidase.  
These data suggest that modulation of neurotransmitter receptors affects the expression and 
activity of different NADPH oxidase isoforms, and that the activity of each NADPH oxidase 
isoform is modulated predominantly through activation of kinases following neurotransmitter 
receptor  modulation,  which  promote  the  phosphorylation  of  cytoplasmic  subunits  of  the 
NADPH oxidase.  
4.3.2  The MAPK signalling pathway is implicated in neurotransmitter receptor 
induced NADPH oxidase activity  
The  Microglial  MAPK  signalling  pathway  is  activated  in  several  neurodegenerative 
conditions. Both p38MAPK and p44/42ERK are downstream of PKC and PI3-K, and are 
implicated  in  microglial  reactivity,  with  ramifications  for  neuronal  survival  during 
neurodegeneration (Koistinaho & Koistinaho 2002). The involvement of the p38MAPK and 264 
 
p44/42ERK signalling cascades in NADPH oxidase dependent superoxide production as a 
consequence of neurotransmitter receptor modulation were therefore investigated.  
Inhibition  of  the  microglial  group  I  mGluR  induced  superoxide  production  and  NADPH 
oxidase activity that was attenuated by p44/42ERK inhibition, however, NADPH oxidase 
activity was significantly increased after p38MAPK inhibition. Inhibition of mGluR5 with 
MTEP decreases the expression of signalling molecules in the MAPK pathway in the rat 
frontal  cortex  (Gass  &  Olive  2008).  Furthermore,  MTEP  treatment  down-regulates 
p44/42ERK phosphorylation in an in vivo rat model of PD (Rylander et al. 2009), suggesting 
that MTEP inhibits the MAPK signalling pathway. This correlates with findings that group I 
mGluR activation with DHPG increases p44/42ERK phosphorylation (Peavy & Conn 1998). 
The  finding  here  that  inhibition  of  the  microglial  group  I  mGluR  induces  superoxide 
production which can be attenuated by inhibition of p44/42ERK is therefore at odds with the 
published data, and could suggest that it is not direct inhibition of the group I mGluRs that 
induces superoxide production, but that group I mGluR inhibition may induce the release of 
factors that can feedback onto microglia and induce NADPH oxidase activation. Antagonism 
of the group I mGluRs with MTEP induces a reactive microglial phenotype (Byrnes et al. 
2009), which promotes the release of neurotoxic factors such as TNFʱ and glutamate (Pocock 
&Kettenmann 2007), which feedback onto TNFRs  (Mir et al. 2009) and other glutamate 
receptors  (Harrigan  et  al.  2008)  to  induce  NADPH  oxidase  activation.  Furthermore, 
activation  of  microglial  group  I  mGluRs  following  treatment  with  LPS  attenuates  TNFʱ 
release, which could be enhanced by mGluR group I antagonists (Farso et al.  2009), lending 
support to the suggestion that here, group I mGluR antagonism may induce TNFʱ release, 
which  could  feedback  onto  microglia  and  induce  NADPH  oxidase  activation  through 
p44/42ERK activation. In support of this, activation with CD40 ligand (a member of the TNF 
superfamily) promotes microglial reactivity and p44/42MAPK activation (Tan et al. 2000) 265 
 
and microglial activation can induce p44/42ERK phosphorylation (Pocock & Liddle 2001), 
which in turn induces superoxide production through NADPH oxidase activation (Schröder et 
al. 2009). This could therefore suggest that MTEP mediates  superoxide production in an 
indirect  manner  through  induction  of  microglial  reactivity  and  subsequent  p44/42ERK 
activation.  
To further support the role of p44/42ERK in MTEP induced NADPH oxidase activation, 
Western  blot  analysis  showed  that  MTEP  treatment  increased  p44  phosphorylation  in  an 
NADPH oxidase dependent manner. ROS mediates p44/42ERK activity (Anilkumar et al. 
2008); therefore antagonism of the group I mGluR may induce NADPH oxidase activation 
through p44/42ERK activation, (Fig. 4.15), which could have important consequences for 
sustained superoxide production in microglia.  
Microglial  mGluR3  -  induced  superoxide  production  was  attenuated  by  p38MAPK  and 
p44/42ERK inhibition. Activation of the astrocytic mGluR3 mediates p44/42ERK activation, 
which  is  protective  after  ischaemia  (Ciccarelli  et  al.  2007),  whilst  mGluR3  inhibition  in 
gliomas attenuates p44/42ERK activation and glioma growth in vitro (D‟Onofrio et al. 2003). 
Activation of mGluR3 therefore induces p44/42ERK activation, which was shown here to be 
implicated in NADPH oxidase mediated superoxide production. In addition, Western blot 
analysis revealed that mGluR3 activation promoted p44ERK and p38MAPK phosphorylation 
in  an  NADPH  oxidase  dependent  manner  (Fig. 4.15).  Furthermore,  activation  of  the 
astrocytic  mGluR3  induces  p44/42ERK  and  p38MAPK  phosphorylation,  which  has 
neuroprotective consequences (D‟Onofrio et al. 2001). 
The  suggestion  that  NADPH  oxidase  induced  ROS  can  stimulate  MAPK  activation  is 
supported by findings in astrocytes in which NADPH oxidase activity following treatment 
with the known NADPH oxidase activator menadione stimulates p44/42ERK and p38MAPK 266 
 
phosphorylation, which could be attenuated by apocynin (Zhu et al. 2009). These reports 
therefore lend support to the suggestion that here, mGluR3 activation  promotes  NADPH 
oxidase activation and ROS production through p44/42ERK and p38MAPK phosphorylation, 
and that this mGluR3 mediated ROS production can also modulate the activity of MAPK 
signalling molecules.   
Group III mGluR induced superoxide production was attenuated by p38MAPK inhibition; 
however,  Western  blot  analysis  showed  that  p38MAPK  phosphorylation  was  not  up-
regulated by L-AP4 treatment, although activation of the group III mGluRs induced p44ERK 
phosphorylation  in  an  NADPH oxidase dependent  manner. Activation neuronal  group  III 
mGluRs promotes p44/42ERK activation (Iacovelli et al. 2002), and in microglia, activation 
of group III mGluRs attenuates microglial reactivity (Taylor et al. 2003). Microglial group III 
mGluR activation may therefore induce superoxide production through p38MAPK activation, 
which mediates p44ERK phosphorylation, which could have neuroprotective consequences. 
This suggestion is supported by studies in astrocytes, in which ERK activation promotes the 
protection of neurons through the release of glial derived neurotrophic factor (GDNF) (Chu et 
al. 2008), which should be investigated further in microglia treated with L-AP4.  
Microglial GABAA receptor - induced superoxide production and NADPH oxidase activity 
was  inhibited  by  p38MAPK  and  p44/42ERK  inhibition  (Fig.  4.15).  However,  muscimol 
induced ROS had no effect on p38MAPK or p44/42ERK phosphorylation, suggesting that 
GABAA  receptor  induced  superoxide  production  could  not  perpetuate  MAPK  signalling. 
GABAA  receptor  activation  is  modulated  by  p38MAPK  and  p44/42ERK  activity  (Bell-
Horner  et  al.  2006),  which  suggests  that  MAPK  signalling  exacerbates  GABA  receptor 
induced superoxide production. The findings  here that activation of the GABAA receptor 
induced Nox2 expression and activity could imply that there is  cross-talk between Nox2 
derived ROS and the p44/42ERK signalling pathway (Song et al. 2011), as inhibition of this 267 
 
signalling molecule reduced superoxide production, suggesting that activation of the GABAA 
receptor may mediate superoxide production in a p44/42ERK dependent manner. Muscimol 
also  promotes  Nox4  activation  and  superoxide production  through  p44/42ERK  signalling 
(Tyagi  et  al.  2009).  Furthermore,  Nox4  is  regulated  by  p44/42ERK  in  preadipocytes 
(Schröder  et  al.  2009),  and  Nox4  mediated  ROS  can  also  modulate  p44/42ERK 
phosphorylation  in  vascular  cells  (Gorin  et  al.  2004;  Anilkumar  et  al.  2008).  The  data 
presented here therefore suggest that GABAA receptor activation promotes MAPK signalling, 
which induces NADPH oxidase mediated superoxide production.  
P2Y2/4  receptor  induced  superoxide  production  was  attenuated  by  p38MAPK  inhibition, 
whilst p44/42ERK inhibition increased NADPH oxidase activity. P2Y2/4 receptor activation 
in  chromaffin  cells  mediates  p44/42ERK  phosphorylation  (Luke  &  Hexum  2008),  which 
corresponds with the Western blot analysis presented here. Furthermore, stimulation of the 
neuronal  P2Y  receptor  promotes  p44/42ERK  phsophorylation,  which  mediates  neurite 
outgrowth  (Lakshmi  &Joshi 2006) and Nox4 activation  (Schröder et al.  2009). The data 
presented here therefore suggests that P2Y2/4 receptor  activation  may  induce superoxide 
dependent phosphorylation of p44/42ERK, however p44/42ERK may not regulate NADPH 
oxidase activation in microglia, as inhibition of p44/42ERK could not attenuate superoxide 
production. Instead, P2Y2/4 induced p44/42ERK activation, mediated by NADPH oxidase 
activity,  may  promote  microglial  reactivity,  which  could  further  enhance  superoxide 
production through the release of cytokines which feedback onto microglia to exacerbate 
activation (Mir et al. 2009).  
In  mesengial  cells,  P2Y2/4  receptor  activation  with  UTP  mediates  p38MAPK  activation 
(Huwiler  et  al.  2000),  therefore  supporting  the  findings  here  that  p38MAPK  inhibition 
attenuated  P2Y2/4  receptor  induced  superoxide  production  (Fig.  4.15).  The  activation  of 
p38MAPK is also associated with Nox2 induction through p67phox phosphosylation (Dang 268 
 
et al. 2003), which corresponds with findings here that P2Y2/4 receptor activation induces 
Nox2 activity.  
Modulation of the iGluRs induced superoxide production in a p38MAPK and p44/42ERK 
dependent manner. Superoxide production in primary microglia following NMDA treatment 
was  attenuated  by  p38MAPK  and  p44/42ERK  inhibition.  Furthermore,  p38MAPK 
phosphorylation  was  enhanced  by  NMDA  induced  superoxide  production  in  an  NADPH 
oxidase dependent manner, suggesting that NMDA induced superoxide production modulates 
p38MAPK  activation  (Fig.  4.15).  In  VSMC‟s,  NMDA  receptor  activation  promotes 
p38MAPK activation (Doronzo et al. 2010). Furthermore, NMDA induced ROS production 
promotes p38MAPK phosphorylation in cortical neurons (Park et al. 2004). NMDA therefore 
induces superoxide production through p38MAPK activation, and NMDA receptor induced 
ROS also modulates p38MAPK activation, in support of the data presented here. AMPA 
receptor  activation  induced  superoxide  production  in  a  p38MAPK  dependent  manner; 
however  inhibition  of  the  AMPA  receptor  also  increased  p38MAPK  phosphorylation. 
Activation  of  p38MAPK  following  AMPA  receptor  activation  is  seen  after  injury  in 
astrocytes (Zhou et al. 2011). It could therefore be suggested that AMPA receptor activation 
may  occur  following  injury  and  excess  glutamate  levels,  which  promotes  p38MAPK 
activation and superoxide production.   269 
 
 
 
 
Figure 4.15 Schematic of mechanisms of neurotransmitter mediated Nox isoform activation. The data in this 
chapter show that inhibition of the group I mGluR with MTEP induces PKC and PI3-K activation. Inhibition of 
p44/42ERK attenuated superoxide production, and superoxide production was shown to induce an increase in 
p44ERK phosphorylation. This pointed to the activation of Nox1 and Nox2 by inhibition of group I mGluRs. 
Activation  of  the  group  III mGluR  with  L-AP4  induced  an  increase  in  superoxide  production  that  could  be 
attenuated by inhibition of PI3-K and PKC. Inhibition of p38MAPK also attenuated superoxide production, which 
suggested that L-AP4 induced the activity of Nox2 and Nox4. Superoxide production induced by NMDA receptor 
activation  could  be  attenuated  by  inhibition  of  p38MAPK,  and  activation  of  NMDA  receptors  induced 
phosphorylation of p38MAPK. It was not known which isoform of the NADPH oxidase could be induced by 
NMDA  receptor  activation.  Activation  of  mGluR3  with  NAAG  induced  superoxide  production  that  could  be 
attenuated  by  inhibition  of  p44/42ERK  or  p38MAPK.  NAAG  induced  superoxide  production  also  increased 
p44ERK and p38MAPK phosphorylation, and pointed to the involvement of Nox2 and Nox4. Activation of the 
P2Y2/4 receptor with UTPγS induced superoxide production that could be attenuated by inhibition of PI3-K and 
could also be attenuated by inhibition of p38MAPK , suggesting activation of Nox1 and Nox2. P2Y2/4 receptor 
induced  superoxide  production  also  enhanced  the  phosphorylation  of  p44/42ERK.  Activation  of  the  GABAA 
receptor  induced  the  activity  of  PKC  and  superoxide  production  could  also  be  attenuated  by  inhibition  of 
p38MAPK, suggesting that GABAA receptor activation induces the activity of Nox1.  270 
 
4.3.3  Neurotransmitter induced NADPH oxidase activity and microglial reactivity 
The  findings  that  modulation  of  neurotransmitter  receptors  affected  p44/42ERK  and 
p38MAPK activity and NADPH oxidase activation, lead to an investigation into microglial 
reactivity. Activation of the p38MAPK and p44/42ERK signalling pathways are implicated in 
an activated microglial phenotype (Pocock and Liddle 2001). Microglia exhibit an activated 
phenotype in AD, which is associated with enhanced p38MAPK activation in a transgenic 
mouse model of the disease (Giovannini et al. 2002). Furthermore, activation of microglia 
with LPS elevates p38MAPK activity and promotes TNFʱ release (Nakajima et al. 2004). In 
addition  microglial  p44/42ERK  activation  by  paraquat  induces  a  neurotoxic  phenotype 
following upregulation of the NADPH oxidase (Miller et al. 2007), and traumatic spinal cord 
injury mediates microglial reactivity and a neurotoxic phenotype associated with p44/42ERK 
activation (Xu et al. 2006). The findings here that modulation of microglial neurotransmitter 
receptors  could  induce  activation  of  the  p38MAPK  and  p44/42ERK  signalling  pathways 
therefore prompted an investigation into microglial reactivity.  
Glutamate  and  BzATP  increased  microglial  ED1  expression,  which  is  a  marker  for 
phagocytosis,  however,  iNOS  expression  was  not  induced  by  neurotransmitter  treatment. 
Phagocytosis is upregulated following exposure of microglia to ATP and UTP (Inoue 2007) , 
however short term exposure to ATP (30 min) attenuates phagocytoisis (Fang et al. 2009).  
Here  however,  treatment  was  for  24  h,  and  therefore  long  enough  to  induce  ED1  up-
regulation. Treatment with glutamate also increased this phagocytic phenotype. Activation of 
microglia  with  kainate  promotes  cytoskeletal  rearrangements  seen  during  phagocytosis, 
suggesting  that  microglial  AMPA  receptor  activation  mediates  a  phagocytic  phenotype 
(Christensen  et  al.  2006),  and  that  glutamate  treatment  therefore  promotes  a  phagocytic 
phenptype.  271 
 
Treatment of microglia with the mGluR modulators MTEP, NAAG and L-AP4 significantly 
elevated iNOS expression, which is a marker of microglial activation. Inhibition of group I 
mGluRs promotes a reactive microglial phenotype (Byrnes et al. 2009), however it is not yet 
known whether p44/42ERK activation is implicated. Activation of mGluR3 is also associated 
with  microglial  reactivity  (Taylor  et  al.  2002),  however  activation  of  group  III  mGluRs 
promotes neuroprotection (Taylor et al. 2003), whilst here, an increase in iNOS expression 
was observed. However, as all three mGluR modulators induce p44/42ERK up-regulation, 
this could induce a reactive phenotype. Activation of the microglial P2Y2/4 receptor also 
enhanced  iNOS  expression,  which  correlates  with  suggestions  that  UTP  can  mediate 
microglial chemotaxis and phagocytosis (Inoue et al. 2007), which is suggestive of a reactive 
microglial phenotype.  
4.3.4  Conclusions  
The  data  presented  in  this  chapter  show  that  modulation  of  microglial  neurotransmitter 
receptors induces the activity of different NADPH oxidase isoforms, and that modulation of 
neurotransmitter receptors and subsequent NADPH oxidase isoform activity requires and can 
induce  p44/42ERK  and  p38MAPK  activity,  which  modulates  microglial  reactivity.  The 
ramifications of neurotransmitter and receptor induced Nox isoform activity and subsequent 
microglial activation on neuronal survival have been investigated further in the next chapter.  
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neuronal survival 
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5.1 Introduction and summary of results   
In the previous chapter, modulation of microglial neurotransmitter receptors was shown to 
induce the activity of different NADPH oxidase isoforms, and could also modulate MAPK 
signalling and microglial reactivity. As the activation of different Nox isoforms can induce 
the  release  of  neurotoxic  factors  (Chéret  et  al.  2008),  and  as  activation  of  the  MAPK 
signalling  pathway  mediates  microglial  reactivity  (Pocock  and  Liddle,  2001),  it  was 
important to investigate the ramifications of microglial neurotransmitter receptor modulation 
and  NADPH  oxidase  activation  on  neuronal  survival,  which  may  have  important 
consequences for future therapies.  
The  production  and  release  of  the  cytokine  TNFʱ  from  microglia  treated  with 
neurotransmitters and receptor modulators was investigated, as this cytokine has important 
ramifications for neuronal survival and is regulated by NADPH oxidase activation. TNFʱ is 
implicated in immune surveillance, homeostasis and defence against damaging insults in the 
CNS (Sriram & O‟Callaghan 2007), as well as promoting neuronal recovery after traumatic 
injury (Scherbel et al. 1999). However, TNFʱ is also a pro-inflammatory cytokine, released 
from activated microglia following CNS damage in neurodegenerative diseases, infection, 
and neurotoxicity (Mattson et al. 1997), resulting in neuronal damage (Sriram & O‟Callaghan 
2007).  
Microglia produce TNFʱ following activation with a variety of stimuli (Mattson et al. 1997), 
and  modulation  of  the  microglial  NADPH  oxidase  mediates  TNFʱ  release,  which  can 
feedback  onto  microglial  TNFR‟s  to  perpetuate  NADPH  oxidase  mediated  superoxide 
production,  through  Nox1  activation  (Kim  et  al.  2007).  Furthermore,  microglial  NADPH 
oxidase activation and intracellular ROS production mediates TNFʱ expression in a MAPK 
and PKC dependent manner (Qin et al. 2004). Nox2 activation in spinal cord microglia after 
nerve  injury  induces  ROS  production  which  mediates  TNFʱ  release,  and  contributes  to 274 
 
neuropathic pain (Kim et al. 2010). Furthermore, Aβ induced microglial NADPH oxidase 
activation  promotes  TNFʱ  production  in  a  ROS  dependent  manner,  which  contributes  to 
neurodegeneration (Block 2008), suggesting the importantce of NADPH oxidase mediated 
TNFʱ production in disease.  
TNFʱ release from microglia can be regulated by neurotransmitter receptor modulation, with 
ramifications for neuronal survival (Pocock and Kettenmann, 2007) (Fig. 5.1). Activation of 
the microglial group I mGluRs can reduce TNFʱ production and release induced by LPS, 
which  down-regulates  microglial  reactivity,  and  is  neuroprotective  (Farso  et  al.  2009) 
(Fig. 5.1). In contrast, stimulation of mGluR2, promotes TNFʱ and Fas ligand release (Fig. 
5.1), which induces neuronal apoptosis, however activation of the microglial mGluR3 with 
NAAG does not mediate TNFʱ release or neuronal death (Taylor et al. 2005). Microglial 
group III mGluR activation is neuroprotective through attenuation of the release of stable 
neurotrophic factors (Fig. 5.1), and L-AP4 treatment of microglia reduces LPS, CgA, or Aβ1-
42  induced  microglial  activation  (Taylor  et  al.  2003).  Activation  of  microglial  NMDA 
receptors promotes TNFʱ release with neurotoxic consequences (Zhu et al. 2010) (Fig. 5.1), 
and inhibition of the microglial NMDA receptor with MK-801 down-regulates TNFʱ release 
in a mouse model of hypoxia (Murugan et al. 2011). Activation of the AMPA receptor in 
primary  microglia  mediates  TNFʱ  production,  however  the  ramifications  for  neuronal 
survival are not yet known (Noda et al. 2000).  275 
 
There  are  few  reports  regarding  the  effects  of  GABA  receptor  modulation  on  TNFʱ 
production and neuronal survival, however, antagonism of the microglial GABAA receptor 
with DHEAS (an allosteric antagonist of the GABAA receptor) can reduce TNFʱ release (Di 
Santo et al. 1996) (Fi. 5.1).Microglial P2X7 receptor activation with BzATP promotes TNFʱ 
release which is protective against neuronal excitotoxic injury (Suzuki et al. 2004) through its 
binding to neuronal TNFR2 which mediates p38MAPK signalling, shown to favour neuronal 
survival (Yang et al. 2002). Activation of microglial P2Y receptors also promotes microglial 
TNFʱ release, which may be protective (Ogata et al. 2003) (Fig. 5.1).  
 
Figure 5.1 Schematic of known ramifications of microglial neurotransmitter receptor modulation. Activation 
of the group I mGluRs, the group III mGluRs and mGluR3 are protective through the down-regulation of 
microglial activation and TNFα production. Activation of the NMDA receptor and mGluR2 mediates TNFα 
release  and  neuronal  apoptosis.  Activation  of  the  microglial  P2Y  receptors  mediates  TNFα  release  with 
protective  consequences;  whilst  the  ramifications  of  GABAA  receptor  mediated  release  of  TNFα  is  as  yet 
unknown. 276 
 
As  modulation  of  microglial  neurotransmitter  receptors  can  regulate  TNFʱ  release  and 
neuronal survival, it was important to investigate whether this was dependent on NADPH 
oxidase  activation.  Initially,  microglial  TNFʱ  production  and  release  was  investigated. 
Treatment of microglia with glutamate, GABA or BzATP induced TNFʱ expression but not 
release.  Activation  of  the  GABAA  receptor  with  muscimol  or  the  P2Y2/4  receptor  with 
UTPγS significantly increased TNFʱ release in an NADPH oxidase dependent manner, and 
inhibition  of  superoxide  production  from  microglia  treated  with  the  group  I  mGluR 
antagonist  or  the  group  III  mGluR  agonist  significantly  elevated  TNFʱ  gene  expression, 
whilst protein expression was increased by treatment with the mGluR3 agonist NAAG and 
the group I antagonist MTEP in an NADPH oxidase dependent manner. Activation of the 
microglial AMPA receptor with QA significantly elevated TNFʱ expression in an NADPH 
oxidase dependent manner.  
Induction of microglial TNFʱ release with muscimol, or TNFʱ expression with L-AP4 plus 
apocynin  increased  neuronal  death  in  MGCM  studies,  which  was  mediated  by  neuronal 
caspase 12 cleavage and TNFR1 expression. Furthermore, microglial TNFʱ production after 
MTEP  plus  apocynin  treatment  decreased  neuronal  death,  suggesting  that  this  TNFʱ 
production  is  neuroprotective.  Inhibition  of  mGluR3  induced  superoxide  production  also 
attenuated neuronal death by decreasing caspase 12 cleavage, whilst AMPA receptor induced 
microglial  superoxide  production  elevated  neuronal  apoptosis  in  MGCM  studies  in  an 
NADPH oxidase dependent manner, suggesting a role for AMPA induced NADPH oxidase 
dependent TNFʱ production in neuronal apoptosis.  
These data demonstrate that activation of the microglial NADPH oxidase through modulation 
of  microglial  neurotransmitter  receptors  affects  neuronal  survival  through  the  release  of 
neurotoxic or neurotrophic factors, which may be therapeutically relevant.    277 
 
5.2 Results  
5.2.1  Microglia express and release TNFα in an NADPH oxidase dependent manner 
following treatment with neurotransmitters and receptor agonists or antagonists  
Intracellular superoxide production acts as a signalling molecule to promote the expression 
and release of cytokines from microglia (Qin et al. 2004; Turchan-Cholewo et al. 2009). As 
the release of soluble factors from microglia can contribute to neurotoxicity or protection (Li 
et al. 2009), it was considered important to investigate whether exposure of microglia to 
neurotransmitters or modulation of neurotransmitter receptors known to induce superoxide 
production, mediated cytokine release. Microglia express TNFʱ following activation of the 
NADPH oxidase (Jekabsone et al. 2006;Qin et al. 2004), therefore the expression and release 
of TNFʱ was investigated following treatment of microglia with neurotransmitters, and then 
following treatment with receptor agonists and antagonists.   
Initially,  microglia  were  treated  with  the  neurotransmitters  glutamate  (1  µM),  GABA 
(100 µM) or BzATP (250 µM), and the positive controls LPS (1 µg/ml), PMA (10 ng/ml) or 
the NADPH oxidase inhibitor apocynin (10 µM) for 24 h. TNFʱ expression was analysed by 
RT-PCR (Fig. 5.2Ai), and was normalised to β-actin to enable densitometry to be performed 
(Fig. 5.2Aii). Microglial TNFʱ release was investigated by ELISA (Fig. 5.2B) after treatment 
with the positive control LPS (1 µg/ml), and the neurotransmitters glutamate (1 µM), GABA 
(100 µM) or BzATP (250 µM) in the presence or absence of apocynin (10 µM) for 24 h. 
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Figure 5.2 Production and release of TNFα by microglia treated with neurotransmitters. The expression of 
TNFα  was analysed in primary microglia by RT-PCR (Ai,  Aii). Primary microglia  were  treated  with the 
positive controls LPS (1 µg/ml), PMA (10 ng/ml), or apocynin (10 µM), or the neurotransmitters glutamate 
(1 µM),  GABA  (100  µM)  or  BzATP  (250  µM)  for  24  h.  Microglia  were  lysed  and  lysates  were  reverse 
transcribed to cDNA, which was subjected to PCR using primers for TNFα or β-actin (Ai). The RT-PCR was 
performed three times, using microglia from three separate preparations, enabling densitometry following 
normalisation to β-actin (Aii). TNFα release was analysed by ELISA following treatment of primary microglia 
with the positive control LPS (1 µg/ml), or the neurotransmitters glutamate (1 µM), GABA (100 µM) or BzATP 
(250 µM) in the presence or absence of apocynin (10 µM) for 24 h (B). All experiments were performed in 
triplicate, and data were analysed by one way ANOVA and Tukey post-hoc analysis, comparing all treatments 
to control groups, and between treatments as shown. *p<0.05, **p<0.01, ***p<0.001.  279 
 
Glutamate  (1  µM),  GABA  (100  µM)  or  BzATP  (250  µM)  each  significantly  elevated 
microglial  TNFʱ  expression  when  compared  with  control  untreated  cells  (***p<0.001) 
(Fig. 5.2Ai, ii). PMA (10 ng/ml) or apocynin (10 µM) treatments also induced a significant 
increase in TNFʱ expression when compared with control untreated cells, however, this was 
less significant (*p<0.05) than treatment with neurotransmitters (***p<0.001). LPS (1 µg/ml) 
significantly elevated microglial TNFʱ release when compared with control untreated cells. 
Treatment with the neurotransmitters alone did not significantly increase TNFʱ release from 
microglia  after  24  h  treatment  when  compared  with  control  untreated  cells  (Fig.  5.2B). 
GABA or BzATP induced TNFʱ release could be significantly reduced by co-treatment of 
microglia with apocynin (Fig. 5.2B), suggesting that any TNFʱ production following GABA 
or BzATP treatment may be dependent on NADPH oxidase activity.  
TNFʱ gene and protein expression were next analysed in primary microglia treated with the 
neurotransmitter receptor agonists or antagonists. Primary microglia were treated with LPS 
(1 µg/ml), PMA (10 ng/ml) or apocynin (10 µM) or the mGluR group I antagonist MTEP 
(100 nM), the mGluR3 agonist NAAG (50 µM), the group III agonist L-AP4 (100 µM), the 
GABAA receptor agonist muscimol (50 µM) or the P2Y2/4 receptor agonist UTPγS (100 µM) 
in the presence or absence of apocynin for 24 h. Microglia were lysed and analysed for TNFʱ 
gene  expression  by  RT-PCR  (Fig.  5.3Ai)  and  expression  was  normalised  to  β-actin  for 
densitometry analysis (Fig. 5.3Aii). Protein  expression was  analysed by Western blotting 
(Fig.  5.3Bi),  and  expression  was  normalised  to  β-actin  to  enable  densitometry  to  be 
performed (Fig. 5.3Bii).  280 
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Figure  5.3  TNFα  expression  in  primary  microglia  treated  with  neurotransmitter  receptor  agonists  or 
antagonists. Primary microglia were treated with LPS (1 µg/ml), PMA (10 ng/ml), apocynin (10 µM) or the 
mGluR group I antagonist MTEP (100 µM), the group III agonist L-AP4 (100 µM), the mGluR3 agonist 
NAAG  (50 µM), the GABAA receptor agonist muscimol  (50 µM) or  the P2Y2/4 receptor agonist UTPγS 
(100 µM) in the presence or absence of apocynin for 24 h. Microglia were then lysed and reverse transcribed 
to cDNA before PCR using TNFα primers and also primers for the loading control β-actin (Ai). Densitometry 
was performed to semi-quantify TNFα expression levels after normalisation to β-actin (Aii). Western blot 
analysis  was  also  performed  to  investigate  TNFα  protein  levels  following  treatment  of  microglia  with 
apocynin (10 µM), or L-AP4 (100 µM), MTEP (100 nM), NAAG (50 µM), UTPγS (100 µM) or muscimol 
(50 µM) in the presence or absence of apocynin for 24 h (Bi). Lysates were run on a 10% SDS-PAGE, and 
were transferred to a PVDF membrane. Following blocking, the membrane was incubated with the goat-anti-
rabbit TNFα primary antibody (1:1000) at 4 ᵒC overnight, before incubation with the secondary antibody, 
goat-anti-rabbit-HRP (1:2000) for 1 h at room temperature. The  membrane was visualised by ECL. The 
membrane was then stripped and re-probed with the rabbit-anti-mouse β-actin antibody (1:2000) for 2 h at 
room temperature, before incubation with the rabbit-anti-mouse HRP secondary antibody (1:1000) for 1 h at 
room temperature. The membrane was visualised by ECL. This enabled densitometry to be performed (Bii). 
Densitometry data were analysed by one way ANOVA and Tukey post-hoc analysis in which all treatments 
were compared with control untreated cells, or comparisons were made between cells treated with agonists / 
antagonists alone or in the presence of apocynin. *p<0.05, **p<0.01, ***p<0.001. All data are n=3. 282 
 
Treatment  of microglia  with  PMA or  LPS significantly increased TNFʱ  gene expression 
when  compared  with  control  untreated  cells  (Fig.  5.3Ai,  ii).  Treatment  with  the 
neurotransmitter agonists or antagonists alone did not elevate TNFʱ expression (Fig. 5.3Ai, 
ii), however, co-treatment of microglia with MTEP and apocynin or L-AP4 and apocynin 
significantly increased TNFʱ expression when compared with MTEP or L-AP4 treatment 
alone  respectively  (Fig. 5.3Ai, ii),  suggesting  that  inhibition  of  superoxide  production 
mediates TNFʱ transcription.  
Treatment of primary microglia with the group I mGluR antagonist MTEP or the mGluR3 
agonist  NAAG  significantly  increased  TNFʱ  protein  levels  when  compared  with  control 
untreated cells, in an NADPH oxidase dependent manner (Fig. 5.3Bi, ii). Treatment with the 
P2Y2/4  receptor  agonist  UTPγS  or  the  GABAA  receptor  agonist  muscimol  significantly 
elevated TNFʱ protein expression, which could be further enhanced by co-treatment with 
apocynin,  suggesting  that  inhibition  of  P2Y2/4  or  GABAA  receptor  induced  superoxide 
production enhances TNFʱ expression (Fig. 5.3Bi, ii).  
TNFʱ release following treatment of microglia with the receptor agonists or antagonists was 
next investigated (Fig. 5.4). Primary microglia were treated with the positive control LPS 
(1 µg/ml) or the group III mGluR agonist L-AP4 (100 µM), the group I mGluR antagonist 
MTEP  (100  nM),  the  mGluR3  agonist  NAAG  (50  µM),  the  GABAA  receptor  agonist 
muscimol  (50  µM)  or  the  P2Y2/4  receptor  agonist  UTPγS  (100  µM)  in  the  presence  or 
absence of apocynin for 24 h before the culture media was removed and used to analyse 
TNFʱ release by ELISA (Fig. 5.4).  
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Figure  5.4  TNFα  release  from  microglia  treated  with  neurotransmitter  receptor  agonists  or  antagonists. 
Primary microglia were treated with LPS (100 µM), or the mGluR group III agonist L-AP4 (100 µM), the mGluR 
group I antagonist MTEP (100 nM), the mGluR3 agonist NAAG (50 µM), the GABAA receptor agonist muscimol 
(50 µM), or the P2Y2/4 receptor agonist UTPγS (100 µM) in the presence or absence of apocynin (10 µM) for 
24 h. Media was then removed from the cells and assessed for TNFα release using a TNFα ELISA. Data were 
analysed using a one way ANOVA with Tukey post-hoc analysis, and comparisons were made between treatments 
and control untreated microglia, and also between cells treated alone and in the presence of apocynin. *p<0.05, 
**p<0.01, ***p<0.001. Data are n=3.  284 
 
TNFʱ  release  was  significantly  elevated  by  treatment  of  primary  microglia  with  LPS 
(1 µg/ml)  (Fig.  5.4).  Treatment  of  primary  microglia  with  the  mGluR  group  III  agonist 
L-AP4, the mGluR group I antagonist MTEP, or the mGluR3 agonist NAAG alone or in the 
presence of apocynin did not modulate TNFʱ release, however activation of the GABAA 
receptor with muscimol or the P2Y2/4 receptor with UTPγS significantly increased TNFʱ 
release  when  compared  with  control  untreated  cells,  which  could  be  attenuated  by  co-
treatment  of  microglia  with  apocynin,  suggesting  that  muscimol  and  UTPγS  induced 
superoxide production mediates TNFʱ release (Fig. 5.4).  
TNFʱ expression in primary microglia treated with iGluR modulators was next investigated. 
Primary microglia were treated with the NMDA receptor agonist NMDA (100 µM) or the 
antagonist MK-801 (10 µM) either alone, in combination, or with apocynin (10 µM); or the 
AMPA  receptor  agonist  QA  (10  µM)  or  the  antagonist  CNQX  (10 µM)  either  alone,  in 
combination, or in the presence of apocynin for 24 h, before RT-PCR was performed using 
primers for TNFʱ and β-actin (Fig. 5.5A) to enable densitometry to be performed (Fig. 5.5B).  
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Figure 5.5 TNFα expression in primary microglia after modulation of iGluRs.  Primary microglia were 
treated with the NMDA receptor agonist NMDA (100 µM), or the antagonist MK-801 (10 µM), either alone, in 
combination or in the presence of apocynin (10 µM); or were treated with the AMPA receptor agonist QA 
(10 µM) or the antagonist CNQX (10 µM) either alone, in combination, or in the presence of apocynin (10 
µM) for 24 h. Microglia were also treated with apocynin alone. Microglia were then lysed and subjected to 
RT-PCR using primers for TNFα or β-actin (A). Densitometry was performed to determine expression levels of 
TNFα normalised to β-actin (B). Data were analysed by one way ANOVA and Tukey post-hoc analysis, making 
comparisons between treatments and control untreated cells, and between treatments as shown. *p<0.05, 
**p<0.01, ***p<0.001.  All data are n=3.  286 
 
NMDA significantly enhanced TNFʱ expression when compared with control untreated cells, 
which could be further increased upon co-treatment with apocynin (Fig. 5.5A, B), suggesting 
that inhibition of NMDA receptor induced superoxide production enhances TNFʱ expression. 
Inhibition of the NMDA receptor with MK-801 also enhanced TNFʱ expression although in 
an NADPH oxidase independent manner, however TNFʱ expression could be significantly 
attenuated upon co-treatment of microglia with NMDA and MK-801 (Fig. 5.5B). Activation 
of the AMPA receptor significantly enhanced TNFʱ expression when compared with control 
untreated  cells  which  could  be  significantly  attenuated  by  co-treatment  with  apocynin. 
Furthermore,  this  AMPA  receptor  induced  increase  in  TNFʱ  expression  could  also  be 
significantly attenuated by co-treatment with the receptor agonist and antagonist (Fig. 5.5B). 
The AMPA receptor antagonist CNQX also enhanced microglial TNFʱ expression, which 
could be attenuated by co-treatment with apocynin or upon co-treatment with QA, suggesting 
that inhibition  of the AMPA receptor enhances TNFʱ expression in  an NADPH oxidase 
dependent manner.  
These data show that neurotransmitter receptor agonists or antagonists can modulate TNFʱ 
expression through activation of the NADPH oxidase. These findings therefore prompted an 
investigation into the ramifications of microglial neurotransmitter receptor induced NADPH 
oxidase activation on neuronal survival.  
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5.2.2  Microglial  conditioned  media  (MGCM)  from  microglia  treated  with 
neurotransmitters  and  receptor  agonists  or  antagonists  modulates  neuronal 
survival in an NADPH oxidase dependent manner 
Following  the  findings  that  modulation  of  microglial  neurotransmitter  receptors  affected 
TNFʱ expression in an NADPH oxidase dependent manner, it was important to determine 
whether the release of toxic or protective factors from microglia treated in this way affected 
neuronal survival. The effects of MGCM from microglia treated with neurotransmitters or 
receptor modulators in the presence or absence of apocynin were first investigated, before an 
analysis of survival and death cascades in neurons treated with MGCM were conducted.  
To investigate the effects of neurotransmitter mediated microglial superoxide production on 
neuronal  survival,  microglia  were  treated  with  the  neurotransmitters  glutamate  (1  µM), 
GABA (100 µM) or  BzATP  (250 µM) in  the  presence or  absence of  apocynin  for 24 h 
(Fig. 5.6A). CGCs grown for 7 DIV were then incubated with MGCM for 24 h and death was 
assessed by fluorescence microscopy using PI, a marker of necrosis and late apoptosis, and 
the nuclear dye Hoechst 33342, for the detection of all cells in the field (Fig. 5.6 Aii). Cells 
were counted and were expressed as a percentage of dead (PI positive) cells (Fig. 5.6Ai). To 
investigate the role of Nox4 in neurotransmitter induced neuronal apoptosis, microglia were 
treated with the neurotransmitters as above, in the presence or absence of the Nox4 inhibitor 
thioridazine (1 µM) for 24 h before media was applied to CGCs for a further 24 h, and cell 
death was assessed as described (Fig. 5.6B). To ensure that excess neurotransmitters in the 
MGCM were not responsible for the effects observed, and therefore to be certain that the 
consequences  for  neuronal  survival  were  due  to  neurotransmitter  induced  release  of 
neurotoxic  or  neurotrophic  factors  from  microglia,  CGCs  were  treated  directly  with  the 
neurotransmitters in the presence or absence of apocynin as described for 24 h, and were 
assessed for death using PI (Fig. 5.6C). 288 
 
   
 
 
 
Figure 5.6 legend overleaf  
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Figure 5.6 CGC death after treatment with MGCM from microglia treated with neurotransmitters in the 
presence or absence of apocynin.  Microglia were treated with the neurotransmitters glutamate (1 µM), 
GABA (100 µM) or BzATP (250 µM) in the presence or absence of apocynin (10 µM) for 24 h. Culture 
medium was removed and placed onto CGC’s grown for 7 DIV, and neurons were incubated for 24 h. CGC’s 
were assessed for death using PI and Hoechst 33342 staining  (Aii). Dead cells (red) were counted and 
expressed as percent CGC death (Ai).To investigate the role of Nox4 in neurotransmitter induced neuronal 
apoptosis,  microglia  were  treated  with  the  neurotransmitters  as  above  in  the  presence  or  absence  of 
thioridazine (1 µM) for 24 h, before media was removed and incubated with CGC’s for a further 24 h to 
enable  survival  to  be  assessed  by  PI  staining  (B).  To  ensure  that  there  was  no  direct  effect  of 
neurotransmitter’s on neuronal survival, CGCs were treated with the neurotransmitters in the presence or 
absence of apocynin as described for 24 h. CGC death was assessed by PI staining and was expressed as 
percent  CGC  death  (C).  Data  were  analysed  by  one  way  ANOVA  with  Tukey  post-hoc  analysis,  and 
comparisons were made between untreated CGCs (basal) and treatments, or as shown. *p<0.05, **p<0.01, 
***p<0.001.   All data are n=3. Scale bar 20 µm.  
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Control MGCM had no effect on neuronal survival; however glutamate, GABA or BzATP 
MGCM  each  significantly  increased  neuronal  death  in  comparison  to  untreated  CGCs 
(Fig. 5.6Ai).  Glutamate  and  apocynin  MGCM  significantly  increased  neuronal  death  in 
comparison to untreated CGCs and also when compared with glutamate MGCM treatments 
alone, suggesting that inhibition of glutamate - induced superoxide production in microglia 
promotes  the  release  of  toxic  factors.  However,  treatment  of  CGCs  with  glutamate  plus 
thioridazine MGCM attenuated the neuronal apoptosis seen with glutamate MGCM alone 
(Fig.5.5B), suggesting that  glutamate  induced activation of Nox4 mediates the release of 
neurotoxic factors. GABA MGCM significantly increased neuronal death when compared 
with untreated CGCs, which could be attenuated by co-treatment of microglia with GABA 
and  apocynin  (Fig.  5.6Ai).  Treatment  of  CGCs  with  GABA  plus  thioridazine  MGCM 
elevated neuronal death when compared with GABA MGCM treatment alone, suggesting that 
inhibition of Nox4 following GABA activation is neurotoxic (Fig. 5.6B). BzATP MGCM 
elevated  neuronal  death,  which  could  be  attenuated  upon  co-treatment  of  microglia  with 
apocynin (Fig. 5.6Ai); suggesting that inhibition of BzATP mediated superoxide production 
attenuates  the  release  of  neurotoxic  factors  (Fig.  5.2B).  Inhibition  of  microglial  BzATP 
induced Nox4 activation with thioridazine could not protect against BzATP induced neuronal 
apoptosis (Fig. 5.6B). 
Only direct treatment of CGCs with glutamate (1 µM) alone significantly increased neuronal 
death (*p<0.05), whilst treatment with glutamate and apocynin or GABA or BzATP in the 
presence or absence of apocynin had no affect on neuronal survival (Fig. 5.6C). Glutamate 
induced CGC death may have been a consequence of neuronal excitotoxicity (Fig. 5.6C), and 
as  glutamate MGCM induced the same effects  as direct glutamate treatment, it could be 
suggested  that  treatment  of  microglia  with  glutamate  has  no  effect  on  the  production  or 
release of toxic factors, however attenuation of the NADPH oxidase following glutamate 291 
 
reatment  in  microglia  enhances  the  release  of  neurotoxic  moieties.  Together,  these  data 
suggest that treatment of microglia with neurotransmitters induces the release of neurotoxic 
or neurotrophic factors in an NADPH oxidase dependent manner, which modulates neuronal 
survival.  
Following  the  findings  that  exposure  of  microglia  to  neurotransmitters  could  modulate 
neuronal survival in an NADPH oxidase dependent manner, it was considered important to 
investigate whether the release of soluble factors from microglia induced the activation of 
cell survival signalling pathways in CGCs. It was anticipated that this would provide further 
information regarding the mechanisms behind neuronal death and survival after modulation 
of the microglial NADPH oxidase.  
Western blotting was performed to investigate phospho-Akt expression. Phosphorylated Akt 
promotes cell survival by inducing the phosphorylation of the pro-apoptotic protein BAD, 
thereby dissociating it from the Bcl-2/Bcl-x complex and inhibiting its pro-apoptotic function 
(Orike  et  al.  2001).  Phospho-Akt  also  mediates  survival  through  NF-κB  activation, 
facilitating  the  expression  of  pro-survival  genes  (Niizuma  et  al.  2009).  Furthermore,  the 
neuronal  Akt signalling  pathway is  modulated  in  neurons  exposed to  Aβ  (Jimenez et  al. 
2011), ischaemia (Shan et al. 2009),  and oxidative stress (Niizuma et al. 2009), in which 
these conditions promote neuronal death through the attenuation of Akt phosphorylation. In 
addition, TNFʱ favours Akt phosphorylation in fibroblasts, promoting cell survival (Chen et 
al.  2006).  Akt  is  therefore  implicated  in  neuronal  survival  in  neurodegeneration,  and  its 
regulation by TNFʱ, which is modulated in microglia by neurotransmitters in an NADPH 
oxidase  dependent  manner,  therefore  makes  this  an  important  signalling  molecule  to 
investigate in neurons following application of neurotransmitter MGCM.  292 
 
CGCs were treated with MGCM from microglia treated with the neurotransmitters glutamate 
(1 µM), GABA (100 µM) or  BzATP  (250 µM) in  the presence or  absence of  apocynin 
(10 µM) for 24 h. CGCs were then lysed and subjected to Western blot analysis for phospho-
Akt,  and  also  for  β-actin  as  a  loading  control  (Fig.  5.7A),  to  enable  densitometry  to  be 
performed (Fig. 5.7B).  293 
 
 
 
 
 
 
Figure 5.7 Analysis of CGC phospho-Akt expression after treatment with MGCM from microglia treated 
with  neurotransmitters  in  the  presence  or  absence  of  apocynin.  Microglia  were  treated  with  the 
neurotransmitters glutamate (1 µM), GABA (100 µM) or BzATP (250 µM) in the presence or absence of 
apocynin (10 µM) for 24 h. Media was then taken and used to treat CGCs for a further 24 h before neurons 
were lysed and lysates were run on a 12% SDS-PAGE. Protein was transferred to a PVDF membrane, 
which  was  probed  for  phospho-Akt  expression  using  a  goat-anti-rabbit  phospho-Akt  antibody  (Ser473) 
at1:1000 overnight at 4 ᵒC, followed by incubation with the anti-rabbit HRP secondary antibody at 1:2000 
for 1 h at room temperature. Visualisation was by ECL. The membrane was then stripped and re-probed 
with  an  anti-mouse  β-actin  antibody at  1:2000  at  room  temperature  for  2  h.  The  membrane  was  then 
incubated  with  the  anti-mouse  HRP  secondary  antibody  at  1:1000  for  1  h  at  room  temperature. 
Visualisation was by ECL (A). Densitometry was performed on n=3 Western blots, after normalisation to β-
actin (B). Data were analysed by one way ANOVA and Tukey post-hoc analysis, comparing all conditions to 
control untreated cells, and also as shown. **p<0.01, ***p<0.001.   294 
 
Control MGCM from untreated microglia favoured Akt phosphorylation (Fig. 5.7A, B) which 
also  correlated  with  enhanced  CGC  survival  (Fig.  5.6Ai,  ii).  Treatment  with  glutamate 
MGCM or glutamate plus apocynin MGCM significantly decreased Akt phosphorylation in 
comparison  with  control  MGCM  treatments,  which  also  correlated  with  neuronal  death 
(Fig. 5.6Ai,  ii).  GABA  MGCM  also  reduced  Akt  phosphorylation,  however  treatment  of 
CGCs with GABA plus apocynin MGCM further decreased Akt phosphorylation, indicative 
of  enhanced  neuronal  death  (Fig.  5.7B),  in  contrast  to  the  live  /  dead  imaging  analysis 
(Fig. 5.6).  BzATP  MGCM  significantly  attenuated  Akt  phosphorylation,  suggestive  of 
enhanced neuronal apoptosis, and BzATP plus apocynin MGCM significantly increased Akt 
phosphorylation (Fig. 5.7B), suggesting neuronal survival in line with the live/dead imaging 
analysis (Fig. 5.6).  
These  data  therefore  show  that  neuronal  death  can  be  induced  by  factors  released  from 
microglia treated with neurotransmitters in an NADPH oxidase dependent manner. Glutamate 
elevated microglial TNFʱ expression, which correlated with enhanced neuronal death and 
decreased  Akt  phosphorylation.  Furthermore,  treatment  of  microglia  with  glutamate  plus 
apocynin further increased neuronal apoptosis and decreased Akt phosphorylation. Treatment 
of microglia with GABA or BzATP induced a significant increase in TNFʱ expression and 
enhanced  TNFʱ  release,  which  was  attenuated  by  co-treatment  with  apocynin,  and  also 
correlated with an increase in neuronal death and a decrease in Akt phosphorylation, which 
could also be attenuated by treatment of microglia with apocynin. This therefore indicates 
that  GABA  or  BzATP  treatment  of  microglia  mediates  the  expression  and  release  of 
neurotoxic factors in an NADPH oxidase dependent manner.  
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The involvement of microglial neurotransmitter receptor modulation in neuronal survival as a 
consequence of NADPH oxidase activation was next explored. Microglia were treated with 
the mGluR group I antagonist MTEP (100 nM), the mGluR3 agonist NAAG (50 µM) or the 
group III mGluR agonist L-AP4 (100 µM) in the presence or absence of apocynin (10 µM) 
for 24 h. Media was then removed, and CGC cultures were incubated with MGCM for a 
further  24  h  before  live/dead  imaging  was  performed  using  PI  and  Hoechst  33342 
(Fig. 5.8 Ai, ii). The number of PI positive cells were counted and expressed as a percentage 
(Fig. 5.8Ai). To ensure that the agonists or antagonists did not directly modulate of CGC 
survival, CGCs were treated with the receptor agonists and antagonists in the presence of 
apocynin  as  outlined above, and were assessed for neuronal  death  using PI  and Hoechst 
33342  (Fig. 5.8B).  
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Figure  5.8  CGC  death  after  treatment  with  MGCM  from  microglia  treated  with  mGluR  agonists  or 
antagonists  in  the  presence  or  absence  of  apocynin.  Microglia  were  treated  with  the  group  I  mGluR 
antagonist MTEP (100 nM), the mGluR3 agonist NAAG (50 µM), or the group III mGluR agonist L-AP4 (100 
µM) in the presence or absence of apocynin (10 µM) for 24 h. Culture medium was removed and placed onto 
CGCs grown for 7 DIV, and neurons were incubated for 24 h. CGC’s were assessed for death using PI and 
Hoescht 33342 staining (Aii). Dead cells (red) were counted and expressed as percent CGC death (Ai). To 
ensure that there was no direct effect of neurotransmitter receptor induced death, CGC’s were treated with the 
mGluR agonists and antagonists in the presence or absence of apocynin as described for 24 h. CGC death was 
assessed by PI staining and was expressed as percent CGC death (B). Data were analysed by one way ANOVA 
with Tukey post-hoc analysis, and comparisons were made between untreated CGC’s (basal) and treatments, 
or as shown. *p<0.05, ***p<0.001.   Data are n=3. Scale bar 20 µm.  
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MGCM from microglia treated with MTEP, NAAG or L-AP4 did not modulate neuronal 
survival,  however,  co-treatment  of  microglia  with  MTEP  and  apocynin,  or  NAAG  and 
apocynin increased neuronal survival when compared with MTEP or NAAG treatments alone 
(Fig. 5.8Ai), however as this reduction in neuronal death is minimal and not significant when 
compared with control MGCM treatments, it could be suggested that this enhanced survival 
may not be a consequence of attenuation of the microglial NADPH oxidase, but may be a 
consequence  of  the  experimental  technique  employed.  L-AP4  and  apocynin  MGCM 
significantly elevated neuronal death when compared with control untreated cells and also 
when compared with L-AP4 MGCM treatment alone (Fig. 5.8Ai). Direct treatment of CGCs 
with  the  mGluR  agonists  and  antagonists  did  not  modulate  neuronal  death  (Fig. 5.8B), 
suggesting that the MGCM data presented in Fig. 5.8Ai is a result of the action of released 
factors from microglia on CGCs.  
CGCs  were  next  treated  with  MGCM  from  microglia  treated  with  the  GABAA  receptor 
agonist muscimol (50 µM) in the presence or absence of apocynin (10 µM) for 24 h. CGC 
survival  was  assessed  by  live/dead  imaging  using  PI  and  Hoechst  33342  as  before 
(Fig. 5.9A, B), and cell death was expressed as a percentage (Fig. 5.9A). CGCs were also 
treated with muscimol (50 µM) in the presence or absence of apocynin (10 µM) directly, to 
determine whether there were any carry-over of effects of muscimol in the culture medium 
(Fig. 5.9A).  
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Figure  5.9  CGC  death  after  treatment  with  MGCM  from  microglia  treated  with  the  GABAA  receptor 
agonist in the presence or absence of apocynin. Microglia were treated with the GABAA receptor agonist 
muscimol (50 µM) in the presence or absence of apocynin (10 µM) for 24 h. Culture medium was removed 
and placed onto CGC’s grown for 7 DIV, and neurons were incubated for 24 h. CGCs were assessed for 
death using PI and Hoechst 33342staining (A, B). Dead cells (red) were counted and expressed as percent 
CGC death (A). To ensure that there was no direct effect of neurotransmitter induced death, CGCs were 
treated with muscimol in the presence or absence of apocynin as described for 24 h. CGC death was assessed 
by PI staining and was expressed as percent CGC death (A). Data were analysed by one way ANOVA with 
Tukey post-hoc analysis, and comparisons were made between control untreated cells (basal) and treatments, 
or as shown. ***p<0.001.   Data are n=3. Scale bar 20 µm.  
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Muscimol MGCM significantly increased neuronal death in an NADPH oxidase dependent 
manner,  when  compared  with  control  untreated  neurons  (Fig.  5.9A).  Direct  treatment  of 
CGCs  with  muscimol  or  muscimol  and  apocynin  did  not  modulate  neuronal  survival, 
suggesting that muscimol promoted TNFʱ release from microglia  in  an NADPH oxidase 
dependent manner, which induced the neuronal death seen in Fig. 5.9A. Microglial GABAA 
receptor induced NADPH oxidase activation therefore contributes to neuronal death.  
CGCs were next incubated with MGCM from microglia treated with the P2Y2/4 receptor 
agonist UTPγS (100 µM) in the presence or absence of apocynin (10 µM) for 24 h. CGCs 
were analysed for death using PI and Hoechst 33342 fluorescence, and PI positive CGCs 
were counted and expressed as a percentage of cell death (Fig. 5.10A, B). CGCs were also 
treated with UTPγS either alone or in the presence of apocynin directly to ensure that the 
effects of MGCM were not a consequence of direct neuronal actvation (Fig. 5.10A). 
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Figure 5.10 CGC death after treatment with MGCM from microglia treated with the P2Y2/4 receptor 
agonist in the presence or absence of apocynin. Microglia were treated with the P2Y2/4 receptor agonist 
UTPγS (100 µM) in the presence or absence of apocynin (10 µM) for 24 h. Culture medium was removed 
and placed onto CGC’s grown for 7 DIV, and neurons were incubated for 24 h. CGC’s were assessed for 
death using PI and Hoechst 33342 staining (A, B). Dead cells (red) were counted and expressed as percent 
CGC death (A). To ensure that there was no direct effect of receptor induced death, CGC’s were treated 
with UTPγS in the presence or absence of apocynin as described for 24 h. CGC death was assessed by PI 
staining and was expressed as percent CGC death (A). Data were analysed by one way ANOVA with Tukey 
post-hoc analysis, and comparisons were made between control untreated cells (basal) and treatments, or 
as shown. *p<0.05. Data are n=3. Scale bar 20 µm.  
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UTPγS  MGCM  or  UTPγS  plus  apocynin  MGCM  did  not  affect  CGC  survival  when 
compared with  untreated CGCs,  however treatment  of CGCs  with  UTPγS  plus  apocynin 
significantly  enhanced  neuronal  survival  when  compared  with  UTPγS  MGCM  treatment 
alone  (Fig.  5.10A,  B).  Attenuation  of  microglial  P2Y2/4  receptor  -  induced  superoxide 
production may therefore prevent the release of neurotoxic factors. Direct treatment of CGCs 
with UTPγS in the presence or absence of apocynin also had no effect on neuronal survival 
(Fig. 5.10A).  
To  investigate  the  mechanisms  behind  neuronal  survival  or  death  following  treatment  of 
CGCs  with  MGCM  from  microglia  treated  with  neurotransmitter  receptor  agonists  and 
antagonists, Western blot analysis was used to analyse phospho-Akt expression as before. 
Microglia were treated with the mGluR group I antagonist MTEP (100 nM), the mGluR3 
agonist NAAG (50 µM), the group III mGluR agonist L-AP4 (100 µM), the GABAA receptor 
agonist muscimol (50 µM), or the P2Y2/4 receptor agonist UTPγS (100 µM) in the presence 
or absence of apocynin (10 µM) for 24 h. CGCs were incubated with this MGCM for a 
further  24  h  before  lysis  and  Western  blot  analysis  for    phospho-Akt  and  β-Actin 
(Fig. 5.11A). Densitometry was performed to quantify phospho-Akt expression normalised to 
β-Actin (Fig. 5.11B).  
 
 
 
 
 302 
 
   
 
 
 
 
 
 
Figure 5.11 Analysis of CGC phospho-Akt expression after treatment with MGCM from microglia 
treated with neurotransmitter receptor agonists or antagonists in the presence or absence of apocynin. 
Microglia were treated with the mGluR group I antagonist MTEP (100 nM), the mGluR3 agonist NAAG 
(50 µM), the group III mGluR agonist L-AP4 (100 µM), the GABAA receptor agonist muscimol (50 µM), 
or the P2Y2/4 receptor agonist UTPγS (100 µM) in  the presence or absence of apocynin (10 µM) for 24 
h. Media was then taken and used to treat CGCs for a further 24 h before neurons were lysed and lysates 
were run on a 12% SDS-PAGE. Protein was transferred to a PVDF membrane, which was probed for 
phospho-Akt expression using a goat-anti-rabbit phospho-Akt antibody (Ser473) at 1:1000 overnight at 4 
ᵒC, followed by incubation with the anti-rabbit HRP secondary antibody at 1:2000 for 1 h at room 
temperature. Visualisation was by ECL. The membrane was then stripped and re-probed with an anti-
mouse β-actin antibody at 1:2000 at room temperature for 2 h. The membrane was then incubated with 
the anti-mouse HRP secondary antibody at 1:1000 for 1 h at room temperature. Visualisation was by 
ECL (A). Densitometry was performed on n=3 Western blots, after normalisation to β-actin (B). Data 
were analysed by one way ANOVA and Tukey post-hoc analysis, comparing all conditions to control 
untreated cells, and also as shown. *p<0.05.   
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Treatment of CGCs with MGCM from microglia treated with the group I mGluR antagonist, 
the  group  III  agonist  L-AP4,  the  mGluR3  agonist  NAAG,  the  GABAA  receptor  agonist 
muscimol, or the P2Y2/4 recptor agonist UTPγS in the presence or absence of apocynin did 
not  significantly  increase  Akt  phosphorylation  (Fig.  5.11A,  B).  These  findings  therefore 
suggest  that  neuronal  survival  following  treatment  of  microglia  with  neurotransmitter 
receptor modulators is not mediated through an Akt dependent pathway.  
As  Akt  phosphorylation  was  not  significantly  modulated  by  application  of  MGCM,  the 
effects of microglial neurotransmitter receptor modulation on neuronal caspase 12 cleavage 
was next investigated. Caspase 12 cleavage is implicated in neuronal death in degenerative 
conditions. In AD, microglia release TNFʱ (Jekabsone et al. 2006), which acts on neuronal 
TNFR1  to  promote  ER  stress,  caspase  12  cleavage,  and  neuronal  apoptosis  (Shibata  & 
Kobayashi 2008). Furthermore, TNFʱ and other pro-inflammatory cytokines elevate caspase 
12 expression in fibroblasts, resulting in apoptosis  (Kalai et  al. 2003). As modulation of 
neurotransmitter receptors was shown to mediate neuronal survival or death in an NADPH 
oxidase  dependent  manner  through  the  release  of  stable  factors,  it  was  important  to 
investigate whether this neuronal death was a consequence of neuronal caspase 12 cleavage.  
Microglia were treated with the mGluR group I antagonist MTEP (100 nM), the mGluR3 
agonist NAAG (50 µM), the group III mGluR agonist L-AP4 (100 µM), the GABAA receptor 
agonist muscimol (50 µM), or the P2Y2/4 receptor agonist UTPγS (100 µM) in the presence 
or absence of apocynin for 24 h. CGCs were incubated with MGCM for a further 24 h, and 
Western blot analysis was performed to detect caspase 12 and cleaved caspase 12. β-actin 
was used as a loading control (Fig. 5.12A). Densitometry was performed to determine the 
levels of cleaved caspase 12 normalised to β-actin (Fig. 5.12B).  304 
 
 
 
 
 
 
 
Figure 5.12 Analysis of caspase 12 cleavage in CGCs after treatment with MGCM from microglia treated 
with neurotransmitter receptor agonists or antagonists in the presence or absence of apocynin. Microglia 
were treated with the mGluR group I antagonist MTEP (100 nM), the mGluR3 agonist NAAG (50 µM), the 
group III mGluR agonist L-AP4 (1 µM), the GABAA receptor agonist muscimol (50 µM), or the P2Y2/4 
receptor agonist UTPγS (100 µM) in  the presence or absence of apocynin (10 µM) for 24 h. Media was 
then taken and used to treat CGC’s for a further 24 h before neurons were lysed and lysates were run on a 
12% SDS-PAGE. Protein was transferred to a PVDF membrane, which was probed for cleaved caspase 12 
expression using a goat-anti-rabbit caspase 12 antibody at1:1000 overnight at 4 ᵒC, followed by incubation 
with the anti-rabbit HRP secondary antibody at 1:1000 for 1 h at room temperature. Visualisation was by 
ECL. The membrane was then stripped and re-probed with an anti-mouse β-actin antibody at 1:2000 at 
room temperature for 2 h. The membrane was then incubated with the anti-mouse HRP secondary antibody 
at 1:1000 for 1 h at room temperature. Visualsation was by ECL (A). Densitometry was performed on n=3 
Western blots, after normalisation to β-actin (B). Data were analysed by one way ANOVA and Tukey post-
hoc analysis, comparing all conditions to control untreated cells, and also as shown. *p<0.05, **p<0.01, 
***p<0.001.   
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Treatment of CGCs with MGCM from microglia treated with the neurotransmitter receptor 
agonists or antagonists modulated caspase 12 cleavage in line with the live/dead analysis. 
Treatment of CGCs with MGCM from microglia treated with the mGluR group III agonist 
L-AP4  did  not  affect  caspase  12  cleavage  when  compared  with  control  untreated  cells, 
however, treatment of CGCs with MGCM from microglia treated with L-AP4 and apocynin 
significantly increased caspase 12 cleavage when compared with control untreated cells and 
also when compared with L-AP4 MGCM treatment alone (Fig. 5.12A, B), which agreed with 
the live/dead analysis whereby L-AP4 and apocynin MGCM significantly increased neuronal 
death (Fig. 5.8Ai). Treatment of CGCs with MTEP MGCM or MTEP plus apocynin MGCM 
had  little  effect  on  caspase  12  cleavage  (Fig.  5.12B).  NAAG  MGCM  did  not  increase 
neuronal caspase 12 cleavage, however co-treatment of microglia with NAAG and apocynin 
significantly  decreased  neuronal  caspase  12  cleavage  (Fig.  5.12A,  B),  suggesting  that 
inhibition  of  NAAG  induced  superoxide  production  in  microglia  is  neuroprotective,  in 
agreement with the live/dead analysis (Fig. 5.8A). UTPγS MGCM or UTPγS plus apocynin 
MGCM  did  not  significantly  alter  neuronal  caspase  12  cleavage,  however,  caspase  12 
cleavage mediated by treatment of CGCs with muscimol MGCM could be attenuated by 
apocynin  (Fig. 5.12A,  B),  suggesting  that  muscimol  induced  superoxide  production  may 
enhance neuronal death in a caspase 12 dependent manner. 
The mechanisms of neuronal death or survival following exposure of CGCs to MGCM from 
microglia treated with neurotransmitter receptor agonists or antagonists in the presence or 
absence  of  apocynin  was  further  explored  by  investigating  neuronal  TNFR1  expression. 
TNFR1 plays an important role in neuronal death, inducing a cascade of events leading to 
apoptosis after exposure to TNFʱ (Yang et al. 2002), and as mentioned previously, mediates 
apoptosis through initiating caspase 12 cleavage (Shibata & Kobayashi 2008), and also a 
caspase 3 death cascade (Harry et al. 2008). TNFR1 expression is modulated by exposure of 306 
 
neurons to activating stimuli, and TNFR1 is shed from neurons after exposure to TNFʱ, 
which promotes neuroprotection by reducing the bioavailability of TNFʱ to membrane bound 
TNFR‟s  (Bartsch  et  al.  2010).  Furthermore,  TNFR1  expression  is  modulated  in  a  time 
dependent manner in in vivo models of ischaemia, which correlates with increased neuronal 
death  during  high  levels  of  TNFR1  expression  (Botchkina  et  al.  1997).  The  suggestions 
therefore that TNFR1 expression may be regulated by TNFʱ levels and that TNFʱ binding to 
TNFR1 is neurotoxic, lead to an investigation into the expression of this receptor on CGCs 
following exposure to MGCM from microglia treated with receptor agonists or antagonists in 
the presence or absence of apocynin. 
 CGCs were treated with MGCM from microglia treated with the mGluR group I antagonist 
MTEP  (100  nM),  the  mGluR3  agonist  NAAG  (50 µM),  the  group  III  agonist  L-AP4 
(100 µM), the GABAA receptor agonist muscimol (50 µM), or the P2Y2/4 receptor agonist 
UTPγS (100 µM) in the presence or absence of apocynin (10 µM), for 24 h. CGCs were then 
lysed and subjected to Western blot analysis for TNFR1 and  β-actin expression (Fig. 5.13A). 
Densitometry was performed to semi-quantify TNFR1 expression after normalisation to β-
actin (Fig. 5.13B). 
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Figure 5.13 Analysis of TNFR1 expression in  CGCs after treatment with MGCM from microglia 
treated with neurotransmitter receptor agonists or antagonists in the presence or absence of apocynin. 
Microglia were treated with the mGluR group I antagonist MTEP (100 nM), the mGluR3 agonist NAAG 
(50 µM), the group III mGluR agonist L-AP4 (100 µM), the GABAA receptor agonist muscimol (50 µM), 
or the P2Y2/4 receptor agonist UTPγS (100 µM) in  the presence or absence of apocynin (10 µM) for 
24 h. Media was then taken and used to treat CGCs for a further 24 h before neurons were lysed and 
lysates  were  run  on  a  12% SDS-PAGE. Protein  was  transferred  to  a  PVDF  membrane,  which  was 
probed for TNFR1 expression using a goat-anti-rabbit TNFR1 antibody at1:1000 overnight at 4  ᵒC, 
followed  by  incubation  with  the  anti-rabbit  HRP  secondary  antibody  at  1:2000  for  1  h  at  room 
temperature. Visualisation was by ECL. The membrane was then stripped and re-probed with an anti-
mouse β-actin antibody at 1:2000 at room temperature for 2 h. The membrane was then incubated with 
the anti-mouse HRP secondary antibody at 1:1000 for 1 h at room temperature. Visualisation was by 
ECL (A). Densitometry was performed on n=3 Western blots, after normalisation to β-actin (B). Data 
were analysed by one way ANOVA and Tukey post-hoc analysis, comparing all conditions to control 
untreated cells, and also as shown. *p<0.05, **p<0.01, ***p<0.001.   
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Treatment of CGCs with MGCM from microglia treated with L-AP4 or L-AP4 plus apocynin 
did  not  significantly  affect  TNFR1  expression  (Fig.  5.13A,  B).  MTEP  or  MTEP  plus 
apocynin MGCM both significantly increased neuronal TNFR1 expression (Fig. 5.13A, B). 
Treatment of CGCs with NAAG MGCM significantly enhanced TNFR1 expression, which 
could be attenuated by co-treatment of microglia with NAAG plus apocynin (Fig. 5.13A, B). 
This correlates with the caspase 12 Western blot analysis (Fig. 5.12A, B), and also with the 
live/dead analysis (Fig. 5.8A), which showed elevated cleaved caspase 12 expression and 
neuronal death which could be attenuated by apocynin, suggesting that microglial mGluR3 
induced NADPH oxidase activation is neurotoxic. Treatment of CGCs with UTPγS or UTPγS 
plus apocynin MGCM significantly increased TNFR1 expression (Fig. 5.13A, B). In addition, 
muscimol MGCM had no effect on TNFR1 expression; however co-treatmemt of microglia 
with muscimol and apocynin enhanced neuronal TNFR1 expression (Fig. 5.13A, B). This is 
in  contrast  to  live/dead  analysis  (Fig.  5.9A)  and  caspase  12  expression  (Fig. 5.12A,  B), 
showing that muscimol MGCM induces neuronal death and elevated caspase 12 cleavage in 
an NADPH oxidase dependent manner.  
Preliminary investigations were also conducted into neuronal survival following treatment of 
CGCs  with  MGCM  from  microglia  treated  with  the  iGluR  agonists  and  antagonists. 
Microglia were treated with the NMDA receptor agonist NMDA (100 µM) or the antagonist 
MK-801 (10 µM), either alone, in combination or in combination with apocynin (10 µM); or 
were  treated  with  the  AMPA  receptor  agonist  QA  (10  µM),  or  the  antagonist  CNQX 
(10 µM), either alone, in combination, or in combination with apocynin (10 µM) for 24 h. 
CGCs were incubated with this MGCM, and were assessed for cell death following fixation 
and incubation with Hoechst 33342, after which the number of pyknotic nuclei (Fig. 5.14B) 
were counted and expressed as a percentage of neuronal apoptosis (Fig. 5.14A). 
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Figure 5.14 Modulation of microglial iGluRs affects neuronal survival.  Primary microglia were 
treated with the NMDA receptor agonist NMDA (100 µM), or the antagonist MK-801 (10 µM), either 
alone, in combination, or in combination with apocynin (10 µM); or were treated with the AMPA 
receptor agonist QA (10 µM), or the antagonist CNQX (10 µM), either alone, in combination, or in 
combination with apocynin (10 µM). Media was taken after 24 h and used to treat CGCs for a further 
24 h. Cells were assessed for death using Hoescht 33342 staining (B), in which the number of pyknotic 
nuclei were counted and expressed as a percentage of apoptotic neurons  (A). Data were analysed 
using a one way ANOVA with post hoc analysis. *p<0.05, **p<0.01, ***p<0.001. Data are n=3. 
Scale bar 20 µm.    
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NMDA plus apocynin MGCM significantly elevated neuronal death in comparison to control 
untreated  cells  and  also  when  compared  with  CGCs  treated  with  NMDA  and  MK-801 
MGCM  (Fig.  5.14A).  This  suggests  that  superoxide  production  from  NMDA  receptor 
activation promotes the production of protective factors. Treatment of microglia with the 
AMPA  receptor  antagonist  also  increased  neuronal  death,  which  was  attenuated  by  co-
treatment with apocynin (Fig. 5.14A), suggesting that CNQX induced superoxide production 
is neurotoxic. However, as controls to investigate the direct effects of NMDA or AMPA on 
CGC survival were not conducted, and as the direct application of NMDA would almost 
certainly  induce  excitotoxic  death  to  CGCs,  these  findings  can  only  be  considered  a 
preliminary investigation.  
In summary, these data show that activation or inhibition of the microglial neurotransmitter 
receptors  can  modulate  neuronal  survival  in  an  NADPH  oxidase  dependent  manner. 
Treatment of microglia with MTEP induced a slight increase in neuronal death, which could 
be attenuated by apocynin inhibition of microglial MTEP induced superoxide production. 
NAAG  treatment  of  microglia  induced  an  increase  in  neuronal  death  which  could  be 
attenuated by apocynin, which correlated with a decrease in caspase 12 cleavage and TNFR1 
expression  upon  treatment  of  CGCs  with  NAAG  plus  apocynin  MGCM,  suggesting  that 
inhibition of NAAG induced NADPH oxidase activation is protective. In contrast, L-AP4 
plus apocynin MGCM significantly increased neuronal death and also elevated caspase 12 
cleavage, suggesting that the inhibition of microglial L-AP4 induced superoxide production is 
neurotoxic. Muscimol MGCM increased CGC death, which was attenuated by co-treatment 
of microglia with apocynin, suggesting that muscimol induced the release of toxic factors, 
and  indeed,  was  shown  to  up-regulate  TNFʱ  release  in  an  NADPH  oxidase  dependent 
manner. Neuronal death was not modulated significantly by treatment with UTPγS MGCM. 
however  UTPγS  plus  apocynin  MGCM  enhanced    neuroprotection.  These  data  therefore 311 
 
indicate that superoxide induced production of released factors from microglia can affect 
neuronal  survival.  The  effects  of  these  factors  on  the  survival  of  damaged  neurons  was 
investigated next.  
5.2.3  MGCM from microglia treated with neurotransmitters and receptor agonists or 
antagonists modulates neuronal survival after treatment with staurosporine, a 
model of neuronal apoptosis, in an NADPH oxidase dependent manner 
Following  the  findings  that  modulation  of  the  microglial  NADPH  oxidase  with 
neurotransmitter receptor agonists or antagonists influenced the survival of healthy neurons, 
it was important to investigate the protective or toxic effects of activation of the microglial 
NADPH  oxidase  by  neurotransmitters  and  receptor  modulation  on  damaged  neurons.  A 
model of apoptosis was used, in which CGCs were treated with staurosporine (Sts, 0.5 µM) 
for  4  h,  which  was  shown  to  induce  a  high  level  of  neuronal  death  by  PI  and  Hoechst 
imaging. Staurosporine has been used as an apoptotic inducer in many studies of neuronal 
apoptosis. It is a broad range protein kinase inhibitor that promotes apoptosis by attenuating 
cellular activity (Gani & Engh 2010). Furthermore, staurosporine has been used as an inducer 
of apoptosis in MGCM studies to investigate the role of released factors from microglia on 
CGC survival (Eleuteri et al. 2008), which lead to the use of staurosporine in this manner 
here.  
Initally,  microglia  were  treated  with  the  neurotransmitters  glutamate  (1  µM),  GABA 
(100 µM)  or  BzATP  (250  µM)  in  the  presence  or  absence  of  apocynin  for  24  h 
(Fig.5.15A, B) or for 8 h, 12 h or 24 h for a time course analysis (Fig. 5.15Ci, ii, iii). CGCs 
were then treated with Sts (0.5 µM) in the presence of MGCM for 4 h, and cell death was 
assessed by PI and Hoechst imaging, and was expressed as a percentage of apoptosis.  
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 Figure 5.15 legend overleaf    
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Figure 5.15 Neuronal apoptosis after treatment of CGCs Sts and MGCM from microglia treated with 
neurotransmitters in the presence or absence of apocynin. Microglia were either left untreated, treated 
with apocynin (10 µM) alone or were treated with the neurotransmitters glutamate (1 µM), GABA (100 
µM) or BzATP (250 µM) in the presence or absence of apocynin (10 µM) for 24 h before media was taken 
and added to CGCs treated with Sts (0.5 µM) for 4 h, after which cells were incubated with PI and Hoechst 
33342 and dead cells were counted to determine the percentage neuronal death (A, B). Microglia were 
also treated with the neurotransmitters glutamate (1 µM) or glutamate plus apocynin for 8 h, 12 h or 24 h 
(Ci), GABA (100 µM) or GABA plus apocynin for 8 h, 12 h or 24 h  (Cii), or BzATP  or BzATP plus 
apocynin for 8 h, 12h, or 24 h (Ciii), before media was taken and added to CGC’s treated with Sts. CGC’s 
were treated for 4 h and cell death was also assessed by PI and Hoechst 33342 staining to determine the 
percentage of CGC apoptosis. Data were analysed by one way ANOVA and Tukey post hoc analysis, in 
which all treatments were compared with Sts treatment alone, and also as indicated. *p<0.05, **p<0.01, 
***p<0.001. Data are n=3. Scale bar 20 µm.   
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Treatment of CGCs with Sts (0.5 µM) for 4 h induced ~45% neuronal death, which was 
significantly attenuated by treatment of Sts treated CGCs with control MGCM (Fig. 5.15A), 
in agreement with Eleuteri et al. (2008); suggesting that resting microglia express trophic 
factors that aid neuronal survival after injury. Glutamate MGCM provided protection against 
Sts induced neuronal apoptosis in an NADPH oxidase dependent manner, as treatment of 
CGCs with glutamate plus apocynin MGCM could not attenuate neuronal death following 
exposure to Sts (Fig. 5.15A).  GABA or GABA plus apocynin MGCM both afforded similar 
levels of neuroprotection against Sts induced neuronal damage (Fig. 5.15A), suggesting that 
GABA induced activation of the microglial NADPH oxidase may not be involved in neuronal 
survival after injury. BzATP MGCM could not protect Sts exposed CGCs from apoptosis 
when compared with CGCs treated with Sts alone, however, exposure of CGCs to BzATP 
plus apocynin MGCM in the presence of Sts was protective in comparison to BzATP MGCM 
treatment  and  also  when  compared  with  Sts  treatment  alone  (Fig.  5.15A).  BzATP  may 
therefore  induce  the  release  of  neurotoxic  factors  from  microglia  in  an  NADPH  oxidase 
dependent manner, and contribute to neuronal death following damage.  
MGCM from microglia treated with glutamate for 8 h did not offer protection against Sts 
induced apoptosis (Fig. 5.15Ci), however, at 12 h treatment of microglia with glutamate, 
MGCM increased Sts induced apoptosis when compared with Sts treatments alone and also 
in comparison with 24 h treatments. Acute exposure of microglia to glutamate may induce an 
increase  in  NADPH  oxidase  activity  and  subsequent  neuronal  damage,  whereas  chronic 
exposure is less damaging. MGCM from microglia treated with GABA for 12 h induced a 
significant level of protection against neuronal apoptosis when compared with Sts treatment 
alone (Fig. 5.15Cii). In addition, MGCM from microglia treated with GABA plus apocynin 
for 12 h significantly decreased neuronal apoptosis when compared with GABA MGCM 
treatment or Sts treatment alone (Fig. 5.15Cii), suggesting that attenuation of GABA induced 315 
 
NADPH oxidase activation may inhibit the release of neurotoxic substances. MGCM from 
microglia  treated  with  BzATP  for  12 h  significantly  decreased  neuronal  apoptosis 
(Fig. 5.15Ciii),  suggesting  that  acute  exposure  of  microglia  to  BzATP  may  be 
neuroprotetcive, whereas chronic exposure of microglia to BzATP is not protective against 
neuronal damage.  
The same experiment was then performed to investigate the effects of MGCM from microglia 
treated with mGluRs in the presence or absence of apocynin on CGC survival after treatment 
with Sts. Microglia were treated with the group I mGluR antagonist MTEP (100 µM), the 
mGluR3 agonist NAAG (50 µM), or the group III agonist L-AP4 (100 µM) in the presence or 
absence  of  apocynin  (10  µM)  for  24  h  before  incubation  with  CGCs  for  4  h  with  Sts 
(Fig. 5.16A, B). A time-course analysis was also performed, in which microglia were treated 
with MTEP (Fig. 5.16Ci), NAAG (Fig. 5.16Cii), or L-AP4 (Fig. 5.16Ciii) in the presence or 
absence of apocynin for 8 h, 12 h or 24 h before media was taken and applied to CGCs co-
treated with Sts for 4 h. Neuronal survival was analysed by PI and Hoechst imaging. 
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Figure 5.16 Neuronal apoptosis after treatment of CGCs Sts and MGCM from microglia treated with 
mGluR receptor agonists or antagonists in the presence or absence of apocynin. Microglia were either left 
untreated, treated with apocynin (10 µM) alone or were treated with the group I mGluR antagonist MTEP 
(100 nM), the mGluR3 agonist NAAG (50 µM) or the group III mGluR agonist L-AP4 (100 µM) in the 
presence or absence of apocynin for 24 h before media was taken and added to CGCs treated with Sts (0.5 
µM) for 4 h, after which cells were indubated with PI and hoescht and dead  cells were counted to determine 
the percentage neuronal death (A, B). Microglia were also treated with the group I mGluR antagonist MTEP 
(100 nM) plus apocynin for 8 h, 12 h or 24 h (Ci), the mGluR3 agonist NAAG (50 µM) in the presence or 
absence of apocynin  for 8 h, 12 h or 24 h (Cii), or the group III mGluR agonist L-AP4 (100 µM) in the 
presence or absence of apocynin for 8 h, 12h, or 24 h (Ciii), before media was taken and added to CGC’s 
treated with Sts. CGCs were treated for 4 h and cell death was also assessed by PI and hoescht staining to 
determine the percentage of CGC apoptosis. Data were analysed by one way ANOVA and Tukey post hoc 
analysis, in which all treatments were compared with Sts treatment alone, and also as indicated. *p<0.05, 
**p<0.01, ***p<0.001. Data are n=3. Scale bar 20 µm.  
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MTEP  or  L-AP4  MGCM  significantly  attenuated  Sts  induced  neuronal  apoptosis  when 
compared with Sts treatment alone (Fig. 5.16A). Furthermore, attenuation of the microglial 
NADPH oxidase activation following MTEP or L-AP4 treatment with apocynin inhibited the 
protective  effect  of  MTEP  or  L-AP4  MGCM  on  the  survival  of  damaged  neurons 
(Fig. 5.16A), suggesting that the production of superoxide in microglia following MTEP or 
L-AP4 treatment for 24 h may induce the release of neuroprotective factors. In contrast, 
NAAG MGCM or NAAG plus apocynin MGCM both significantly attenuated Sts induced 
neuronal death, suggesting that the NADPH oxidase is not implicated in microglial mGluR3 
mediated neuroprotection (Fig. 5.16A).  
MTEP MGCM from microglia treated for 12 h significantly attenuated Sts induced neuronal 
apoptosis  when  compared  with  Sts  treatment  alone  (Fig.  5.16Ci).  MTEP  and  apocynin 
MGCM increased Sts induced neuronal death in comparison to MTEP MGCM treatment, 
however  death  was  significantly  reduced  when  compared  with  Sts  treatment  alone, 
suggesting  that  after  12  h  incubation,  MTEP  mediates  NADPH  oxidase  activation  and 
production of neuroprotective factors (Fig. 5.16Ci). NAAG MGCM from microglia treated 
for  8 h,  12  h  or  24  h  all  significantly  attenuated  Sts  induced  neuronal  apoptosis  when 
compared  with  treatment  of  CGCs  with  Sts  alone  (Fig. 5.16Cii).  This  effect  was  not 
dependent on modulation of the microglial NADPH oxidase, as co-treatment of microglia 
with NAAG and apocynin did not affect CGC survival following incubation with MGCM at 
any time-point (Fig. 5.16Cii). L-AP4 MGCM following treatment of microglia for 12 h was 
neuroprotective against Sts treatment, however this could not be modulated by inhibition of 
the microglial NADPH oxidase in the same way as incubation of microglia with L-AP4 for 
for 24 h (Fig. 5.16Ciii), thereby suggesting that activation of the microglial NADPH oxidase 
following activation of the microglial group III mGluRs occurs at 24 h and at this time point, 
neuroprotective factors are released (Fig. 5.16Ciii).  319 
 
The role of microglial GABAA induced NADPH oxidase activity on neuronal survival after 
treatment with Sts was next investigated (Fig. 5.17). Microglia were treated with the GABAA 
receptor agonist muscimol (50 µM) in the presence or absence of apocynin (10 µM) for 24 h 
before MGCM was taken and added to CGCs treated with Sts for a further 4 h (Fig, 5.17A). 
Neuronal survival was assessed by PI and Hoechst imaging (Fig. 5.17A, B). To determine 
whether the production of toxic or protective factors from microglia treated with muscimol 
was time dependent, a time course analysis was performed (Fig. 5.17C), in which microglia 
were treated with muscimol in the presence of apocynin for 8 h, 12 h or 24 h and MGCM was 
taken and added to CGCs treated with Sts for 4 h.  
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Figure  5.17Neuronal  apoptosis  after  treatment  of  CGCs  with  Sts  and  MGCM  from microglia 
treated with the GABAA receptor agonist in the presence or absence of apocynin. Microglia were 
either left untreated, treated with apocynin (10 µM) alone or were treated with GABAA receptor 
agonist muscimol (50 µM) in the presence or absence of apocynin for 24 h before media was taken 
and added to CGCs treated with Sts (0.5 µM) for 4 h, after which cells were indubated with PI and 
Hoechst 33342 and dead cells were counted to determine the percentage neuronal death  (A, B). 
Microglia were also treated with the GABAA receptor agonist muscimol in the presence or absence 
of apocynin for 8 h, 12h, or 24 h (C), before media was taken and added to CGC’s treated with Sts. 
CGCs were treated for 4 h and cell death was also assessed by PI and Hoechst 33342 staining to 
determine the percentage of CGC apoptosis. Data were analysed by one way ANOVA and Tukey post 
hoc analysis, in which all treatments were compared with Sts treatment alone, and also as indicated. 
*p<0.05, **p<0.01, ***p<0.001. Data are n=3. Scale bar 20 µm.  
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Muscimol  MGCM  (from  microglia  treated  for  24  h)  significantly  attenuated  Sts  induced 
neuronal  apoptosis  when  compared  with  Sts  treatment  alone  (Fig. 5.17A).  This  neuronal 
survival could be further enhanced by treatment of Sts treated CGCs with muscimol plus 
apocynin MGCM, suggesting that inhibition of muscimol induced NADPH oxidase activity 
prevents the release of neurotoxic factors and is neuroprotective (Fig. 5.17A). A time-course 
analysis showed that at 8 h and 12 h treatment of microglia with muscimol or muscimol plus 
apocynin,  MGCM  offered  significant  neuroprotection,  however  there  was  no  difference 
between the effects of muscimol MGCM or muscimol plus apocynin MGCM (Fig. 5.17C), 
suggesting that only after 24 h, activation of the microglial GABAA receptor induces NADPH 
oxidase derived neuroprotection.  
The  role  of  microglial  P2Y2/4  receptor  induced  NADPH  oxidase  activity  on  neuronal 
suurvival  following  treatment  with  Sts  was  also  investigated  (Fig.  5.18).  Microglia  were 
treated with the P2Y2/4 receptor agonist UTPγS (100 µM) in the presence or absence of 
apocynin for 24 h before MGCM was taken and added to CGCs treated with Sts for a further 
4  h  (Fig,  5.18A).  Neuronal  survival  was  assessed  by  PI  and  Hoechst  imaging  and  was 
expressed as a percentage of apoptotic neurons (Fig. 5.18A, B). To determine whether the 
production  of  toxic  or  protective  factors  from  microglia  treated  with  UTPγS  was  time 
dependent,  a  time  course  analysis  was  performed  (Fig.  5.18C),  in  which  microglia  were 
treated with UTPγS in the presence of apocynin for 8 h, 12 h or 24 h and MGCM was taken 
and added to CGCs treated with Sts for 4 h.  
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Figure  5.18  Neuronal  apoptosis  after  treatment  of  CGCs  with  Sts  and  MGCM  from  microglia 
treated with the P2Y2/4 receptor agonist in the presence or absence of apocynin. Microglia were 
either left untreated, treated with apocynin (10 µM) alone or were treated with the P2Y2/4 receptor 
agonist UTP   (100 µM) in the presence or absence of apocynin for 24 h before media was taken and 
added to CGCs treated with Sts (0.5 µM)  for 4 h, after which cells were incubated with PI and 
Hoechst and dead cells were counted to determine the percentage neuronal death (A, B). Microglia 
were also treated with the P2Y2/4 receptor agonist UTPγS the presence or absence of apocynin for 8 
h, 12h, or 24 h (C), before media was taken and added to CGCs treated with Sts. CGCs were treated 
for  4  h  and  cell  death  was  also  assessed  by  PI  and  Hoechst  33342  staining  to  determine  the 
percentage of CGC apoptosis. Data were analysed by one way ANOVA and Tukey post hoc analysis, 
in which all treatments were compared with Sts treatment alone, and also as indicated. *p<0.05, 
**p<0.01, ***p<0.001. Data are n=3. Scale bar 20 µm.  
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UTPγS  MGCM  significantly  decreased  Sts  induced  neuronal  death,  whereas  UTPγS  and 
apocynin MGCM was not protective against Sts induced apoptosis (Fig. 5.18A), suggesting 
that UTPγS treatment after 24 h induces a protective effect through superoxide production in 
an NADPH oxidase dependent manner. The time-course analysis showed that 12 h incubation 
of microglia with UTPγS plus apocynin significantly decreased CGC death after treatment 
with Sts (Fig. 5.18C), which also significantly attenuated neuronal death in comparison to 
treatment with UTPγS MGCM alone. This therefore suggests that at 12 h incubation with 
UTPγS,  microglia  release  neurotoxic  factors  in  an  NADPH  oxidase  dependent  manner, 
whereas  at  24  h  incubation  with  UTPγS,  microglia  release  neuroprotective  factors  in  an 
NADPH  oxidase  dependent  manner,  thereby  indicating  that  the  microglial  response  to 
P2Y2/4 receptor activation is time dependent.  
In  summary  these  data  show  that  NADPH  oxidase  activation  following  treatment  of 
microglia  with  the  group  I  mGluR  antagonist  MTEP  or  the  group  III  agonist  L-AP4  is 
neuroprotective  through  activation  of  the  NADPH  oxidase.  Activation  of  the  microglial 
mGluR3 with NAAG is protective; however this effect is not solely dependent on modulation 
of  the  microglial  NADPH  oxidase.  Activation  of  the  microglial  GABAA  receptor  with 
muscimol is neurotoxic, and this effect could be attenuated by inhibition of the microglial 
NADPH  oxidase  with  apocynin.  Activation  of  the  microglial  P2Y2/4  receptor  is 
neroprotective in an NADPH oxoidase manner, as attenuation of P2Y2/4 receptor induced 
NADPH  oxidase  activation  was  neurotoxic.  These  data  therefore  show  that  microglial 
neurotransmitter  receptors  modulation  mediates  neuronal  survival  in  an  NADPH  oxidase 
dependent manner.  
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5.3 Discussion  
Treatment  of  microglia  with  the  neurotransmitters  and  receptor  agonists  or  antagonists 
modulated TNFʱ expression and release in an NADPH oxidase dependent manner, and also 
affected neuronal survival. The findings here that activation or inhibition of the microglial 
neurotransmitter receptors modulated NADPH oxidase activity and subsequent neurotoxicity, 
could  provide  important  information  for  the  production  of  future  therapies  for 
neurodegenerative conditions.  
5.3.1  Neurotransmitter  mediated  microglial  TNFα  release  and  ramifications  for 
neuronal survival  
Glutamate, GABA or BzATP each induced microglial TNFʱ expression however, could not 
enhance TNFʱ release. These findings could suggest that glutamate, GABA or BzATP may 
not enhance the expression of the metalloproteinase TNFʱ cleavage enzyme (TACE), which 
is responsible for the release of soluble TNFʱ (Moss & Lambert 2002). In agreement with 
this suggestion, substance P has been shown to enhance microglial TNFʱ but not TACE 
expression, thereby attenuating TNFʱ release (Zhou et al. 2010). Furthermore, substance P 
induces NADPH oxidase activation (Block et al. 2006), in the same way that previous reports 
have demonstrated that BzATP induces NADPH oxidase activity (Parvathenani et al. 2003), 
and that glutamate, GABA and BzATP can induce NADPH oxidase activation as shown here. 
It  has  however  been  suggested  that  activation  of  the  Nox1  homologue  Duox1  in  human 
epithelial  cells  with  PMA  enhances  TACE  expression  and  TNFʱ  release,  and  TACE 
expression could be attenuated with Rottlerin, a PKCδ and Nox1 inhibitor (Shao & Nadel 
2005).  This  suggests  that  TACE  expression  may  only  be  induced  by  Nox1  mediated 
superoxide production, and as shown previously, glutmate, GABA and BzATP preferentially 
activate Nox2 and enhance Nox4 expression, which could account for the enhanced NADPH 
oxidase mediated TNFʱ expression but not TNFʱ release seen here.  325 
 
Glutamate MGCM enhanced neuronal apoptosis when compared with untreated CGCs. In 
agreement with the data presented here, exposure of mixed hippocampal neuronal  - glial 
cultures to glutamate for 24 h significantly increased microglial TNFʱ expression, which was 
concomitant with increased neuronal TNFR1 expression and apoptosis (Figiel & Dzwonek 
2007). Here neuronal apoptosis was further enhanced by glutamate plus apocynin MGCM, 
suggesting  that  inhibition  of  glutamate  -  induced  microglial  superoxide  production 
exacerbated the neurotoxic phenotype. In support of this finding, Nox2 activation in a mouse 
model of MS enhanced acute symptoms, however attenuation of Nox2 promoted the release 
of inflammatory mediators and enhanced chronic disease severity  (Hultqvist et al. 2004), 
suggesting that attenuation of Nox2 activation is neurotoxic. Neuronal apoptosis following 
glutamate or glutamate and apocynin MGCM treatment correlated with a significant decrease 
in Akt phosphorylation (Fig. 5.19A), suggesting that factors released from microglia mediate 
cell death by attenuating neuronal Akt phosphorylation (Niizuma et al. 2009). In support of 
this suggestion, cytokines such as TNFʱ can promote cortical neuron apoptosis through Akt 
signalling (Rickle et al. 2006).   
Glutamate  mediates  the  production  of  neurotrophic  factors  through  PKC  signalling  in 
microglia, which is neuroprotective (Liang et al. 2010). Furthermore, PKC mediates NADPH 
oxidase activation (Nakajima et al. 2004), and NADPH oxidase derived ROS promote the 
activation of transcription factors (Pawate et al. 2004), suggesting that glutamate induced 
NADPH  oxidase  activation  may  promote  the  expression  of  neurotrophic  factors.  Here, 
however,  glutamate  MGCM  enhanced  neuronal  apoptosis,  which  supports  findings  that 
neurotrophic factors can enhance neuronal apoptosis (Kim et al. 2002). The release of trophic 
factors from glial cells after damage to the brain can perpetuate neuronal degeneration (Koh 
et al. 1995; Greenfield & Vaux 2002), suggesting that damaged neurons are susceptible to 
apoptosis by neurotrophic factors (Greenfield & Vaux 2002). Exposure of cortical neurons in 326 
 
vitro  to  BDNF  induces  necrosis  (Kim  et  al.  2002),  suggesting  that  here,  microglia  may 
release BDNF after glutamate exposure, which may be enhanced by attenuation of NADPH 
oxidase  activity,  suggesting  that  superoxide  production  may  prevent  glutamate  induced 
BDNF release.   
Glutamate and thioridazine MGCM reduced glutamate induced neurotoxicity, suggesting that 
inhibition of glutamate induced Nox4 activation in microglia is neuroprotective. Microglial 
Nox4 expression enhances IL-6 release (Li et al. 2009) which has neurotoxic consequences in 
AD, and promotes the cognitive decline seen in animal models of the disease (Lanzrein et al. 
1998). In addition, microglial Nox4 activation promotes glutamate release (Harrigan et al. 
2008), suggesting that here, glutamate activation of microglial Nox4 may promote neuronal 
death by glutamate excitotoxicity (Piani & Fontana 1994). Furthermore, microglial NADPH 
oxidase isoform expression is dependent on the activation state of the cell (Li et al. 2009), 
and as glutamate can induce a neurotoxic phenotype, particularly through activation mGluR2 
(Taylor et al. 2002), it could be suggested that the exposure of microglia to glutamate here 
may induce microglial reactivity and subsequent Nox4 activation, resulting in the release of 
neurotoxic factors which may promote neuronal death in a Nox4 dependent manner. 
Glutamate MGCM was protective against Sts induced neuronal apoptosis, whilst glutamate 
plus  apocynin  MGCM  increased  Sts  induced  death.  Exposure  of  microglia  to  glutamate 
induces BDNF production, which is protective against excitotoxic neuronal injury (Liang et 
al. 2010), which could suggest a mechanism whereby glutamate induced NADPH oxidase 
activation  mediates  BDNF  release  that  protects  neurons  against  Sts  induced  apoptosis. 
Glutamate MGCM from microglia treated with glutamate for 12 h enhanced Sts induced 
neuronal apoptosis when compared with 24 h treatment. This could suggest a mechanism in 
which  the  microglial  phenotype  changes  from  neurotoxic  to  neuroprotective  over  time, 
possibly as a consequence of the activation of different Nox isoforms (Li et al. 2009). This 327 
 
suggestion is supported by findings that 6 h following ischaemia, microglial Nox4 expression 
is elevated which is followed by enhanced Nox2 expression and activity at later time points 
in the rat brain (McCann et al. 2008). Although the consequences of this modulation of Nox 
expression and activity  remain to  be elucidated, it has  been shown that Nox2 and Nox4 
activity  are  temporally  regulated  in  human  microglial  cells,  which  may  have  important 
consequences for the regulation of the immune response (Li et al. 2009). These findings show 
that  different  NADPH  oxidase  isoforms  are  activated  at  different  time  points  following 
treatment of microglia with glutamate, with differing ramifications for neuronal survival.  
GABA MGCM significantly enhanced neuronal death in the presence and absence of Sts, 
which  was  attenuated  by  treatment  with  GABA  plus  apocynin  MGCM  (Fig.  5.19B). 
Furthermore,  GABA  significantly  elevated  microglial  TNFʱ  expression  in  an  NADPH 
oxidase dependent manner. Activation of the microglial GABA recptors mediates cytokine 
release, with GABAB receptor activation mediating IL-6 release (Kuhn et al. 2004), which 
has both pro- and anti-inflammatory properties (Scheller et al. 2011). Furthermore, GABAA 
receptor activation in endothelial cells promotes Nox4 activation (Tyagi et al. 2009a), and 
activation of human microglial Nox4 mediates the constitutive expression and release of IL-6 
(Li  et  al.  2009).  Attenuation  of  microglial  Nox4  following  GABA  treatment  enhanced 
neurotoxicity  after  application  of  MGCM  to  CGCs,  indicating  that  the  inhibition  of 
microglial  Nox4  following  GABA  activation  may  be  detrimental  to  neuronal  survival, 
although  the  mechanisms  involved  should  be  investigated  further.  In  support  of  these 
findings, Nox4 activation is protective in a model of retinal cell stress (Groeger et al. 2009); 
suggesting  that  GABA  induced  Nox4  activation  may  promote  microglial  derived 
neuroprotection,  whilst  activation  of  microglial  Nox1  has  been  shown  to  be  neurotoxic 
(Chéret et al. 2008), thereby supporting the findings here that inhibition of microglial GABA 
induced Nox1/2 activation is neuroprotective.  328 
 
BzATP enhanced microglial TNFʱ expression, in accordance with reports that microglial 
P2X7  receptor  activation  mediates  TNFʱ  production  (Suzuki  et  al.  2004).  Furthermore, 
BzATP MGCM neurotoxicity was attenuated by inhibition of the microglial NADPH oxidase 
with  apocynin  (Fig.  5.19B),  but  not  with  thioridazine,  suggesting  that  BzATP  induced 
Nox1/2  activation  may  mediate  the  release  of  toxic  factors,  in  line  with  findings  that 
microglial Nox1 activation is neurotoxic (Chéret et al. 2008). In agreement with the findings 
here, activation of the microglial P2X7 receptor with BzATP can induce NADPH oxidase 
activation with neurotoxic consequences (Parvathenani et al. 2003), and ATP treatment of 
microglia promotes TNFʱ release (Hide et al. 2000). The enhanced neuronal apoptosis after 
BzATP MGCM treatment shown here may therefore be a consequence of superoxide induced 
production of neurotoxic factors.  Furthermore, BzATP plus apocynin MGCM attenuated Sts 
induced  neuronal  death,  suggesting  that  activation  of  the  microglial  NADPH  oxidase 
following  BzATP  treatment  enhances  neuronal  apoptosis.  This  was  shown  to  be  time 
dependent, as at 12 h incubation of microglia with BzATP, MGCM was protective against Sts 
induced  neuronal  death.  These  findings  concur  with  suggestions  that  different  microglial 
NADPH oxidase isoforms are activated at different time points following neuronal damage, 
which also modulates the expression and release of neurotoxic or neuroprotective factors 
(McCann et al. 2008). Furthermore, the neurotoxic Nox1 isoform is upregulated 24 h after 
ischaemia in the rat brain which correlates with neuronal death (Kahles et al. 2010). Acute 
treatment of microglia with BzATP may therefore induce Nox4 activation, favouring  the 
release of protective factors, whereas chronic treatment may induce Nox1 activation, which 
mediates the release of toxic factors from microglia.  
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5.3.2  Receptor mediated microglial TNFα production and ramifications for neuronal 
survival  
Microglial  mGluR  modulation  affected  neuronal  survival  through  NADPH  oxidase 
activation. Treatment of microglia with the group I mGluR antagonist MTEP did not elevate 
TNFʱ  expression  or  release;  however,  protein  levels  were  significantly  enhanced  in  an 
NADPH oxidase dependent manner. The discrepancy between gene and protein expression 
could  suggest  a  role  for  MTEP  induced  NADPH  oxidase  activation  in  the  regulation  of 
translation. Nox2 and Nox4 co-localise with the ER marker calreticulin in endothelial cells, 
 
 
Figure 5.19Schematic of microglial mediated neuronal death or survival following exposure of microglia to 
neurotransmitters. Microglia treated with glutamate (A) produce superoxide through activation of the NADPH 
oxidase, which up regulates TNFα gene expression. Glutamate induced NADPH oxidase activation in microglia 
reduces  Akt  phosphorylation  which  correlates  with  an  increase  in  neuronal  death.  Treatment  of  microglia 
glutamate plus apocynin attenuates NADPH oxidase activation, however this was concomitant with further 
decreased Akt phosphorylation and further enhanced neuronal apoptosis. Inhibition of the microglial NADPH 
oxidase following treatment with GABA or BzATP (B) mediated enhanced neuronal survival, suggesting that 
GABA or BzATP treatments alone mediate the release of toxic factors in an NADPH oxidase dependent manner.  330 
 
suggesting a role in  the regulation  of protein folding and translation (Petry  et  al.  2006). 
Furthermore, in human smooth muscle cells, Nox4 activation promotes the phosphorylation 
and activation of the eukaryotic translation initiation factor 4E binding protein-1 (4E- BP1), 
which regulates protein synthesis (Sturrock et al. 2007). Antagonism of the group I mGluRs 
may therefore induce TNFʱ translation through enhanced NADPH oxidase activity, rather 
than induction of transcription. 
 
The  elevated  microglial  TNFʱ  protein  expression  after  inhibition  of  the  group  I  mGluR 
correlates with findings that inhibition of the microglial group I mGluR in rat spinal cord 
injury  promotes  microglial  activation  and  cytokine  release  (Byrnes  et  al.  2009).  Here 
however,  MTEP  treatment  of  microglia  did  not  promote  TNFʱ  release.  The  differences 
reported here and by Byrnes et al (2009) may be a result of the in vivo nature of the published 
report. Neuronal damage provides additional microglial activating stimuli, such as ATP that 
is released from damaged neurons (Franke et al. 2006) and acts on microglial P2X7 receptors 
to promote TNFʱ release from microglia (Suzuki et al. 2004); suggesting that antagonism of 
the microglial group I mGluRs may contribute to, rather than induce, microglial reacitivity. 
The  findings  here  therefore  indcicate  that  antagonism  of  the  microglial  group  I  mGluRs 
enhances TNFʱ protein expression in an NADPH oxidase dependent manner in the absence 
of  other  stimuli;  however  additional  activating  stimuli  may  be  required  to  induce  TNFʱ 
release (Loane et al. 2009) (Fig. 5.20).  
MTEP MGCM did not significantly enhance neuronal apoptosis, however further protection 
was observed following treatment with MTEP plus apocynin MGCM, although because this 
protection  was  not  significantly  more  than  that  seen  with  control  MGCM,  it  could  be 
suggested that this is not a consequence of attenuation of the NADPH oxidase. The findings 
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protective  could  suggest  that  inhibition  of  the  microglial  group  I  mGluRs  also  affects 
neuronal  survival  through  an  NADPH  oxidase  independant  pathway.  In  support  of  this 
suggestion,  attenuation  of  the  microglial  group  I  mGluRs  mediates  neuroprotection  after 
ischaemia in vivo (Kohara et al. 2008); however the mechanisms behind this protection are 
not well understood (Byrnes et al. 2009). 
 Neuronal Akt phosphorylation was enhanced upon treatment of CGCs with MTEP MGCM, 
correlating with neuronal survival (Fig. 5.20). Furthermore, neuronal caspase 12 cleavage 
was not affected by MTEP or MTEP plus apocynin MGCM, lending further support to the 
suggestion that NADPH oxidase activation after inhibition of microglial group I mGluRs may 
be protective. Neuronal TNFR1 expression was significantly enhanced following treatment 
with  MTEP  or  MTEP  plus  apocynin  MGCM,  which  could  suggest  a  mechanism  of 
neuroprotection through enhanced TNFR1 shedding (Bartsch et al. 2010), thereby preventing 
the  binding  of  TNFʱ  to  membrane  bound  receptors,  attenuating  apoptosis 
(Pinckard et al. 1997).   
MTEP MGCM was neuroprotective against Sts induced apoptosis, which was reversed by 
attenuation  of  NADPH  oxidase  activation,  suggesting  that  inhibition  of  the  microglial 
NADPH oxidase enhanced the death of damaged neurons. As previous studies have reported 
that activation of the microglial mGluR group I induces a neuroprotective phenotype through 
inhibition  of  the  NADPH  oxidase  (Loane  et  al.  2009,  Byrnes  et  al.  2009)  it  could  be 
suggested that inhibition of the group I mGluR is protective through activation of protective 
isoforms of the NADPH oxidase, such as Nox2 (Chéret et al. 2008; Groeger et al. 2009) and 
that inhibition of this superoxide production induces the release of neurotoxic substances. 
Treatment of microglia with the mGluR3 agonist NAAG significantly elevated TNFʱ protein 
expression,  but  not  release,  in  an  NADPH  oxidase  dependent  manner  (Fig.  5.20).  This 332 
 
NADPH oxidase induced TNFʱ production did not enhance neuronal apoptosis (Fig. 5.20); 
however  NAAG  plus  apocynin  MGCM  offered  significant  neuroprotection.  Furthermore, 
both NAAG and NAAG plus apocynin MGCM were protective against Sts induced neuronal 
apoptosis. This could suggest that activation of the microglial mGluR3 is protective in both 
an NADPH oxidase dependent and independent manner. In support of this suggestion, it has 
been shown that NAAG MGCM (from microglia treated for 24 h) is not neurotoxic (Taylor et 
al. 2005). Furthermore, activation of microglial mGluR3 is protective in a variety of diseases. 
Glial mGluR3 expression is upregulated in a rat model of temporal lobe epilepsy, and is 
responsible  for  neuroprotection  through  the  release  of  TGFβ  (Aronica  et  al.  2000). 
Furthermore,  activation  of  glial  mGluR3  promotes    IL-6  release,  which  has  plieotroic 
properties (Scheller et al. 2011), has been shown to be protective in rat models of stroke 
(Loddick et al. 1998), and can promote neuronal survival in vitro (März et al. 1997). It could 
therefore be suggested that activation of the microglial mGluR3 induces the production of 
protective cytokines, which is not solely dependent on activation of the NADPH oxidase.  
This  cytokine  production  could  however,  be  partially  dependent  on  NADPH  oxidase 
activation, as neuroprotection was enhanced upon attenuation of mGluR3 induced NADPH 
oxidase  activation.  As  mentioned  previously,  many  cytokines  have  pleiotropic  properties 
(Scheller et al. 2011), and it could be suggested that the activation of the NADPH oxidase up-
regulates the production of these cytokines, however, attenuation of their production may 
confer  further  protection,  as  shown  here.  For  example,  IL-6  is  up-regulated  by  Nox4 
activation in a human microglial cell line, which modulates the inflammatory response in 
neurodegenerative disease (Li et al. 2009). Whilst IL-6 release may be neuroprotetcive (März 
et al. 1997), the inhibition of NADPH oxidase induced IL-6 production further enhances 
neuroprotection (Turchan-Cholewo et al. 2009), thereby suggesting that if NAAG mediates 
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neuroprotection may be further enhanced by inhibition of NAAG induced NADPH oxidase 
activation. Together these data support a role for microglial mGluR3 activation in neuronal 
survival through modulation of NADPH oxidase activity, however the data and evidence 
from published findings could suggest that attenuation of mGluR3 induced NADPH oxidase 
activation may further enhance neuronal survival. 
Further investigations into neuronal apoptosis showed that NAAG MGCM did not modulate 
neuronal caspase 12 cleavage, however, in line with the study of neuronal death, neuronal 
caspase  12  cleavage  was  significantly  attenuated  after  NAAG  and  apocynin  MGCM 
treatment.  Neuronal  TNFR1  expression  was  significantly  enhanced  upon  treatment  with 
NAAG MGCM, which was down-regulated by treatment with NAAG plus apocynin. This 
could again suggest a protective mechanism in which the shedding of TNFR1 prevents death 
signalling from the binding of TNFʱ to membrane bound receptors (Bartsch et al. 2010). 
Furthermore,  expression  of  microglial  TNFʱ  protien  may  promote  the  up-regulation  of 
TNFR1 expression, which has been shown in slice cultures (Harry et al. 2008), and here both 
TNFʱ  and  TNFR1  protien  levels  were  attenuated  by  inhibition  of  the  mGluR3  NADPH 
oxidase activation. These findings therefore suggest that mGluR3 NADPH oxidase activation 
is implicated in neuroprotection, however other pathways may also be involved.   
Activation of the microglial group III mGluR with L-AP4 did not modulate TNFʱ protein 
expression  or  release,  however,  treatment  of  microglia  with  L-AP4  and  apocynin 
significantly elevated TNFʱ gene expression. Furthermore, L-AP4 plus apocynin MGCM 
significantly elevated neuronal death, which also correlated with increased neuronal caspase 
12 cleavage and TNFR1 expression, suggesting that neuronal death following the inhibition 
of microglial group III mGluR mediated NADPH oxidase activation was a consequence of 
the activation of these death cascades (Fig. 5.20), and that apoptosis was mediated by the 334 
 
induction of ER stress (Shibata & Kobayashi 2008) as a consequence of L-AP4 plus apocynin 
MGCM treatment. 
Activation of the microglial group III mGluR with L-AP4 is neuroprotective (Taylor et al. 
2003), and can protect against myelin induced neurotoxicity (Pinteaux-Jones et al. 2008). In 
addition, treatment of mixed neuronal – glial cultures with L-AP4 is protective against Aβ 
induced neuronal apoptosis (Copani et al. 1995), and activation of group III mGluRs with 
L-AP4 in vivo is protective against 6-hydroxydopamine toxicity in a model of PD (Vernon et 
al. 2007). In support of these published findings, L-AP4 MGCM was protective against Sts 
induced neurotoxicity, which was attenuated upon treatment of Sts treated CGCs with L-AP4 
plus  apocynin  MGCM,  suggesting  that  activation  of  the  microglial  group  III  mGluRs  is 
protective through activation of the NADPH oxidase.  
The  finding  here  that  attenuation  of  microglial  group  III  mGluR  mediated  superoxide 
production promotes neurotoxicity suggests that activation of group III mGluRs mediates 
protection  in  a  Nox2  dependent  manner.  Nox2  activation  is  protective  in  models  of 
autoimmune disease (Hultqvist et al. 2009), and has been shown to decrease disease severity 
in a mouse model of MS (Hultqvist et al. 2004). Furthermore, Nox2 activation aids recovery 
after ischaemia in in vivo rat models, in which Nox2 knockout mice showed larger infarct 
volumes  than  wild  type  mice  after  ischaemia  (Kunz  et  al.  2007),  and  Nox2  activation 
provides neuroprotection against excitotoxic injury in vivo (Kawano et al. 2007). This, and 
the data presented here therefore suggest that microglial group III mGluR activation of Nox2 
is protective.   
Preliminary investigations showed that modulation of the microglial iGluRs affected neuronal 
survival, however, controls whereby CGCs were directly treated with the iGluR modulators 
were  not  conducted,  and  would  be  needed  to  ensure  that  the  effects  seen  were  not  a 335 
 
consequence of direct modulation of neuronal iGluRs. However, NMDA MGCM did not 
increase neuronal apoptosis, whereas NMDA plus apocynin MGCM significantly elevated 
neuronal death. Treatment of microglia with glutamate at levels consistent with activation of 
the NMDA receptor mediates the release of protective factors (Liang et al. 2010), suggesting 
that  the  neuroprotection  seen  here  may  be  due  to  NMDA  receptor  mediated  release  of 
neurotrophic factors in an NADPH oxidase dependent manner. Microglial activation of the 
NMDA receptor in vivo induces the translocation of NF-κB to the nucleus (Murugan et al. 
2011), which promotes the transcription of cytokines such as TNFʱ in a ROS dependent 
manner (Quan et al. 2011), which under certain conditions may be protective (Kraft et al. 
2009). Furthermore, NADPH oxidase activation mediates the activity of transcription factors 
(Pawate  et  al.  2004);  therefore  NMDA  receptor  induced  ROS  production  may  mediate 
cytokine  expression.  TNFʱ  is  protective  against  neuronal  excitotoxicity  (Marchetti  et  al. 
2004), and it could  therefore be suggested that NMDA mediated release of TNFʱ could 
promote the neuroprotection seen here.  
Activation  of  microglia  with  NMDA  increased  TNFʱ  expression,  which  was  further 
enhanced by co-treatment with NMDA and apocynin, which also correlated with an increase 
in neuronal death. It has been suggested that low levels of NMDA receptor activation and 
subsequent TNFʱ release enhances neuronal survival before ischaemia, and that this pre-
conditioning  may  be  protective  (Watters  &  O‟Connor  2011).  The  low  levels  of  TNFʱ 
released from microglia treated with NMDA may protect neurons from apoptosis, as seen 
here; whereas elevated levels of TNFʱ induced by inhibition of NMDA induced NADPH 
oxidase activation may promote neuronal apoptosis. The findings presented here therefore 
suggest  that inhibition  of microglial  NMDA induced NADPH oxidase activation may be 
neurotoxic  through  the  production  of  TNFʱ  which  facilitates  neuronal  death.  Microglial 
NMDA receptor mediated NADPH oxidase activation may therefore be protective.  336 
 
Inhibition of the microglial AMPA receptor with CNQX enhanced TNFʱ expression and 
elevated neuronal death in an NADPH oxidase dependent manner, which supports published 
findings that activation of the AMPA receptor does not induce Nox4 activation and H2O2 
production in cortical neurons, which is neuroprotective (Ha et al. 2010).  Suggesting that 
antagonism  of  the  microglial  AMPA  receptor  may  mediate  TNFʱ  expression  in  a  Nox4 
dependent manner, in agreement with findings that Nox4 can up-regulate IL-6 expression (Li 
et  al.  2009). Previous studies  have shown that  microglial  AMPA receptor activation  can 
induce  TNFʱ  release  (Noda  et  al.  2000),  and  co-treatment  of  microglia  with  the  AMPA 
receptor agonist and the antagonist CNQX can attenuate microglial TNFʱ release (Hagino et 
al. 2004). It is not known whether inhibition of the AMPA receptor alone modulates the 
expression or release of TNFʱ, however, the data presented here show that TNFʱ expression 
is elevated following CNQX treatment in an NADPH oxidase dependent manner, which is 
detrimental to neuronal survival.    
Activation of  the microglial  GABAA  receptor significantly increased TNFʱ  release in  an 
NADPH oxidase dependent manner, which correlated with increased neuronal apoptosis that 
could  be  attenuated  by  co-treatment  of  microglia  with  muscimol  and  apocynin  MGCM 
(Fig. 5.20). Muscimol plus apocynin MGCM also attenuated Sts induced neuronal apoptosis, 
suggesting that inhibition of microglial GABAA receptor induced superoxide production is 
protective to damaged neurons.  
Neuronal caspase 12 cleavage was attenuated by co-treatment of microglia with muscimol 
and  apocynin.  Modulation  of  the  microglial  GABAA  receptor  therefore  induces  TNFʱ 
production  in  an  NADPH  oxidase  dependent  manner,  which  induces  neuronal  apoptosis 
through caspase 12 activation and an ER stress pathway. This apoptotic pathway is seen in 
cardiomyocytes subjected to ischemic conditions, whereby TNFʱ is elevated and activates 
apoptosis through caspase 12 cleavage (Bajaj & Sharma 2006), and has also been shown in 337 
 
fibroblasts in vitro, whereby TNFʱ application can mediate caspase 12 dependent apoptosis 
(Kalai et al. 2003).  Neuronal TNFR1 expression was not modulated by muscimol MGCM, 
however TNFR1 expression was increased following treatment of CGCs with muscimol plus 
apocynin MGCM. This may represent a protective mechanism in which TNFR1 is shed from 
neurons  to  prevent  TNFʱ  binding  to  TNFR1  on  the  membrane  and  subsequent  neuronal 
apoptosis, which has been demonstrated in a mouse model of motor neurone disease (Bartsch 
et al. 2010), which also agrees with the protective properties of muscimol plus apocynin 
MGCM seen here. CGCs treated with muscimol plus apocynin MGCM may therefore elevate 
the  production  of  soluble  TNFR1  to  facilitate  neuroprotection.  The  low  level  of  TNFR1 
expression  following  exposure  of  neurons  to  muscimol  MGCM  could  suggest  that  the 
receptor has been internalised and degraded following binding to TNFʱ (Harry et al. 2008), 
which correlates with enhanced neuronal death. Interestingly, Akt phosphorylation was not 
modulated by treatment of neurons with muscimol MGCM, however, it has been suggested 
that TNFʱ can mediate Akt phosphorylation in fibroblasts (Chen et al. 2006), which was seen 
here.  
The GABAA receptor is up-regulated on activated glia, in particular in gliomas (Synowitz et 
al. 2001), suggesting that GABAA receptor expression is enhanced on activated microglia, 
suggesting a neurotoxic role. Furthermore, application of GABA to lymphocytes can induce 
cytotoxcity  (Bergeret  et  al.  1998),  supporting  the  findings  here  that  GABAA  receptor 
activation may induce the release of toxic factors from microglia. Furthermore, application of 
muscimol to adult rat brain slices induced an increase in the release of the inflammatory 
chemokine MIP-1ʱ (Cheung et al. 2009), which is up-regulated in the MPTP model of PD 
and contributes to neuronal apoptosis (Kalkonde et al. 2007). In addition, GABAA receptor 
activation in endothelial cells promotes Nox4 activation and ERK modulation (Tyagi et al. 
2009), which, in microglia, is consistent with an activated phenotype and the production of 338 
 
pro-inflammatory cytokines (Qian et al. 2008). Taken together, these published data support a 
role  for  microglial  GABAA  receptor  activation  in  the  release  of  neurotoxic  factors  in  an 
NADPH oxidase dependent manner, resulting in neuronal death.  
Activation of the microglial P2Y2/4 receptor significantly elevated TNFʱ protein expression, 
however this was not modulated by co-treatment with apocynin, although microglial TNFʱ 
release was enhanced by treatment with UTPγS in an NADPH oxidase dependent manner 
(Fig. 5.20). Neuronal apoptosis was not significantly elevated by UTPγS MGCM, however 
further neuroprotection was seen following treatment with UTPγS plus apocynin MGCM 
(Fig. 5.20), suggesting that attenuation of TNFʱ release as a consequence of UTPγS mediated 
NADPH oxidase inhibition is protective. Neuronal caspase 12 clevage was not significantly 
altered following treatment with UTPγS MGCM, however neuronal TNFR1 expression was 
significantly enhanced in the presence of UTPγS MGCM or UTPγS plus apocynin MGCM, 
suggesting  that  the  presence  of  TNFʱ  may  promote  TNFR1  shedding  from  neurons  to 
facilitate protection (Bartsch et al. 2010).  
UTPγS MGCM mediated neuronal apoptosis was not significant, however, attenuation of 
microglial  P2Y2/4  receptor  induced  NADPH  oxidase  activation  significantly  enhanced 
neuroprotection,  suggesting  a  slight  toxic  effect  of  P2Y2/4  receptor  mediated  microglial 
NADPH  oxidase  activation.  Activation  of  microglial  P2Y2/4  receptors  can  attenuate 
microglial reactivity after exposure to LPS (Boucsein et al. 2003); however, TNFʱ release 
from  microglia  has  been  observed  following  treatment  with  UTP  (Ogata  et  al.  2003). 
Activation of the microglial P2Y receptors is implicated in the recruitment of leukocytes to 
the  brain  tissue,  which  could  have  important  ramifications  for  inflammatory  processes 
(Boucsein  et  al.  2003).  Furthermore,  Nox2  activation  in  macrophages  can  regulate  the 
immune response by  activating T-cells  (Hildeman et  al.  2003), and it could  therefore be 
suggested  that  activation  of  microglial  P2Y2/4  receptors,  which  mediates  microglial 339 
 
chemotaxis (Inoue 2002), may also promote the activation of Nox2 which may facilitate the 
recruitment of immune cells to the sites of neuronal injury, in addition to having a slight toxic 
effect through the release of cytokines, which may be a consequence of Nox1 activation 
(Chéret et al. 2008). In support of this suggestion, activation of the microglial P2Y receptors 
was found to enhance PMA induced superoxide production which elevated TNFʱ release 
(Ogata et al. 2003). Attenuation of this NADPH oxidase activation may therefore promote the 
neuroprotective effects seen here following treatment of CGCs with UTPγS plus apocynin 
MGCM.    
Neuronal apoptosis following treatment with Sts was attenuated by treatment with UTPγS 
MGCM. In support of these findings, activation of the microglial P2Y receptors with UTP is 
neuroprotective against hypoxic insult through the release of TNFʱ (Morigiwa et al. 2000). 
This  therefore  suggests  that  TNFʱ  release  following  UTPγS  mediated  NADPH  oxidase 
activation  may  be  protective  to  apoptotic  neurons.  Furthermore,  Akt  phosphorylation 
remained  elevated  following  treatment  of  neurons  with  UTPγS  MGCM,  suggesting  that 
TNFʱ release may confer protection through Akt phosphorylation, as shown in fibroblasts 
(Chen et al. 2006). This is supported by findings from Groeger et al. (2009), who show that 
Nox2 and Nox4 activation is protective against retinal cell stress induced in vitro. Purinergic 
receptor  mediated  NADPH  oxidase  activation  can  enhance  cytokine  release  (Brown  & 
Griendling  2009)  which  can  feedback  onto  microglia,  inducing  further  Nox4  activation 
(Basuroy et al. 2009), which mediates protection (Groeger et al. 2008). This could account 
for  the  attenuation  of  apoptosis  of  Sts  treated  neurons  following  application  of  UTPγS 
MGCM.  Activation  of  the  microglial  P2Y2/4  receptor  and  subsequent  NADPH  oxidase 
activation therefore promotes TNFʱ production, which may be both protective and toxic.  340 
 
 
 
 
Figure  5.20  Summary  of  the  mechanisms  of  neuronal  survival  and  death  after  modulation  of  the 
microglial  NADPH  oxidase  following  treatment  with  receptor  agonists  or  antagonists.  Treatment  of 
microglia  with  the  mGluR  group  I  antagonist  MTEP  induced  a  significant  increase  in  TNFα  protein 
expression in an NADPH oxidase dependent manner, which mediated neuronal Akt phosphorylation and 
survival. Inhibition of mGluR group I mediated NADPH oxidase activation decreased TNFα expression, 
which  further  enhanced  neuronal  survival.  Treatment  of  microglia  with  the  mGluR3  agonist  NAAG 
increased TNFα expression which mediated Akt phosphorylation and neuronal survival, however inhibition 
of mGluR3 induced superoxide production also favoured neuronal survival through the inhibition of TNFα 
expression.  Attenuation  of  mGluR  group  III  mediated  superoxide  production  enhanced  TNFα  gene 
expression which correlated with an increase in neuronal caspase 12 clevage and apoptosis, suggesting 
activation  of  the  microglial mGluR  group  III  is  protective  through  modulation  of  the  NADPH  oxidase. 
Treatment of microglia with the GABAA or P2Y2/4 receptor agonists induced an increase in TNFα release 
which promoted increased neuronal apoptosis when compared with treatments in the presence of apocynin, 
which could also attenuate TNFα release and neuronal apoptosis.  341 
 
5.3.3  Conclusions  
The data presented here suggest that modulation of the microglial neurotransmitter receptors 
mediate intracellular superoxide production that is used as a signalling molecule to promote 
the production of neuroprotective or neurotoxic factors, which has ramifications for neuronal 
survival. Attenuation of the microglial group I mGluRs mediates Nox1 and Nox2 derived 
superoxide production, which promotes the production and release of neuroprotective factors 
and favours neuronal survival. Activation of the microglial mGluR3 or the group III mGluRs 
promotes superoxide production in a Nox2 and Nox4 dependent manner, which also has 
neuroprotective  properties.  Activation  of  the  GABAA  receptor  and  the  P2Y2/4  receptors 
facilitated  superoxide  production  in  a  Nox1  dependent  manner,  which  promoted 
neurotoxicity through the production and release of TNFʱ. Furthermore, neuronal apoptosis 
induced  by  microglial  conditioned  media  from  microglia  treated  with  muscimol  induced 
caspase 12 cleavage, suggesting an ER stress drived mechanism of neuronal death, which 
could be attenuated by inhibition of the microglial NADPH oxidase. These findings therefore 
suggest that modulation of the microglial mGluRs mediates neuronal survival in an NADPH 
oxidase  dependent  manner,  whilst  activation  of  the  GABAA  or  P2Y2/4  receptors  may 
promote  neurotoxicity  in  an  NADPH  oxidase  dependent  manner.  The  modulation  of 
microglial  neurotransmitter  receptors  may  therefore  have  important  ramifications  for  the 
regulation  of  the  inflammatory  response  through  mediating  NADPH  oxidase  activation, 
which could have imortant consequences for the treatment of neuroinflammatory conditions.   
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6.  General Discussion  
The research presented in this thesis focused on investigating the mechanisms behind, and 
subsequent  ramifications  of  microglial  NADPH  oxidase  activation  in  response  to 
neurotransmitters  and  modulation  of  microglial  neurotransmitter  receptors.  The  data 
presented  show  that  microglial  neurotransmitter  receptor  mediated  NADPH  oxidase 
activation  can  regulate  neuronal  survival,  which  provides  important  information  for  the 
generation of future therapies for neurodegenerative conditions.  
Neurotransmitter dysregulation, microglial reactivity, and ROS production are a hallmark of 
several  neurodegenerative  diseases.  Excitatory  neurotransmitters  such  as  glutamate  are 
present  in  the  CSF  of  MS  patients  (Stover  et  al.  1997),  and  GABA  is  released  into  the 
extracellular  space  during  ischaemia,  which  may  occur  in  an  attempt  to  counteract  the 
excitatory  actions  of  glutamate,  to  promote  neuroprotection  (Hutchinson  et  al.  2002). 
Glutamate  is  released  from  astrocytes  and  neurons  during  neurodegenerative  conditions, 
which  contributes  to  neuronal  excitotoxicity  and  microglial  activation  (Rossi  &  Volterra 
2009). Furthermore, in AD, GABAergic neurons in the hippocampus are not susceptible to 
death, and may contribute to the abnormal neuronal activity through the release of GABA, 
thereby perpetuating disease progression (Davies et al. 1998). Furthermore, the GABA tone 
in post-mortem AD brains is elevated in comparison to controls, suggesting that GABAergic 
transmission  may  contribute  to  AD  pathology  (Marczynski  1998).  In  addition,  GABA 
accelerates  excitotoxic  death  in  cortical  neuronal  cultures  through  activation  of  GABAA 
receptors (Erdö et al. 1991). ATP levels are also elevated after neuronal injury (Volonté et al. 
2003),  which  can  act  on  microglia  to  induce  chemotaxis  to  the site of neuronal  damage 
(Nimmerjahn et al. 2005). Pathological levels of ATP (1 mM) promote microglial activation 
and subsequent NADPH oxidase dependent ROS production (Parvathenani et al. 2003), in 344 
 
addition  to  the  release  of  cytokines  such  as  TNFʱ  (Hide  et  al.  2000)  with  detrimental 
consequences.  
In addition to the pathological role of neurotransmitter dysregulation, microglial NADPH 
oxidase activation is considered detrimental to neuronal survival. The microglial NADPH 
oxidase is activated by Aβ and contributes to AD progression (Wilkinson & Landreth 2006; 
Block 2008), and microglial NADPH oxidase activation is also seen in PD,  and is induced by 
toxins  such  as  paraquat  (Miller  et  al.  2007),  MPTP  and  rotenone  (Gao  et  al.  2003). 
Furthermore, microglial NADPH oxidase activation is seen in MS, in which ROS production 
is  induced  by  myelin  phagocytosis,  which  contributes  to  neurotoxicity  (Liu  et  al.  2006). 
Attenuation of microglial NADPH oxidase activity following activation by Aβ (Wilkinson et 
al. 2010), rotenone (Gao et al. 2003), paraquat (Miller et al. 2007), or myelin (Liu et al. 
2006), can protect against neurotoxicity.  
Microglia express a wide repertoire of neurotransmitter receptors  (Pocock & Kettenmann 
2007),  which  respond  to  physiological  and  pathological  levels  of  neurotransmitters  with 
varying  ramifications  for  microglial  reactivity  and  disease  progression.  Furthermore, 
microglia also express three isoforms of the NADPH oxidase: Nox1 (Chéret et al. 2008), 
Nox2  (Wilkinson  &  Landreth  2006)  and  Nox4  (Harrigan  et  al.  2008).  It  was  therefore 
considered  important  to  investigate  the  hypothesis  that  modulation  of  microglial 
neurotransmitter receptors may induce NADPH oxidase activation which may promote either 
a neurotoxic or neuroprotective phenotype.  
6.1 Modulation  of  microglial  neurotransmitters  induces  NADPH  oxidase  activation 
with ramifications for neuronal survival  
The data presented here demonstrated that exposure of microglia to glutamate, GABA or 
ATP  induced  NADPH  oxidase  activation.  Whilst  exposure  of  microglia  to  ATP  and 345 
 
activation  of  P2X7  receptors  has  been  shown  to  mediate  NADPH  oxidase  activation 
(Parvathenani et al. 2003), it has not been previously reported that exposure of microglia to 
glutamate or GABA can mediate NADPH oxidase activity. Following on from these studies, 
the role of neurotransmitter receptors in superoxide production was investigated. Inhibition of 
the microglial group I mGluRs, activation of the group II mGluR3, activation of the group III 
mGluRs, modulation of the microglial iGluRs, and activation of the GABAA and P2Y2/4 
receptors  were  shown  to  induce  superoxide  production  through  activation  of  different 
NADPH oxidase isoforms, with consequences for neuronal survival.  
Superoxide  production  following  modulation  of  the  microglial  glutamate  receptors  was 
neuroprotective  through  activation  of  NADPH  oxidase  isoforms  (Fig. 6.1,  Table  8). 
Inhibition of the microglial group I mGluRs with MTEP induced Nox1 and Nox2 mediated 
superoxide  production  through  PKC  and  PI3-K  activation  and  p44/42ERK  induction 
Furthermore,  MTEP  induced  superoxide  production  from  Nox1  and  Nox2  activation 
mediated p44/42ERK phosphorylation (Fig. 6.1). MTEP induced superoxide production also 
elevated  TNFʱ  expression,  and  application  of  MTEP  MGCM  to  CGCs  was  protective 
through enhanced Akt phosphorylation (Fig. 6.1).  
Treatment of microglia with the mGluR group I agonist can down-regulate NADPH oxidase 
activation, which is protective in models of spinal trauma (Byrnes et al. 2009) and in vitro 
(Loane et al. 2009). This supports findings here that antagonism of the group I mGluRs 
promotes superoxide production, however, as inhibition of the microglial group I mGluR did 
not induce neuronal apoptosis, MTEP induced superoxide production may be mediated by a 
Nox  isoform  considered  to  be  protective.  Nox2  activation  can  protect  against  immune 
mediated degeneration in a mouse model of rheumatoid arthritis (Hultqvist et al. 2009), and 
attenuates disease severity in a mouse model of MS (Hultqvist et al. 2004). Furthermore, 
Nox2 activation is protective in models of ischaemia (Kunz et al. 2007) and excitotoxicity 346 
 
(Kawano et  al.  2007).  The data  presented here therefore suggests that attenuation of the 
microglial group I mGluR promotes neuroprotection through Nox2 activation.  
Interestingly,  treatment  of  microglia  with  MTEP  plus  apocynin  up-regulated  Nox1 
expression, which also correlated with increased neuronal death following treatment with the 
apoptotic inducer staurosporine and MTEP plus apocynin MGCM, however healthy neurons 
were  not  affected  by  this  treatment.  Activation  of  the  microglial  Nox1  is  neurotoxic, 
mediating the release of IL-1β, and promoting neuronal death  in vitro (Chéret et al. 2008), 
and  attenuation  of  Nox1  activation  following  ischaemia  in  the  rat  brain  promotes 
neuroprotection (Kahles et al. 2010). IL-1β has no effect on the survival of healthy neurons in 
vitro, only enhancing degeneration after excitotoxic injury (Stone & Behan 2007), lending 
support  to  the  suggestion  that  Nox1  induction after  MTEP  plus  apocynin  treatment  may 
mediate IL-1β production to enhance the apoptosis of staurosporine damaged neurons only.  
Attenuation of MTEP induced Nox2 activation may mediate the expression and activation of 
Nox1 through MTEP induced PKC signalling, which has been shown to up-regulate Nox1 
expression  (Wei  et  al.  2010)  and  activity  (Fan  et  al.  2005).  Furthermore,  a  neurotoxic 
NADPH oxidase is preferentially induced after treatment of microglia with paraquat, which 
also mediates PKC and p44/42ERK signalling (Miller et al. 2007), lending support to the 
findings here that antagonism of the microglial group I mGluR may mediate Nox1 activation 
through PKC and p44/42ERK activation.  The data presented here therefore show that Nox2 
activation  by  group  I  mGluR  antagonism  represents  a  neuroprotective  phenotype,  whilst 
activation of Nox1 following Nox2 inhibition enhances neuronal death.   
Activation of the microglial mGluR3 induced superoxide production through Nox2 and Nox4 
activation (Fig. 6.1, Table 8), and induced a neuroprotective phenotype, in line with findings 
from Taylor et al. (2005), who demonstrated that mGluR3 activation with NAAG could not 
induce microglial reactivity or neurotoxicity after treatment with peptides associtated with 347 
 
AD; and correlating with findings that activation of mGluR3 reduces microglial reactivity in 
response  to  myelin  exposure  (Pinteaux-Jones  et  al.  2008).  Furthermore,  Nox2  and  Nox4 
activation is protective in a model of retinal cell stress (Groeger et al. 2009); supporting the 
findings here that microglial mGluR3 activation is protective through Nox2 and Nox4.  
Activation  of  microglial  Nox2  following  NAAG  treatment  may  mediate  the  protective 
phenotype. Attenuation of NAAG induced Nox2 activation with apocynin could not mediate 
the same level of neuroprotection in staurosporine treated neurons. This could suggest that 
Nox4 activation (which is not inhibited by apocynin) may induce the release of cytokines 
such as IL-6 (Li et al. 2009), which may not protect apoptotic neurons in the same ways that 
IL-6  provides  protection  to  healthy  neurons  (Scheller  et  al.  2011).  In  support  of  this 
suggestion, activation of the astrocytic mGluR3 induces IL-6 release (Aronica et al. 2005), 
which  could  be  through  a  Nox4  dependent  mechanism  (Li  et  al.  2009).  These  studies 
therefore lend support to the findings here that activation of the microglial mGluR3 mediates 
neuronal protection through Nox2 activation, and that Nox2 inhibition may enhance Nox4 
activity, thereby slightly attenuating the survival of staurosporine treated neurons.  
In  this  thesis,  activation  of  the  microglial  mGluR3  mediated  superoxide  production  in  a 
p38MAPK and p44/42ERK dependent manner; and superoxide production through Nox2 and 
Nox4 activation also induced phopshorylation of these signalling molecules (Fig. 6.1). In 
astrocytes,  mGluR3  activation  mediates  p38MAPK  and  p44/42ERK  activation  which 
facilitates survival (Ciccarelli et al. 2007). It could therefore be suggested that this MAPK 
activation  is  perpetuated  by  NADPH  oxidase  induction  after  mGluR3  activation,  thereby 
promoting the protective phenotype seen here and reported by Taylor et al (2005). Microglial 
mGluR3 activation also induced TNFʱ expression, which mediated neuronal survival in an 
NADPH oxidase dependent manner (Fig. 6.1). The protective effects of mGluR3 activation 
are therefore mediated by Nox2 activity, which facilitates TNFʱ production with protective 348 
 
consequences  for  healthy  neurons,  mediating  homeostasis  and  protection  against  insults 
(Sriram & O‟Callaghan 2007). Furthermore, TNFʱ mediates the survival of fibroblasts in an 
Akt dependent manner (Chen et al. 2006), which correlates with findings here that neuronal 
Akt phosphorylation was up-regulated following exposure to NAAG MGCM. These findings 
therefore also support a role for microglial Nox2 activation in protection, and could represent 
a mechanism whereby microglial Nox2 activation through treatment with mGluR3 agonists 
could regulate the immune response in neurodegeneration, as seen in other immune diseases 
(Hultqvist et al. 2009).  
Activation of the microglial  group III mGluR mediated neuroprotection through NADPH 
oxidase  activation.  Treatment  of  microglia  with  the  group  III  agonist  L-AP4  induced 
p38MAPK activation which mediated Nox2 and Nox4 activation, down-regulating TNFʱ 
expression and promoting neuronal survival (Fig. 6.1, Table 8). Furthermore, attenuation of 
the  microglial  NADPH  oxidase  after  activation  of  the  group  III  mGluR  significantly 
increased neuronal apoptosis, which correlated with increased TNFʱ expression. Activation 
of microglial group III mGluRs mediates protection against exposure of microglia to myelin 
(Pinteaux-Jones et al. 2008), and down-regulates microglial reactivity in response to CgA or 
Aβ,  with  neuroprotective  consequences  (Taylor  et  al.  2003).  Furthermore,  activation  of 
microglia with glutamate at levels concurrent with group III mGluR activation mediates the 
production of neurotrophic factors in a PKC dependent manner (Liang et al. 2010), and as 
NADPH oxidase activation is induced by PKC activity (Yamamori et al. 2000), it could be 
suggested  that  activation  of  the  microglial  group  III  mGluRs  mediates  neuroprotection 
through the production of neurotrophic factors in an NADPH oxidase dependent manner. In 
addition, activation of group III mGluRs expressed on a stably transfected cell line induces 
p38MAPK  activity  (Ferraguti  et  al.  1999),  which  promotes  a  protective  phenotype  in 
astrocytes (Ciccarelli et al.  2007). Together these published findings and the data presented 349 
 
here show that activation of the microglial group III mGluRs mediates neuronal survival 
through the release of trophic factors in a Nox2 dependent manner through the p38MAPK 
signalling cascade.  
Treatment  of  microglia  with  the  AMPA  receptor  agonists  did  not  mediate  superoxide 
production, and did not significantly modulate neuronal survival, although attenuation of the 
AMPA  receptor  enhanced  neuronal  death  in  an  NADPH  oxidase  dependent  manner. 
However,  it  has  been  shown  that  activation  of  the  AMPA  receptor  has  little  effect  on 
neuronal Nox4 activation in comparison with activation of the NMDA receptor, which had a 
greater  effect  on  Nox4  activity  (Ha  et  al.  2010),  in  line  with  the  data  presented  here. 
Activation of the microglial NMDA receptor mediated superoxide production in an NADPH 
oxidase dependent manner through a p38MAPK dependent mechanism (Fig. 6.1, Table 8). 
Furthermore, activation of the microglial NMDA receptor down-regulated TNFʱ expression 
in an NADPH oxidase dependent manner, and also mediated neuronal survival (Fig. 6.1). 
Microglial NMDA receptor activation can induce the production of neurotrophic cytokines in 
a  PKC  dependent  manner  (Liang  et  al.  2010),  and  PKC  also  mediates  NADPH  oxidase 
activation (Fan et al. 2005), suggesting that here, microglial NMDA receptor activation could 
mediate neuronal survival in an NADPH oxidase dependent manner. In addition, activation of 
the  microglial  group  II  mGluRs  can  induce  NMDA  receptor  activation  through  a  PKC 
dependent pathway in cortical neurons (Tyszkiewicz et al. 2004), and it could therefore be 
suggested  that  in  microglia,  activation  of  the  group  II  mGluRs  and  subsequent  NMDA 
receptor activation could perpetuate superoxide production through activation of the NADPH 
oxidase, with neuroprotective consequences.  350 
 
   
 
Figure 6.1 Microglial glutamate receptor induced superoxide productions and ramifications for neuronal 
survival. The data presented here show that treatment of primary microglia with the mGluR group I receptor 
antagonist induces PKC and PI3-K activation, which could induce p44/42ERK activation and Nox1 and 
Nox2 mediated superoxide production. Furthermore, MTEP induced superoxide production also mediated 
the phosphorylation of p44/42ERK. Subsequent superoxide production induced the expression of TNFα, 
which  correlated  with  an  increase  in  neuronal  Akt  phosphorylation  and  subsequent  neuronal  survival. 
Activation of the microglial mGluR3 induced the production of superoxide through Nox2 and Nox4 through 
activation of the p38MAPK and p44/42ERK, which could also mediate phosphorylation of these signalling 
molecules. Nox2 and Nox4 activation also mediated TNFα expression which was shown to induce neuronal 
Akt  phosphprylation  and  neuronal  survival.  Treatment  of  microglia  with  the  mGluR  group  III  agonist 
induced p38MAPK activation and Nox2 and Nox4 activation, which down-regulated TNFα expression and 
mediated neuronal survival. Finally, activation of the microglial NMDA receptor was shown induced the 
activation of the NADPH oxidase in a p38MAPK dependent manner, and superoxide production could also 
regulate p38MAPK phosphorylation. This also resulted in neuronal survival. 351 
 
Treatment of microglia with the GABAA receptor agonist or the P2Y2/4 receptor agonist was 
neurotoxic  through  activation  of  the  NADPH  oxidase  (Fig.  6.2,  Table  8).  Treatment  of 
microglia  with  the  GABAA  receptor  agonist  muscimol  significantly  increased  superoxide 
production  in  a  Nox1  dependent  manner,  which  was  dependent  on  PKC  and  p38MAPK 
signalling  (Fig.  6.2).  Furthermore,  Nox1  induced  superoxide  production  significantly 
elevated TNFʱ release, which correlated with increased neuronal apoptosis (Fig. 6.2).  
Although this  is  the first  time that it has  been shown that modulation of the microglial 
GABAA receptor mediates superoxide production with neurotoxic consequences, it has been 
found that GABAA receptor expression is up-regulated on gliomas (Synowitz et al. 2001), 
suggesting a role in pathology. Furthermore, activation of the astrocytic GABAA receptor 
mediates IL-6 release in a p38MAPK dependent manner (Roach et al. 2008). IL-6 is released 
from  human microglia  expressing  active  Nox4  (Li et al.  2009), and  muscimol  regulates 
Nox4 activation in endothelial cells (Tyagi et al. 2009), therefore lending support to the 
findings  here  that  activation  of  the  microglial  GABAA  receptor  may  induce  superoxide 
production in an NADPH oxidase dependent manner. Muscimol treatment was shown to 
induce Nox1 activation, which correlated with a neurotoxic phenotype, in agreement with 
Chéret  et  al.  (2008)  who  show  that  microglial  Nox1  activation  induces  the  release  of 
cytotoxic factors. These data therefore demonstrate that in diseases such as AD, in which the 
GABA  tone  is  enhanced  (Marczynski  1998),  the  elevated  GABA  levels  may  induce 
activation of microglial GABAA receptors which could perpetuate neurodegeneration. 
Activation  of  the  microglial  P2Y2/4  receptor  significantly  elevated  Nox1  and  Nox2 
mediated  superoxide  production  in  a  PI3-K  and  p38MAPK  dependent  manner  (Fig. 6.2, 
Table 8). Furthermore, this Nox1/2 mediated superoxide production induced p44/42ERK 
phosphorylation  which  is  implicated  in  enhanced  microglial  activation  (Thellung  et  al. 
2007), and can perpetuate cytokine release and neuronal apoptosis. P2Y2/4 receptor induced 352 
 
Nox1/2 activation induced TNFʱ expression, which correlated with neuronal apoptosis in an 
NADPH oxidase dependent manner (Fig. 6.2). 
Activation of microglial P2Y receptors mediates cytokine release (Ogata et al. 2003) and 
promotes a phagocytic phenotype (Inoue 2002). Furthermore, the phagocytic phenotype is 
elicited following the leakage of  UDP and UTP in  the hippocampus after excitotoxicity 
(Inoue  et  al.  2009).  It  could  therefore  be  suggested  that  microglial  P2Y2/4  receptor 
activation in pathological conditions may favour microglial reactivity and neuronal death in 
an NADPH oxidase dependent manner, which may be dependent on p44/42ERK activation 
(Luke & Hexum 2008), shown to induce a reactive microglial phenotype and promote TNFʱ 
release, which contributes to neurodegenerative conditions (Hide 2003), in agreement with 
the data presented here. These data show that the upstream mediator of p44/42ERK- induced 
TNFʱ  release  is  Nox1,  which  promotes  the  release  of  cytotoxic  factors  from  microglia 
(Chéret et al.  2008). Furthermore, it has been shown in vivo that activation of the microglial 
P2Y  receptors  facilitates  the  migration  of  immune  cells  to  the  sites  of  neuronal  injury 
(Boucsein et al. 2003), and activation of the NADPH oxidase in macrophages can regulate 
the immune response by activating T-cells (Hildeman et al. 2003), which could suggest an 
immune  regulatory  role  for  superoxide  production  as  a  consequence  of  activation  of 
microglial P2Y2/4 receptors in vivo. These findings therefore suggest that activation of the 
microglial GABAA or the P2Y2/4 receptors mediates neurotoxicity through Nox1 activation 
(Fig. 6.2).  
 
 
 353 
 
 
 
 
Figure  6.2  Activation  of  the  microglial  GABAA  receptor  or  P2Y2/4  receptors  are  neurotoxic 
through activation of Nox1. Treatment of microglia with the GABAA receptor agonist muscimol 
induced Nox1 activation through the activity of PKC and p38MAPK phosphorylation. This induced 
a  significant  increase  in  TNFα  release  which  enhanced  neuronal  death  in  an  NADPH  oxidase 
dependent manner. Activation of the microglial P2Y2/4 receptor induced a significant increase in 
superoxide production through PI3-K and p38MAPK activation, which induced Nox1 and Nox2 
activity,  resulting  in  the  release  of  TNFα  and  enhanced  neuronal  apoptosis,  and  also  induced 
p44/42ERK phosphorylation in an NADPH oxidase dependent manner.  354 
 
Microglial 
neurotransmitter 
receptors 
modulated  
Microglial 
NADPH 
oxidase isoform 
stimulated  
Microglial 
Signalling 
cascades activated  
Neuroprotective 
or neurotoxic 
consequences  
Neuronal death / 
survival 
cascades 
activated  
Group I mGluR 
antagonism 
Nox1 and Nox2   PKC, PI3-K, 
p44/42ERK 
Neuroprotective   Akt / Unknown 
Group II mGluR3 
activation 
Nox2 and Nox4   p44/42ERK, 
p38MAPK 
Neuroprotective   Akt / Unknown 
Group III mGluR 
activation 
Nox2 and Nox4   p38MAPK  Neuroprotective   Unknown 
NMDA receptor 
activation  
Unknown   p38MAPK  Neuroprotective  Unknown  
GABAA receptor 
activation 
Nox1   PKC, p38MAPK – 
mediates TNFʱ 
production and 
release  
Neurotoxic   Caspase 12 
cleavage  
P2Y2/4 receptor 
activation  
Nox1 and Nox2  PI3-K, p38MAPK 
– mediates TNFʱ 
production and 
release  
Neurotoxic   Unknown  
Table 8. Summary table of NADPH oxidase activation and signalling cascades elicited 
by modulation of microglial neurotransmitter receptors 
 
6.2 Conclusions  
The  data  presented  here  show  that  modulation  of  microglial  neurotransmitter  receptors 
mediates NADPH oxidase activation with consequences for neuronal survival. In line with 
published findings, the data in this thesis shows that treatment of microglia with the mGluR3 
agonist  NAAG  (Taylor  et  al.  2002)  and  activation  of  the  group  III  mGluR  with  L-AP4 
(Taylor et al. 2003) is neuroprotective, which is mediated by Nox2 and Nox4. Stimulation of 
the microglial Nox2 and Nox4 isoforms could therefore modulate the inflammatory response 
in  the  CNS,  with  protective  consequences  for  neurodegeneration  (Hultqvist  et  al.  2004; 
Groeger  et  al.  2009).  Antagonism  of  the  microglial  group  I  mGluR  also  promoted 
neuroprotection through Nox2. In addition, activation of the microglial NMDA receptor was 
neuroprotective in line with published findings showing that the NMDA receptor induces the 
release of neurotrophic factors from microglia (Liang et al. 2010). Furthermore, it could be 355 
 
suggested  that  microglia  take  up  excess  glutamate  released  in  degenerative  conditions 
through the mGluR and NMDA receptors to facilitate neuronal survival. This could represent 
a  mechanism  in  which  microglial  Nox2  and  Nox4  activation  mediate  neuroprotection 
following exposure to glutamate in conditions such as AD and ischaemia, in which high 
levels  of  glutamate  are  found  in  the  extracellular  space.  Modulation  of  these  glutamate 
receptors  could  therefore  represent  a  protective  mechanism  through  activation  of  Nox2, 
which is protective in other systemic inflammatory conditions (Hultqvist et al. 2009). 
In contrast, microglial GABAA and P2Y2/4 receptor activation was neurotoxic through Nox1 
activation and TNFʱ release in an NADPH oxidase dependent manner. Reports have shown 
that the GABAA receptor is up-regulated on gliomas (Synowitz et al. 2001), representative of 
microglial  reactivity, and high levels  of GABA are present  in  the CNS following stroke 
(Hutchinson et al. 2002), and in the AD brain (Marczynski 1998) suggesting that neuronal 
damage  may  be  facilitated  through  GABA  activation  of  microglia  and  subsequent  Nox1 
activation.  Furthermore,  GABA  perpetuates  the  cytotoxicity  of  immunocompetent  cells 
(Bergeret et al. 1998), and the findings here suggest that this may be dependent on NADPH 
oxidase activation. Activation of the microglial P2Y receptors mediates TNFʱ expression and 
promotes a phagocytic phenotype (Koizumi et al. 2007). Furthermore, as UTP is released 
from hippocampal neurons following excitotoxicity (Inoue 2009), it could be suggested that 
the subsequent  neurotoxicity is  a consequence  of P2Y2/4 mediated Nox1 activation, and 
inhibition of the microglial P2Y2/4 receptor may therefore be protective against degenerative 
conditions. Antagonism of the microglial GABAA receptor could also be protective through 
inhibition of Nox1 activation in conditions such as AD and ischaemia.  
This thesis therefore shows that modulation of microglial glutamate receptors represents a 
neuroprotective therapy for the treatment of neurodegenerative conditions through activation 
of Nox2, whilst activation of the microglial GABAA and P2Y2/4 receptors could perpetuate 356 
 
neurodegeneration  through  activation  of  the  neurotoxic  Nox1  isoform  of  the  NADPH 
oxidase.   
6.3 Suggested future work 
Whilst the work presented here details the mechanism behind superoxide production and 
NADPH  oxidase  isoform  activation  as  a  consequence  of  modulation  of  microglial 
neurotransmitter receptors, further investigations could be performed into the mechanisms 
behind  neuronal  survival  or  death.  A  more  comprehensive  investigation  into  the  factors 
released from microglia following treatment with neurotransmitter receptor modulators in an 
NADPH oxidase manner should be performed using a proteomic approach, to provide further 
information on which cytokines or released factors are responsible for modulating neuronal 
survival. Furthermore, a detailed investigation into the effects of microglial neurotransmitter 
receptor modulation, and subsequent NADPH oxidase activation on neuronal survival in a 
more physiological setting should be conducted; for example, investigating the effects of 
microglial NADPH oxidase modulation on neuronal survival after exposure to Aβ, CgA or 
myelin. Following on from these studies, an in vivo system should be used to analyse the 
effects of modulation of the microglial neurotransmitter receptors and subsequent NADPH 
oxidase activation in animal models of neurodegenerative disease. In addition, it would be 
interesting  to  see  whether  microglial  neurotransmitter  receptor  induced  NADPH  oxidase 
activation regulates the activation of other immune cells, or a disruption of the BBB, to 
mediate  the  activity  of  the  peripheral  immune  system,  which  could  have  important 
ramifications for attenuating disease progression. It would be important to see whether the 
data presented here translates to human cells, whereby human macrophages could be used. 
These studies would be beneficial to build upon the work presented here and to investigate 
the  hypothesis  that  modulation  of  microglial  neurotransmitter  receptors  could  mediate 357 
 
neuronal survival in an NADPH oxidase dependent manner in greater detail and in a more 
physiologically relevant setting.  
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